Fatty Acids, Cognition, School Performance, and Mental Well-being in Children and Adolescents by van der Wurff, I.S.M.
Fatty Acids, Cognition, School Performance, 
and Mental Well-Being in Children and 
Adolescents
I.S.M. van der Wurff
 Universiteit
Fat y acids, Cognit on, Scho l Performance 
and Mental Well-Being in Children and 
Adolescents
I.S.M. van der Wurff
  
The work presented in this thesis was conducted at the Welten Institute, Research Centre 
for Learning, Teaching and Technology under the research line Fostering Effective, 
Efficient and Enjoyable Learning (FEEEL), within the topic Brain, Lifestyle and Learning 
(BLL) in the context of the research school Interuniversity Centre for Educational 
Research (ICO).  
 
Food2Learn was funded by the grant Food, Cognition and Behaviour from the Dutch 
Scientific Organisation (grant number 057-13-002), Aker Biomarine (Norway) who 
provided the krill and placebo capsules, and Omegametrix (Germany) who was responsible 
for the blood analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© copyright Inge van der Wurff, Heerlen, the Netherlands 2018 
 
Cover design: Monique Vossen 
 
Printing, layout: Datawyse | Universitaire Pers Maastricht 
 
ISBN/EAN 9789492739063 
   
  
 
 
 
 
 
 
PROEFSCHRIFT 
 
 
ter verkrijging van de graad van doctor aan de Open Universiteit op gezag van de rector 
magnificus prof. mr. A. Oskamp ten overstaan van een door het College voor promoties 
ingestelde commissie in het openbaar te verdedigen  
op vrijdag 9 februari 2018 te Heerlen om 16.00 uur precies 
door 
 
Inge Silvia Marinus van der Wurff 
geboren op 18 april 1989 te Maastricht 
 
  
Fatty Acids, Cognition,  
School Performance, and Mental Well-Being in  
Children and Adolescents 
Promotores  
Prof. dr. R.H.M. de Groot, Open Universiteit 
Prof. dr. P.A. Kirschner, Open Universiteit 
Prof. dr. M.P. Zeegers, Universiteit Maastricht 
Overige leden beoordelingscommissie  
Prof. dr. J.F.C. Glatz, Universiteit Maastricht  
Prof. dr. A.C. Krabbendam, Vrije Universiteit Amsterdam 
Prof. dr. J.F.M. Claessen, Open Universiteit 
Prof. dr. E.H.S. Lechner, Open Universiteit 
Dr. C. Thijs, Universiteit Maastricht  
Dr. P. Van Dael, DSM Nutritional Products 
 5 
Table of content  
 
 
Chapter 1  General introduction 7 
Chapter 2 Maastricht essential fatty acid birth cohort 25 
Chapter 3 Association between prenatal and current exposure to selected 41 
LCPUFAs and school performance at age 7 
Chapter 4 A protocol for a randomised controlled trial investigating the effect of 57 
increasing Omega-3 index with krill oil supplementation on learning, 
cognition, behaviour and visual processing in typically developing 
adolescents. 
Chapter 5 Association between blood Omega-3 Index and cognition in typically 77 
developing Dutch adolescents 
Chapter 6 Exploring the association between whole blood long-chain 95 
polyunsaturated fatty acid levels and depression and self-esteem in 
adolescents of lower general secondary education 
Chapter 7 Effect of 1 year krill oil supplementation on cognitive achievement of 113 
Dutch adolescents: a double-blind randomized controlled trial. 
Chapter 8 Effect of 1 year krill oil supplementation on depression and self- 135 
esteem of Dutch adolescents: a randomized controlled trial. 
Chapter 9 A review of recruitment, adherence and drop-out rates in omega-3 153 
polyunsaturated fatty acid supplementation trials in children and 
adolescents 
Chapter 10 General discussion 187 
Summary  213 
Samenvatting  219 
Dankwoord  225 
Curriculum vitae 227 
ICO dissertation series 229 
 
  
   
7 
Chapter 1 
General introduction 
  
  
General introduction 
9 
General introduction 
Long-chain polyunsaturated fatty acids (LCPUFA) are important constituents of the cell 
membrane. Several studies have shown that essential fatty acids and their longer chain 
derivatives, LCPUFA play a role in brain functioning. This notion has led to research that 
has studied the relation between LCPUFA and cognitive functioning in children and adults 
[1,2] as well as cognitive decline in elderly [3,4]. They have also been studied in relation to 
mental disorders such as ADHD and autism [5,6], and affective disorders such as 
depression and bipolar disorder [7,8]. In contrast to the many studies in which the 
influence of LCPUFA on cognition in infants, children, and elderly has been studied (for 
review see among others [1,2,9,10]), there are, as far as we are aware, no LCPUFA 
supplementation studies with a focus on cognition in adolescents. Moreover, even though 
the relation between LCPUFA and cognition in children has been studied extensively, there 
are, to our knowledge, no studies focusing on the relationship between LCPUFA and 
school performance in children. In adolescents there are a number of studies in which a 
positive association between fish consumption (most important source of LCPUFA) and 
school performance is shown [11–13]. 
LCPUFA have also attracted attention for their possible influence on depression. There 
are many studies investigating the influence of LCPUFA supplementation on depression in 
adults (for meta-analyses see [14–16]). However, as depression is especially common in 
adolescents [17], and it can have profound long lasting negative effects [18], it seems 
especially important to study the influence of LCPUFA in this age group. Unfortunately, 
the influence of LCPUFA supplementation on mental well-being (i.e., depression and self-
esteem, as self-esteem is a core construct in mental health) in adolescents, has, to our 
knowledge, not yet been studied.  
Taking all above into consideration, the aim of this thesis is to study the: 
(1) relationship between LCPUFA and school performance in children (2) influence of 
LCPUFA on cognitive functioning in typically developing adolescents, and (3) influence of 
LCPUFA on mental well-being in typically developing adolescents.  
To study the relationship between LCPUFA and school performance in children, data 
from the historic Maastricht Essential Fatty Acid Birth cohort (MEFAB) were used. To 
study the influence of LCPUFA on cognition and mental well-being (i.e., both depressive 
feelings and self-esteem) in typically developing adolescents, Food2Learn, a double-blind 
randomized, placebo controlled repeated measures intervention study was designed.  
The next paragraphs start with background information on fatty acids, LCPUFA in the 
diet, krill oil supplementation, LCPUFA in relation to brain functioning, and brain 
development. Next, information on school performance, cognition, and mental well-being 
and the role of LCPUFA in each is discussed. Then, the aim of this thesis and the studies 
included in this thesis are discussed. The chapter ends with the outline of this thesis.  
Fatty acids  
A fatty acid is a chain of 6 to 32 carbon atoms with 1 or 2 hydrogen atoms attached to every 
carbon atom, an acid group (COOH) on one end and a methyl group (CH3) on the other (see 
Figure 1.1). A fatty acid chain can have no, one or more double bounds between carbon 
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atoms. If a fatty acid has no double bound, the fatty acid is a saturated fatty acid. A fatty acid 
that has one double is called a monounsaturated fatty acid (MUFA). A fatty acid with more 
than one double bond in the chain is a polyunsaturated fatty acid (PUFA). Note that fatty acids 
with 20 or more carbon atoms are called long-chain polyunsaturated fatty acids (LCPUFA).  
 
 
Figure 1.1: Basic formula of (a) a saturated fatty acid with no double bond, and (b) an unsaturated fatty acid with 
one double bond. 
 
Fatty acids can vary in chain length (i.e., number of carbon atoms) and the number of 
double bonds, but also the location of the double bond can vary. The position of the first 
double bond counted from the methyl end (CH3) gives the fatty acid its omega number. 
For example, a fatty acid with its first double bond on the third carbon from the methyl 
end is an omega-3 fatty acid, also noted as n-3 or ω-3 fatty acid. If the first double bond 
appears on the sixth carbon atom, it is an omega-6 fatty acid, also noted as n-6 or ω-6 fatty 
acid. There are various families of unsaturated fatty acids. This thesis focuses on the fatty 
acids from the n-3 and n-6 families.  
All fatty acids have a specific name and most also an abbreviation (e.g., docosahexaenoic 
acid, DHA), but there is also a short hand notion based on the number of carbon atoms, 
number of double bonds, and the position of the first double bond. For example, for DHA, 
the short hand notion is C22:6n-3, which indicates that DHA has 22 carbon atoms, 6 double 
bonds, and that the first double bond is located at the third position. In the current thesis 
both the name or abbreviation and the number notation will be used.  
The n-3 and n-6 fatty acids are essential fatty acids, or, in other words, the human body 
cannot make these fatty acids de novo. A lack of these fatty acids leads to deficiency 
symptoms such as impairment in visual acuity and skin lesions [19,20]. The human body 
cannot produce n-3 and n-6 fatty acids de novo because it lacks the enzymes to insert a 
double bond at the third or the sixth position. This inability to introduce a double bond at 
the third or the sixth position makes the parent n-3 and n-6 fatty acids α-linolenic acid 
(C18:3n-3, ALA) and linoleic acid (C18:2n-6, LA) essential fatty acids (i.e., they have to be 
taken in via the diet). Both ALA and LA can be converted in their longer chain more 
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unsaturated derivatives, such as DHA and AA, via chain elongations, desaturation and beta 
oxidation (see Figure 1.2). However, the conversion of ALA to EPA and conversion from 
ALA to DHA is an inefficient process. Conversion of ALA to EPA has been suggested to 
be around 8% (i.e., about 8% of ingested ALA will be converted into EPA) and the 
conversion from ALA to DHA below 1% [21,22]. Moreover, since the n-3 and n-6 fatty 
acids are metabolized by the same desaturase enzymes, competition for these enzymes 
exists between the families. Consequently, higher intake of the n-6 fatty acid LA leads to 
inhibition of the conversion of ALA to stearidonic acid (C18:4n-3), and higher intake of n-
3 fatty acid ALA leads to inhibition of conversion of LA to gamma-linoleic acid (C18:3n-6, 
GLA). Moreover, the consumption of preformed EPA and DHA leads to a much higher 
increase in the concentrations of these fatty acids in the blood than what can ever be 
achieved by consumption of any n-3 precursor. It has therefore been suggested that at least 
DHA is a semi-essential nutrient (i.e., a nutrient that can be synthesized by the body, but 
not in amounts adequate for health and should therefore be consumed in the diet) [23,24]. 
Again, it is therefore essential that these parent fatty acids, ALA and LA, as well as their 
elongation products, predominantly EPA, DHA, and AA are consumed with the diet.  
 
 
Figure 1.2: Schematic overview of n-3 and n6 fatty acid conversion.  
elongase
Δ 4 desaturase
Δ 5 desaturase
elongase
Δ 6 desaturase
α-linolenic acid 
C18:3n-3; ALA
stearidonic acid 
C18: 4n-3
linoleneic acid 
C18:2n-6; LA
γ-linoleneic acid 
C18:3n-6; GLA
eucosatetraenoic acid 
C18:4n-3
dihomo-γ-linoleneic acid
C20:3n-6; DHGLA
eicosapentaenoic acid 
C20:5n-3; EPA
docosapentaenoic acid 
C22:5n-3; DPA
docosahexaenoic acid 
C22:6n-3; DHA
arachidonic acid 
C22:4n-6; AA
adrenic acid 
C22:4n-6
docosapentaenoic acid 
C22:5n-6
Omega-3 fatty acids Omega-6 fatty acids 
Chapter 1 
12 
LCPUFA in the diet  
As noted earlier ALA, LA, EPA, DHA, and AA are (semi) essential nutrients and should 
be consumed via the diet. ALA can be found in seeds and nuts (e.g., flaxseeds, walnuts) 
and vegetable oils (e.g., canola oil, soybean oil). LA can be found in vegetable oils (e.g., 
corn, sunflower), meat and nuts and seeds. AA is found in meat and eggs. EPA and DHA 
are found mainly in fish and shellfish, supplements, human milk, and infant formulae.  
The Western diet contains n-6 fatty acids in higher concentrations than the n-3 fatty 
acids. The ratio of n-6 to n-3 fatty acid intake in Western countries is about 20-30:1 [25]. 
Similarly, in the Dutch Consumption Survey, the average consumption of LA (11-17g per 
day) is also multiple times higher than the consumption of ALA (1166 - 2069mg per day; 
see Table 1.1) [26]. Moreover, the consumption of EPA + DHA is also very low in the 
Dutch population varying from 66 to 133mg per day (see Table 1.1). This is well below the 
amount of 450mg EPA + DHA as recommended by the Dutch Health Council. Fish 
consumption, the most important source of EPA and DHA, is also very low. Of the 
children between 7 and 18 years old, 6 to 9% consumes fish twice or more per week 
(recommended amount), for adults this varies between 11 and 28% [26]. 
Foetuses are dependent on supply of DHA and other LCPUFA via the placenta. The 
amount of LCPUFA the mother consumes, influences the amount of LCPUFA which is 
available to transfer via the placenta to the foetus [27]. After birth, supply of DHA via 
breast milk or infant formulae is needed for the infant to get sufficient amounts of the fatty 
acid. The amount of DHA in breast milk is dependent on the maternal diet and ranges 
between 0.17% and 1.0% of total fatty acids in breast milk [28,29].  
The low intakes of n-3 fatty acids can possibly have health consequences, as they have 
many functions in the human body, varying from influence on vision, to regulation of 
gene-expression, to brain functioning .  
Table 1.1: Median intake of ALA, LA and EPA + DHA per day of the Dutch population, data from [26] 
 ALA (mg/day)  LA (g/day)  EPA + DHA (mg/day) 
Age Male Female Male Female Male  Female 
7-8 1237 1166 11 11 62 66 
9-13 1489 1267 13 11 65 66 
14-18 1745 1343 16 11 67 71 
19-30 1972 1390 17 11 75 76 
31-50 2069 1444 17 12 97 100 
51-69 1930 1465 15 11 131 133 
Krill oil supplementation 
For those who are not able or willing to consume fish and, consequently, do not get 
DHA/EPA via that route in their diet, supplements are available. Supplements are often 
made of fish (i.e., fish oil), but another option is krill. The form of supplementation used in 
the studies in this thesis is krill oil. 
In fish oil the fatty acids are mostly in the triglyceride form. In krill oil, approximately 
30-65% of fatty acids are in phospholipid form. Phospholipids have amphiphilic 
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properties, and thus emulsifying properties that enhance absorption [30,31]. Moreover, 
DHA and AA in the phospholipid form seem to be accreted at higher rates in the brain as 
compared to DHA and AA in triglyceride form [32].  
LCPUFA and brain functioning  
LCPUFA have many functions in the body. With regard to influencing brain functioning 
and brain health, six key mechanism of n-3 LCPUFA have been identified [24].  
(1) LCPUFA are structural components of the cell membranes in the brain. 
Especially AA and DHA are important structural components of brain cells and are 
abundant in the brain. For example, about 15% of total fatty acid composition of grey 
matter of the frontal cortex in adults is DHA, and around 10% is AA [33].  
(2) LCPUFA are needed for neurite growth. For the outgrowth of a neurite from a 
neuron, the membrane surface needs to be increased first, and this process relies on DHA 
and AA. DHA and AA are needed to promote fusion of membrane phospholipid bilayer, 
and with that, the outgrowth of the neurite. Moreover, it has been shown that DHA 
stimulates neurogenesis and increases synaptogenesis and dendritic spines [34,35].  
(3) LCPUFA influence membrane fluidity. Cell membranes are made up of a 
phospholipid layer with protein and cholesterol imbedded. The spatial arrangement of the 
membrane depends on the specific fatty acyl chains associated with the phospholipids, 
which are incorporated in the membrane. The spatial arrangement of a saturated fatty acid 
with no double bond is more compact than an unsaturated fatty acid with a double bond 
(i.e., with a curve in its tail; see Figure 1.1 and Figure 1.3). The flexibility or the fluidity of 
the membrane is influenced by the incorporation of PUFAs such as DHA. In other words, 
the more poly-unsaturated fatty acids incorporated in the cell membrane, the more fluid the 
membrane will be, and the better the movement through the lipid bilayer will be. The 
fluidity of the membrane also influences the activity of the enzymes which are bound to the 
membrane. 
 
 
Figure 1.3: Schematic overview of a cell membrane including phospholipid molecules (left). Schematic overview 
of spatial arrangement of a saturated and an unsaturated fatty acid (right) taken without adaptation from [36]). 
 
(4) LCPUFA influence neurotransmitters. The influence of DHA on membrane 
fluidity and increase in synapses also influence the functioning of proteins in the 
membrane, which in turn influence neurotransmitter functioning. Low n-3 LCPUFA levels 
lead to reduced activity of the proteins, which are needed to open the ion channels, 
allowing the signals of neurotransmitters to be transmitted. In that case, more 
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neurotransmitter is needed to depolarize the cell and transmit the signal. Thus, for effective 
neurotransmission, n-3 LCPUFA have to be present in the brain.  
(5) LCPUFA and endothelial: eicosanoids and blood brain barrier. Eicosanoids 
can be formed from polyunsaturated fatty acids. Eicosanoids are cell signalling molecules 
which are involved in many processes in the body such as inflammation, immunity, platelet 
aggregation and smooth muscle contraction. There are many eicosanoids subfamilies 
(e.g., prostaglandins, leukotrienes, resolvins) and these subfamilies include many different 
metabolites. The eicosanoids, which are formed from the n-3 LCPUFA, are prostaglandins 
and leukotrienes from the 3 and 5 series. These eicosanoids reduce blood clotting, increase 
blood flow, and have anti-inflammatory and vasodilatory effects. Moreover, DHA can also 
inhibit the production of inflammatory products. N-3 LCPUFA have also an effect on 
glucose transport to and glucose uptake by the brain; this is a very important process, as 
glucose is the main source of energy for the brain. In rats it has been shown that decreased 
DHA leads to less glucose uptake across the brain blood barrier. Lastly, LCPUFA might 
also play a role in the endothelial function in the brain, it may improve the blood flow in 
the brain, improve the brain blood barrier integrity, and decrease inflammation in the brain. 
(6) Neuronal survival. The presence of DHA in the brain protects the brain from 
neuronal loss. The exact mechanisms via which DHA exerts this protection against 
neuronal loss are not known. It has been suggested to be related to the incorporation of 
DHA in phosphatidylserine (i.e., a specific phospholipid which is part of the cell 
membrane), but it could also be related to the anti-inflammatory effects of DHA or its 
influence on neurogenesis.  
Brain development  
The development of the brain starts very early in pregnancy and does not stop for at least 
the 25 years thereafter [37]. Brain development starts early on in pregnancy with the closing 
of the neural tube, it continues throughout pregnancy, and a brain growth spurt occurs 
during the last trimester of pregnancy and the first two years postnatally. The physical size 
of the brain increases only up to about the age of seven. After that age, the weight of the 
brain does not change much anymore [38]. Even though the brain does not increase in 
weight anymore, the brain does undergo profound development up to at least the mid-
twenties. The major changes that occur during this development are the myelination of 
axons and changes in synaptic density. The areas of the brain with many myelinated axons 
are called the white matter, and areas with mainly neuronal cell bodies and synapses with 
almost no myelinated axons are called grey matter. 
The white matter mass increases continuously and linear with age throughout 
childhood, adolescence and early adulthood. The myelination occurs throughout the whole 
brain and enhances the neuronal conduction, speed, and, with that, neuronal 
communication [39]. In contrast, the grey matter mass development follows an inverted u-
shape. There is a drastic increase in the formation of synapses (i.e., synaptogenesis) during 
the postnatal period, which leads to a synaptic density much higher than the adult levels. 
After the peak of synaptic density, a process of eliminations of over-abundant and weaker 
synapses (i.e., pruning) and strengthening of habitual used synaptic connections occurs 
[38]. However, the development of grey matter (i.e., the synaptogenesis and pruning) does 
not occur simultaneously in all regions of the brain: the time course is brain region specific 
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(see Figure 1.4). The parts of the brain associated with more basic functions (i.e., primary 
motor cortex) develop earlier than the brain regions associated with the more advanced 
complex functions (i.e., the prefrontal cortex and temporal lobe) [37]. The fact that the 
brain is still in development until at least the mid-twenties and the fact that pruning is 
thought to be an experience-based and life-long process indicate that the brain 
development can most likely be influenced by environmental influences such as nutrition, 
exercise and teaching, at least up to the mid-twenties. 
 
 
Figure 1.4: Cortical grey matter development from age 5 to age 20; the darker the colour (i.e., blue or purple), the 
more developed. Taken from [37] copyright (2004) National Academy of Sciences, U.S.A.  
School performance 
School performance is the most important outcome measure of education and can be 
measured in a variety of ways. It can for example be measured as grades on specific school 
subjects (e.g., English or Dutch), an average grade over all school subjects, or scores on a 
standardized test such as a spelling, reading, or arithmetic test. School performance can be 
affected by a large number factors including, but not limited to, sex, socio economic status, 
parental educational level, attitude towards school, motivation, personality, executive 
functions, time spent on homework, teacher quality, and school resources [40–43]. 
However, lifestyle factors and especially nutrition might also influence school performance. 
It has for example been suggested that providing adequate DHA may lead to small 
improvements in multiple cognitive functions, which combined could influence school 
performance such as reading and spelling [44]. Moreover, there is a number of studies 
showing a positive association between fish consumption and school performance in 
adolescents [11,12]. There are also a few studies investigating the relationship between 
LCPUFA and spelling, reading, math, and/or grade average in children [45–49]. The results 
of these studies are mixed, with some showing no effect of supplementation [45,49], and 
others showing an effect of supplementation or an association between LCPUFA and 
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school performance [46–48]. However, all but one study did not include blood values [47]. 
Moreover, we are not aware of any studies investigating the association between prenatal 
fatty acid exposure and school performance during childhood, while a programming effect 
might be possible.  
To sum this up, there is some evidence that LCPUFA intake or concentrations 
measured in blood are associated with school performance in children and adolescents. 
However, most studies do not include blood measurement. Furthermore, there are no 
studies investigating the association between prenatal exposure to LCPUFA and later 
school performance. 
Cognition  
Cognition is a broad term that refers to mental processes involved in for example attention, 
memory, inhibition, and planning. Concurrent with the brain development, as discussed 
above, cognitive development occurs. For example, performance on tasks assessing 
inhibitory control, processing speed, working memory, and decision making continues to 
improve throughout childhood and adolescence [50–52]. During adolescence, specifically, 
the prefrontal cortex continues to develop. It can be expected that while specific regions of 
the brain develop, the cognitive functions which rely on that brain region also develop. The 
cognitive functions which rely mainly on the prefrontal cortex are the executive functions. 
Executive functions are a specific group of top-down mental processes which are 
needed to be able to concentrate and pay attention and to show adaptive goal directed 
behaviour [53]. It is mostly agreed that there are three core executive functions: (1) shifting 
between tasks or mental sets (i.e., shifting), (2) updating and monitoring of working memory 
representation (i.e., working memory), and (3) inhibition of dominant response (i.e., inhibition) 
[54]. These executive functions are used to build higher order skills such as planning, 
decision making, reasoning, and problem solving. This makes the executive functions very 
important for school performance and cognitive development [43,55]. 
Executive functions and their development are already apparent very early in 
development. For example, infants aged 7.5-9 months perform worse on the delayed 
Piaget’s A not B task than do infants aged 12 months [56]. In that task, a toy is hidden in 
one of two possible spots. After the hiding, the infant is not allowed to look for a certain 
period of time (i.e., number of seconds also called the delay period). The delay period is 
increased with each trial. After the delay period the infant is supposed to reach into the 
direction of the hidden toy. Piaget’s A not B task is one of the earliest measures of 
intentional goal-directed behaviour. Most infants of 7.5-9 months old fail when there is a 1-
5 second delay in being allowed to reach for the toy, while infants aged 12 months succeed 
even in trials with a 10 second delay.  
The executive functions have been shown to develop and improve during childhood 
and adolescence. For example, in the study of Luna and colleagues, participants were asked 
to not look at a randomly appearing stimulus, but instead to look in the opposite directions 
(i.e., a measure of inhibition). Eight year old children were able to execute this inhibition 
task, but performance increased greatly up to age 14-15 years when adult level 
performances were reached [51]. Also working memory improves during childhood and 
adolescence. Crone and colleagues showed that children aged 8-12 years performed worse 
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on a working memory task (i.e., number correct and reaction time), especially the 
manipulation task, compared to 13-17 year olds and 18-25 years olds [57]. In another study 
of Crone et al., a steep decrease in errors on a shifting task was shown when comparing 
8-10 year olds with 12-14 year olds, and a smaller decrease was shown comparing 12-14 
year olds with 16-18 year olds [58]. The higher order skills such as decision making also 
have been shown to improve during childhood and adolescence. It has, for example, been 
shown that older adolescents perform better on tests to assess the ability to make long term 
advantageous choices (i.e., ability to anticipate the future consequences of decisions), than 
children and younger adolescents [59,60].   
The possible positive influences of LCPUFA, specifically DHA and EPA, on brain 
functioning has led to a large number of observational studies and supplementation trials in 
which the relationship between LCPUFA and cognition was investigated. The majority 
focus on either pregnant women and infants, children below the age of 12, participants 
with developmental disorder such as ADHD or autism spectrum disorder, adults, or elderly 
with cognitive decline, Alzheimer’s disease, or dementia. These studies have been 
summarized in a multitude of reviews, for example [1,2,9,44,61–64]. Conclusions of these 
reviews are opaque. Some conclude that there is evidence for an effect of LCPUFA on 
cognition [1,2,44,61], others conclude that there is only proof for prenatal effects [63,64] 
on later life cognition, and others conclude that there is no effect [62].  
Adolescents, however, have received rather limited attention. There are, to our 
knowledge, only three observational studies available in adolescents in which the 
association between fish consumption (i.e., the most important dietary source op EPA and 
DHA) and school performance, cognitive performance, and vocabulary was studied 
[11-13]. Åberg and colleagues reported an association between high fish consumption at 
age 15 and better cognitive performance at age 18 [13]. Kim et al. showed that adolescents 
who regularly consumed fish had higher school performance scores compared to their 
peers who did not consume fish [12]. Lastly, de Groot et al. revealed a quadratic (i.e., 
inverted u shape) association between fish consumption (never, < 1 per week, 1-2 times 
per week, > 2 times per week) and average end term grade and vocabulary score [11].  
All in all, observational studies in adolescents point to a positive relationship between 
fish consumption and both cognitive performance and school performance. However, 
observational studies cannot prove causality, and intervention studies or long term follow 
up studies in for example a birth cohort are needed.  
Mental well-being 
In this thesis, mental well-being refers to both self-esteem and depressive feelings. 
Self-esteem is a core construct of mental health and refers to the subjective evaluation of 
ones worth as a person [65]. Depressive feelings are characterized by sadness, loss of interests 
and pleasure, feelings of guilt or low self-worth, distributed sleep and/or appetite, feelings 
of tiredness, and poor concentration [66]. Both depressive feelings and low self-esteem are 
common in adolescents and have profound and long term effects such as lower educational 
attainment and negative mental health outcomes [17,18,67,68].  
LCPUFA have attracted a lot of attention in relationship to depression, as many of the 
biological changes associated with depression (alteration in immune function, increased 
Chapter 1 
18 
levels of inflammation, blood flow abnormalities, and decreased glucose metabolism) are 
processes in which LCPUFA are involved. Thus, it seems possible that LCPUFA could 
reduce or counteract the biological chances associated with depression.  
There are many studies looking at the relationship between fish consumption and 
depression, or between LCPUFA blood values and depression. But also studies comparing 
LCPUFA blood concentration between depressed and non-depressed participants, and 
LCPUFA supplementation interventions in depressed adult individuals. These studies have 
been summarized in a vast number of reviews and meta-analyses, for example [14–16,69–
71]. All these reviews come to the conclusion that there is some proof that n-3 fatty acids 
can be effective in depression.  
Depression often has its onset during adolescence. Adolescents are therefore an 
important population to study the influence of LCPUFA on depression. There are a 
number of observational studies in which the association between intake of LCPUFA 
[72,73], or LCPUFA concentration in blood [74], or LCPUFA in adipose tissue [75,76] and 
depression in adolescents is studied. However, there are, to our knowledge, no studies in 
which the influence of LCPUFA supplementation on depressive feelings in adolescents is 
studied. Moreover, to our knowledge, there are no earlier studies investigating the influence 
of LCPUFA on self-esteem, another important aspect of mental health.  
To summarize, observational studies in adolescents do point to a positive relationship 
between LCPUFA and depression (i.e., higher n-3 LCPUFA, less depression). LCPUFA 
supplementation studies in adults also indicate a positive effect of n-3 LCPUFA on 
depression. However, as observational studies cannot indicate causality, a supplementation 
study investigating the effect of LCPUFA supplementation on depression in adolescents is 
needed.  
Aim and research questions 
The aim of this thesis is threefold. Firstly, to investigate the association between LCPUFA, 
measured during pregnancy, at birth, and at age 7, and school performance in children at 
age 7. Secondly, to investigate the influence of LCPUFA supplementation in the form of 
krill oil supplementation on cognition of developing adolescents attending general 
secondary education in the Netherlands. Thirdly, to investigate the influence of LCPUFA 
supplementation in the form of krill oil supplementation on mental well-being (i.e., 
depressive feelings and self-esteem) in typically developing adolescents attending general 
secondary education in the Netherlands.  
The hypothesis was that higher n-3 LCPUFA levels during pregnancy, at birth and at 
age 7 would be associated with higher school performance scores at age 7. Furthermore, a 
second hypothesis was that a year of krill oil supplementation would lead to improved 
cognitive scores in adolescents, which would possibly also translate to better school 
performance scores. Moreover, it was hypothesized that a year of krill oil supplementation 
would lead to lower scores with respect to depressive feelings in the same population.  
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Design  
The current thesis uses data collected in two studies: the Maastricht Essential Fatty Acids 
Birth Cohort (MEFAB) and Food2Learn.  
MEFAB cohort  
MEFAB was founded in 1989 and was set-up to investigate how fatty acid concentrations 
changed during pregnancy, how these changes related to fatty acids concentration of the 
neonate, and the association between essential fatty acid status during pregnancy and birth 
outcomes. MEFAB included multiple follow-up moments: at age 7-8 (only those born 
before 1994; MEFAB 2), age 4 (only those born 1994-1995; MEFAB 3), at age 12 
(MEFAB 4), and age 20-25 (MEFAB 5). In MEFAB, a vast array of data was collected (for 
an overview see Chapter 2).  
Food2Learn 
Food2Learn was a double-blind randomized, placebo controlled repeated measures 
intervention in adolescents (age 13-15 years) attending lower general secondary education 
in the Netherlands. Data on cognition, mental well-being, and school performance were 
collected. In Chapter 4, the study design of Food2Learn is presented in full detail.  
Outline of this thesis  
In Chapter 2 and 3 the focus is on the MEFAB cohort. In Chapter 2, an overview of the 
MEFAB cohort can be found. Furthermore, an elaboration on why the MEFAB cohort 
was set up, which data were collected at which time-point, and the main findings from 
MEFAB 1 to MEFAB 4 are summarized. In Chapter 3, the association between fatty acid 
concentrations during pregnancy, at birth, and at age 7 and school performance scores at 
age 7 is presented.  
In Chapter 4 to 8 the focus is on the study Food2Learn. In Chapter 4, the design of 
Food2learn and the rationale behind the research design is presented. In Chapter 5, the 
baseline association between DHA + EPA concentration measured in blood (i.e., the 
Omega-3 Index) and cognitive measures from the Food2Learn study is described. In 
Chapter 6, the association between LCPUFA levels in blood of the Food2Learn at 
baseline and depression and self-esteem are reported. In Chapter 7 and 8, the focus is on 
the results of one year of krill oil supplementation. In Chapter 7, the influence of one year 
of krill oil supplementation on cognitive achievements are shown. In Chapter 8, the effect 
of one year of krill oil supplementation on both self-esteem and depression is reported. 
Chapter 9 is a review study in which the recruitment, adherence and drop-out rates in 
omega-3 polyunsaturated fatty acid supplementation trials in children and adolescents was 
investigated.  
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Finally, in Chapter 10, an overview of the results reported in Chapter 2 to 9 is given. 
The results are put in perspective of other studies, the limitations of the studies mentioned 
in this thesis are given as well as directions for future research.  
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Abstract  
The Maastricht Essential Fatty Acid Birth cohort (MEFAB) was established in 1989 to 
study the changes in fatty acid concentration during pregnancy and how this related to the 
fatty acid concentrations of the neonate. The original sample contains data of 1203 
subjects. Some participants whom participated in the original MEFAB study also 
participated in follow-up studies at age 4, 7 or 12; 41%, 52% and 35% of eligible 
participants, respectively. Collected data include maternal fatty acid concentrations at 
multiple points during pregnancy and at birth and at age 7 for the child, but also 
anthropometric measurements during development, assessments of cognitive development, 
asthma, atopy and cardiovascular risk factors. Data of MEFAB have been used in 37 
articles in peer-reviewed journals and 4 doctoral theses have been completed. Data of 
MEFAB is upon request available for new research questions 
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Why was the cohort set up? 
From the 1970s onwards essential fatty acids (EFA) and especially their longer-chain, more 
unsaturated derivatives, the long-chain polyunsaturated fatty acids (LCPUFA) have been a 
topic of research and discussion because of their potential beneficial effects on numerous 
health conditions. In the past decades beneficial associations have been found with for 
example heart disease, metabolic syndrome, cognitive decline, asthma, immune support, 
visual development and depression (for a review see for example [1]). In the late 1980’s it 
was serendipitously found that the walls of umbilical arteries and the veins demonstrate 
biochemical signs of EFA deficiency [2]. This led to the question whether the suboptimal 
supply of EFA during foetal life would exert an influence on development. Moreover, it 
was not known how maternal availability of LCPUFA during pregnancy related to the 
concentrations of the infants and whether a particular period in pregnancy or a specific 
fatty acid had a distinct importance. It was hypothesized that the maternal EFA and 
LCPUFA status was inadequate to support optimal tissue concentrations in the developing 
foetus. Because of the important biological activities of these fatty acids and the inability of 
the foetus to produce the n-3 LCPUFA in sufficient amount itself, this insufficient supply 
could have important implications for later health and functioning. 
The Maastricht Essential Fatty Acid Birth cohort (MEFAB) was established in 1989 to 
study the changes in fatty acid concentration during pregnancy and how this related to the 
fatty acid concentrations of the neonate. Furthermore the association between LCPUFA 
status of mothers during pregnancy and of their infants at birth in relation to various birth 
outcomes (weight, length and head circumference) was studied. For this purpose 42 
different fatty acids were determined in maternal plasma in early, middle and late 
pregnancy. Furthermore, these fatty acids were determined in the blood vessels of the 
umbilical cord and plasma of the child. Thus the association between the status of mother 
and the status of the child could be determined. Later three follow-up studies were added 
at age 4, 7 and 12 where further assessments of cognitive development, asthma/atopy, 
growth and cardiovascular disease risks were performed. MEFAB was originally founded 
by Professor Gerard Hornstra at the department of Human Biology, Maastricht University. 
After his retirement in 2003, the NUTRIM School for Nutrition, Toxicology and 
Metabolism at Maastricht University took over the MEFAB cohort. A multidisciplinary 
steering committee continues the follow-up of this cohort for its 25th year now. 
Who is in the cohort? 
Pregnant women attending one of 3 antenatal clinics in the South of Limburg (a province 
located in the South of the Netherlands) at the time of their first antenatal visit between 
1989 and 1995 were asked to participate in the study. Women were eligible to participate if 
they were less than 16 weeks pregnant and did not suffer from any cardiovascular, 
neurological, renal or metabolic condition. A total of 1334 pregnant women were screened 
for this study. 131 women were either excluded or dropped out before partus, leaving 1203 
subjects available for analyses (90%). 
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How often have they been followed-up 
For the flow diagram see Figure 2.1. The pregnant women were followed during pregnancy 
and after pregnancy and their neonates were studied at birth (MEFAB 1). Between 1997 
and 2000, when the children were approximately 7 years old a follow-up study was 
executed to investigate the longer term associations between their prenatal and perinatal 
exposure to EFA and LCPUFA and selected aspects of their mental and physical 
development (MEFAB 2). For this follow-up singletons born before 1994 of whom an 
umbilical blood sample was available, were eligible for participation. Parents of children 
born between January 1994 and September 1995 were asked to let their children participate 
in a follow-up when they were approximately 4 years old (MEFAB 3). The main focus of 
MEFAB 3 was cognitive development. Parents of children born between 1990 and 1993 
who participated in both MEFAB 1 and MEFAB 2 were asked to let their child participate 
in MEFAB 4 between 2002 and 2005. The focus of MEFAB 4 was body composition and 
obesity. Exclusion criteria for MEFAB 4 were any chronic illnesses or depression in the 
child. Currently a 25-year follow-up is in preparation, which will focus on cardio metabolic 
risk factors and brain functioning. 
Ethics 
Pregnant woman who entered the study gave written consent for their participation and for 
the use of the plasma, red blood cells and/or umbilical cord of their neonate (MEFAB 1). 
For both MEFAB 2 and MEFAB 3 both parents (if possible) gave written consent for their 
own participation and for that of their child in the study. For MEFAB 2 consent was 
obtained for questionnaires, blood sampling, and for the execution of cognitive function 
tests, motor function tests, physical fitness tests and peak flow measurements. Some 
parents only gave consent for either the tests or the questionnaires. For MEFAB 3 parents 
gave their informed consent for both the questionnaires and the cognitive development 
test or for the questionnaires only. For MEFAB 4 both parents and children gave their 
informed consent for participation in the study and for the use of the questionnaires, blood 
sampling and body composition measurements. The initial study and all follow-up studies 
were approved by the Ethics committee of the University hospital Maastricht/Maastricht 
University. 
Attendance 
The number of available maternal blood samples during pregnancy and immediately after 
delivery differed per time point and varied between 1057 (79%) and 1123 (84%). 
For MEFAB 2 750 children were eligible to participate. Of these 728 (97%) were traced 
and 691 (92%) could be invited. A total of 364 parents did not reply or did not consent, 21 
children dropped out during the study. The final study population eventually consisted of 
306 children (41%), with blood samples of 265 children (39%). For MEFAB 3 246 children 
were eligible. Of these children, 1 had passed away, 38 could not be localized, 36 parents 
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only consented to the questionnaires, 39 parents did not consent at all and 4 children 
dropped out, leaving 128 (52%) children in the study population. For MEFAB 4 305 
children were eligible (participated both in MEFAB 1 and 2), 105 (35%) of these children 
participated (See Figure 2.1). 
 
 
Figure 2.1: Flow-chart of MEFAB  
MEFAB 3 (1998-1999)
Age 4
Children born 1994-1995
Participated n = 128
MEFAB 2 (1997-2000)
Age 7-8
Children born before 1994
Traced n=728
Participated n=306 
Blood sample n = 264 
Questionnaire n=299-306
Tests n= 256-298
MEFAB 1 (1989-1995)
1334 screened
131 excluded
Clinical data partus n=1203
Maternal blood sample n =1056-1123
Maternal RBC fatty acid n = 277-313
Infant RBC n= 252
Infant plasma n= 1019
Umbilical cord n =540
MEFAB 4 (2002-2005)
Age 12
Children born 1990-1993
Questionnaire n=105
Tests n= 105
Blood sample n= 102
MEFAB 5 
Age 20-25
In preparation
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What has been measured? 
In Table 2.1 all measurements from MEFAB 1 to MEFAB 4 are listed. Fatty acid 
composition of maternal plasma phospholipids was assessed in blood collected at study entry 
(approximately 14 weeks of pregnancy), 22 and 32 weeks of pregnancy and immediately after 
delivery. Additionally, fatty acid measurements were performed in umbilical cord plasma 
phospholipids of their neonates and in phospholipids isolated from the walls of umbilical 
arteries and veins. The standardized methods used to measure plasma fatty acid 
concentrations and the other study parameters at baseline and during follow-ups have been 
described in detail by Al et al. [3]. During the follow-up of the children, anthropometric 
parameters (height, weight, skin fold thickness measurements, and waist circumference) were 
collected at age 0.5, 1, 2, 3, 4 (data received from local health services) and at age 7.  
Children who participated in MEFAB 2 donated blood for the determination of the 
plasma lipoprotein profile, haematology profile, clotting profile, apolipoprotein E (ApoE) 
and cholesteryl ester transfer protein (CETP) and polymorphisms and plasma leptin, C 
reactive protein, glucose, insulin and proinsulin concentrations. Children who participated 
in MEFAB 2 also underwent a Bruce treadmill test to measure physical fitness. They also 
performed extensive peak flow measurements. For children who participated in MEFAB 3 
information on children’s neurodevelopment was collected at age 4 (Groningen 
Developmental Scale, motor scale of the McCarthy Scales of Children’s Mental Abilities) 
for those who participated in MEFAB 2 this information was collected at age 7 (Kaufman 
Assessment Battery for Children, Maastricht Motor Test, Revised Amsterdam Child 
Intelligence Test, Child Behavior Checklist). 
Mothers of the children who underwent the neurodevelopment test completed the 
RAVEN test to measure intelligence. Participants in MEFAB 4 again donated blood in 
which serum leptin concentration, polymorphism of obesity related genes coding for 
PPARγ2, glucocorticoid receptor and ciliary neurotrophic factor were determined. 
Furthermore they filled out a questionnaire about attitude towards eating and a 
questionnaire about their physical activity.  
What has been found? Key findings and publications 
At this moment 37 articles using MEFAB data have been published in peer reviewed journals 
and 4 doctoral theses have been completed (for all articles see Supporting Table 2.1). 
MEFAB 1 
Results concerning MEFAB 1 have been summarized by Al and Hornstra [4–6]. In this 
paper we will focus on the findings of the follow-up studies; however all articles can be 
found in Supporting Table 2.1. In the current paper we will shortly summarize the most 
important findings from MEFAB 1, for more in depth information the reviews can be 
consulted. The maternal plasma concentration of phospholipid-associated essential PUFA 
increased during pregnancy by on average 40%, however the non-essential fatty acids 
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increased more than 65%. Furthermore, it was shown that absolute and relative amount of 
docosahexaenoic acid (DHA) in the maternal plasma phospholipids were significantly 
lower in multigravidae compared to primigravidae. Strong correlations between maternal 
and foetal EFA and LCPUFA were observed. Presence of trans fatty acids in the cord 
tissue was associated with proportional lower amount of essential PUFA. Preterm infants 
had a significantly lower LCPUFA status compared to term neonates, but this appeared a 
physiological phenomenon. Significant positive associations were found between the 
maternal intake of n-3 fatty acids plus arachidonic acid (AA) and birth length (BL), whereas 
the intake of linoleic acid (LA) was negatively related to head circumference (HC) [7]. In 
addition, a positive association was observed between maternal DHA concentrations early 
in pregnancy and birth weight (BW) and HC [8]. 
Table 2.1: Data available at the different parts of the MEFAB cohort. 
MEFAB 1  
1989-1995 
Maternal 
 
 
 
Neonatal 
Social economic status (based on postal code).  
Clinical data during pregnancy and delivery from hospital records.  
Fatty acid profile of phospholipids (PL) during pregnancy (< 16, 22, 32 weeks) and 
at delivery or maternal fatty acid composition of erythrocyte PL at same time points. 
Birth outcome (weight, length and head circumference) and conditions at birth 
(Apgar score, and pH and pCO2 of cord blood).  
Fatty acid profile of cord plasma PL, umbilical artery wall PL, umbilical vein wall PL 
or cord blood erythrocyte PL (multiple possible).  
MEFAB 2  
1997-2000 
Maternal 
 
 
Children  
Medical questionnaire related to pregnancy and birth and family anamnesis.  
Intelligence (RAVEN),  
Fatty acid profile of maternal plasma PL at follow up.  
Growth (weight and height) during early childhood.  
Body composition based on skin folds (body fat, fat mass, fat free mass).  
Early development, medical history and medical examination of children at age 7. 
Atopy questionnaire.  
Mental processing (Kaufman ABC).  
School results (spelling, reading, arithmetic and vocabulary).  
Motor functions (Kaufman motor ABC and Maastricht motor test).  
Child Behaviour Checklist.  
Neurological examination.  
Physical fitness at age 7 (blood pressure heart rate, exercise test).  
Peak flow measurement at rest and at physical exhaustion. 
Blood sample: Haematology profile. Clotting profile. Plasma lipoprotein profile, ApoE, 
CETP polymorphisms. Leptin and C reactive protein in plasma. Fatty acid 
composition of children’s plasma PL. Fasting plasma glucose, insulin and proinsulin 
concentrations. 
Subsample: Language (Revision Amsterdam child intelligence test) and mental fatigue 
score.  
MEFAB 3 
1998-1999 
Parental 
 
Children 
Maternal intelligence measured with Progressive Matrices test of Raven. 
Maternal and paternal education (8 point scale).  
Kaufman Assessment Battery for Children 
Groningen Developmental Scale 
McCarthy Scales of Children’s Mental Ability (motor scale only).  
MEFAB 4 
2002-2005 
Parental 
 
Children 
Weight and height 
Attitude towards eating ( Three factor eating Questionnaire). 
Weight, height and BMI at age 1, 7, 12.  
Body composition (body fat, fat mass and fat free mass).  
Attitude towards eating ( Three factor eating Questionnaire).  
Physical activity (Baecke questionnaire).  
Blood sample: Serum leptin concentration, polymorphism of obesity 
related genes coding for PPARγ2, glucocorticoid receptor and ciliary 
neurotrophic factor.  
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In contrast, maternal concentrations in late pregnancy and/or at delivery of AA and 
dihomo γ-linolenic acid (DGLA, the direct precursor of AA) were negatively related to BW 
and BL. This suggests that maternal DHA content may program foetal growth in a positive 
way and that the maternal AA may be involved in foetal growth limitation. Interestingly, 
significant negative associations were observed between BW and umbilical plasma this is 
caused by a limited DHA transfer from mother to foetus, resulting in lower DHA 
concentrations in larger foetuses [9]. This would imply that relationships with function 
variables are less convincing for neonatal than for maternal fatty acid concentrations. 
Metabolic syndrome 
In MEFAB 2 the association between early life time exposure to LCPUFA and markers of 
the metabolic syndrome (e.g., obesity and insulin resistance) was studied. Rump et al. 
showed that umbilical cord plasma phospholipid concentrations of γ-linolenic acid and 
DGLA were negatively related to plasma insulin concentrations and the calculated insulin 
resistance at age 7 [10]. Gamma-linoleic acid was also negatively related to body fatness, 
pro-insulin levels and leptin concentrations at age 7. Interestingly, in the study of De Vries 
et al. it was shown that maternal DGLA concentrations throughout pregnancy were 
positively associated with an increased BMI at age 7 [11]. 
Neural development 
Another focus of MEFAB 2 (and MEFAB 3) was the association between early LCPUFA 
exposure (as reflected by umbilical plasma and red cell AA and DHA concentrations) and 
later brain function, cognition and behaviour. Neither at age 4 [12] nor at age 7 [13] were 
significant associations found between LCPUFA exposure during pregnancy and cognition. 
Bakker et al. did observe that movement quality (a measure of brain-muscle interaction and 
a low score of which may predict ADHD and later learning problems) at age 7 was 
positively associated with plasma phospholipid DHA levels measured at birth, but were 
unrelated to DHA concentrations at follow-up [14]. This suggests that prenatal LCPUFA 
availability may be more important for later motor function than childhood dietary 
LCPUFA intake. In contrast, associations with early AA levels tended to be negative, but 
were not significant. When looking at behaviour, research has found that higher levels of 
DHA at birth are associated with lower levels of internalizing behaviour at age 7 [15]. 
Relationships with DHA status at follow-up were, again, not significant. This could imply 
that the perinatal exposure to higher DHA levels may reduce the risk for depression in 
adult life. 
Other measurements 
No clear and consistent associations were found between prenatal AA status and lung 
function or plasma inflammation markers at age 7 [16]. 
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What are the main strengths and weaknesses? 
One of the main strengths of the MEFAB study and database, is that it is, as far as we 
know, world-wide the only prospective mother-child cohort containing extensive data on 
maternal plasma fatty acid composition at various time points during pregnancy and at 
delivery. In addition, fatty acid data are available from umbilical plasma as well as from the 
walls of umbilical veins and arteries. This enables the assessment of perinatal (umbilical 
plasma) and earlier (umbilical vessel walls) fatty acid exposure of the developing foetus. 
MEFAB is one of the few fatty acid related cohorts that is being followed up for a long 
period of time and has presently the potential to contact participants 25 years after birth. 
Another strength of the cohort is the fact that all common essential and nonessential fatty 
acids have been measured, including the non-essential longer-chain, more unsaturated 
derivatives. Since some of these latter fatty acids (20:3n-9 and 22:3n-9) are essential fatty 
acid status markers, MEFAB data can be used to relate later functions to pre and perinatal 
EFA and LCPUFAs statuses. Furthermore, fatty acid data are available from different time 
points during pregnancy; consequently, later functional conditions can be related to fatty 
acid exposures during early or later fetal development. Alongside the measurements of fatty 
acids, a vast array of other measurements were taken at different follow-ups which are now 
available to study the influence of pre- and perinatal LCPUFA exposure to a large number 
of health outcomes. Data collection in the MEFAB cohort started around 25 years ago, 
follow-ups provide cost-effective opportunities to examine the long-term impact of 
maternal LCPUFA status in early, mid- and late pregnancy on future offspring health and 
function. Such data may assist in determining critical development periods during which 
dietary fat modulation has the potential to influence later function and health. Weaknesses 
include the loss to follow-up over time. However, this issue affects many observational 
studies and clinical trials with a long follow-up, especially those covering such an extended 
time period as MEFAB. This leads to a relative small cohort, findings should thus be 
interpreted with caution. Another weakness is the lack of data on other dietary factors, 
which might exert a confounding role in the association of prenatal LPUFA status with 
later health. Lastly, the study was executed in the South of Limburg, a province of the 
Netherlands, which has a predominantly Caucasian population. Therefore results are not 
generalizable to more multicultural populations. But the homogeneity of the study 
population does add to the validity of the studies. 
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Supporting Table 2.1: Overview of all articles published on the MEFAB cohort. 
Main author(s) MEFAB Research question and main finding 
Houwelingen & 
Hornstra [17] 
1 How does the maternal status of trans fatty acid change over pregnancy and how 
does this relate to the foetal status of trans fatty acid and essential fatty acids? How 
do birth outcome relate to the trans fatty acids exposure? 
The degree of intrauterine trans fatty acid exposure is related to maternal values of 
trans fatty acids. The amount of C18:1 trans isomer did not increase during 
pregnancy. Birth weight (BW) and head circumference (HC) are significantly 
correlated with C18:1 trans fatty acid. 
Al  
[3] 
1 What is the relationship between EFA status of mothers and their new-borns and 
pregnancy-induces hypertension (PIH)?  
Altered EFA status was observed late in the pregnancy in PIH, indicating that EFA 
is unlikely to contribute to the pathogenesis of PIH. 
Al 
[18] 
1 What is the course of maternal EFA status during an uncomplicated pregnancy? 
How do the maternal and foetal EFA status relate? 
Total amount of fatty acids, individual fatty acids and fatty acid families increased 
significantly. The relative amount of LA did not change, while the relative amounts 
of AA decreased. Overall maternal EFA status steadily declined during pregnancy. 
Correlation between maternal and umbilical relative amounts for LA, AA and 
DHA were high. 
Al  
[19] 
1 How are the EFA composition of the maternal diet, maternal EFA status and EFA 
status of healthy infants related? 
Maternal dietary fat consumption was consistent during pregnancy. A high 
maternal LA intake had a lowering effect on maternal and neonatal n-3 fatty acid 
status. Neonatal EFA status was strongly related to maternal EFA status. 
Houwelingen  
[20] 
1 What is the EFA status of foetus during intrauterine development? 
The relative amount of LA slightly increased during development, the same was 
true for both relative and absolute amounts of DHA. AA decreased both absolute 
and relative. EFA profile of foetal samples were equal with postnatal results of 
infants with the same gestational age. 
Foreman-van 
Drongelen  
[21] 
1 Does multiple pregnancy lead to lower EFA status of the infants born? 
Levels of n-3 and n-6 were lower, while EFA deficiency indicating n-9 PUFA were 
significantly higher in infants born after multiple pregnancy compared to first born 
infants. 
Al  
[22] 
1 Do succeeding pregnancies affect maternal and neonatal DHA status? 
The maternal DHA status was significantly lower in multigravidae (MG) compared 
to primigravidae (PG). The relative amount of DHA in umbilical artery and vein 
vessel walls was significantly lower in MG- than in PG-neonates. 
Badart-Smook  
[7] 
1 Are dietary factors in pregnancy related to foetal growth? 
Maternal intake of n-3 fatty acids plus AA and of riboflavin was positively 
associated with foetal growth. Linoleic acid intake was negatively associated with 
foetal growth. 
Zeijdner  
[23] 
1 Is maternal EFA supply the limiting factor to the neonatal EFA status?  
A slightly lower EFA status was found in maternal and umbilical plasma for 
multiplets compared to singletons. Correlation between maternal and umbilical 
plasma EFA levels were comparable for multiple and singleton pregnancies. 
Otto  
[24] 
1 To study EFA status in plasma and erythrocyte phospholipids in woman before 
conception and during the first 10 weeks of pregnancy and to assess diet during 
that period. 
Maternal plasma and erythrocyte phospholipid DHA levels started to increase very 
early in pregnancy, which could not be explained by diet alone. 
Otto  
[25] 
1 How does maternal plasma and erythrocyte LCPUFA and especially DHA develop 
post-partum in relation to lactation and dietary LCPUFA intake.  
After delivery LA, AA, EPA and docosapentaenoic acid% increased over time, the 
pattern of change did not differ significantly between lactating and non-lactating. 
The DHA level declined significantly in both lactating and non-lactating women, 
but more in lactating women. 
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Main author(s) MEFAB Research question and main finding 
Rump  
[9] 
1 Are there relationships between EFA composition of cord and maternal plasma 
phospholipids and birth weight in term neonates? 
Lower EFA status in umbilical cord plasma and a larger decrease in maternal 
plasma LCPUFA’s was associated with higher weight-for-gestational age at birth. 
AA and DHA were both negatively related to weight SD scores.  
Rump  
[26] 
1 Is there a relationship between plasma leptin concentration and the DHA content 
of plasma phospholipids during early pregnancy and post-partum? 
Total amounts of phospholipids associated fatty acids was related to plasma leptin 
concentration before and during early pregnancy but not in late pregnancy and 
post-partum. 
Ghys  
[12] 
3 What is the relationship between LCPUFA status at birth and cognitive 
development at 4 years of age. No significant association was found between DHA 
or AA status at birth and cognitive development at age 4. 
Rump & Hornstra 
[27] 
1 Overview of the distribution of n-3 and n-6 PUFA in the plasma phospholipid 
fraction of pregnant women on a Western diet and their neonates. Distribution is 
reported for first, second and third trimester of pregnancy, at delivery and from 
umbilical vein at birth. 
Rump  
[10] 
2 Does fatty acid composition of cord blood relate to childhood body composition 
and glycaemic control? 
Cord plasma phospholipid γ-linolenic acid and DGLA concentrations were 
negatively related to insulin concentrations and insulin resistance (calculated) at age 
7. This association remained significant after adjustment for birth weight. γ-
linolenic acid concentration was negatively related to body fatness and proinsulin 
and leptin concentrations at several ages. 
Rump  
[28] 
2 Do the gene variations in ApoE and CETP interact with regard to their influence 
on lipoprotein levels? 
Children with ApoE E2E3 had lower concentration LDL cholesterol and ApoB 
than those with Apo E4E3 or Apo E3E3. The associations were only significant in 
children who were homozygous or heterozygous for the absence of the Taq-IB 
polymorphism at the CETP gene locus. The difference in HDL level between the 
CETP genotype groups was only significant in E2E3 carriers. 
Rump 
[29] 
2 What is the relation between frequently used indicators of cardiorespiratory fitness, 
sex, and body composition in young prepubescent children? 
Result showed that when oxygen uptake measurement is not possible, calculated 
total work or maximal power output (expressed per kilogram fat free mass) seem 
to provide better indicators of aerobic power than endurance time. 
Bakker  
[13] 
2 What is the relationship between LCPUFA status at birth and at 7 years of age and 
cognitive performance at 7 years of age. 
No significant associations were found between DHA and AA status at birth and 
cognitive performance at 7 years of age. The LCPUFA levels at 7 years of age were 
also not associated with cognitive outcomes. 
Otto  
[30] 
1 What is the relationship between postpartum depression and the change in DHA 
concentrations in maternal plasma phospholipids after delivery and during 
lactation? 
Slower postpartum normalization of functional DHA status (22:6n-3/22:5n-6 
ratio) is related to higher occurrence of depressive symptoms. 
Vlaardingerbroek 
& Hornstra  
[31] 
1 Are erythrocyte phospholipids as reliable as plasma phospholipids to reflect the 
EFA status of an individual? 
The relative concentrations of erythrocytes and plasma phospholipids fatty acids 
were strongly correlated, but not in early pregnancy. The changes in fatty acid 
concentrations and absolute amounts during pregnancy were comparable between 
plasma and erythrocytes, although this decreased at the end of the pregnancy. 
Neonatal erythrocyte values also correlated strongly with maternal values early in 
the pregnancy. 
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Main author(s) MEFAB Research question and main finding 
Hornstra  
[32] 
1 What is the influence of trans fatty acids on foetal development? 
BL and HC were significantly and negatively associated with C18:1 trans 
concentration in umbilical plasma (HC), umbilical arterial walls (BL and HC) or 
umbilical venous walls (BL). 
Vogels 
[33] 
4 What is the effect of early development, parental and genetic variables, and 
behavioural determinants on overweight at age 12? 
Rapid increase in weight during first year, BMI of the father and high dietary 
restraint score of the mother was significantly associated with overweight at age 12. 
No genetic relations were observed. Overweight was positively associated with 
dietary restraint of the child, body fat percentage was negatively correlated with 
child’s activity score. 
Krabbendam  
[15] 
2 Is there a relationship between LCPUFA status at birth and later development of 
problem behaviour at age 7? 
Association between LCPUFA status at birth and later development of problem 
behaviour was studied. Higher levels of DHA at birth were associated with lower 
levels of internalising problem behaviour at age 7, this association was only present 
in infants fed infant formula. 
Rutters  
[34] 
4 Are genetic, behavioural, parental and psychological factors involved and to what 
extend in the development of body weight at age 12-13? 
Genetic distribution was not different between lean and overweight children. 
Overweight children and the parents of overweight children showed higher dietary 
restraint and disinhibition scores. Leptin appeared to play a role in the 
development of body weight during puberty. 
Slinger  
[35] 
2 What is the association between insulin resistance and physical fitness, leptin 
concentration, body composition and family history of diabetes in young children? 
Plasma leptin concentration was independently associated with the development of 
insulin resistance. There was an association between physical fitness and insulin 
resistance which was mediated by the sum of the skin folds..  
Dirix 
[8] 
1 Are there associations between BW, BL or HC and the relative content of DHA, 
AA, DGLA and 18:1 trans in maternal plasma phospholipids during early, middle 
and late pregnancy and at delivery? 
Maternal DHA (especially in early pregnancy) was positively associated with BW 
and HC. AA status in late pregnancy and at delivery was negatively associated with 
BW and BL. Maternal DGLA contents at delivery was negatively associated with 
BW and BL. 
Dirix 
[16] 
2 Is prenatal AA associated with immune-related clinical conditions and plasma 
markers at age 7?  
After correction for covariates no significant associations between AA and atopy, 
lung function and plasma inflammation markers were found. 
Dirix 
[36] 
1 Are there associations between term birth dimensions and prenatal exposure to 
some of the LCPUFA reflected by neonatal status at birth. 
A negative association between BW and umbilical plasma DHA was shown. AA 
concentration in umbilical plasma and arterial and venous vessel walls was also 
negatively associated with BW and BL. BL was negatively associated with arterial 
vessel wall AA concentration only. C18:1 trans in cord erythrocytes was negatively 
associated with BW. 
Dirix 
[37] 
1 Is there an association between foetal brain functioning and the early essential poly 
unsaturated fatty acid status? 
Positive trends were observed between short term memory measures before 38 
weeks of pregnancy and mead acid and Mead acid + dihomo Mead acid, and 
between long term memory and levels of Osbond acid. 
Bakker  
[14] 
2 What is the relationship between motor function at age 7 and AA and DHA levels 
in umbilical venous plasma phospholipids and in plasma phospholipids at age 7? 
Umbilical plasma DHA concentrations were significantly and positively related 
with Maastricht Motor Test both total and quality score. DHA and AA were not 
significant related to quantitative movement scores. 
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Main author(s) MEFAB Research question and main finding 
Rutters  
[38] 
4 What is the relationship between sleep duration and BMI from Tanner stages 1 to 
5 (stages of puberty)? 
Changes in BMI during puberty were inversely related to changes in sleep duration, 
independent of confounders. 
Veldwijk  
[39] 
2 Is there an association between BMI and cognitive ability in young children in 
primary school? 
Study did not find any associations between BMI and cognitive ability in school 
aged children. 
De Vries  
[11] 
2 What is the association between maternal PUFA status during pregnancy and 
offspring adiposity at age 7? 
Maternal DGLA throughout gestation was associated with increased BMI and 
some other measures of adiposity at age 7. 
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Chapter 3 
Association between prenatal and current 
exposure to selected LCPUFAs and school 
performance at age 7 
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Association between prenatal and current exposure to selected LCPUFAs and school 
performance at age 7. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 
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Abstract  
Introduction: Long-chain polyunsaturated fatty acids (LCPUFAs) are important for brain 
functioning and might, thus, influence cognition and school performance. However, 
research investigating LCPUFAs relationships with school performance is limited. The 
objective of this study was to determine the association between levels of the LCPUFAs 
docosahexaenoic acid (DHA), arachidonic acid (AA), eicosapentaenoic acid (EPA) and n-6 
docosapentaenoic acid (Osbond acid, ObA) at study entry, 22 weeks of pregnancy, 32 
weeks of pregnancy, at partus, in umbilical cord plasma and child's plasma at age 7 and 
school performance scores at age 7. 
Methods: Data from the Maastricht Essential Fatty Acid Birth cohort (MEFAB) were 
used for this study. Fatty acid levels of plasma phospholipids were measured in maternal 
blood plasma at study entry, 22 weeks of pregnancy, 32 weeks of pregnancy and partus. 
Childs fatty acid levels of plasma phospholipids were measured a in umbilical cord blood 
plasma, and in blood plasma of the child at age 7. Scores on national standardised tests for 
spelling, reading and arithmetic at age 7 were obtained via the school (scores were available 
for 149, 159 and 155 children, respectively). Associations between LCPUFA levels and 
school performance scores were analysed with categorical regression analyses with 
correction for covariates (smoking, maternal education, sex, breastfeeding, maternal 
intelligence, birth weight and BMI at age 7). 
Results: Significant (p < .001) associations between DHA level at age 7 and both reading 
(β = 0.158) and spelling (β = 0.146) were found. Consistent significant negative 
associations were observed between all maternal DHA plasma levels and arithmetic scores 
at age 7 (all p < .001, all β < −0.019). Additional significant negative associations were 
observed between maternal LCPUFA plasma levels at study entry and both reading and 
spelling scores at age 7; these associations were less consistent. 
Conclusion: Plasma DHA levels at age 7 were positively associated with reading and 
spelling scores at age 7. Consistent significant negative associations between maternal 
plasma DHA levels and arithmetic scores of the child at age 7 were found. Although this is 
an observational study, which cannot proof causality, the consistent negative associations 
observed between maternal plasma DHA levels and the arithmetic scores of the children at 
age 7 calls upon prudence when considering DHA supplementation during pregnancy. 
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Introduction 
Long-chain polyunsaturated fatty acids (LCPUFAs) are important constituents of all cell 
membranes. In this way they are involved in, among others, neuronal membrane fluidity, 
neurotransmission, signal transduction, brain blood flow and blood-brain barrier integrity 
[1,2]. With respect to brain functioning, four LCPUFAs are of major importance: 
docosahexaneoic acid (DHA) and arachidonic acid (AA) are important components of the 
neuronal membrane [3] , eicosapentaenoic acid (EPA) influences a large number of brain 
processes [4], and n-6 docosapentaenoic acid (Osbond acid, ObA) is a deficiency marker of 
DHA [5] . Because these LCPUFAs seem to be essential for brain functioning they might 
in turn affect school performance. Therefore, the associations between LCPUFA levels in 
maternal plasma at study entry (< 16 weeks of pregnancy), 22 weeks of pregnancy, 32 
weeks of pregnancy and at partus, in umbilical cord blood plasma, and in blood plasma of 
the child at age 7 and school performance at age 7 were investigated in this study. The 
maternal plasma levels were used as a proxy for the foetal exposure, as a number of studies 
have shown that maternal LCPUFA plasma levels correlate highly with the LCPUFA levels 
of foetuses [6–8]. 
In earlier studies the association between fish intake (primary source of DHA and 
EPA) [9–15], LCPUFAs intake calculated based on answers to questions regarding fish 
consumption [10,12,15] and/or LCPUFA concentrations in blood [12,14–19] and 
cognition has been studied, but the results of these studies do not show consistent patterns. 
Similarly, results from randomized controlled trials are mixed. Some supplementation trials 
studying the influence of maternal n-3 LCPUFA supplementation during pregnancy and/or 
lactation and/or n-3 supplementation to infants after birth on cognition of the child have 
shown positive results [20–29], others have found null results [16,23,30] and some found 
negative results [31–35].  
To the best of our knowledge, the association between LCPUFA intake or levels during 
early life and school performance at age 7 has not yet been addressed. This is unfortunate 
since children are not judged on their cognition but, rather, on their school performance. 
Although no studies are available about this association in children, some studies in 
adolescents have been executed. De Groot et al. showed an inverted u-shaped association 
in 700 adolescents (age 12–18) between reported fish intake and vocabulary. Thus higher 
fish consumption was associated with a higher vocabulary score, however fish intake higher 
than twice a week was associated with a lower vocabulary score. A similar trend (non-
significant) trend, was found for the average school grades of Dutch, English and 
mathematics [36]. Likewise, Kim et al. found a strong positive association between the 
number of meals containing fish per week and average end-term grade across 16 school 
subjects in adolescents age 15 years [37]. These studies suggest a possible relation between 
school performance and LCPUFA intake during adolescence, a period of life which is 
characterised by development of the prefrontal cortex [38,39] . 
Brain development is also prominent during pregnancy and childhood. Considering the 
observed positive association between fish consumption and school grades in adolescents, 
one could infer that a relationship between LCPUFA levels during pregnancy and 
childhood and school performance is also possible. Brain development starts very early in 
pregnancy with neural tube formation and continues throughout pregnancy with in the last 
trimester and the first 2 years of postnatal life a brain growth spurt. In this growth-spurt 
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DHA rapidly accumulates in the brain [40,41]. DHA availability is in this period therefore 
very important, as the foetus is largely dependent on supply of DHA and other LCPUFAs 
via the placenta [42–44]. After birth supply of DHA via breast milk or infant formula is 
needed to provide sufficient amounts [45]. Lastly, during childhood, DHA might also play 
a role in brain development and maturation since brain development continues until late 
adolescence [38]. 
Overall, the exact influence of LCPUFA exposure during development on school 
performance remains unclear. Therefore, the objective of the current study is to investigate 
the associations between pre-, peri-, and postnatal exposures to DHA, EPA, AA and ObA 
and school performance at age 7. Exposure data were inferred from LCPUFA 
concentrations in phospholipids from maternal plasma collected at study entry, 22 weeks of 
pregnancy, 32 weeks of pregnancy, at partus, in umbilical cord plasma, and in plasma 
phospholipids of the children at age 7. It is hypothesised that higher LCPUFA exposure 
during pregnancy, in umbilical cord plasma and child's plasma at age 7 are associated with 
higher school performance scores in children aged 7. 
Participants and methods 
Design 
Data from the Maastricht Essential Fatty Acid Birth (MEFAB) cohort were used for this 
study. Founded in 1989, MEFAB was originally set-up to investigate the association 
between essential fatty acid status during pregnancy and birth outcomes (MEFAB 1, for an 
overview see [46,47]). Later, the children and their parents were asked to participate in 
various follow-up studies (MEFAB 2, 3 and 4, for an overview see [48]). 
For the current study data from MEFAB 1 and 2 were used to study the association 
between selected LCPUFA levels (DHA, AA, EPA an ObA) in maternal non-fasted plasma 
phospholipids collected at study entry (before 16 weeks of pregnancy; µ=10.93 weeks), at 
22 weeks and 32 weeks of pregnancy and at delivery and school performance scores at age 
7. Furthermore, LCPUFA levels of the children were determined in phospholipids from 
umbilical cord plasma and from non-fasted venous plasma at age 7, these levels were also 
used to study the associations between selected LCPUFAs and school performance at age 
7. The study was approved by the Ethics Committee of the University Hospital 
Maastricht/ Maastricht University. 
Participants 
The eligible study population consisted of 750 Caucasian children aged 7–8 years born 
between December 1990 and January 1994. After 7 years, 728 of these children were 
traced. Of them 3 were deceased and 34 moved abroad and therefore did not participate in 
the follow-up. In addition, 133 parents did not reply to the invitation. The parents of 231 
children refused to give consent for participation in the follow-up, primarily mentioning 
lack of time and concerns about the burden on their child as reason for refusal. As a result, 
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the parents of 327 children gave their consent for participation. During the MEFAB 2 
study period, 21 children dropped out leaving a final study population of 306 children. 
Unfortunately, not all schools attended by the participants administered the 
standardised school performance tests. In addition, some schools administered the tests at 
another age or were not willing to provide the results. The school performance scores were 
obtained for 149, 159 and 155 children for reading, spelling and arithmetic, respectively. 
For the flow diagram, see Figure 3.1. 
Blood and fatty acid analyses 
Fatty acid profiles of maternal and umbilical plasma phospholipids were determined by gas-
liquid chromatography as described by Al et al. [46]. The analysis of the blood samples at 
age 7 was slightly different, total lipids were extracted with the method of Blight and Dyer 
[49]. The gas-chromatographic methodology enabled the quantitative measurement of 
forty-two fatty acids [46]. Focus of the current paper is on DHA, AA, EPA, and ObA, as 
previously indicated. Fatty acid data are presented as relative levels (% of weight of total 
phospholipid-associated fatty acids). 
 
 
Figure 3.1: Flow diagram of children enrolled in the study and followed up until 7 years of age.  
Measurements of academic achievement 
To assess school performance at age 7, scores from the standard Dutch Cito-system 
(Central institute of test development) for spelling, reading and arithmetic were obtained 
from the school [50]. Results on the Cito tests are given as a letter (A through E). This 
letter is based on the scores of a normative group of children on the tests. If the score of a 
child is in the same range as the 25% best scoring children in the normative group the child 
Enrolled at birth 
(n 750) 
7 year: school performance score 
(n 170) 
Reading
(n 149) 
Spelling
(n 159) 
Arithmetic
(n 155) 
Lost to follow-up, deceased or 
emigrated (n 59) 
No reply (n 133) 
No consent (n 231) 
Drop out (n 21)
School did not administer test or did 
not react (n 136)
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will receive an A. The 25% above average is indicated by a B, 25% below average is 
indicated by a C, the 15% far below average are indicated by a D and the 10% worst scores 
are indicated by E. To achieve even groups, group D and E have been combined for the 
current study. 
Covariates 
A number of factors known to be important determinants of cognitive development were 
included as covariates in the analyses: breastfeeding (yes/no)[51] , birth weight in grams 
[52,53], the sex of the child [54] [54], maternal intelligence[55], maternal education 
(low/high) [55,56], maternal smoking during pregnancy (yes/no) [57,58], and the child's 
BMI at 7 years of age [59]. Maternal intelligence was based on the Raven's Standard 
Progressive Matrices (RAVEN) with a maximum score of 60 [60]. Body weight was 
measured to the nearest 100 g on a SECA electronic digital scale, while children wore light 
underwear only. Height was measured to the nearest millimetre using a wall mounted 
stadiometer (Holtain LTD, Crymych, UK) as described in detail by Gerver and de Bruin 
[61]. BMI (kg/m2) was calculated and classified for boys as underweight (BMI ≤ 14.03), 
healthy weight (BMI 14.04–17.91) or overweight (BMI ≥ 17.92) and for girls as underweight 
(BMI ≤ 13.85), healthy weight (BMI 13.86–17.74) or overweight (BMI ≥ 17.75) [62]. 
Statistical analyses 
Because of missing values, multiple imputations (i.e., fully conditional specification 
technique) were used to analyse the data [63]. Categorical regression analysis[64] was used to 
estimate the association between DHA, AA, EPA or ObA levels measured at study entry, 22 
weeks of pregnancy, 32 weeks of pregnancy, partus, in umbilical cord blood plasma, and in 
blood plasma of the child at age 7 and school performances at age 7. All covariates were 
entered in the initial model. When the Pratt-coefficient of relative importance for a given 
covariate was <.05 or the p-value was > .1 that covariate was excluded from the analysis. 
The beta and p-value of the fatty acid levels at specific time points in the adjusted model are 
reported The beta value as reported is the normal standardized regression coefficient of the 
optimally transformed variables. CATREG computes quantifications for each category by 
optimizing a least squares criterion. For example, if one looks at the association between 
maternal DHA level at study entry and arithmetic score (A, B, C or D), the categories A, B, 
C, and D get the values 0.80, −0.50, −1.55 and −2.02, respectively. Here the beta for DHA 
is −0.170. This implies that an increase of 1SD in DHA would lower the predicted score of 
the transformed arithmetic scale with 0.170. For example, a difference between C and D, 
which is −2.02 + 1.55 = 0.47, can be quantified in 0.47/0.170 = 2.76 standard deviations of 
DHA. This is 2.76 * 0.82 = 2.26%wt/wt of total FA. 
Due to the large number of analyses p <. 01 was considered statistically significant, 
unless noted otherwise. Analyses were carried out using SPSS statistics version 22 (IBM). 
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Quality check 
As check for selection bias characteristics of participants who participated in MEFAB 1 
only and those who also participated in MEFAB 2 were compared. Data was first checked 
for normality. If scale data was normally distributed an independent t-tests was performed, 
if not a Mann Withney U test was performed. For the nominal and ordinal data a 
Chi-squared test was performed. These analyses were performed for all fatty acids at all 
time-points, birthweight, birth length, head circumference, gestational age, age mother, 
maternal intelligence, maternal education sex child and smoking during pregnancy. This 
procedure was also followed to check for differences between participant of MEFAB 2 of 
whom school performance scores were available and those whose scores were not 
available. Lastly the procedure was repeated to check whether there was a difference 
between mothers who suffered from adverse pregnancy events (intrauterine growth 
restriction, preeclampsia or pregnancy induced hypertension) and those who did not suffer 
from adverse pregnancy events. For these analyses p <. 05 was considered statistically 
significant. 
Results 
For 170 children, one or more school performance scores were available. The 
characteristics of these participants and their mothers can be found in Table 3.1. 
Table 3.1: Participants’ characteristics. 
1 Mean of participants who were breastfed 2 Defined as for boys: underweight (BMI ≤ 14.03), healthy weight 
(BMI 14.04-17.91), overweight (BMI ≥ 20.63) and for girls as underweight (BMI ≤ 13.85), healthy weight (BMI 
13.86-17.74) or overweight (BMI ≥ 17.75) 3 Maternal smoking at study entry.  
  Value (mean+/- SD or n)  n 
Infant   
Sex (male/female)  94/75 169 
Gestational age (d) 278 ± 12.3  138 
Birth length (cm) 50.1 ± 2.4  158 
Birth weight (g) 3340 ± 511 169 
Head circumstance (cm) 34.3 ± 1.77 143 
Birth order (first child/other) 109/60 169 
In uterine growth restriction (normal/too small/too big for gestational age) 135/16/16 167 
Preeclampsia  2 
Pregnancy induced hypertension  4 
Breastfed (yes/no) 81/82 163  
Duration breastfeeding1 (mo.) 4.8 ± 5.1 81 
BMI at age 7  15.5 ± 1.7 161 
Underweight, normal, overweight/obese2 21/125/15 161 
Mother   
Maternal smoking (yes/no)3 38/130 168 
Maternal age (yrs.)  30.1 ± 4.1 169 
Maternal education (low /high)  105/56 161 
Maternal intelligence (RAVEN) 46.6 ± 6.5 162 
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Plasma phospholipid fatty acid levels 
Of the 170 children, 140 donated non-fasted blood to determine the plasma phospholipid 
fatty acid levels at follow-up. The levels of these fatty acids at age 7 can be found in Table 
3.2. This table also contains the maternal fatty acid levels at study entry (mean pregnancy 
duration 10.93 weeks), at 22 and 32 weeks of pregnancy, and at partus, as well as the 
umbilical plasma fatty acid levels. 
School performances scores 
School performance scores for reading, spelling and arithmetic were available for 149, 159 
and 155 children respectively. Table 3.3 shows the frequency of the available school 
achievement scores, as well as the percentage of students in this school performance 
quartile. 
Table 3.2: Selected fatty acids levels (% w/w, mean ± s.d. and range (smallest-to largest value) of maternal plasma 
at study entry (µ=10.93), 22 and 32 weeks pregnancy, and at delivery, umbilical cord plasma at birth and children’s 
blood plasma phospholipids at age 7. 
Fatty acid 
(%wt/wt of 
total FA) 
Maternal plasma 
PL at entry  
study (n= 152) 
Maternal plasma 
PL at 22wks. 
(n= 152) 
Maternal plasma 
PL at 32wks. 
(n= 148) 
Maternal plasma 
PL at partus. 
(n= 149) 
Umbilical plasma 
PL (n=157) 
Plasma PL at 
7 years 
(n =140) 
DHA 22:6n-3 3.96 ± 0.82 
2.34-6.34 
4.07 ± 0.81 
2.59-7.14 
3.95 ± 0.73 
2.51-7.02 
3.82 ± 0.71 
2.08-5.60 
6.04 ± 1.34 
3.43-10.12 
2.99 ± 0.80 
1.61-6.73 
EPA 20:5n-3 0.51 ± 0.39 
0.16-4.04 
0.36 ± 0.16 
0.15-1.25 
0.37 ± 0.23 
0.14-1.40 
0.33 ± 0.18 
0.09-1.63 
0.23 ± 0.12 
0.0-0.73 
0.66 ± 0.40 
0.2-2.79 
AA 20:4n-6 9.63 ± 1.50 
5.95-15.10 
8.55 ± 1.23 
5.67-12.16 
8.12 ± 1.15 
5.49-11.16 
8.30 ± 1.38 
5.23-12.58 
16.5 ± 1.7 
11.04-20.28 
9.15 ± 1.18 
6.22-12.69 
ObA 22:5n-6 0.35 ± 0.12 
0.08-0.98 
0.45 ± 0.15 
0.14-0.98 
0.47 ± 0.14 
0.19-0.93 
0.51 ± 0.16 
0.19-0.94 
0.85 ± 0.26 
0.03-1.77 
0.28 ± 0.09 
0.00-0.54 
PL = phospholipids  
Table 3.3: Number of participants (and percentage of total) at every level for the school performances scores on 
the CITO test at 7 years of age.  
 
Achievement scores were divided in quartiles based on the scores in a normative group of 
children with respectively A representing very good (highest quartile in the normative 
group), B good, C moderate, D weak (lowest quartile). 
Associations between fatty acids and school performance 
For arithmetic scores at age 7 the analyses showed significant negative associations with 
maternal DHA levels throughout the pregnancy, and with umbilical plasma DHA level (all 
 Level   
 A B C D n 
Reading (%) 58 (39) 40 (27) 42 (28) 9 (6) 149 
Spelling (%) 95 (60) 32 (20) 20 (13) 12 (8) 159 
Arithmetic (%) 82 (53) 44 (28) 22 (14) 7 (5) 155 
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p < .001) (see Figure 3.2). The association with children's plasma DHA level at age 7 was 
not significant (p = .20). 
For reading and spelling, the associations with DHA levels throughout pregnancy and at 
partus and in umbilical cord blood plasma were non-significant. Significant positive 
associations were found for spelling (p < .001), and reading scores (p < .001), and children's 
plasma DHA level at age 7. 
 
  
  
Figure 3.2: Results of adjusted model CATREG analyses: Beta of fatty acid (DHA, AA, EPA, ObA) at specified 
time point for arithmetic, reading or spelling scores. *p value of fatty acid < .01 Full models included the 
following covariates: breastfeeding (yes/no), birth weight, sex of child, maternal intelligence (RAVEN score) 
maternal education, maternal smoking during pregnancy (yes/no), child’s BMI at age 7 (underweight, healthy, 
overweight). Covariates were excluded if p value > .1 or Pratt coefficient of relative importance < 0.05. The first 
fatty acid assessment (here named 16 weeks) was done on blood collected at study entry mean= 10.93 weeks 
pregnant.  
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Maternal AA level at study entry was negatively associated with both arithmetic (p = .008) 
and reading (p = .005) scores. In addition, AA level in umbilical cord blood plasma was 
negatively associated with reading (p = .001) as well as spelling (p < .001). 
Maternal EPA levels at study entry, at 22 weeks of pregnancy, and at partus showed 
significant negative associations with arithmetic scores (all p < .001). The level of EPA at 
study entry was also negatively associated with spelling scores at age 7 (p < .001). 
Furthermore, there was a positive association between EPA level in umbilical cord plasma 
and reading scores at age 7 (p = .005). 
Lastly, maternal ObA levels at 22 and 32 weeks of pregnancy and level in umbilical 
cord blood plasma were positively associated with arithmetic scores (p = .006, p = .004 and 
p = .003, respectively). All these associations were positive, and since a higher ObA level 
reflects a lower DHA status [5], this finding confirms the negative relationship between 
DHA status and arithmetic scores. 
Quality check results 
The group of children whose school performance scores were available and those whose 
scores were not available were compared, and some group differences were seen. Of 
special interest was the difference in the maternal RAVEN score, which was higher in 
those with school performance scores available. However, upon further inspection of the 
data, three extreme outliers were identified in the group without school performances 
available (RAVEN scores of 8, when the average score was 40). When these outliers were 
removed the group difference faded out. When the results of children whose mothers 
suffered adverse pregnancy outcomes were compared to those who had a healthy 
pregnancy, only a difference on birthweight was seen (µ = 3166.9 vs µ = 3383.9, p = .027), 
which is to be expected as this included children whom were small for gestational age. The 
data-analyses were corrected for birthweight; this difference is thus not expected to 
influence results. 
Discussion and conclusion 
In line with our hypothesis a positive association between DHA level at age 7 and spelling 
and reading scores at age 7 was shown. In contrast, mostly significant negative associations 
were found between maternal DHA levels throughout pregnancy and arithmetic score at 
age 7. This was supported by ObA, a functional deficiency marker of DHA [5], which 
showed significant positive associations with arithmetic. 
The positive associations between DHA level at age 7 and spelling and reading scores 
are mostly in line with previous studies in adolescents. The negative associations between 
DHA levels and arithmetic scores in the current study are mostly in contrast to studies in 
adolescents that showed a positive association between fish consumption (most important 
source of DHA) and school grades [36,37]. De Groot et al. did, however, show a negative 
association when fish consumption was more than twice a week [36]. Though, the studies of 
De Groot et al. and of Åberg et al., assessed fish intake, which is only a proxy for n-3 
LCPUFAs status in the blood [65]. Furthermore, these studies in adolescents looked at grade 
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average over a number of school subjects; this could have led to averaging out negative 
associations in one school subject with positive associations in another school subject. 
While studies investigating the association between LCPUFA concentrations in blood 
and school performance in children are, to our knowledge, not available, studies that look 
at the association between LCPUFA blood levels and cognitive measures are available. 
Some of these studies looking at the association between LCPUFA levels and cognitive 
measures showed negative associations [31,32,34,35,66,67], while others showed positive 
[17,19] or no associations [14,16]. Intervention studies also show mixed results: positive 
[20–29], negative [31–35] or neutral [16,23,30]. These mixed results have been speculated 
to be due to the large methodologically difference between the studies: differences in 
cognitive tests used moment, sort and dosage of supplementation [68]. It is however 
important to keep into mind that cognition and school performance are related, but not the 
same [69,70]. School performance is dependent on more factors such as motivation, 
personality and time spend on homework [71]. Thus a positive association between 
LCPUFA and cognition, does not mean that LCPUFA and school performance are 
positively associated. 
Previous reported results thus remain mixed, with positive, negative and neutral 
associations being reported between LCPUFAs levels in blood and cognitive measures, and 
the association with school performance mostly unstudied. In the current study negative 
associations between maternal plasma levels during pregnancy and arithmetic scores at age 
7 are shown, while the association between DHA level at age 7 and reading and spelling 
scores at age 7 was positive. The opposing associations between LCPUFA levels and 
arithmetic and LCPUFA levels and spelling/reading are surprising. 
Since a positive association for spelling and reading scores at age 7 was found and this 
was not found for arithmetic scores, one could speculate that this is because these skills are 
located in different brain region. The brain does not develop uniformly, every regions has 
its own development curve [38]. Arithmetic is related to executive functioning [72], which 
is mainly located in the pre-frontal cortex, a region of the brain which develops late in the 
development. Language is located mainly in the parietal lobes, a brain region which 
develops earlier in the development [38]. 
Though a number of studies observe negative associations between LCPUFA levels 
and cognitive measurement, most fail to explain these negative associations. No 
biochemical explanation for the negative associations were found in the literature, with the 
exception of the possible detrimental effects of high levels of toxic substances present in 
some fish species (e.g., mercury, cadmium, PCBs and dioxins). However, not all studies 
that looked at these substances showed unfavourable neurological development (for review 
see among others Oken [73]). Therefore, it seems time that the research community pays 
attention to, and further explores the possible unfavourable association between LCPUFA 
levels and cognition and school performance. 
This observational study had a number of limitations. Unfortunately, school 
performance scores were only available for about 150 children, resulting in 21% of the 
original sample being analysed on school performance. The non-availability of the school 
performance scores was due to the fact that some schools did not administer the tests 
(such tests are not obligatory), administered the tests at another time point than age 7, or 
the school did not respond to the request for the test scores. These missing data could have 
influenced the results, especially since the number of children with a score in the lower 
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quartiles was limited. However, no difference between children whose school performance 
scores were available and children whose school performance scores were not available 
were seen on a number of covariates. Maternal and child plasma LCPUFA levels are 
furthermore similar to those found in other studies (e.g., [74,75]). Maternal LC n-3 PUFA 
intake from the women in the current study did not change during pregnancy [76] and the 
maternal LC n-3 PUFA intake was similar to other pregnant populations [77]. 
Maternal plasma LCPUFA concentrations were measured frequently during gestation 
which is a valuable aspect of this study. Plasma phospholipids were used as a measure of 
fatty acids level as they are a good indicator of longer term dietary fatty acid intake [78] and 
as foetal blood values are correlated with maternal blood values [6–8], this is a good 
measure of foetal fatty acid exposure. Furthermore, participants were followed up until age 
7, which allows the study of long-term associations of early life time exposure to 
LCPUFAs. Finally, even with the more conservative p of .01, results were significant, 
pointing to robust associations. 
This study is of associative nature and the sample size is rather limited, only 
randomized-controlled trials can confirm or refute the findings of the current observational 
study. However, with the negative associations in mind and the fact that such intervention 
studies, with a long-term follow-up, are difficult to design and covariates might influence 
the results as well, a randomized controlled trial might not be feasible. Thus, the results of 
the current study are an useful proxy, which can be used for hypothesis formation. 
To summarize, this study is the first, to our knowledge, to investigate the association 
between prenatal, perinatal and current LCPUFA exposure and school performance scores 
in children aged 7. Interestingly, consistent significant negative associations were observed 
between pre- and perinatal exposures to DHA and arithmetic scores at age 7. These results 
are in line with a few studies regarding cognition that also show negative associations [31–
35,67].  
In contrast, the association between DHA level at age 7 and spelling and reading scores 
was positive. To conclude, although this is an observational study not implying causality, 
the consistent negative associations observed between maternal plasma DHA levels during 
pregnancy and the arithmetic scores of the children at age 7 calls upon prudence when 
considering DHA supplementation during pregnancy. 
 
  
Prenatal and current exposure to selected LCPUFAs and school performance at age 7 
53 
References  
1.  Assisi, A.; Banzi, R.; Buonocore, C.; Capasso, F.; Muzio, V. Di; Michelacci, F.; Renzo, D.; Tafuri, G.; Trotta, 
F.; Vitocolonna, M.; Garattini, S. Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty 
acids in cognitive development and neurological disorders. Int Clin Psychopharmacol 2006, 21, 319–336. 
2.  Parletta, N.; Milte, C.; Meyer, B. J. Nutritional modulation of cognitive function and mental health. J. Nutr. 
Biochem. 2013, 24, 725–743. 
3.  McNamara, R. K.; Carlson, S. E. Role of omega-3 fatty acids in brain development and function: Potential 
implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot. Essent. Fat. Acids 
2006, 75, 329–349. 
4.  Richardson, A. n-3 Fatty acids and mood: the devil is in the detail. Br. J. Nutr. 2008, 99, 221–223. 
5.  Neuringer M. Connor WE. Lin DS. Barstad L. Luck S. Biochemical and functional effects of prenatal and 
postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad. Sci. U. S. A. 
1986, 83, 4021–4025. 
6.  van Houwelingen, A. C.; Puls, J.; Hornstra, G. Essential fatty acid status during early human development. 
Early Hum. Dev. 1992, 31, 97–111. 
7.  Zeijdner, E. E.; van Houwelingen, A.; Kester, A.; Hornstra, G. Essential fatty acid status in plasma 
phospholipids of mother and neonate after multiple pregnancy. Prostaglandins. Leukot. Essent. Fatty Acids 1997, 
56, 395–401. 
8.  van Houwelingen, A. C.; Foreman-van Drongelen, M. M.; Nicolini, U.; Nicolaides, K. H.; Al, M. D.; Kester, 
A. D.; Hornstra, G. Essential fatty acid status of fetal plasma phospholipids: similar to postnatal values 
obtained at comparable gestational ages. Early Hum. Dev. 1996, 46, 141–152. 
9.  Gale, C. R.; Robinson, S. M.; Godfrey, K. M.; Law, C. M.; Schlotz, W.; O’Callaghan, F. J. Oily fish intake 
during pregnancy--association with lower hyperactivity but not with higher full-scale IQ in offspring. J. Child 
Psychol. Psychiatry 2008, 49, 1061–1068. 
10.  Hibbeln, J. R.; Davis, J. M.; Steer, C.; Emmett, P.; Rogers, I.; Williams, C.; Golding, J. Maternal seafood 
consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an 
observational cohort study. Lancet 2007, 369, 578–585. 
11.  Daniels, J. L.; Longnecker, M. P.; Rowland, A. S.; Golding, J. Fish Intake During Pregnancy and Early 
Cognitive Development of Offspring. Epidemiology 2004, 15, 394–402. 
12.  Oken, E.; Radesky, J. S.; Wright, R. O.; Bellinger, D. C.; Amarasiriwardena, C. J.; Kleinman, K. P.; Hu, H.; 
Gillman, M. W. Maternal fish intake during pregnancy, blood mercury levels, and child cognition at age 3 
years in a US cohort. Am. J. Epidemiol. 2008, 167, 1171–1181. 
13.  Oken, E.; Østerdal, M. L.; Gillman, M. W.; Knudsen, V. K.; Halldorsson, T. I.; Strøm, M.; Bellinger, D. C.; 
Hadders-Algra, M.; Michaelsen, K. F.; Olsen, S. F. Associations of maternal fish intake during pregnancy and 
breastfeeding duration with attainment of developmental milestones in early childhood: A study from the 
Danish National Birth Cohort. Am. J. Clin. Nutr. 2008, 88, 789–796. 
14.  Valent, F.; Mariuz, M.; Bin, M.; Little, D.; Mazej, D.; Tognin, V.; Tratnik, J.; McAfee, A. J.; Mulhern, M. S.; 
Parpinel, M.; Carrozzi, M.; Horvat, M.; Tamburlini, G.; Barbone, F. Associations of Prenatal Mercury 
Exposure From Maternal Fish Consumption and Polyunsaturated Fatty Acids With Child 
Neurodevelopment: A Prospective Cohort Study in Italy. J. Epidemiol. 2013, 23, 360–370. 
15.  Gustafsson, P.; Duchén, K.; Birberg, U.; Karlsson, T. Breastfeeding, very long polyunsaturated fatty acids 
(PUFA) and IQ at 6 1/2 years of age. Acta Paediatr. 2004, 93, 1280–1287. 
16.  Bakker, E.; Ghys, A.; Kester, A.; Vles, J.; Dubas, J.; Blanco, C.; Hornstra, G. Long-chain polyunsaturated 
fatty acids at birth and cognitive function at 7 y of age. Eur. J. Clin. Nutr. 2003, 57, 89–95. 
17.  Boucher, O.; Burden, M. Neurophysiologic and neurobehavioral evidence of beneficial effects of prenatal 
omega-3 fatty acid intake on memory function at school age. Am. J. Clin. Nutr. 2011, 93, 1027–1035. 
18.  Ghys, A.; Bakker, E.; Hornstra, G.; van den Hout, M. Red blood cell and plasma phospholipid arachidonic 
and docosahexaenoic acid levels at birth and cognitive development at 4 years of age. Early Hum. Dev. 2002, 
69, 83–90. 
19.  Strain, J.; Davidson, P. W.; Thurston, S.; Harrington, D.; Mulhern, M.; McAfee, A.; van Wijngaarden, E.; 
Shamlaye, C.; Henderson, J.; Watson, G.; Zareba, G.; Cory-Slechta, D.; Lynch, M.; Wallace, J.; McSorley, E.; 
Bonham, M.; Stokes-Riner, A.; Sloane-Reeves, J.; Janciuras, J.; Wong, R.; Clarkson, T.; Myers, G. Maternal 
PUFA Status but Not Prenatal Methylmercury Exposure Is Associated with Children’s Language Functions 
at Age Five Years in the Seychelles. J. Nutr. 2012, 142, 1943–1949. 
Chapter 3 
54 
20.  Bouwstra, H.; Dijck-Brouwer, D.; Decsi, T.; Boehm, G.; Boersma, E.; Muskiet, F.; Hadders-Algra, M. 
Neurologic condition of healthy term infants at 18 months: positive association with venous umbilical DHA 
status and negative association with umbilical trans-fatty acids. Pediatr. Res. 2006, 60, 334–9. 
21.  Colombo, J.; Carlson, S.; Cheatham, C.; Shaddy, D.; Kerling, E.; Thodosoff, J.; Gustafson, K.; Brez, C. 
Long-term effects of LCPUFA supplementation on childhood cognitive outcomes. Am. J. Clin. Nutr. 2013, 
1–10. 
22.  Helland, I.; Smith, L.; Saarem, K.; Saugstad, O.; Drevon, C. Maternal Supplementation With Very-Long-
Chain n-3 Fatty Acids During Pregnancy and Lactation Augments Children’s IQ at 4 Years of Age. Pediatrics 
2003, 111, e39–e44. 
23.  Campoy, C.; Escolano-Margarit, M.; Ramos, R.; Parrilla-Roure, M.; Csabi, G.; Beyer, J.; Ramirez-Tortosa, M.; 
Molloy, A.; Decsi, T.; Koletzko, B. Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation 
on cognitive development of children at 6.5 y of age. Am. J. Clin. Nutr. 2011, 94, 1880S–1888S. 
24.  van Goor, S.; Dijck-Brouwer, D.; Erwich, J.; Schaafsma, A.; Hadders-Algra, M.; Dijck-Brouwer, D. The 
influence of supplemental docosahexaenoic and arachidonic acids during pregnancy and lactation on 
neurodevelopment at eighteen months. Prostaglandins. Leukot. Essent. Fatty Acids 2011, 84, 139–146. 
25.  Escolano-Margarit, M.; Ramos, R.; Beyer, J.; Csábi, G.; Parrilla-Roure, M.; Cruz, F.; Perez-Garcia, M.; 
Hadders-Algra, M.; Gil, A.; Decsi, T.; Koletzko, B.; Campoy, C. Prenatal DHA status and neurological 
outcome in children at age 5.5 years are positively associated. J. Nutr. 2011, 141, 1216–1223. 
26.  Willatts, P.; Forsyth, J. S.; DiModugno, M. K.; Varma, S.; Colvin, M. Effect of long-chain polyunsaturated 
fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998, 352, 688–691. 
27.  Birch, E.; Carlson, S. The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a 
double-masked, randomized controlled clinical trial of the maturation of infant. Am. J. Clin. Nutr. 2010, 91, 
848–859. 
28.  Drover, J. R.; Hoffman, D.; Castañeda, Y.; Morale, S.; Garfield, S.; Wheaton, D.; Birch, E. Cognitive 
function in 18-month-old term infants of the DIAMOND study: A randomized, controlled clinical trial with 
multiple dietary levels of docosahexaenoic acid. Early Hum. Dev. 2011, 87, 223–230. 
29.  Drover, J. R.; Hoffman, D.; Castañeda, Y.; Morale, S.; Birch, E. Three randomized controlled trials of early 
long-chain polyunsaturated fatty acid supplementation on means-end problem solving in 9-Month-olds. 
Child Dev. 2009, 80, 1376–1384. 
30.  Auestad, N.; Scott, D.; Janowsky, J.; Jacobsen, C.; Carroll, R. E.; Montalto, M. B.; Halter, R.; Qiu, W.; Jacobs, 
J.; Connor, W.; Connor, S. L.; Taylor, J.; Neuringer, M.; Fitzgerald, K. M.; Hall, R. Visual, cognitive, and 
language assessments at 39 months: a follow-up study of children fed formulas containing long-chain 
polyunsaturated fatty acids to 1 year of age. Pediatrics 2003, 112, e177–e183. 
31.  de Jong, C.; Kikkert, H.; Fidler, V.; Hadders-Algra, M. Effects of long-chain polyunsaturated fatty acid 
supplementation of infant formula on cognition and behaviour at 9 years of age. Dev. Med. Child Neurol. 2012, 
54, 1102–1108. 
32.  Engel, S.; Tronhjem, K.; Hellgren, L.; Michaelsen, K.; Lauritzen, L. Docosahexaenoic acid status at 9 months 
is inversely associated with communicative skills in 3-year-old girls. Matern. Child Nutr. 2013, 9, 499–510. 
33.  Kirby, A.; Woodward, A.; Jackson, S.; Wang, Y.; Crawford, M. A double-blind, placebo-controlled study 
investigating the effects of omega-3 supplementation in children aged 8-10 years from a mainstream school 
population. Res. Dev. Disabil. 2010, 31, 718–730. 
34.  Cheatham, C.; Nerhammer, A.; Asserhøj, M.; Michaelsen, K.; Lauritzen, L. Fish oil supplementation during 
lactation: effects on cognition and behavior at 7 years of age. Lipids 2011, 46, 637–645. 
35.  Drover, J. R.; Felius, J.; Hoffman, D.; Castañeda, Y.; Garfield, S.; Wheaton, D.; Birch, E. A randomized trial 
of DHA intake during infancy: School readiness and receptive vocabulary at 2-3.5years of age. Early Hum. 
Dev. 2012, 88, 885–891. 
36.  De Groot, R.; Ouwehand, C.; Jolles, J. Eating the right amount of fish: inverted U-shape association 
between fish consumption and cognitive performance and academic achievement in Dutch adolescents. 
Prostaglandins. Leukot. Essent. Fatty Acids 2012, 86, 113–117. 
37.  Kim, J.; Winkvist, A.; Äberg, M.; Äberg, N.; Sundberg, R.; Torén, K.; Brisman, J. Fish consumption and 
school grades in Swedish adolescents: A study of the large general population. Acta Paediatr. 2010, 99, 72–77. 
38.  Gogtay, N.; Giedd, J. N.; Lusk, L.; Hayashi, K. M.; Greenstein, D.; Vaituzis, A.C.; Nugent, T. F.; Herman, 
D. H.; Clasen, L. S.; Toga, A. W.; Rapoport, J. L.; Thompson, P. M. Dynamic mapping of human cortical 
development during childhood through early adulthood. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 8174–8179. 
39.  Crone, E. A.; Richard Ridderinkhof, K. The developing brain: From theory to neuroimaging and back. Dev. 
Cogn. Neurosci. 2011, 1, 101–109. 
40.  Innis, S. Essential fatty acid transfer and fetal development. Placenta 2005, 26, S70–S75. 
Prenatal and current exposure to selected LCPUFAs and school performance at age 7 
55 
41.  Martínez, M.; Mougan, I. Fatty acid composition of human brain phospholipids during normal development. 
J. Neurochem. 1998, 71, 2528–2533. 
42.  Hoffman, D.; Uauy, R. Essentiality of dietary omega 3 fatty acids for premature infants: plasma and red 
blood cell fatty acid composition. Lipids 1992, 27, 886–895. 
43.  Clandinin, M.; Chappell, J.; Leong, S.; Heim, T.; Swyer, P.; Chance, G. Intrauterine fatty acid accretion rates 
in human brain: implications for fatty acid requirements. Early Hum. Dev. 1980, 4, 121–129. 
44.  Innis, S. Dietary (n-3) fatty acids and brain development. J. Nutr. 2007, 137, 855–859. 
45.  Koletzko, B.; Lien, E.; Agostoni, C.; Böhles, H.; Campoy, C.; Cetin, I.; Decsi, T.; Dudenhausen, J.; Dupont, 
C.; Forsyth, S.; Hoesli, I.; Holzgreve, W.; Lapillonne, A.; Putet, G.; Secher, N. N. J.; Symonds, M.; Szajewska, 
H.; Willatts, P.; Uauy, R. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and 
infancy: review of current knowledge and consensus recommendations. J. Perinat. Med. 2008, 36, 5–14. 
46.  Al, M. D.; van Houwelingen, A. C.; Kester, A. D.; Hasaart, T. H.; de Jong, A. E.; Hornstra, G. Maternal 
essential fatty acid patterns during normal pregnancy and their relationship to the neonatal essential fatty acid 
status. Br. J. Nutr. 1995, 74, 55–68. 
47.  Al, M. D.; van Houwelingen, A. C.; Badart-Smook, A.; Hasaart, T. H.; Roumen, F. J.; Hornstra, G. The 
essential fatty acid status of mother and child in pregnancy-induced hypertension: a prospective longitudinal 
study. Am. J. Obstet. Gynecol. 1995, 172, 1605–1614. 
48.  van der Wurff, I. S. M.; de Groot, R. H. M. R.; Stratakis, N.; Gielen, M.; Hornstra, G.; Zeegers, M. M. 
Maastricht essential fatty acid birth cohort. Lipid Technol. 2015, 27, 59–62. 
49.  Blight, E.; Dyer, W. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 
37, 911–917. 
50.  Hollenberg, J.; van der Lubbe, M. Toetsen op School: Primair Onderwijs [Testing at school: primary education]; 
Arnhem, 2011; 
51.  Kramer, M.; Aboud, F.; Mironova, E.; Vanilovich, I.; Platt, R.; Matush, L.; Igumnov, S.; Fombonne, E.; 
Bogdanovich, N.; Ducruet, T.; Collet, J.; Chalmers, B.; Hodnett, E.; Davidovsky, S.; Skugarevsky, O.; 
Trofimovich, O.; Kozlova, L.; Shapiro, S. Breastfeeding and child cognitive development: new evidence 
from a large randomized trial. Arch. Gen. Psychiatry 2008, 65, 578–584. 
52.  Shenkin, S. D.; Starr, J.; Deary, I. Birth weight and cognitive ability in childhood: a systematic review. Psychol. 
Bull. 2004, 130, 989–1013. 
53.  Rahu, K.; Rahu, M.; Pullmann, H.; Allik, J. Effect of birth weight, maternal education and prenatal smoking 
on offspring intelligence at school age. Early Hum. Dev. 2010, 86, 493–497. 
54.  Halpern, D. F.; Benbow, C. P.; Geary, D. C.; Gur, R. C.; Hyde, J. S.; Gernsbacher, M. A. The science of sex 
differences in science and mathematics. Psychol. Sci. Public Interes. Suppl. 2007, 8, 1–51. 
55.  Tong, S.; Baghurst, P.; Vimpani, G.; McMichael, A. Socioeconomic Position, Maternal IQ, Home 
Environment, and Cognitive Development. J. Pediatr. 2007, 151, 284–288. 
56.  Jefferis, B. J. M. H.; Power, C.; Hertzman, C. Birth weight, childhood socioeconomic environment, and 
cognitive development in the 1958 British birth cohort study. BMJ 2002, 325, 305. 
57.  Batstra, L.; Hadders-Algra, M.; Neeleman, J. Effect of antenatal exposure to maternal smoking on 
behavioural problems and academic achievement in childhood: Prospective evidence from a Dutch birth 
cohort. Early Hum. Dev. 2003, 75, 21–33. 
58.  Julvez, J.; Ribas-Fitó, N.; Torrent, M.; Forns, M.; Garcia-Esteban, R.; Sunyer, J. Maternal smoking habits and 
cognitive development of children at age 4 years in a population-based birth cohort. Int. J. Epidemiol. 2007, 
36, 825–832. 
59.  Sigfúsdóttir, I.; Kristjánsson, A.; Allegrante, J. P. Health behaviour and academic achievement in Icelandic 
school children. Health Educ. Res. 2007, 22, 70–80. 
60.  Raven, J. C. The Raven’s progressive matrices: change and stability over culture and time. Cogn. Psychol. 2000, 
41, 1–48. 
61.  Gerver, W.; de Bruin, R. Paediatric Morphometrics: A Reference Manual.; Bunge: Utrecht, 1996; 
62.  Talma, H.; Schönbeck, Y.; B, B. Groeidiagrammen 2010: handleiding bij het meten en wegen van kinderen 
en het invullen van groeidiagrammen [Growth diagrams 2010: manual for measuring and weighing of 
children and the use of growth diagrams]. 2010. 
63.  Sterne, J.; White, I.; Carlin, J.; Spratt, M.; Royston, P.; Kenward, M.; Wood, A.; Carpenter, J. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. Br. Med. J. 2009, 
338, b2393. 
64.  Van Der Kooij, A. J.; Meulman, J. J.; Heiser, W. J. Local minima in categorical multiple regression. Comput. 
Stat. Data Anal. 2006, 50, 446–462. 
65.  Äberg, M.; Äberg, N.; Brisman, J.; Sundberg, R.; Winkvist, A.; Torén, K. Fish intake of Swedish male 
adolescents is a predictor of cognitive performance. Acta Paediatr. 2009, 98, 555–560. 
Chapter 3 
56 
66.  Kirby, A.; Woodward, A.; Jackson, S.; Wang, Y.; Crawford, M. A. Childrens’ learning and behaviour and the 
association with cheek cell polyunsaturated fatty acid levels. Res. Dev. Disabil. 2010, 31, 731–742. 
67.  Scott, D.; Janowsky, J.; Carroll, R.; Taylor, J.; Auestad, N.; Montalto, M. Formula supplementation with 
long-chain polyunsaturated fatty acids: are there developmental benefits? Pediatrics 1998, 102, E59. 
68.  Kuratko, C.; Barrett, E. C.; Nelson, E.; Salem, N. The relationship of docosahexaenoic acid (DHA) with 
learning and behavior in healthy children: A review. Nutrients 2013, 5, 2777–2810. 
69.  Willoughby, M.; Kupersmidt, J.; Voegler-Lee, M. Is preschool executive function causally related to 
academic achievement? Child Neuropsychol. 2012, 18, 79–91. 
70.  Best, J. R.; Miller, P. H.; Naglieri, J. A. Relations between Executive Function and Academix Achievement 
from ages 5 to 17 in Large, Representative National Sample. Learn. Individ. Differ. 2011, 21, 327–336. 
71.  Boschloo, A. School performance in adolescents: an educational neuropsychology perspective, 2012. 
72.  Espy, K. A.; McDiarmid, M. M.; Cwik, M. F.; Stalets, M. M.; Hamby, A.; Senn, T. E. The contribution of 
executive functions to emergent mathematic skills in preschool children. Dev. Neuropsychol. 2004, 26, 465–
486. 
73.  Oken, E.; Bellinger, D. C. Fish consumption, methylmercury and child neurodevelopment. Curr. Opin. 
Pediatr. 2008, 20, 178–183. 
74.  Otto, S. J.; Houwelingen, A.C.; Antal, M.; Manninen, A; Godfrey, K. M.; López-Jaramillo, P.; Hornstra, G. 
Maternal and neonatal essential fatty acid status in phospholipids: an international comparative study. Eur. J. 
Clin. Nutr. 1997, 51, 232–242. 
75.  Elias, S. L.; Innis, S. M. Infant plasma trans, n-6, and n-3 fatty acids and conjugated linoleic acids are related 
to maternal plasma fatty acids, length of gestation, and birth weight and length. Am. J. Clin. Nutr. 2001, 73, 
807–814. 
76.  Al, M. D.; Badart-Smook, A.; von Houwelingen, A. C.; Hasaart, T. H.; Hornstra, G. Fat intake of women 
during normal pregnancy: relationship with maternal and neonatal essential fatty acid status. J. Am. Coll. 
Nutr. 1996, 15, 49–55. 
77.  Blumfield, M. L.; Hure, A. J.; MacDonald-Wicks, L.; Smith, R.; Collins, C. E. Systematic review and meta-
analysis of energy and macronutrient intakes during pregnancy in developed countries. Nutr. Rev. 2012, 70, 
322–336. 
78.  Arterburn, L. M.; Hall, E. B.; Oken, H. Distribution, interconversion, and dose response of n-3 fatty acids in 
humans. Am. J. Clin. Nutr. 2006, 83, 1467S–1476S. 
 
  
57 
Chapter 4 
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investigating the effect of increasing Omega-3 
index with krill oil supplementation on 
learning, cognition, behaviour and visual 
processing in typically developing adolescents. 
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behaviour and visual processing in typically developing adolescents. BMJ open, 6(7), 
e011790.  
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Abstract  
Introduction: The influence of n-3 long-chain polyunsaturated fatty acids (LCPUFA) 
supplementation on brain functioning is debated. Some studies have found positive effects 
on cognition in children with learning difficulties, elderly people with cognitive impairment 
and depression scores in depressed individuals. Other studies have found null or negative 
effects. Observational studies in adolescents have found positive associations between fish 
consumption (containing n-3 LCPUFAs) and academic achievement. However, 
intervention studies in typically developing adolescents are missing. 
Objective: The goal of this study is to determine the influence of increasing Omega-3 
Index on cognitive functioning, academic achievement and mental well-being of typically 
developing adolescents. 
Methods and data analysis: Double-blind, randomised, placebo controlled intervention; 
264 adolescents (age 13–15 years) attending lower general secondary education started daily 
supplementation of 400 mg eicosapentaenoic acid and docosahexaenoic acid (EPA + 
DHA) in cohort I (n=130) and 800 mg EPA + DHA in cohort II (n=134) or a placebo for 
52 weeks. Recruitment took place according to a low Omega-3 Index (< 5%). The Omega-
3 Index was monitored via a finger prick at baseline and after 3, 6 and 12 months. The 
supplement dose was adjusted after 3 months (placebo analogously) to reach an Omega-3 
Index of 8–11%. At baseline, 6 and 12 months, a neuropsychological test battery, a number 
of questionnaires and a standardised math test (baseline and 12 months) were administered. 
School grades were collected. In a subsample, sleep quality and quantity data (n=64) 
and/or eye-tracking data (n=33) were collected. 
Ethics and dissemination: Food2Learn is performed according to Good Clinical 
Practice. All data collected are linked to participant number only. The results will be 
disseminated on group level to participants and schools. The results will be presented at 
conferences and published in peer-reviewed journals. The study is approved by the Medical 
Ethical Committee of Atrium-Orbis-Zuyd Hospital and is registered at the Netherlands 
Trial Register (NTR4082). 
Trial registration numbers: NTR4082 and NCT02240264; Pre-results. 
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Introduction 
There is a debate whether long-chain polyunsaturated fatty acids (LCPUFA) improve 
cognitive performance. LCPUFAs from the n-3 family such as docosahexaenoic acid 
(DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) are involved in many aspects of 
brain functioning, for example, neuronal membrane fluidity and neurotransmission [1,2]. 
There is evidence that consumption of Omega-3 LCPUFAs plays a protective role in age-
related cognitive decline [3] and Alzheimer’s disease [4]. In premature babies, it has been 
shown that higher Omega-3 LCPUFAs consumption is associated with advanced cognitive 
development [5]. Furthermore, in children, it might lead to improvement of symptoms 
associated with autism and attention deficit hyperactivity disorder (ADHD) [6]. Although 
previous research is not conclusive, it does suggest that in certain sensitive periods Omega-
3 LCPUFAs might contribute to optimising cognitive performance and/or cognitive 
development. Adolescence has received limited attention in studies on n-3 LCPUFAs. The 
brain and prefrontal cortex continue to develop until the late 20s [7–11]. It is thus crucial to 
study the role of Omega-3 LCPUFA in adolescence as they play an important role in brain 
development and functioning. For example, DHA is an important structural component of 
the neural cell membrane, influencing membrane fluidity and signal transduction [12,13]. 
Moreover, higher DHA intake has been associated with changes in the functional activity 
of the prefrontal cortex in boys aged 8–10 years [14]. Even though EPA is only present in 
very small amounts in the brain,15 it is also involved in important brain processes such as 
neurite outgrowth, regulation of gene expression and in anti-inflammatory, antithrombotic 
and vasodilatory processes which might assist brain functioning [15]. Studies on the 
relationship between measured LCPUFA status or supplementation and cognitive 
functioning in adolescents are, to the best of our knowledge, not available. Observational 
studies investigating the association between fish intake and cognitive functioning in 
adolescents are, however, available. Kim et al. [16] showed that adolescents aged 15 years 
who regularly consumed fish had significantly better academic performance than their non-
fish consuming or less fish consuming peers. Åberg et al. [17] demonstrated that high fish 
consumption in boys at age 15 years was associated with better cognitive performance at 
age 18 years. Finally, de Groot et al. [18] studied 700 adolescents aged 12–18 years for 
whom fish consumption data, end-term grades (for Dutch, English and Math) and score on 
the Amsterdam Vocabulary Test was collected. Contrast analyses demonstrated a u-shape 
association between fish consumption and vocabulary (p = .01) and a nearly significant 
association with average end-term grades (p = .07). Thus, higher fish intake was associated 
with more advanced vocabulary and an almost significant higher average end-term grade. 
However, eating more fish than the recommended amount (> 2 fish portion/week) was 
not associated with a beneficial outcome. Studies looking at the measured LCPUFA status 
and depression in typically developing adolescents are also limited. We are only aware of 
the study by Mamalakis that showed a negative association between EPA measured in 
adipose tissue and score on the Beck Depression Inventory (i.e., higher EPA, fewer 
depressive symptoms). Furthermore, a positive association between dihomogamma 
linolenic acid (DGLA, C20:3n-6) measured in adipose tissue and score on the Centre for 
Epidemiologic Studies Depression Scale (CES-D) (i.e., higher DGLA, more depressive 
symptoms) was shown [19]. This was, however, only true after correction for adiponectin. 
Although self-esteem has often been associated with depression [20], we found no studies 
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taking self-esteem into account when studying the association between LCPUFA and 
depression in adolescents. While observational studies point to a beneficial association 
between fish intake (the main source of DHA and EPA) and school grades in adolescents 
and since causality cannot be proven by observational studies, intervention studies are 
needed. Furthermore, little is known about the effects of Omega-3 fatty acids on 
depression and self-esteem in typically developing adolescents. This paper describes the 
design of Food2Learn, a double-blind, randomised, placebo controlled intervention in 
which the influence of an increase in the Omega-3 Index with 1-year of krill oil 
supplementation on cognition, academic achievement and behaviour in typically developing 
adolescents is investigated. In addition, we try to counteract design issues such as 
bioavailability, baseline Omega-3 Index and study population which could have caused 
neutral results in earlier trials [21]. 
Bioavailability 
The bioavailability of DHA and EPA depends mostly on the form in which they are bound 
and the food matrix with which the DHA and EPA are taken. Most previous trials have 
chosen unemulsified ethyl-ester or triglycerides and have advised participants to consume 
capsules with breakfast, both of which lead to lower absorption of the LCPUFAs [21–23]. 
In Food2Learn, krill oil is used as supplementation. Krill oil contains 30–65% of the EPA 
and DHA in the phospholipid form. Phospholipids have amphiphilic properties and 
therefore emulsifying properties that enhance absorption [24–26] and are also better 
absorbed by the brain than triglycerides [27]. Another factor important for DHA and EPA 
absorption is the presence of fat in the meal. Some studies report a trifold higher LCPUFA 
absorption when LCPUFA capsules are taken with a high fat meal, compared to a low fat 
meal [23]. This is hypothesised to be caused by the stimulating effect of fat on pancreatic 
lipase [22]. Therefore, participants in Food2Learn are asked to consume the capsules with 
dinner, the fattiest meal of the day [28].  
Baseline Omega-3 Index  
In earlier studies, participants were often recruited without researchers knowing the 
baseline Omega-3 fatty acid status of participants. This has led to participants with a wide 
range in statuses being included, while one can expect that effects of supplementation are 
more likely in participants with a low Omega-3 fatty acid status. This wide range in statuses 
can lead to similar end Omega-3 statuses in the placebo and treatment groups and thus 
similar outcome measures. To increase the chance of observing any effects of 
supplementation, participants for Food2Learn are recruited on the basis of a low Omega-3 
Index (< 5%) [29]. The Omega-3 Index is defined as EPA plus DHA in erythrocytes and is 
based on a standardised analytical method [21]. Additionally, to counteract interpersonal 
variability in the uptake/ metabolism of the LCPUFA supplementation, a dose adjustment 
based on the individual Omega-3 Index blood levels after 3 months of supplementation 
was applied. This dose adjustment should ensure that participants in the active treatment 
group achieve the target range of 8–11%. This target range is an estimate based on the 
Omega-3 Index associated with the lowest mortality risk in coronary heart disease [29].  
Study design of Food2Learn 
61 
Study population  
Richardson showed that LCPUFA supplementation was especially beneficial in the 20% 
lowest performing children [30]. In the Netherlands, secondary education is divided into 
three levels: pre-university, higher general and lower general secondary education (LGSE). 
Approximately 38% of all adolescents attend LGSE [31]. LGSE is further divided into four 
sublevels. For the current study, students from the highest sublevel, the theoretical learning 
pathway (TLP), were recruited. Approximately 40% of students attending LGSE are in the 
TLP. 
Objective and hypotheses 
The primary objective of Food2Learn is to study the effect of an increase in the Omega-3 
Index due to 1-year of krill oil supplementation in 13–15 year-old typically developing 
adolescents from LGSE on cognitive performance. The secondary objective is to study the 
effect of an increase in the Omega-3 Index due to 1 year of krill oil supplementation in 
13-15 year-old typically developing adolescents from LGSE on academic achievement and 
behaviour. Furthermore, the relationship between Omega-3 Index and cognitive 
performance, academic achievement and behaviour in typically developing adolescents will 
be further explored. The hypothesis is that 1 year krill oil supplementation and a higher 
Omega-3 Index will lead to improved cognition, academic achievement scores and 
behaviour scores in typically developing Dutch adolescents attending the LGSE. The third 
objective is to study the effect of an increase in the Omega-3 Index due to 1 year of krill oil 
supplementation in 13–15-year-old typically developing adolescents from LGSE on sleep 
quality and quantity, and visual processing. 
Methods 
Study design 
Food2Learn is a double-blind, randomised, placebo-controlled trial, with repeated 
measurements (at baseline, 3 months, 6 months and 12 months) to study the effect of an 
increase in the Omega-3 Index due to 1-year of krill oil supplementation on cognitive 
performance, academic achievement and behaviour of second year LGSE students. 
Informed consent was obtained from all participants and their parent(s) and/or 
guardian(s). 
This trial is registered at The Netherlands Trial Register (NTR4082) and at 
ClinicalTrials.gov (NCT02240264). The Items from the WHO Trial Registration Data Set 
can be found in the online supplementary files. 
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Participants 
Inclusion and exclusion criteria 
All second year students attending high school at the LGSE TLP level with a baseline 
Omega-3 Index < 5% were eligible to participate in the study. Students were excluded if 
they had (1) a baseline Omega-3 Index of > 5%, (2) an allergy to fish or shellfish or (3) 
haemophilia. 
Determination of participation 
Participants could discontinue participation at any time during the study. If a participant 
indicated that he/she wished to stop supplementation, the reason for discontinuation was 
asked and the participant was asked to continue with the test sessions according to the 
intention to treat principle, but both were voluntary. 
Recruitment and screening 
One hundred and twenty-three schools in the southern provinces of the Netherlands were 
contacted to participate in Food2Learn. Eventually, 17 school boards gave approval. The 
target group was then approached in a classroom setting. A video explaining the study was 
shown, the capsules and the finger prick were shown, and any questions were answered. 
Students received an information letter and were asked to discuss the study with their 
parents. If requested, a voluntary additional information evening was held. If the student 
wanted to participate, the informed consent form had to be signed by the student and 
parent(s) and/or guardian(s) and handed in to the researchers at site. All students who 
handed in an informed consent form received a finger prick to determine the Omega-3 
Index; no other pre-screening methods were used. If the participant completed the whole 
study, he/she received a voucher for the cinema. In cohort I of Food2Learn, the needed 
number of participants was not enrolled; therefore, a second cohort was added to the 
study. Currently, cohort II is in progress. 
Randomisation and blinding 
On entry, participants received a participant number. An independent researcher was 
responsible for treatment allocation. The participants were stratified by sex and were 
randomly allocated to the placebo or krill oil group by an independent researcher. Equal 
numbers of participants were randomised to the active treatment and the placebo groups. 
The group allocation sequence was computer generated and executed by an independent 
researcher. Researchers at site were only told which box number had to be given to which 
participant number and were not aware how boxes were divided over placebo/krill oil 
group. To prevent the risk of unblinding, each participant received a personalised box with 
capsules. The packaging and the capsules themselves were identical for the active treatment 
and placebo groups. The capsules were coloured black to hide the redness of krill oil. 
Furthermore, a vanilla odour was added to hide any possible fishy smell/taste. Neither the 
researchers at the site nor the participants were informed of group allocation prior to the 
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completion of the whole study (cohorts I and II). Preliminary unblinding of the trial was to 
be executed only by an independent researcher in the case of severe adverse effects. 
Procedure—baseline 
Before starting supplementation, participants underwent a neuropsychological test battery, 
filled out questionnaires and performed a standardised math test (see outcome measure, 
Figure 4.1 and Table 4.1); these tests were executed at school in a classroom setting. Three 
cognitive tests were administered in a group setting (10 students max): The Letter Digit 
Substitution Test (LDST), D2 test of Attention (D2) and Digit Span Forward (DSF) and 
Backward (DSB). These tests were led by one researcher via a standardised protocol, while 
one or two other researchers (depending on group size) made sure that participants 
understood the tests and complied with the protocol. All tests were first explained and a 
practice version was always completed by the participants. After this group test session, all 
participants filled out the questionnaires individually, during which participants were called 
one by one to perform the Stroop Test and Concept Shifting Test (CST) individually under 
supervision of one researcher. After data collection, participants completed a standardised 
computerised math test, in silence, in a classroom setting. 
 
 
Figure 4.1: Timeline of study  
NPT = neuropsychological tests, at all time points equal: The Letter Digit Substitution Test, D2, digit span 
forward and backward, Concept Shifting Test and Stroop Test.  
1 Eye tracking was done in a subsample of participants 2 Sleep was measured in a subsample of participants in the 
second year with a combination of ActivPal and self-reported sleep diary, furthermore participants filled out the 
Adolescent Sleep-Wake Scale and the Adolescents Sleep Hygiene Scale. 3 Saliva was collected to determine Apoe 
status  
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Table 4.1: questions and questionnaires at different time-points  
Question / questionnaire  Before Baseline 3 months 6 months 12 months 
Weight X     
Length X     
Level of parental education X     
Nationality   X    
Country of birth  X    
Language spoken at home  X    
School carrier (focus chosen, skipping or 
staying behind a year) 
 X    
Medical: medicine use, diagnoses, 
glasses/contacts 
 X  X X 
Allergies  X    
Use of vitamins and fish oil  X    
Pubertal Development Scale  X   X 
Alcohol and cigarette use  X   X 
Fish Questionnaire  X  X X 
Centre for Epidemiologic Studies 
Depression Scale 
 X  X X 
The Rosenberg Self-Esteem Scale  X  X X 
Motivated Strategies for Learning 
Questionnaire 
 X  X X 
Self-reported capsule adherence   X X X 
Self-reported side-effects     X X 
Self-reported group allocation     X 
Procedure—3 months follow-up 
After 3 months of supplementation, participants again received a finger prick to determine 
the Omega-3 Index. Blood analyses and dose adjustments were executed by a researcher 
who was not actively involved in the study. When the increase in the Omega-3 Index in a 
participant of the active group was insufficient, the supplementation dose was adjusted in 
this participant and in one participant in the control group with the same number of 
capsules. This was carried out to ensure blinding of the researchers. However, the Omega-3 
Indexes of the participants of cohort I were found to be significantly lower than the target 
range at 3 months. Therefore, it was decided that the dose of all participants would be 
increased to eight capsules per day. Furthermore, it was decided to increase the starting dose 
of the cohort II to eight capsules per day to ensure that the target range would be achieved. 
Procedure—6 months and 12 months follow-up 
The procedure completed at baseline was repeated again after 6 months. This process was 
again repeated after 12 months of intervention. The standardised math test was only 
completed at baseline and after 12 months (for an overview, see Figure 4.1). 
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Intervention 
After baseline neuropsychological testing, participants started with supplementation. The 
krill oil contained at least 40 g phospholipids per 100 g krill oil. The fatty acid profile of 
these phospholipids was at least 14 g EPA and 6 g DHA. The remaining composition of 
krill oil was mainly triglycerides (32%), free fatty acids (6–7%) and small amounts of 
cholesterol, cholesterol esters, ash and a trace amount of astaxanthin (80 μg/100 g). One 
krill oil capsule contained a total of 0.5 g krill oil, which supplied 65 mg EPA and 35 mg 
DHA. For the placebo capsules, a fatty acid mixture was chosen that reflects the fatty acid 
composition of the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18: 1–9, 
16.7% C18:2–6, 2.1% C18:3–3, 0% C20:4–6 and 14.8% other compounds) [32]. The 
placebo contained a mix of olive oil, corn oil, palm oil and medium chain triglycerides in 
the following ratio 4:4:9:3. The placebo contained no marine n-3 fatty acids. In cohort I, 
participants were instructed to start with an intake of four capsules per day containing in 
total 260 mg EPA and 140 mg DHA, almost the daily recommended amount of 450 mg of 
EPA + DHA per day as set by the Dutch health council [33]. In cohort II, the starting dose 
was increased to eight capsules, as cohort I showed that the initial dose of 400 mg DHA + 
EPA did not lead to a sufficient increase in the Omega-3 Index. Eight capsules provide 520 
mg EPA and 280 mg DHA per day. To increase adherence to the protocol, participants 
could receive a daily text message reminder. Furthermore, participants who had an 
insufficient increase in their blood Omega-3 Index after 3 months of supplementation and 
an equal number of participants from the placebo, as noted by the independent researcher, 
received a phone call to try to increase adherence. Participants were asked to return all left-
over capsules at the end of the study or when they decided to drop out, so adherence could 
be calculated on the basis of the number of capsules returned. 
Outcome measures—cognitive performance measurements 
The cognitive tests were selected on the basis of their usability as determined in other 
studies with adolescents reference scores are thus available. These tests have also previously 
been shown to increase activation of the frontal cortex, the area of the brain associated 
with the accumulation of DHA [14], furthermore the prefrontal cortex is the brain area 
most in development during adolescence [9]. Tests used were: the LDST to measure speed 
of information processing, D2 as a measure for selective attention, DSF and DSB as 
measures of short-term memory and working memory, CST as a measure for cognitive 
shifting and Stroop task as a measure for cognitive inhibition. For an explanation of the 
tests, see online supplementary appendix A. 
Academic achievement 
Math test 
All students complete a standardised math test at baseline and at the end of the study. This 
math test is based on the end terms as set by the Dutch government. The test is computer-
based and participants have to take the test without a calculator [34]. 
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School performance 
All schools provide school grades (ranging from 1.0=very bad to 10.0=excellent) of 
participants for the subjects Dutch, English and Mathematics. These subjects are chosen as 
they are considered core subjects and are therefore compulsory for all students. 
Behaviour measurements 
Absenteeism 
Schools provide the number of hours the participants were absent and the reason for 
absence. 
Motivation 
The Motivated Strategies for Learning Questionnaire consists of two parts: a motivation 
part and a learning strategies part [35]. In this study, only the motivation part is used. The 
motivation section assesses student goals and value beliefs concerning school, their beliefs 
about their skills to succeed in school and their test anxiety. The internal consistency for 
the section measuring motivation is very good (α between 0.62 and 0.93) [36]. 
Mood 
Mood is assessed with the Dutch version of the Centre for Epidemiologic Studies 
Depression Scale (CES-D) [37], a tool sensitive for detecting depressive symptoms and 
distinguishing between depressed and non-depressed individuals [38,39]. The CES-D has a 
high internal reliability in adolescents (α=0.88) [40]. The 20 questions questionnaire 
assesses the presence of depressive symptoms in the past week. Total sum scores are 
calculated (range 0-60), with higher scores indicating more depressive symptoms. 
Self-worth/self-esteem 
The Rosenberg Self-Esteem Scale (RSE) is a measure of self-esteem [41]. The internal 
reliability in adolescents is high (α=0.88) [42,43] and construct validity has been shown [43]. 
This test consists of 10 questions requiring participants to indicate their level of agreement 
with a series of statements about themselves. Higher scores indicate a higher self-esteem. 
Other measurements 
Fish consumption is measured with a short, validated self-reported questionnaire [44]. The 
pubertal phase is assessed with the Pubertal Development Scale [45]. This questionnaire 
assesses the pubertal status of adolescents by asking to what extent a number of bodily 
changes related to puberty are present. Furthermore, nationality, country of birth of the 
participants and parents and/or guardians, language spoken at home, use of medicine, 
diagnosis related to learning (e.g., ADHD or autism), allergies, whether the student wears 
glasses or contact lenses, whether he/she takes vitamins or fish oil supplements, drinking 
and smoking behaviour were assessed via a questionnaire. Finally, questions about school 
career such as whether the participant has ever skipped or repeated a year are asked. At 
follow-up, additional questions with regard to adherence, side effect and group allocation 
are asked. For an overview, see Table 4.1. 
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Biological measurements 
Blood analysis 
Blood samples are collected with a finger prick. First, the finger of the participants is 
disinfected with alcohol. Then a prick with an automated one-time use lancet is 
administered at the fingertip after which blood drops are collected on specially prepared 
filter paper. Erythrocyte fatty acid compositions are analysed according to the HS-Omega-3 
Index methodology as described previously [29,46]. Fatty acid methyl esters are generated 
by acid transesterification and analysed by gas chromatography using hydrogen as the 
carrier gas. Fatty acids are identified by comparison with a standard mixture of fatty acids. 
Results are given as the Omega-3 Index, which is EPA + DHA expressed as a percentage 
of total identified fatty acids after response factor correction and a correction for the fact 
that whole blood was used instead of erythrocytes [46]. Furthermore, the concentrations of 
26 other fatty acids are determined. The coefficient of variation for EPA plus DHA 
typically is 5%. Analyses are quality controlled according to DIN ISO 15189. 
ApoE4- analyses 
Apolipoprotein E (APOE, protein; Apoe, gene) is a protein which plays an important role 
in lipid homeostasis. The Apoe gene has four polymorphisms: ε2, ε3 and ε4. Studies have 
suggested that ε4 carriers have an increased risk of late-onset Alzheimer’s disease and 
accelerated brain atrophy and that healthy carriers of the ε4 allele have poorer performance 
on neuropsychological tests [47]. Furthermore, the effect of an Omega-3 supplement on 
cognitive performance might be modulated by the presence of ε4 polymorphisms [48]. 
However, not all studies show an interaction between Apoe status and cognitive 
performance [49–51]. To elucidate whether Apoe status interacts with cognitive 
performance in typically developing adolescents consuming LCPUFA supplementation, all 
participants donate 2 mL saliva for the determination of Apoe status. The analyses of the 
Apoe gene will be executed by the departments of Molecular Genetics and Clinical 
Genetics of the Maastricht University Medical Center+, according to the procedure as 
described by the Duke University Clinical Molecular Diagnostics Laboratory [52]. Shortly, 
PCR amplification followed by Sanger DNA sequencing is used to determine the genotype 
of two single nucleotide polymorphisms in the APOE gene Rs7412 and Rs429 358 and the 
associated APOE genotype. With the participant’s and parents’ approval (indicated in the 
informed consent form), samples will be kept for a maximum of 15 years. 
Sub studies 
All students entering the main study in cohort II were asked to participate in the sleep 
study. Pupils of four schools (due to logistic constraints) in both cohorts were asked to 
participate in the eye tracking study. Participation in both sub studies was voluntary and 
pupils could participate in the main study regardless of participation in the sub studies. 
Sub study I: eye tracking 
A subsample of participants (n=33) participated in an eye tracking study at baseline, 6 
months and 12 months. Eye tracking is a method in which eye movements of participants 
are recorded and can be used to calculate measures such as number of blinks, number of 
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fixations and total duration of fixations. Eye movement measures can help reveal 
underlying cognitive processes such as amount of visual processing, what participants are 
processing and the mental effort expended. In Food2Learn, eye tracking is used to measure 
the effect of krill oil supplementation on cognitive processing in the form of visual 
processing and mental effort (for more information, see online supplementary appendix B). 
Sub study II: sleep 
In cohort II, a subsample (n=64) is included in a study investigating the relation between 
increasing Omega-3 fatty status and sleep quality and duration. Montgomery et al. [53] 
showed that DHA supplementation in children led to increased sleep duration and fewer 
waking episodes per night. Since sufficient sleep is essential for good health, cognitive 
performance and school performance [54–56], and insufficient sleep is common in 
adolescents[57,58], this was included as a sub study. Participants wore an ActivPAL3 
(Paltechnologies, Glasgow, UK) accelerometer for seven consecutive days at baseline and 
seven consecutive days after 12 months of intervention. With the help of algorithms, 
ActivPal data can be used to determine sleep duration and quality. Furthermore, 
participants filled out a diary in which they noted their bedtime and wake-up time during 
this week. Finally, they filled out the Adolescent Sleep-Wake Scale and the Adolescent 
Sleep Hygiene Scale [59]. 
Power calculation 
Originally, the sample size calculation was based on a power of 0.8 and a medium effect 
size of 0.3 and analysis of variance (ANOVA) as the analysis method. However, new 
insights led to the conclusion that not ANOVA but a mixed methods analysis would be 
more appropriate. The power analyses were thus redone for this. Also, the new power 
calculation took into account that there were multiple measurement moments and that 
dropout is possible. Multiple calculation in RMASS software with standardised input 
numbers such as an average effect size of d=0.25 at 6 month follow-up and an equal or 
10% higher effect size at 12 months follow-up and a dropout of 25% per measurement 
moment (and thus a total dropout rate of 43%), an error variation varying from 0.4 to 0.5 
and a intercept variation of 0.3 to 0.5 with a slope variation of 0.0 (fixed effects), showed 
that between 183 and 285 participants at baseline should be sufficient to achieve a power 
of 0.8. The power calculation for the sleep sub study suggested that 42 students (21 in the 
placebo group and 21 in the krill oil group) were sufficient. This number of students is 
based on power calculation with a power of 0.8, α = 0.05 and the ability to detect a 20 min 
difference in sleep duration. For the eye tracking study, no power calculation was executed. 
As a study looking at the effect of krill oil supplementation on cognitive processing 
measured with eye tracking had never been executed before, we did not believe that a 
reliable power calculation would be possible. 
Data analysis plan 
Data are scored by one of the researchers and both D2 and CST tests are checked a second 
time by another researcher; 10% of the LDST and digit span are also checked by a second 
researcher. All data are entered twice and any discrepancies between the two data entries 
Study design of Food2Learn 
69 
are checked and corrected. Data analysis will be performed by both the intention-to-treat 
procedure and related to the blood Omega-3 Index. The main effects of the intervention 
(krill oil condition in intention-to-treat analyses) and of the Omega-3 Index on the change 
from baseline with regard to cognitive test scores (primary), scores on questionnaires 
(secondary) and school grades average (z-score; secondary) will be estimated using mixed 
models that account for the correlation of repeated measurements within participants. All 
estimates will be adjusted for drinking behaviour, smoking behaviour, level of parental 
education, age, sex, body mass index, pubertal status, cohort number and time trends 
(baseline, 6 months, 12 months) if necessary. Furthermore, moderation analyses for sex 
and APOE status will be executed and, if necessary, separate group analyses will be 
executed. Finally, an interaction between treatment condition and time trend will be used to 
estimate the difference between the groups regarding time trend effects. After these 
analyses, secondary sensitivity analyses will be executed with treatment adherence instead 
of intervention condition. These analyses will also be run with the sub scores of the 
neuropsychological tests as outcome variables. 
Study monitoring 
The study is monitored by the METC, NWO (Dutch Scientific Organisation) and the 
director clinical trials research and development of AkerBiomarine. The METC and NWO 
receive a yearly update. NWO had one site visit. The director clinical trials research and 
development visits the research site twice every year and checks whether all data are 
complete and the research is executed according to Good Clinical Practice. The risk of 
participating in the study is judged to be very low as no severe adverse effects of krill oil are 
known; however, any adverse effects will be registered and the METC will be notified. 
Ethics and dissemination 
Any major amendments to the protocol will be submitted to the Medical Ethics Committee 
for approval. A signed and dated informed consent form is required from all participants 
signed by the participant and parent(s)/guardian(s). All collected data will be linked to the 
participant number and only the principal investigators will have access to the non-
anonymised data. The principal investigators have access to all trial data. The results of the 
study will be disseminated on group level to participants and schools. The results of this 
study will also be presented at international conferences and published in peer-reviewed 
journals. 
Included participants 
In total, 288 students provided informed consent. No blood sample was obtained for four 
participants. One participant suffered severe hyperventilation after the blood sampling and 
was excluded. Two participants withdrew their consent before the study started. Fifteen 
participants had an Omega-3 Index of > 5%. Thus, 266 participants were included in the 
supplementation study; baseline characteristics can be found in Table 4.2. 
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Table 4.2. Baseline participant characteristics and blood values of selected fatty acids. 
Participant characteristics Mean ± SD or  
N [%] 
N Fatty acid 
(%wt/wt of total FA) 
Mean ± SD  
(N=261) 
Age (years) 14.10 ± 0.49 266 Omega-3 Index 3.83 ± 0.60 
Male/Female 127/139 [47.7/52.3%] 266 DHA 22:6n-3 2.58 ± 0.49 
Smoking no/yes1 239/26 [90.2/9.8%] 265 EPA 20:5n-3 0.39 ± 0.16 
BMI 19.92 ± 3.00 248 AA 20:4n-6 11.19 ± 1.25 
Underweight, healthy 
weight, overweight2  
28 (10.5%)  
182 (68.4%)  
39 (14.7%)  
 ObA 22:5n-6 0.43 ± 0.10 
Alcohol units per week3 0.46 ± 1.77 266   
LPE4 5.07 ± 1.52 248   
1 Smoking was defined as anybody who indicated to smoke more than 0 cigarettes per week. 2 BMI cut-off points: 
Boys 14 years : underweight < 16.40, healthy weight 16.41-22.61, overweight > 22.62. Girls 14yr: underweight  
< 16.87, healthy weight 16.88-23.33, overweight > 23.34. 3 Alcohol units per week was operationalised as number 
of day per week that alcohol is consumed times units per consumption moment. A unit of alcohol was defined as 
one standard unit e.g., one wineglass of wine,4 Highest level of parental education. Parents/guardians were asked 
to report both parents’/guardians educational level. Socioeconomic status was defined as the highest educational 
level of the parents/guardians. 
Discussion 
To the best of our knowledge, Food2Learn is the first intervention study in which the 
influence of an increase in the Omega-3 Index due to 1 year of krill oil supplementation on 
cognition, academic achievement and behaviour in typically developing adolescents is 
assessed. Adolescence is a period of brain maturation in general, and especially of the 
higher order cognitive skills, as well as social and emotional behaviour. Furthermore, 
adolescence is a critical phase in the school career of students.  
All in all, adolescence is an important life period to study the association between 
LCPUFAs and cognition/school performance. Food2Learn is also one of the first studies 
which has recruited the participants based on a low Omega-3 Index and which makes use 
of a personalized dose adjustment based on individual response to supplementation. The 
sub studies will shed light on areas that have not received much attention of the LCPUFA 
research community yet: sleep quantity and quality and visual processing and mental 
workload. The first students were enrolled in March of 2014; the final data will be collected 
in August 2016. The first longitudinal results of Food2Learn are expected in the second 
semester of 2016. 
  
Study design of Food2Learn 
71 
References 
1.  Assisi, A.; Banzi, R.; Buonocore, C.; Capasso, F.; Muzio, V. Di; Michelacci, F.; Renzo, D.; Tafuri, G.; Trotta, 
F.; Vitocolonna, M.; Garattini, S. Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty 
acids in cognitive development and neurological disorders. Int Clin Psychopharmacol 2006, 21, 319–336. 
2.  Parletta, N.; Milte, C.; Meyer, B. J. Nutritional modulation of cognitive function and mental health. J. Nutr. 
Biochem. 2013, 24, 725–743. 
3.  Morris, M.; Evans, D.; Tangney, C.; Bienias, J.; Wilson, R. Fish consumption and cognitive decline with age 
in a large community study. Arch. Neurol. 2005, 62, 1849–1853. 
4.  Morris, M.; Evans, D.; Bienias, J.; Tangney, C.; Bennett, D.; Wilson, R.; Aggarwal, N.; Schneider, J. 
Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60, 940–
946. 
5.  Uauy, R.; Dangour, A. D. Nutrition in brain development and aging: role of essential fatty acids. Nutr. Rev. 
2006, 64, S24–S33. 
6.  Milte, C.; Sinn, N.; Howe, P. Polyunsaturated fatty acid status in attention deficit hyperactivity disorder, 
depression, and Alzheimer’s disease: Towards an omega-3 index for mental health? Nutr. Rev. 2009, 67, 573–
590. 
7.  Gogtay, N.; Giedd, J. N.; Lusk, L.; Hayashi, K. M.; Greenstein, D.; Vaituzis, A. C.; Nugent, T. F.; Herman, 
D. H.; Clasen, L. S.; Toga, A. W.; Rapoport, J. L.; Thompson, P. M. Dynamic mapping of human cortical 
development during childhood through early adulthood. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 8174–8179. 
8.  Crone, E. A.; Richard Ridderinkhof, K. The developing brain: From theory to neuroimaging and back. Dev. 
Cogn. Neurosci. 2011, 1, 101–109. 
9.  Crone, E. A.; Dahl, R. E. Understanding adolescence as a period of social–affective engagement and goal 
flexibility. Nat. Rev. Neurosci. 2012, 13, 636–650. 
10.  Paus, T. Mapping brain maturation and cognitive development during adolescence. Trends Cogn. Sci. 2005, 9, 
60–68. 
11.  Toga, A. W.; Thompson, P. M.; Sowell, E. R. Mapping brain maturation. Trends Neurosci. 2006, 29, 148–159. 
12.  Svennerholm, L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J. 
Lipid Res. 1968, 9, 570–579. 
13.  Sastry, P. S. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res. 1985, 24, 69–176. 
14.  McNamara, R. K.; Able, J.; Jandacek, R.; Rider, T.; Tso, P.; Eliassen, J.; Alfieri, D.; Weber, W.; Jarvis, K.; 
Delbello, M.; Strakowski, S.; Adler, C. M. C. Docosahexaenoic acid supplementation increases prefrontal 
cortex activation during sustained attention in healthy boys : a placebo-controlled , dose-ranging , functional 
magnetic resonance imaging study. Am. J. Clin. Nutr. J Clin Nutr 2010, 91, 1060–1067. 
15.  Chen, C. T.; Liu, Z.; Ouellet, M.; Calon, F.; Bazinet, R. P. Rapid beta-oxidation of eicosapentaenoic acid in 
mouse brain: an in situ study. Prostaglandins. Leukot. Essent. Fatty Acids 2009, 80, 157–63. 
16.  Kim, J.; Winkvist, A.; Äberg, M.; Äberg, N.; Sundberg, R.; Torén, K.; Brisman, J. Fish consumption and 
school grades in Swedish adolescents: A study of the large general population. Acta Paediatr. 2010, 99, 72–77. 
17.  Äberg, M.; Äberg, N.; Brisman, J.; Sundberg, R.; Winkvist, A.; Torén, K. Fish intake of Swedish male 
adolescents is a predictor of cognitive performance. Acta Paediatr. 2009, 98, 555–560. 
18.  De Groot, R.; Ouwehand, C.; Jolles, J. Eating the right amount of fish: inverted U-shape association 
between fish consumption and cognitive performance and academic achievement in Dutch adolescents. 
Prostaglandins. Leukot. Essent. Fatty Acids 2012, 86, 113–117. 
19.  Mamalakis, G.; Kiriakakis, M.; Tsibinos, G.; Hatzis, C.; Flouri, S.; Mantzoros, C.; Kafatos, A. Depression and 
serum adiponectin and adipose omega-3 and omega-6 fatty acids in adolescents. Pharmacol. Biochem. Behav. 
2006, 85, 474–479. 
20.  Orth, U.; Robins, R. W.; Roberts, B. W. Low self-esteem prospectively predicts depression in adolescence 
and young adulthood. J. Pers. Soc. Psychol. 2008, 95, 695–708. 
21.  Von Schacky, C. Omega-3 fatty Acids in cardiovascular disease - An uphill battle. Prostaglandins Leukot. 
Essent. Fat. Acids 2014, 92, 41–47. 
22.  Schuchardt, J. P.; Hahn, A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fat. 
Acids 2013, 89, 1–8. 
23.  Lawson, L. D.; Hughes, B. G. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil 
triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem. Biophys. Res. Commun. 1988, 
156, 960–963. 
Chapter 4 
72 
24.  Köhler, A.; Sarkkinen, E.; Tapola, N.; Niskanen, T.; Bruheim, I. Bioavailability of fatty acids from krill oil, 
krill meal and fish oil in healthy subjects–a randomized, single-dose, cross-over trial. Lipids Health Dis. 2015, 
14, 1–10. 
25.  Ulven, S. M.; Kirkhus, B.; Lamglait, A.; Basu, S.; Elind, E.; Haider, T.; Berge, K.; Vik, H.; Pedersen, J. I. 
Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in 
healthy volunteers. Lipids 2011, 46, 37–46. 
26.  Ramprasath, V. R.; Eyal, I.; Zchut, S.; Jones, P. J. H. Enhanced increase of omega-3 index in healthy 
individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health 
Dis. 2013, 12, 178. 
27.  Wijendran, V.; Lawrence, P.; Diau, G.-Y.; Boehm, G.; Nathanielsz, P. W.; Brenna, J. T. Significant utilization 
of dietary arachidonic acid is for brain adrenic acid in baboon neonates. J. Lipid Res. 2002, 43, 762–767. 
28.  Van Rossum, C. T. M.; Fransen, H. P.; Verkaik-Kloosterman, J.; Buurma-Rethans, E. J. M.; Ocké, M. C. 
Dutch National Food Consumption Survey 2007-2010 - Diet of children and adults aged 7 to 69 years; Bilthoven, the 
Netherlands, 2011; 
29.  Harris, W. S.; Von Schacky, C. The Omega-3 Index: a new risk factor for death from coronary heart disease? 
Prev Med 2004, 39, 212–220. 
30.  Richardson, A.; Montgomery, P. The Oxford-Durham study: a randomized, controlled trial of dietary 
supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115, 
1360–1366. 
31.  Centraal Bureau Voor de Statistiek (Statistics Netherlands) VO; leerlingen, onderwijssoort in detail, leerjaar 
(Secondary education, students, type of education in detail per teaching year) Available online: 
http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLnl&PA=80040NED&LA=nl (accessed on Jul 
22, 2015). 
32.  Bull, N. L.; Day, M. J.; Burt, R.; Buss, D. H. Individual fatty acids in the British household food supply. 
Hum. Nutr. 1983, 37, 373–377. 
33.  Health Council of the Netherlands Guidelines for a healthy diet 2006.; The Hague, 2006; 
34.  AMN Product Information Math Test (Product Informatie Blad - Rekentoets) Available online: 
http://www.amn.nl/amn-voor-scholen/taal-en-rekentoetsen/ (accessed on Aug 12, 2015). 
35.  Duncan, T.; McKeachie, W. The Making of the Motivated Strategies for Learning Questionnaire. Educ. 
Psychol. 2005, 40, 117–128. 
36.  Pintrich, P. R.; Smith, D. A. F.; Garcia, T.; Mckeachie, W. J. Reliability and Predictive Validity of the 
Motivated Strategies for Learning Questionnaire (Mslq). Educ. Psychol. Meas. 1993, 53, 801–813. 
37.  Radloff, L. S. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. 
Appl. Psychol. Meas. 1977, 1, 385–401. 
38.  Weissman, M. M.; Sholomskas, D.; Pottenger, M.; Prusoff, B. A.; Locke, B. Z. Assessing depressive 
symptoms in five psychiatric populations: a validation study. Am. J. Epidemiol. 1977, 106, 203–214. 
39.  Beekman, A.; Deeg, D. J.; Van Limbeek, J.; Braam, A.; De Vries, M. Z.; Van Tilburg, W. Criterion validity of 
the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of 
older subjects in The Netherlands. Psychol. Med. 1997, 27, 231–235. 
40.  Stockings, E.; Degenhardt, L.; Lee, Y. Y.; Mihalopoulos, C.; Liu, A.; Hobbs, M.; Patton, G. Symptom 
screening scales for detecting major depressive disorder in children and adolescents: A systematic review and 
meta-analysis of reliability, validity and diagnostic utility. J. Affect. Disord. 2015, 174, 447–463. 
41.  Stoodley, B.; Rosenberg, M. Society and the Adolescent Self-Image. Am. Sociol. Rev. 1966, 31, 125. 
42.  Gray-Little, B.; Williams, V. S. L.; Hancock, T. D. An Item Response Theory Analysis of the Rosenberg 
Self-Esteem Scale. Personal. Soc. Psychol. Bull. 1997, 23, 443–451. 
43.  Robins, R. W.; Hendin, H. M.; Trzesniewski, K. H. Measuring Global Self-Esteem: Construct Validation of a 
Single-Item Measure and the Rosenberg Self-Esteem Scale. Personal. Soc. Psychol. Bull. 2001, 27, 151–161. 
44.  de Groot, R.; van Boxtel, M.; Schiepers, O.; Hornstra, G.; Jolles, J. Age dependence of plasma phospholipid 
fatty acid levels: potential role of linoleic acid in the age-associated increase in docosahexaenoic acid and 
eicosapentaenoic acid concentrations. Br. J. Nutr. 2009, 102, 1058–1064. 
45.  Petersen, A. C.; Crockett, L.; Richards, M.; Boxer, A. A self-report measure of pubertal status: Reliability, 
validity, and initial norms. J. Youth Adolesc. 1988, 17, 117–133. 
46.  Harris, W. S.; von Schacky, C.; Park, Y. Standardizing methods for assessing omega-3 fatty acid biostatus. In 
The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention; McNamara, R. K., Ed.; Nova 
Science Publishers, Inc, 2013; pp. 385–398. 
47.  Savitz, J.; Solms, M.; Ramesar, R. Apolipoprotein E variants and cognition in healthy individuals: A critical 
opinion. Brain Res. Rev. 2006, 51, 125–135. 
Study design of Food2Learn 
73 
48.  Plourde, M.; Vohl, M. C.; Vandal, M.; Couture, P.; Lemieux, S.; Cunnane, S. Plasma n-3 fatty acid response 
to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V 
polymorphism in men. Br. J. Nutr. 2009, 102, 1121–1124. 
49.  Stonehouse, W.; Conlon, C. A.; Podd, J.; Hill, S. R.; Minihane, A. M.; Haskell, C.; Kennedy, D. DHA 
supplementation improved both memory and reaction time in healthy young adults: a randomized controlled 
trial. Am. J. Clin. Nutr. 2013, 97, 1134–1143. 
50.  Turic, D.; Fisher, P. J.; Plomin, R.; Owen, M. J. No association between apolipoprotein E polymorphisms 
and general cognitive ability in children. Neurosci. Lett. 2001, 299, 97–100. 
51.  Deary, I.; Whalley, L.; St. Clair, D.; Breen, G.; Leaper, S.; Lemmon, H.; Hayward, C.; Starr, J. The influence 
of the ε4 allele of the apolipoprotein E gene on childhood IQ, nonverbal reasoning in old age, and lifetime 
cognitive change. Intelligence 2003, 31, 85–92. 
52.  Duke University Health System DUHS Clinical Molecular Diagnostics Laboratory Innovative Testing for 
Better Patient Care APOLIPOPROTEIN E (APOE) GENOTYPING Available online: 
http://dukemolecular.duhs.duke.edu/TemplateTest.aspx?ID=10011&MenuItem=3 (accessed on May 9, 
2016). 
53.  Montgomery, P.; Burton, J.; Sewell, R.; Spreckelsen, T.; Richardson, A. Fatty acids and sleep in UK children: 
subjective and pilot objective sleep results from the DOLAB study - a randomized controlled trial. J. Sleep 
Res. 2014, 23, 364–388. 
54.  Lim, J.; Dinges, D. F. A meta-analysis of the impact of short-term sleep deprivation on cognitive variables. 
Psychol. Bull. 2010, 136, 375–389. 
55.  Hofman, W. F.; Steenhof, L. Sleep Characteristics of Dutch Adolescents are Related to School Performance. 
Sleep-Wake Res. Netherlands 1997, 8, 51–55. 
56.  Wolfson, A. R.; Carskadon, M. A. Understanding adolescents’ sleep patterns and school performance: a 
critical appraisal. Sleep Med. Rev. 2003, 7, 491–506. 
57.  Foundation, N. S. Teens and sleep. Sleep in America Polls Available online: www.sleepfoundation.org/ 
article/sleep-america-polls/2006-teens-and-sleep. 
58.  Loessl, B.; Valerius, G.; Kopasz, M.; Hornyak, M.; Riemann, D.; Voderholzer, U. Are adolescents chronically 
sleep-deprived? An investigation of sleep habits of adolescents in the Southwest of Germany. Child. Care. 
Health Dev. 2008, 34, 549–556. 
59.  LeBourgeois, M. K.; Giannotti, F.; Cortesi, F.; Wolfson, A. R.; Harsh, J. The relationship between reported 
sleep quality and sleep hygiene in Italian and American adolescents. Pediatrics 2005, 115, 257–265. 
 
  
Chapter 4 
74 
Appendix A: Cognitive Tests 
Letter Digit Substitution Test 
The LDST is a measure of speed of information processing. A nine letter/digit key is noted 
at the top of a page, underneath rows with only letters are printed. Participants are asked to 
fill out as many corresponding numbers as possible in 60 seconds. The total number of 
correctly filled out numbers in 60 seconds is used as a measure of speed of information 
processing. Three version of the LDST are used which have been randomised over schools 
and over test moments. 
D2 Test of Attention 
The D2 test is a paper-pencil task to measure selective attention. Participants are presented 
with 14 rows each consisting of 47 stimuli. Stimuli are the letters d and p with a varying 
number of dashes (between 1 and 4), below, above, or on both sides. Participants are 
instructed to only cross out the d with two dashes (d2) and ignore all other stimuli. 
Participants must process as many stimuli as possible in 20 seconds after which they have 
to continue with the next row without pausing. The following measures per row and in 
total are noted after completion: total number of stimuli processed, number of correctly 
crossed out d2’s, number of d2’s not crossed out, number of stimuli wrongly crossed out. 
The main outcome variable is the concentration performance, this is calculated as the total 
number of correctly cancelled stimuli minus the total number incorrectly cancelled stimuli 
and is used as a measure of concentration. 
Digit Span Forward and Backward 
The Digit Span Forward (DSF) is a measure for short-term memory. The Digit Span 
Backward (DSB) activates the executive component directly and shows the dynamic 
relationship between passive storage and active manipulation of information held in the 
memory. The DSF consists of 10 sequences varying in length (3-8 digits, each length 
twice). Digits are announced by researcher at a rate of 1 digit per second, after completing 
of the sequence participants write down the sequence. The DSB is similar to the DSF, 
except for the fact that it consists of 10 digit sequences varying in length (2-7 digits, each 
length twice) and after completion of the sequence by the researcher, students are asked to 
write down the sequence backwards. The longest digit span is noted, this is the longest 
length sequence of digits for which the participant had correctly written down at least one 
digit sequences. For every test moment a different set of digit sequences is used. 
Concept Shifting Test 
The Concept Shifting Test (CST) is a measure for cognitive shifting. The test consists of 4 
parts. All parts consist of a sheet of paper with 16 small circles that are grouped in one 
large circle. In task A, the small circles are randomly filled with numbers, in task B the 
circles are filled with letters and in test C the circles are filled with both. Students are asked 
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to cross out the items in the correct order (A: 1-2-3-4; B: A-B-C-D; C: 1-A-2-B). Lastly, 
there is Test Zero, which consists of empty circles, where students are asked to cross out 
the circles as fast as possible as a measure of basic motor speed. For all tests the time taken 
to complete and the number of errors is noted. The extra time which is needed to complete 
task C compared to task A and B is attributed to shifting. Three versions of the CST were 
used and these versions were randomised over participants and test moments. 
Stroop test 
The Stroop test provides a measure for cognitive inhibition. The Stroop test consists of 
three cards containing 40 stimuli each: colour names printed in black (Task 1), coloured 
patches (Task 2) and colour names printed in congruent or incongruent colour (Task 3). 
For task 1 participants are asked to read the name out loud, for task 2 participants have to 
name the colour of the patches, and for task 3 participants have to name the ink colour the 
word is printed in. Task 3 is a measure of mental flexibility and ability to inhibit a dominant 
response (reading). An interference score is calculated (Time task 3 – (Time task 1 – Time 
task 2)) this is a measure for inhibition. Three versions of the Stroop are used and the 
versions are randomised over participants and test moment. 
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Appendix B: Eye-tracking 
In Food2Learn, eye tracking is used to measure the effect of krill oil supplementation on 
cognitive processing in the form of perceptual processing and mental effort. Eye 
movement is recorded with a SMI RED 250 system with a temporal resolution of 250Hz. 
The eye tracking apparatus is adapted to the participant’s individual features by the use of a 
9-point calibration and 4-point validation at the start of the procedure. After calibration 
and validation, participants read aloud a 1-page text and then study this text for 3 minutes. 
After this participants are asked to recall as much information as possible, which is scored 
on surface information and detailed information, this is a measure of immediate recall. 
During the reading and recall, eye movement is continuously recorded. Basic parameters 
and paragraph related parameters will be calculated. Basic parameters include number of 
blinks, number of fixations, total duration of fixations, average fixation duration, average 
dispersion of fixation positions, average saccadic amplitude and average saccadic velocity. 
Paragraph related parameters will include time spent on each paragraph (number and 
duration of fixations) time elapsed until first looking a paragraph and amount of times 
going back to a paragraph. 
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Chapter 5 
Association between blood Omega-3 Index 
and cognition in typically developing 
Dutch adolescents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: van der Wurff, I., Von Schacky, C., Berge, K., Zeegers, M., Kirschner, P. 
A., & de Groot, R. (2016). Association between blood omega-3 index and cognition in 
typically developing Dutch adolescents. Nutrients, 8(1), 13.  
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Abstract  
The impact of omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) on cognition is 
heavily debated. In the current study, the possible association between omega-3 LCPUFAs 
in blood and cognitive performance of 266 typically developing adolescents aged 13–15 
years is investigated. Baseline data from Food2Learn, a double-blind and randomized 
placebo controlled krill oil supplementation trial in typically developing adolescents, were 
used for the current study. The Omega-3 Index was determined with blood from a finger 
prick. At baseline, participants finished a neuropsychological test battery consisting of the 
Letter Digit Substitution Test (LDST), D2 test of attention, Digit Span Forward and 
Backward, Concept Shifting Test and Stroop test. Data were analysed with multiple 
regression analyses with correction for covariates. The average Omega-3 Index was 3.83% 
(SD 0.60). Regression analyses between the Omega-3 Index and the outcome parameters 
revealed significant associations with scores on two of the nine parameters. The association 
between the Omega-3 Index and both scores on the LDST (β = 0.136 and p = .039), and 
the number of errors of omission on the D2 (β = 0.053 and p = .007). This is a possible 
indication for a higher information processing speed and less impulsivity in those with a 
higher Omega-3 Index. 
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Introduction 
In recent decades, an increasing interest in the health benefits of long-chain 
polyunsaturated fatty acids (LCPUFAs) has been developed. Aside from its influence on 
cardiovascular health, it has also attracted attention because of its association with mental 
health (ADHD, autism, dyslexia) [1], cognitive functioning of healthy individuals [2–4] and 
cognitive decline in the elderly [5–7]. LCPUFAs and especially docosahexaenoic acid, 
22:6n-3 (DHA), and eicosapentaenoic acid 20:5n-3 (EPA) are involved in many aspects of 
brain functioning such as neuronal membrane fluidity, neurotransmission, signal 
transduction, brain blood flow, and blood-brain barrier integrity [8,9]. The interest in the 
possible positive influence of LCPUFAs on brain functioning has led to a large number of 
both observational and experimental studies (for a review see [10,11]). These studies have, 
however, mainly focused on either diseased populations of infants, children, adults, and the 
elderly. Studies in typically developing adolescents are limited. The current study addresses 
this deficit. Adolescence is a period in which LCPUFAs could be of special importance. 
During adolescence, the brain, especially the prefrontal cortex, undergoes development 
which continues until after age 20 [12,13]. The development of the prefrontal cortex is of 
utmost importance, since this development lays the basis for higher order cognitive 
functions that have been associated with academic achievements [14]. Moreover, the 
prefrontal cortex is a brain region especially enriched in DHA [15], and higher DHA intake 
has been associated with changes in the functional activity of the prefrontal cortex in boys 
aged 8–10 [16]. To our knowledge, three observational studies looking at the association 
between fish intake (the most important source of omega-3 LCPUFAs) and cognitive 
functioning in adolescents have been executed. Kim and colleagues showed that 
adolescents aged 15 years who regularly consumed fish had significantly better academic 
performance than peers who never or hardly ever consumed fish [17]. Åberg et al. 
demonstrated that high fish consumption in boys at age 15 was associated with better 
cognitive performance at age 18 [18]. Lastly, de Groot et al. studied 700 Dutch high school 
students aged 12–18 years. Fish consumption data, end term grades in Dutch, English and 
Math, scores on the Amsterdam Vocabulary Test, and scores on the Youth Self-Report (a 
self-reported measure for attention problems) were collected [19]. Results revealed that 
13.6% of the Dutch adolescents never ate fish, 63.1% ate fish but too little to meet at least 
half of the recommended amount, 16.9% reached half of the recommended amount, and 
6.4% met national guidelines (fish twice per week). Analysis of the variance showed 
significant differences between the four fish consumption groups (never, < 1 per week 
(e.g., 1 time per month), 1 to 2 times per week, > 2 times per week) in vocabulary, and a 
trend for significance was found for the average end term grade. Significant quadratic 
associations (u-shape association) between fish consumption, vocabulary (p = .01), and 
average end term grades (p = .001) were shown. Higher fish intake was associated with a 
more advanced vocabulary and an almost significantly higher average end term grade. 
However, eating more fish than the recommended amount (> 2 fish portions/week) 
seemed to no longer be beneficial. Overall, the observational studies in adolescents point to 
a beneficial association between fish intake (the main source of the omega-3 LCPUFAs 
DHA and EPA) and school grades. Fish consumption is the most important dietary source 
of LCPUFAs but not the only source [20]. 
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Moreover, there is a large interpersonal variability in the uptake of LCPUFAs [21]. 
Thus, to be sure about the association between LCPUFAs and cognition in adolescents, 
measurement of LCPUFAs in blood is needed. Therefore, the main objective of this study 
is to investigate the association between the Omega-3 Index (EPA + DHA in erythrocytes 
as percentage of total fatty acids measured [22]) measured in blood and cognitive 
performance in typically developing adolescents of lower general secondary education 
(LGSE). Cognition is a very broad term that includes both lower order simple responses 
and higher order processes. The higher order processes are also called the executive 
functions, and it is generally agreed that there are three core executive functions namely: 
(i) inhibition and interference; (ii) working memory; and (iii) cognitive flexibility [23]. These 
executive functions are used to build higher order skills such as reasoning and problem 
solving. Therefore, the executive functions are important for academic success and 
cognitive development [23]. These executive functions are located in the prefrontal cortex, 
the brain area most in development during adolescence [24]. The cognitive tasks used in 
the current study are standard tasks of cognitive/executive functioning for this age group 
and have previously been shown to increase activation of the frontal cortex, the area of the 
brain associated with the accumulation of DHA [16]. In addition to the main objective, two 
sub-objectives will be addressed. A number of earlier studies have shown differences in the 
LCPUFA status between typically developing participants and participants with disorders 
such as ADHD, autism, and dyslexia [25,26]. However, to our knowledge, whether 
LCPUFAs are associated with cognition in participants with learning disorders differently 
than in those without learning disorders has not yet been assessed. The second objective of 
the current study is, therefore, to explore whether the association between the Omega-3 
Index and cognitive ability is different between adolescents with and without learning 
disorders. Social economic status, often operationalized as educational level, has been 
shown to be associated with diet quality (i.e., people with a higher SES have better diet 
quality) [27]. Moreover, in adults, higher social economic status has been found to be 
associated with higher fish consumption [28]. However, even though it is known that 
students from lower general secondary education (LSGE) levels have a less healthy diet and 
lifestyle than students from the higher levels [29], how much fish students from the LSGE 
consume has, to our knowledge, not yet been assessed. Therefore, the third objective of 
this study is to explore the fish consumption of second year students of the LSGE. 
Materials and methods 
Design 
This study was part of a larger randomized controlled clinical trial (Food2Learn) studying 
the influence of omega-3 LCPUFA supplementation on cognitive performance, mental 
well-being, and academic achievement scores in adolescents attending LGSE. Baseline data 
of Food2Learn were used to study the association between the Omega-3 Index measured 
in whole blood and cognition. Food2Learn has been approved by the Medical Ethical 
Committee of Atrium-Orbis-Zuyd Hospital (now Zuyderland), Heerlen, The Netherlands 
(NL45803.096.13). Food2Learn has been registered at the Netherlands Trial Register 
(NTR4082), which is connected to Clinicaltrials.gov (registered as NCT02240264.) 
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Procedure and participants 
Participants were recruited from 17 schools in the south of the Netherlands. For students 
who wanted to participate, an informed consent form had to be signed by themselves as 
well as by both parents and/or guardians. After informed consent was received, students 
underwent a finger prick to measure their Omega-3 Index. Inclusion criteria for 
Food2Learn were: 1 Omega-3 Index < 5%, as it was expected that omega-3 fatty acid 
supplementation will be especially beneficial for participants with a very low baseline 
Omega-3 Index [22]; and 2 attending the second year of LSGE because Richardson et al. 
showed that omega-3 supplementation was especially beneficial in the 20% lowest 
performing students [30]. Therefore, the choice for students at one of the lowest 
educational levels in The Netherland’s LGSE was made. In the Netherlands, secondary 
education is divided into three levels: pre-university, higher general secondary education, 
and LGSE. Approximately 38% of all adolescents follow LGSE [31]. LGSE is further 
divided up into four sublevels. For this study, students from the highest sublevel, the 
theoretical learning pathway (TLP), were recruited. Approximately 40% of students 
attending LGSE are in the TLP [31]. No other inclusion criteria were applied, thus, all 
second year students of the LSGE with an Omega-3 Index < 5% could participate. 
After inclusion, participants underwent a neuropsychological test battery in a small 
group setting (10 students max) consisting of: Letter Digit Substitution Task (LDST), D2 
test of Attention (D2), Digit Span Forward (DSF), and Backward (DSB). In addition, they 
filled out a number of questionnaires to collect important background information. The 
tests were led by one researcher via a standardized protocol, while one or two other 
researchers (depending on the group size) were monitoring to ensure that participants 
understood the tests and complied with the protocol. Before continuing with the real tests, 
students received a practice version of the tests, feedback was given, and the students 
confirmed they understood the tests. After this group test session, all participants filled out 
a questionnaire individually (data not used in the current study), during which participants 
were called one by one to perform the individual neuropsychological tests: Stroop Test and 
Concept Shifting Test (CST) under the supervision of one researcher.  
Dependent variable—blood analysis 
Whole blood was obtained from a finger prick with an automated lancet and directly 
transferred to a filter paper (Whatman 903, General Electric, Frankfurt, Germany) pre-treated 
with a stabilizer. Filter papers were shipped immediately to Omegametrix, Martinsried, 
Germany for analysis. Whole blood fatty acid compositions were analysed according to the 
HS-Omega-3 Index methodology [32]. Fatty acid methyl esters are generated by acid 
transesterification and analysed by gas chromatography using a GC2010 Gas Chromatograph 
(Shimadzu, Duisburg, Germany) equipped with a SP2560, 100-m column (Supelco, 
Bellefonte, PA, USA) using hydrogen as a carrier gas. Fatty acids are identified by comparison 
with a standard mixture of fatty acids. Results are given as EPA plus DHA expressed as a 
percentage of total identified fatty acids after response factor correction. 
Since the Omega-3 Index is defined as EPA + DHA in erythrocytes, it was calculated 
using a sliding correction factor. The coefficient of variation for EPA plus DHA typically is 
5%. Analyses are quality-controlled according to DIN ISO 15189. 
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Independent variables—cognitive measures 
Letter Digit Substitution Task 
The LDST is a paper-pencil task used to measure speed of information processing [33]. A 
nine letter/digit key is noted at the top of a page. Below this key, rows of letters are 
printed, and participants are asked to write the corresponding number in the box 
underneath the letter as quickly as possible. The number of correctly filled in numbers in 
60 s is used as a measure of speed of information processing. 
D2 Test of Attention 
The D2 test is a paper-pencil task used to measure selective attention [34]. Participants are 
presented with 14 rows each consisting of 47 stimuli. Stimuli are the letters d and p with a 
varying number of dashes (between 1 and 4), below, above, or on both sides. Participants 
are instructed to only cross out the d with two dashes (2 above, 2 below or one on both 
sides) and ignore all other stimuli. Participants have to process as many stimuli as possible 
in 20 s per line after which they have to continue with the next row without pausing. The 
following measures per row and in total are noted after completion: total number of stimuli 
processed, number of correctly crossed out d2’s, number of d2’s not crossed out, and 
number of stimuli wrongly crossed out (thus, non d2). The total number of stimuli 
processed is used as a measure for information processing speed. The number of target 
stimuli not crossed out (i.e., errors of omission) and non-target stimuli crossed out (i.e., 
errors of commission) are used as a measure for inattention and impulsivity, respectively. 
Digit Span Forward and Backward 
The DSF is a measure for short-term memory that primarily activates the phonological 
loop. The DSB activates the executive component directly and shows the dynamic 
relationship between passive storage and active manipulation or transformation of 
information held in the memory [35] and is thus a measure for working memory (the ability 
to hold information in the mind and work with it). The DSF consists of 12 sequences of 
digits varying in length from three to eight digits (each length twice). Digits are announced 
by the researcher at a rate of approximately one digit per second. After completion of the 
digit sequence, participants are asked to write down the sequence. The DSB is similar to 
the DSF, except for the fact that it consists of 12 digit sequences varying in length from 
two to seven digits (each length twice) and after completion of the sequence by the 
researcher, students are asked to write down the sequence backwards, starting with the last 
number announced. The longest sequence of numbers of which participants had correctly 
written down at least one of the two rows was used as a measure for working memory.  
Concept Shifting Task 
The CST is a measure for cognitive shifting [36]. Cognitive shifting is the ability to adapt to 
changes in the environment by switching from one mental set to another [37]. The task 
consists of four parts. All parts consist of a sheet of paper with 16 small circles grouped in 
one large circle. In task A, the small circles are randomly filled with numbers, in task B the 
circles are filled with letters, and in task C the circles are filled with both. Participants are 
asked to cross out the items in the correct order (A: 1 to 12; B: A to P; C: 1–A–2–B to 
8-H). Lastly, there is Task Zero, which consists of empty circles, where participants are 
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asked to cross out the circles as quickly as possible. Task Zero is administered twice, and 
the average of these times is used to correct for basic motor speed in the other tasks. For 
all tasks, the time taken to complete and the number of errors are noted. The average of 
motor-speed corrected time needed for A and B was subtracted from the motor speed 
corrected time needed for C and used as a measure for shifting.  
Stroop test 
The Stroop test provides a measure for cognitive inhibition. Cognitive inhibition is the 
ability to inhibit an overlearned response in favour of a more unusual one [38]. The Stroop 
task, as used in Food2Learn, consists of three cards containing 40 stimuli each: colour 
names printed in black (Task 1), coloured patches (Task 2), and colour names printed in 
congruent or incongruent colour (Task 3). For Task 1, participants are asked to read the 
name out loud. For Task 2, participants name the colour of the patches, and for Task 3, 
participants name the ink colour the word is printed in. Task 3 is a measure of mental 
flexibility and the ability to inhibit a dominant response (reading). The time needed for 
Task 2 was subtracted from the time needed for Task 1, the result of this sum was 
subtracted from the time needed for Task 3. The result of this sum was used as a measure 
for inhibition. 
Additional measures 
Students filled out a questionnaire to assess covariates. The following covariates were 
assessed as they are known to correlate with cognition: BMI (weight/length2, self-reported) 
[39], sex [40], age[38] , alcohol consumption [41], smoking [42], and parental level of 
education [43]. Alcohol consumption was assessed with two questions: the number of 
days/week the participant generally drank alcohol and the number of units the participant 
drinks on a day that (s)he drinks alcohol. Alcohol consumption was defined as the number 
of alcohol units/time multiplied by the number of drinking days/week, and the 
measurement was used as a continuous measure. Smoking was assessed with the question: 
“How many cigarettes do you smoke per week?”. If the participant indicated consuming 
cigarettes, (s)he was classified as smoker. Parental level of education was filled out by the 
parents on an ordinal eight-point scale [44]. Parental level of education was defined as the 
parent with the highest level of education, which is an indication for social economic status 
[45]. Additionally, fish consumption was assessed with a short, validated, and self-reported 
questionnaire [3]. Different kinds of fish were divided based on their DHA content: low 
(fish fingers, prawns, pickled herring, cod, mussels, plaice, tuna, tilapia); medium (trout, raw 
herring, smoked eel, smoked salmon, canned salmon); and high (smoked herring, herring 
and tomato sauce, mackerel, canned sardines, salmon). The consumption (never, once a 
month, two to three times a month, once a week or more than once a week) was used to 
calculate the fish consumption score. For the low DHA fish 0, 1, 2, 4, 8 points; for the 
medium DHA fish, 0, 2, 4, 8, 16 points; and for the high DHA fish, 0, 3, 6, 12, 24 points. 
The score for fish consumption could thus vary between 0 and 48 points. Lastly students 
were asked to indicate whether they had a disorder which could influence learning 
(examples were given) and who had made that diagnosis.  
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Quality control 
To ensure the quality of the data, all tests were scored by two independent researchers. Any 
discrepancies were solved by discussion. Furthermore, in order to prevent typing mistakes, 
all data were entered in the database twice, after which the two files were automatically 
compared. Any discrepancies between the two data files were checked and corrected by a 
third researcher. 
Statistical analyses 
Data were checked for normality and if necessary, transformation was applied. Data were 
analysed with linear regression or generalized linear regression (Poisson) for count data and 
data with a skewed distribution. For all analyses, first, a model with all covariates (i.e., 
smoking, alcohol consumption units per week), BMI, age, level of parental education, sex, 
and diagnosis) was built; Model A. In Model B, the Omega-3 Index was added. In a 
separate analysis, potential moderation between the Omega-3 Index and diagnosis was 
tested. If results were significant, a sub-group analysis for typically developing adolescents 
and those who had indicated to have some sort of learning disorder (autism, dyslexia, 
ADHD, etc.) were executed in the same way (diagnosis was not entered as a covariate). For 
all analyses, a p-value below .05 was considered to be significant. All analyses were carried 
out using SPSS statistics version 22. 
Results 
Participants 
A total of 286 students consented to participate in the study. Of these, four dropped out 
before blood sampling due to personal reasons and 16 had an Omega-3 Index > 5%. Thus, the 
associations between the Omega-3 Index and cognition of 266 participants (127 boys, 139 
girls; Mage = 14.1 years) are discussed in this paper. Characteristics of the participants can be 
found in Table 5.1. Omega-3 Index and LCPUFAs as determined in blood can be found in 
Table 5.2. Scores on the cognitive tests can be found in Table 5.3. In this sample, 69 
participants indicated having a disorder which can impact learning; 14 indicated having 
Attention Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD); 45 
indicated having dyslexia or dyscalculia; eight reported an autism spectrum disorder; and two 
indicated a depression. In the total sample of 266 adolescents, 13.8% indicated never 
consuming fish, 77% indicated eating fish very irregularly (i.e., less than half of the recommend 
amount of 450 mg DHA + EPA per day), 8.4% consumed at least half of the recommended 
amount (once a week), and 1% indicated consuming fish more than once a week. There was a 
significant difference in fish consumption between boys and girls (p = .024), with boys 
consuming more fish than girls. However, this did not result in significant differences in the 
Omega-3 Index (p = .561). The total score on the fish questionnaire correlated significantly 
with both the Omega-3 Index (n = 216, r = 0.294, p < .001) and DHA concentration 
(n = 216, r = 0.287, p < .001). 
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Cognitive performance 
Analyses revealed a significant association between the Omega-3 Index and score on the 
LDST (β= 0.136, p = .039). The addition of the Omega-3 Index to the model increased the 
r2 with 0.017 (Table 5.4), i.e., an additional 1.7% of the variance was explained. 
Furthermore, a significant association between the Omega-3 Index and errors of omission 
on the D2 was shown (β = 0.053, p = .007) (Table 5.5). The analysis for errors of omission 
also showed a significant moderator effect (p = .005). No other significant associations 
between the Omega-3 Index and any of the other cognitive measures were found.  
Table 5.1: Participant characteristics. 
 All Participants  With diagnosis1  Without diagnosis2  
 Mean ± SD 
or N [%] 
N Mean ± SD or 
N [%] 
N Mean ± SD or 
N [%] 
N P5 
Age (years) 14.10 ± 0.49 266 14.26 ± 0.51  69 14.05 ± 0.47  196 0.002 
Male/Female 127/139 
[47.7/52.3%] 
266 36/33 
[52.2/47.8%]  
69 93/103 
[47.5/52.5%] 
196 0.499 
Smoking no/yes3 239/26 
[90.2/9.8%] 
265 59/10 
[85.5/14.5%] 
69 179/16 
[91.8/8.2%] 
195 0.132 
BMI 19.92 ± 3.00 248 20.34 ± 3.61  65 19.77 ± 2.74  183 0.187 
Alcohol units per week4 0.46 ± 1.77 266 0.69 ± 2.85  69 0.39 ± 1.19  196 0.218 
LPE 5.07 ± 1.52 248 5.21 ± 1.40 66 5.02 ± 1.56 182 0.371 
1 Diagnosis was defined as a diagnosis possible to influence learning; this was indicated by students themselves 
and included (but not limited to) dyslexia, dyscalculia, depression, autism and ADHD. 2 Without diagnosis was 
defined as all students who did not indicate to have a diagnosis. 3 Smoking was defined as anybody who indicated 
to smoke more than 0 cigarettes per week. 4 Alcohol units per week was operationalized as number of day per 
week that alcohol is consumed times units per consumption moment. 5 Comparison between those with and those 
without diagnoses. ANOVA was used for age, BMI, LPE and alcohol units per week, Chi Square for smoking and 
sex. Significant difference p < .05 are noted in bold.  
Table 5.2: Fatty acid blood 
Fatty acid 
(%wt/wt of total FA) 
All participants 
N = 261 
Mean ± SD  
With 
diagnosis1 
N=68 
Mean ± SD  
Without 
diagnosis2 
N=193 
Mean ± SD  
P3 
Omega-3 Index 3.83 ± 0.60 3.79 ± 0.61  3.84 ± 0.60  0.537 
DHA 22:6n-3 2.58 ± 0.49 2.56 ± 0.50 2.59 ± 0.49 0.667 
EPA 20:5n-3 0.39 ± 0.16 0.38 ± 0.13 0.39 ± 0.16 0.356 
AA 20:4n-6 11.19 ± 1.25 11.49 ± 1.34 11.08 ± 1.20 0.022 
ObA 22:5n-6 0.43 ± 0.10 0.43 ± 0.11 0.44 ± 0.10 0.725 
1 Diagnosis was defined as a diagnosis possible to influence learning; this was indicated by students themselves 
and included (but not limited to) dyslexia, dyscalculia, depression, autism and ADHD. 2 Without diagnosis was 
defined as all students who did not indicate to have a diagnosis.3 Comparison between those with and those 
without diagnoses. Significant difference p < .05 are noted in bold 
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Table 5.3: Scores on the cognitive tests  
Measures  All 
participants 
N = 261 
Mean ± SD  
With 
diagnosis1 
N=68  
Mean ± SD  
Without 
diagnosis2 
N=196  
Mean ± SD  
P3 
LDST (number)  34.47 ± 5.46 33.52 ± 6.51 34.80 ± 5.02 0.094  
D2- correct (number)  163.13 ± 22.95 160.04 ± 24.24 164.22 ± 22.45 0.194 
D2 – error of omission (number) 11.83 ± 10.73 11.25 ± 8.07 12.04 ± 11.53 0.598 
D2 – error of commission (number) 1.31 ± 10.73 1.54 ± 1.96 1.22 ± 1.43 0.161 
D2 – Total (number) 417.33 ± 56.46 408.93 ± 55.11 420.29 ± 56.77 0.151 
Shifting score (sec) 11.70 ± 6.83 11.69 ± 6.50 11.71 ± 6.96 0.980 
Inhibition score (sec) 31.35 ± 8.50 34.85 ± 9.19 30.12 ± 7.91 0.000 
Digit span Forward (digits) 5.58 ± 0.88 5.26 ± 0.87 5.70 ± 0.85 0.616 
Digit Span Backward (digits)  4.56 ± 0.98 4.51 ± 0.93 4.58 ± 1.00 0.000 
1 Diagnosis was defined as a diagnosis possible to influence learning; this was indicated by students themselves 
and included (but not limited to) dyslexia, dyscalculia, depression, autism and ADHD. 2 Without diagnosis was 
defined as all students who did not indicate to have a diagnosis.3 Comparison between those with and those 
without diagnoses. Significant differences ( p < .05) are noted in bold 
Table 5.4: Results of multiple linear regression analyses between Omega-3 Index and score on the LDST in the 
complete sample.  
Predictor variable  Β (standardized)1 P2 
Model A (r2 = 0.058, df  = 7, p = 0.051)   
Smoking 0.028 0.679 
Alcohol consumption 0.031 0.649 
BMI 0.089 0.171 
Age 0.047 0.477 
Sex 0.177 0.007 
Highest LPE -0.056 0.387 
Diagnosis  -0.104 0.113 
Model B (r2 = 0.075, df  = 8, p = 0.019)   
Smoking 0.031 0.643 
Alcohol consumption 0.045 0.500 
BMI 0.080 0.218 
Age 0.036 0.584 
Sex 0.172 0.008 
Highest LPE3 -0.084 0.203 
Diagnosis  -0.094 0.147 
Omega-3 Index 0.136 0.039 
1 Standardized beta refers to how many standard deviations the dependent variable will change per standard 
deviation change in the predictor variable. Smoking, sex and diagnosis were not standardized as they are 
dichotomous variables. 2 Significant results (p < .05) are printed in bold. 3 LPE= level of parental education. 
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Table 5.5: Results of generalized linear model analyses between Omega-3 Index and number of error of omission 
on the D2 test in the complete sample.  
Predictor variable  Β (standardized)1 P2 
Model A (χ2 = 47.90 df =7, p < 0.001)   
Smoking 0.066 0.310 
Alcohol consumption 0.036 0.030 
BMI 0.043 0.026 
Age 0.036 0.068 
Sex -0.047 0.226 
Highest LPE -0.087 0.000 
Diagnosis -0.071 0.109 
Model B (χ2 = 51.852, df  = 8, p < 0.001)   
Smoking 0.062 0.349 
Alcohol consumption 0.030 0.078 
BMI 0.043 0.028 
Age 0.041 0.037 
Sex -0.052 0.181 
Highest LPE3 -0.077 0.000 
Diagnosis -0.083 0.063 
Omega-3 Index -0.053 0.007 
1 Standardized beta refers to how many standard deviations the dependent variable will change per standard 
deviation change in the predictor variable. Smoking, sex and diagnosis were not standardized as they are 
dichotomous variables. 2 Significant results (p < .05) are printed in bold. 3 LPE= level of parental education.  
Table 5.6: Results of generalized linear model analyses between Omega-3 Index and number of error of omission 
on the D2 test in the typically developing participant sample.  
Predictor variable  Β (standardized)1 P2 
Model A (χ2 = 42.11 df  = 6, p < 0.001)   
Smoking 0.032 0.685 
Alcohol consumption 0.036 0.277 
BMI 0.091 0.000 
Age 0.002 0.914 
Sex -0.136 0.003 
Highest LPE -0.085 0.000 
Model B (χ2 = 55.642, df  = 7, p < 0.001)   
Smoking 0.029 0.714 
Alcohol consumption 0.027 0.410 
BMI 0.089 0.000 
Age 0.015 0.515 
Sex -0.138 0.002 
Highest LPE3 -0.067 0.003 
Omega-3 Index -0.083 0.000 
1 Standardized beta refers to how many standard deviations the dependent variable will change per standard 
deviation change in the predictor variable. Smoking and sex were not standardized as they are dichotomous 
variables.2 Significant results (p < .05) are printed in bold.3 LPE= level of parental education. 
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Sub-group analyses 
When participants were divided into those without learning disorders and those who 
indicated having one or more learning disorders, differences between the two groups arose. 
Those with a diagnosis were significantly older (Table 5.1, p = .002, 14.26 ± 0.51, and 
14.05 ± 0.47, respectively) than those without a diagnosis. Furthermore, they had a slightly 
higher AA status (Table 5.2, 11.08 ± 1.20, and 11.49 ± 1.34, respectively). With regard to 
the test scores, there was a significant difference in average score between those with and 
those without a diagnoses in inhibition as measured with the Stroop test (p < .001, 
34.85 ± 9.19, and 30.12 ± 7.91, respectively) and on the digit span backwards (p < .001, 
5.26 ± 0.869, and 5.7 ± 0.851, respectively). 
When a moderation term was added to the regression analysis, a moderation effect was 
seen for the number of errors of omission (p = .005), i.e., the association between the 
Omega-3 Index and score on the D2—the errors of omission were different between those 
with and those without diagnosis. Therefore, a separate group regression analysis was 
executed. This analysis showed no significant associations in adolescents with one or more 
learning disorders between the Omega-3 Index and errors of omission (p = .073). For 
typically developing adolescents, a significant association between the Omega-3 Index and 
errors of omission was seen (Table 5.6), students with a higher Omega-3 Index had a lower 
number of errors.  
Discussion 
The main aim of this study was to investigate the association between the Omega-3 Index 
measured in blood and cognitive performance of 14-year-old Dutch adolescents. The 
Omega-3 Index was significantly associated with information processing operationalized as 
LDST score. This indicates that a higher Omega-3 Index was associated with better 
information processing speeds. Every 1% increase in the Omega-3 Index was associated 
with an increase of 1.23 digits on the LDST. Also, students with a higher Omega-3 Index 
had fewer errors of omission on the D2 test of attention, an indicator of 
inattention/impulsivity (i.e., they paid more attention than students with a lower Omega-3 
Index). An increase of 1% in the Omega-3 Index was associated with a decrease of 0.94 
stimuli forgotten to cross out. Associations with all other cognitive measures were not 
significant. To our knowledge, this is the first study assessing the association between the 
Omega-3 Index measured in blood and cognition in typically developing adolescents from 
the general population. There are a number of observational studies of adolescents that 
found positive associations between fish consumption, the most important source of 
omega-3 LCPUFAs, and school grades [17–19]. However, even though cognition/executive 
functioning and school performance are correlated, they are not equal. School performance 
depends on additional factors such as time spent on homework [46] and personality [47]. 
Although we are not aware of studies looking at the association/relationship between 
LCPUFA status and cognition in adolescents, multiple studies of children are available. For 
example, Portillo-Reyes et al. found an improvement in processing speed in their 
supplementation study (180 mg DHA and 270 mg EPA per day for three months) of 
marginally malnourished children age 8–12 years [48]. Parletta et al. also found a positive 
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effect of supplementation (750 mg EPA + DHA per school day for 40 weeks) on a non-
verbal cognitive test [49]. However, there are also a number of studies that do not show an 
association or relationship between omega-3 LCPUFAs and cognition in children [50–52]. 
Overall, results remain mixed, and a number of possible explanations for these differences 
have been proposed [52,53]. For example, it has been suggested that an effect of LCPUFAs 
on cognition might be more likely to be demonstrated in underperforming children and 
adolescents, as shown in the study of Richardson et al. [30]. We tried to address this in the 
current study by recruiting students from one of the lowest educational levels in the 
Netherlands. Additionally, it has been suggested that LCPUFAs might only be beneficial in 
certain periods of life when the brain is developing, the so-called windows of opportunity. 
We tried to address this by including adolescents because the brain undergoes profound 
development in adolescence [12]. A number of earlier studies have shown a positive 
relationship between LCPUFAs and cognition in people with learning disorders [30,54–56]. 
Therefore, a moderator analysis was executed to check whether the association between the 
Omega-3 Index and score on the cognitive test was different between those with and those 
without a learning disorder. If a moderator effect was shown, separate analyses for 
adolescents who indicated to have a learning disorder versus typically developing 
adolescents were executed. There was a significant association between the covariate 
diagnosis and score on errors of commission and on the interference score. The moderator 
effect could, however, only be shown for errors of omission. Firstly, the number of 
students with a diagnosis was relatively low (n = 69), which could have led to a reduced 
statistical power. Secondly, the self-reporting of diagnosis and the fact that many 
adolescents did not know who made the diagnosis could have led to attenuation of the 
associations. Thus, the measure of diagnosis might not be accurate. However, when the 
test scores of those with and those without a diagnosis were compared, students with a 
diagnosis score lower on the test of interference (Stroop). This would suggest that the 
assessment of a learning disorder is accurate, since it has been shown before that patients 
with ADHD and other psychiatric problems have impaired performance on this test [57]. 
Moreover, the variation in the Omega-3 Index (inherent to our pre-selection of participants 
with an Omega-3 Index < 5%) was relatively low (SD = 0.61), which makes the appearance 
of associations less likely. In contrast, even though this spread was also low (SD = 0.60) in 
typically developing adolescents, a significant association between Omega-3 Index and 
cognitive measures could be shown. This could be explained by the fact that the number of 
students with a diagnosis was only 69; therefore, the power to detect an association was not 
sufficient [58]. The Omega-3 Index (3.83%) in this sample was relatively low (well below 
the recommended range of 8%–11% [22]). This could be due to the exclusion of 
participants with a high Omega-3 Index, although if these were included the mean was still 
only 3.89 (SD 0.67). The low Omega-3 Index in this sample is no surprise since 13.9% of 
the students did not consume any fish and 77% consumed fish rarely, as measured by the 
fish consumption questionnaire. This frequency of fish consumption is somewhat lower 
than the consumption of the adolescents in the sample of de Groot et al. [19]. However, the 
study of de Groot et al. was carried out with students in higher general secondary education 
or pre-university education with a somewhat higher social economic status (assessed by 
level of education of the parents) than the students in the current study. The number of 
students that never consume fish is also in line with the results from the National Dutch 
Consumption Survey, which indicates that 11% of boys and 18% of girls never consume 
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fish [59]. Similarly in our sample, girls also consumed significantly less fish than boys. 
However, the number of adolescents who consumed fish twice or more a week was in only 
1% in this sample, while in the survey 9% of the boys and 7% of the girls consumed the 
recommended amount of fish. 
The main strength of the current study is that the Omega-3 Index was measured in 
blood. Furthermore, standardized and validated cognitive tests that assess several aspects of 
executive functioning were used. The main limitation of the study is that it is an 
observational study and can, therefore, not prove causality. Also, the variation in the 
Omega-3 Index was rather small. Furthermore, no Bonferroni correction for multiple 
statistical was applied, with correction significant results were not present anymore, which 
weakens the certainty of the associations found. However, the data presented here are part 
of a large intervention study, which will elucidate the effect of LCPUFA supplementation 
on cognition, mood, and academic achievement in adolescence. Furthermore, the 
supplementation study will achieve a higher Omega-3 Index and a larger spread in the 
Omega-3 Index, which could lead to more significant results (a number of associations 
were borderline significant). 
In conclusion, this study has revealed a positive association between the Omega-3 
Index measured in blood from typically developing adolescents and two of the nine 
cognitive measures. The results of the supplementation study will further elucidate the 
effect of LCPUFA supplementation on cognition. If a positive effect of LCPUFA 
supplementation on cognition is shown, this could help improve cognitive functioning and 
possibly the school performance of adolescents in a relatively inexpensive way. 
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Abstract 
Purpose: Depression is common in adolescents and long-chain polyunsaturated fatty acids 
(LCPUFA) are suggested to be associated with depression. However, research in 
adolescents is limited. Furthermore, self-esteem has never been studied in relation to 
LCPUFA. The objective here was to determine associations of depression and self-esteem 
with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), Omega-3 Index (O3I), 
n-6 docosapentaenoic acid (ObA), n-3 docosapentaenoic acid (DPA), and arachidonic acid 
(AA) concentrations in blood of adolescents attending lower general secondary education 
(LGSE).  
Methods: Baseline cross-sectional data from a krill oil supplementation trial in adolescents 
attending LGSE with an O3I < 5% were analysed using regression models built with the 
BayesFactor package in R. Fatty acids and O3I were determined in blood. Participants 
filled out the Centre for Epidemiologic Studies Depression (CES-D) scale and the 
Rosenberg Self-Esteem Scale.  
Results: Depression (CES-D ≥ 16) was found in 29.4% of the respondents. Of all fatty 
acids, we found extreme evidence (BayesFactor [BF] > 100) for a weak negative association 
between ObA and depression score (-.15; 95% credible interval [CI] -.28 to -.04; 
BF10 = 252), and substantial evidence for a weak positive association between ObA and 
self-esteem score (.09; 95% CI, -0.03 to 0.20; BF10 = 4).  
Conclusion: No evidence was found for associations of DHA, EPA and O3I with 
depression or self-esteem scores in LGSE adolescents with O3I < 5%. The associations of 
higher ObA status with lower depression and higher self-esteem scores warrant more 
research.  
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Introduction 
Depression affects approximately 350 million people worldwide and is especially common 
in adolescence [1,2]. It has been suggested that 14-25% of adolescents will experience at 
least one depressive episode before the age of 18 [3]. Adolescent depression has been 
associated with many adverse short-term outcomes such as poor social relationships, lower 
concentration and lower school performance [4] and long-term outcomes such as negative 
physical and mental health outcome and increased risk for adult depression [5–7]. Sub-
threshold depression (i.e., depressive symptoms are present but criteria for a major 
depression are not met) is also common, with a prevalence between 1 and 23% in 
adolescents [8] and life-time prevalence up to age 17 varying between 5.3 and 12% [9]. Sub-
threshold depression has also been related to poorer quality of life, socio-emotional 
dysfunction, and increased risk for the development of major depression [8,10].  
Depression is a complex and heterogeneous disorder and its aetiology is not completely 
understood. Many factors have been related to the commencement of depression: heritability, 
childhood adversity, acute stressful live events, and chronic stress among others [11–15]. 
These factors can lead to changes in brain structures, production of proinflammatory factors, 
neuroinflammation, alteration of the immune system, dysfunction and elevation of 
homocysteine levels, blood flow abnormalities, and a decrease in glucose metabolism [16–21].  
Long-chain polyunsaturated fatty acids (LCPUFA) have long been suggested to be 
associated with depression. LCPUFA are important constituents of all cell membranes and 
are involved in many aspects of brain functioning such as neuronal membrane fluidity, 
brain blood flow, signal transduction and neurotransmission[22,23].The body cannot 
produce the LCPUFA de novo, they have to be consumed via the diet. Moreover, LCPUFA 
have been suggested to modulate neuroendocrine factors, have anti-inflammatory 
properties and may in this way help counteract or reduce the neurobiological changes 
associated with depression [24]. Multiple observational studies have shown an association 
between higher fish consumption (source of n3-LCPUFA) and a decreased risk for 
depression in adults [25–27]. Furthermore, it has been shown that blood and brain 
eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3)) 
concentrations are lower in people with a depression compared to non-depressed controls 
[28–31]. The observational studies, thus, point to a possible role of LCPUFA in depression 
occurrence. This notion has been supported by a number of intervention trials [32–35], but 
not all [36,37].  
Studies in adolescents either focus on adolescents in treatment for depression[38,39], 
on dietary intake of LCPUFA [40,41], or on adolescents and adults together [42]. There is 
only one study, to the best of our knowledge, which investigates LCPUFA status and 
depressive symptoms in adolescents from the general population [43]. Mamalakis et al. 
showed a negative association between EPA measured in adipose tissue and depression 
score measured by the Centre for Epidemiologic Studies Depression (CES-D) scale after 
correction for adiponectin, indicating that a lower EPA status was associated with more 
depression. Furthermore, they showed a positive association between dihomo-gamma 
linolenic acid (DGLA, C20:3n-6) in adipose tissue and depression score measured with the 
Beck Depression Inventory, again after correction for adiponectin, indicating that a lower 
DGLA status is associated with less depression. Lastly, depression occurs more often in 
adults and adolescents with a lower socioeconomic status [44,45]. However, the association 
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between the Omega-3 Index (O3I) measured in blood and depression in adolescents with a 
lower education level has, to our knowledge, not yet been studied. 
The main aim of this study is to estimate the association between the O3I and 
depression in in adolescents with a lower education level. The O3I is defined as the amount 
of EPA plus DHA in erythrocytes and is based on a standardized analytical method [46]. 
The suggested target range for O3I is 8 -11% which is based on the lowest mortality risk in 
coronary heart disease [47]. However, most people do not reach this target range. Stark and 
colleagues showed that the majority of countries with blood data on EPA + DHA had low 
to very low levels, with just a handful of countries or regions in which the target range is 
achieved (i.e., Norway, Japan, Greenland and Alaska)[48].  
Thus, little is known about the association between omega-3 fatty acids and depression 
in healthy adolescents of a lower educational level. We investigated the association between 
the O3I, measured in blood and depression in a sample of second year students of lower 
general secondary education (LGSE). We expected that a higher O3I is associated with less 
depressive feelings. Secondary, associations between DHA, EPA, DPA, AA, and ObA 
measured in blood and depression were explored. We focussed on AA, DHA and EPA 
because they are implicated to play a role in mental health [49], whereas ObA is considered 
to be a functional shortage indicator of DHA [50] and DPA as the major intermediate 
between DHA and EPA. Therefore, it was expected that higher DHA, EPA and DPA 
were associated with lower depression scores and that higher AA and ObA were associated 
with higher depression scores in adolescents. Furthermore, exploratively, we estimated the 
associations of the fatty-acids with self-esteem. Self-esteem is a core construct of mental 
health as it represents a person’s overall evaluation of his or her own worth [51]. Low self-
esteem has been associated with poor health behaviour and many forms of mental illness, 
including an association between low self-esteem and major depression in adolescents [51–
53] and even negative long term physical and mental health outcomes[52,54]. However, to 
our knowledge, studies are lacking that explore an association between fatty acids and self-
esteem.  
Methods  
This study used baseline data from a large double-blind, randomised, placebo controlled 
intervention study (Food2Learn) to study the effect of one year of krill oil supplementation 
on cognitive performance, academic achievement, and mental well-being of students in the 
second year of LGSE. Full details about the cohort and measurements have been reported 
previously[55]. Food2Learn was approved by the Medical Ethical Committee of Atrium-
Orbis-Zuyd Hospital Heerlen, the Netherlands (NL45803.096.13). Each participant as well 
as parent(s) and/or guardian(s) provided written informed consent for participation in the 
study. Food2Learn is registered at The Netherlands Trial Register (NTR4082) and at 
Clinicaltrials.gov (NCT02240264).  
Data collection  
Students of 17 schools offering LGSE in the Netherlands participated in Food2Learn. In 
the Netherlands, secondary education is divided into three levels: pre-university, higher 
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general and lower general secondary education (LGSE). Approximately 38% of all 
adolescents in the Netherlands attend LGSE, which is again subdivided into four levels; for 
the current study, students from the highest sublevel, the theoretical learning pathway 
(TLP), were recruited. Approximately 40% of students attending LGSE are in the TLP 
[56]. We approached students in the second year of the LGSE-TLP, who are between 13 
and 15 years of age. LGSE-TLP students at participating schools were approached in a 
classroom setting and the study was explained orally by a research assistant who also used 
video material to support the presentation. Students then received an information letter 
and were asked to discuss their participation with their parent(s) and/or guardian(s). If 
students wanted to participate, they had to hand in an informed consent form signed by 
both themselves and their parent(s) and/or guardian(s). After informed consent was 
received the student received a finger prick to determine the O3I. Only students with a low 
O3I (defined as O3I < 5%) could participate in the study as this was a selection criterion of 
the main Food2Learn study. At baseline, participants filled out a number of questionnaires 
to determine mood status and self-esteem and to collect information with respect to a 
number of covariates.  
Blood analyses  
A finger prick was administered by a trained researcher or research assistant with an 
automated one-time use lancet; blood was collected on specially prepared filter paper. 
Whole blood acid compositions were analysed according to the HS-Omega-3 Index® 
methodology as described previously [47,57]. Fatty acid methyl esters were generated by 
acid transesterification and analysed by gas chromatography using hydrogen as carrier gas. 
Fatty acids were identified by comparison with a standard mixture of fatty acids. Results are 
given as the O3I, which is EPA + DHA expressed as a percentage of total identified fatty 
acids after response factor correction and a correction for the fact that whole blood was 
used instead of erythrocytes. Typically, the coefficient of variation for EPA plus DHA is 
5%. Analyses are quality-controlled according to DIN ISO. Furthermore, 26 other fatty 
acids were determined. We focussed on AA, DHA, EPA, ObA, and DPA.  
Questionnaires 
Centre for Epidemiologic Studies Depression Scale  
Depressive feelings were assessed with the Dutch version of the CES-D scale [58], one of 
the most commonly used screening tools for depression that has been shown to be able to 
distinguish between depressed and non-depressed individuals in both clinical and 
community populations [58]. The questionnaire consists of 20 questions assessing whether 
six symptoms of depression were experienced by the participant in the last week. The 
CES-D has shown a high internal reliability in adolescents (α=.88) [59]. The measured 
symptoms include depressed mood, guilt/worthlessness, helplessness/hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance. For each question, the 
participants has to indicate whether a symptom occurred seldom or never (< 1 day), 
sometimes or a few times (1–2 days), often (3–4 days), or most of the time/always (5–7 
days). Each answer is scored as 0, 1, 2, or 3 respectively and a total sum score is calculated. 
The score of the CES-D can thus vary between 0 and 60, with a higher score indicating 
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more depressive feelings. It has been suggested that depression should be considered as a 
continuum of increasing severity [9]. Therefore, the CES-D score was taken as a 
continuous variable in the current study. A CES-D score of 16 or higher is, in general, 
accepted as an indication of depression [60], although some have suggested that a higher 
cut-off point might be more appropriate in adolescents i.e., a score of 22 or higher [61]. We 
used a score of > 16 in descriptive analyses to indicate the number of adolescents with 
possible depression in our sample. 
The Rosenberg Self-Esteem Scale 
Self-esteem was measured with the Dutch version of the Rosenberg Self-Esteem Scale 
(RSE). The internal reliability for the RSE has been found to be high in adolescents (α=.88) 
[62,63] and construct validity with other measures of self-esteem has been shown [63]. The 
RSE consists of 10 questions scored on a 4-point response system (from strongly disagree 
=0 to strongly agree = 3) requiring participants to indicate their level of agreement with a 
series of statements about themselves. The total score of the RSE can vary between 0 and 
30, with a higher score indicating higher self-esteem. The RSE score was also taken as a 
continuous variable. 
Additional measures  
Students filled out a questionnaire to assess covariates. The following variables were 
assessed as they are known to be associated with depression: BMI (weight/length2, self-
reported) [64,65], sex [66,67], age in years [68], alcohol consumption (number of days per 
week that alcohol was consumed times units consumed per consumption moment) [69], 
smoking (yes/no, yes if the participant had indicated to smoke more than 0 cigarettes per 
week) [70] , parental level of education (subdivided in 8 levels from primary school to 
university) [71], pubertal status conform according to the categorisation suggested by 
Petersen et al. (subdivided in 5 levels from prepubertal to postpubertal) [72] (association 
between pubertal status and depression [73,74]), and diagnosis which might influence 
learning (yes/no, e.g. autism, dyslexia, ADHD) [75,76].  
Data analyses  
Twelve participants had a maximum of two missing data points for the CES-D, these 
missing points were imputed by the person average score of the other CES-D items (if 
necessary reversed scored) as explained by Bono et al. [77]. For the RSE the same 
procedure was used. All continuous variables (all fatty acids and BMI) were standardized.  
We estimated the effect sizes for the association between the fatty acids and depression 
score/self-esteem using Bayesian statistical approach. This approach makes it possible to 
incorporate prior knowledge about relationships (called a prior), and, using a Bayes factor, 
to compare different models including the model representing the null hypotheses. Bayes 
Factor10 (BF) indicates how many times the alternative hypothesis (H1, e.g., DHA is related 
to depression) is more likely compared to the null hypothesis (H0, e.g., DHA is not related 
to depression) or another hypothesis. It is, in general, accepted that a BF10 between 0.33 
and 3 indicates that data do not favour either H0 or H1, the data are insensitive. A BF10 for 
the comparison of H1 to H0 of less than 0.33 indicates evidence in favour of the H0 and a 
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BF10 of more than 3 indicates evidence for the H1 [78]. We considered the degree of 
evidence in favour of a model in accordance with Jeffrey’s classification: BF10 of 1 for no 
evidence; 1 to 3 (resp. when BF10 is 1/3 to 1 there is evidence in favour of null hypothesis) 
for anecdotal evidence in favour of alternative hypothesis; 3 to 10 (1/10 to 1/3) for 
substantial evidence; 10 to 30 (1/30 to 1/10) for strong evidence; 30-100 for very strong 
evidence, (1/100 to 1/30); > 100 (< 1/100) for extreme evidence [79]. Next to estimating 
BF10 indices, we also used a top-down approach in which the full model is compared with a 
model with all factors but one (i.e., inclusion of all fatty acids but DHA). BFomit indicates 
whether removing the factor from the model is deleterious, it is suggested that a BFomit < 3 
indicates that the factor is beneficial for the model and a BFomit > 3 that removing the 
factor is better for the model [80]. Because of the same denominator, BF10 indices of 
different models with all possible combinations of covariates and predictors can be 
compared. For estimated effect-sizes, a 95% credibility interval is provided that describes 
intervals where the parameters fall within a 95% probability given the observed data.  
Analyses were executed in the R statistical environment (R studio version 3.3.2) with 
the package BayesFactor (version 0.9.12-2). We used the standard settings of the package: 
the package considers the regression parameters to be distributed normally around zero, 
with negative effects and positive effects being equally likely, and smaller effects being 
more likely than larger effects. For the descriptive comparisons of characteristics between 
those with and without depression, ANOVA and Chi-square analyses were carried out. To 
explore the associations between each respective fatty acid or the O3I and depression 
respectively self-esteem, regression models were built predicting CES-D and RSE from the 
fatty acids. 
Next to the analyses with each fatty acid as individual predictor, two regression models 
were additionally built (one for depression and one for self-esteem) with all fatty acids as 
predictors in one analysis, which allows adjustment of the effect of a fatty acid for the 
effects of other fatty acids. All regression models were corrected for covariates ,which were 
selected by comparing BFs of regression models with all possible combinations of 
covariates and the fatty acid. For estimation of the effect size 10.000 Monte Carlo iterations 
were run.  
Results  
In total, 286 students provided informed consent. For three participants no blood sample 
was obtained. Additionally, one participant was excluded because of severe hyperventilation 
after blood sampling , one participant withdrew consent before the study started, and one 
student quit during the first test session and was therefore excluded. Fourteen participants 
had an O3I > 5% and were therefore, based on the protocol of the main Food2Learn study, 
excluded. Nine additional students did have an O3I above 5% but were not excluded before 
the start of the study, they were however excluded from analyses. 
In total 257 students started the study, however baseline data on depression were 
available for 252 participants and self-esteems scores for 255 participants. Characteristics of 
all participants are presented in Table 6.1. A total of 74 (29.4%) students (with CES-D 
score available) scored ≥16 on the CES-D indicative of a depression. When using the 
stricter criterion of ≥22, a total of 43 students (17.1%) could be classified as possibly 
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having depression. Comparing those with a depression (CES-D ≥ 16) and those without a 
depression (CES-D ≤ 15) there was extreme evidence (BF10 = 1.1E+4) that girls had more 
often a depression (42.3% with CES-D ≥ 16) than boys (15.6%). There was substantial 
evidence (BF = 5.64) that those with a depression had a higher BMI (M = 20.84, 
SD = 3.10) than those without depression (M = 19.64, SD = 2.93) and extreme evidence 
(BF10 = 3.7E+3) that those with a depression were further in puberty (80% were advanced 
or postpubertal ) than those without depression (51.7% advanced or postpubertal). There 
was extreme evidence  
(BF10 = 1.7E+28) that self-esteem was significantly lower in those with a depression 
(M = 15.4, SD = 5.64) compared to those without (M = 23.88, SD = 3.96). Also when 
looking at the association between self-esteem and depression, their association was strong 
(self-esteem regressed on depression, regression coefficient = -.77 [95% credibility interval 
-.85 to -.68]; BF10 = 7.76E43). 
When comparing models predicting CES-D from potential confounders (namely 
smoking, alcohol, age, sex, BMI, LPE, pubertal status and diagnosis), the models with the 
highest BF10 included the variables smoking, sex and BMI. We, therefore, included these 
variables as covariates in the main analyses. For RSE, the best models contained smoking, 
sex and diagnosis, or smoking and sex. We, therefore, only included smoking, sex and 
diagnosis as covariates in the analyses for RSE. Excluding participants with missing data, 
data of 230 participants was available for CESD and data of 249 participants for RSE.  
Table 6.1: Participants’ characteristics  
 N Mean SD Fatty acid 
(%wt/wt of total FA, 
except for O3I) 
N Mean SD 
Age (years) 257 14.11 0.50 Omega-3 Index 257 3.78 0.56 
Male/Female 257 124/133 
[48.2/51.8%] 
- DHA 22:6n-3 257 2.55 0.46 
Smoking no/yes1 255 231/24 
[89.9/9.3%] 
- EPA 20:5n-3 257 0.38 0.15 
BMI 240 19.98 3.00 DPA 22:5n-3 257 1.22 0.19 
Alcohol units per week2 256 0.47 1.80 AA 20:4n-6 257 11.15 1.27 
LPE 240 5.05 1.5 ObA 22:5n-6 257 0.44 0.10 
O3I = Omega-3 Index, LPE = level of parental education  
1 Smoking was defined as anybody who indicated to smoke more than 0 cigarettes per week.  
2 Alcohol units per week was operationalized as number of day per week that alcohol is consumed times units per 
consumption moment. 
 
Individual models that predicted CES-D scores from a fatty acid showed negative 
regression coefficients with 95% credibility intervals without zero for AA (regression 
coefficient = -.13 [95% credibility interval -.25 to -.02]; BF10 = 2.65), DPA (-.13 [-.24 to -
.02]; BF10 = 1.01), and ObA (-.16 [-.28 to -.04]; BF10 = 251.95) (see Table 6.2). This 
indicates that higher levels of these fatty acids in blood are associated with lower 
depression scores. However, BF10 indicated evidence in favour of the association for ObA 
only (extreme evidence, BF10 > 100). The BF10 for O3I and DHA were below .33, which 
indicates that there is more evidence for the H0 i.e., no association between O3I and DHA 
and depression. When all fatty acids were taken in one model as predictors of CES-D (BF10 
for the model = 1.2E+5), the regression coefficient for ObA became smaller and its 95% 
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CI contained a zero score (-.09. [-.22 to .03]). The regression coefficient of DPA was 
almost identical to that in the individual model -.11 [-.25 to .03]), but 95% CI for DPA, as 
well as for all other fatty acids, contained zero. The BFomit indicated that the model will be 
improved when DHA was omitted (BFomit > 3). For other acids, BFomit indices were not 
higher than 3 or lower than 0.33, thus removing them would not improve or worsen the 
model.  
Table 6.2: Bayesian analyses, fatty acids as predictor for score on the CESD, both separate and combined in one 
model. 
One fatty acid  All fatty acids in 1 model  
Predictor fatty 
acid  
Regression 
coefficient 
95% credibility 
interval1 
BF10 2  Regression 
coefficient 
95% credibility 
interval 
BFomit3 
Omega-3 Index -0.016 -0.14;0.11 0.14     
DHA -0.04 -0.16;0.08 0.15 DHA -0.02 -0.15;0.11 3.12 
EPA 0.06 -0.06;0.18 0.34 EPA 0.09 -0.05;0.22 1.42 
AA -0.13 -0.25;-0.02 2.65 AA -0.03 -0.18;0.11 2.79 
DPA -0.13 -0.24;-0.02 1.01 DPA -0.11 -0.25;0.03 0.84 
ObA  -0.16 -0.28;-0.04 251.95 ObA -0.09 -0.22;0.03 1.20 
One fatty acid model, is a model in which only one predictor of interest is entered (Omega-3 Index, DHA, EPA, 
AA, DPA, or ObA). All fatty acids model is a model in which all fatty acids (DHA, EPA, AA, DPA, and ObA) 
are entered, i.e. for example the association between DHA and self-esteem is corrected for the other fatty acids 
(EPA, AA, DPA, ObA). All analyses were adjusted for BMI, smoking (yes/no), and sex.  
1 Credibility intervals are analogous to confidence intervals in traditional statistics. 2 BF10 refers to the evidence for 
the model with the specific fatty acid compared to a model with only covariates.3 BFomit indicates whether the 
model improves with the omission of that specific fatty acid. BFomit numbers above 3 indicate that keeping the 
variable in the model is not preferable. 
Table 6.3: Bayesian analyses, fatty acids as predictor for score on the RSE, both separate and combined in one 
model. 
One fatty acid  All fatty acids in 1 model 
Predictor fatty 
acid  
Regression 
coefficient 
95% credibility 
interval1 
BF102  Regression 
coefficient 
95% credibility 
interval 
BFomit3 
Omega-3 Index -0.05 -0.18;0.08 0.18     
DHA -0.03 -0.15;0.10 0.15 DHA 0.001 -0.13;0.13 3.12 
EPA -0.09 -0.20;0.03 0.32 EPA -0.08 -0.21;0.05 1.59 
AA 0.008 -0.12;0.10 0.14 AA -0.06 -0.20;0.08 2.04 
DPA -0.02 -0.09;0.14 0.16 DPA 0.07 -0.07;0.20 1.76 
ObA  0.09 -0.03;0.20 4.15 ObA 0.07 -0.05;0.20 1.63 
One fatty acid model, is a model in which only one predictor of interest is entered (Omega-3 Index, DHA, EPA, 
AA, DPA or ObA). All fatty acids model is a model in which all fatty acids (DHA, EPA, AA, DPA and ObA) are 
entered, i.e., for example the association between DHA and self-esteem is corrected for the other fatty acids 
(EPA, AA, DPA, ObA). All analyses were adjusted for smoking (yes/no), sex and diagnosis (yes/no).  
1 Credibility intervals are analogous to confidence intervals in traditional statistics. 2 BF10 refers to the evidence for 
the model with the specific fatty acid compared to a model with only covariates.3 BFomit indicates whether the 
model improves with the omission of that specific fatty acid. BF omit above 3 indicate that keeping the variable in 
the model is not preferable. 
 
Bayesian analyses for regressions that predicted the RSE score showed no 95% CIs that did 
not include zero (see Table 6.3). When looking at the Bayes factors, there was only 
substantial evidence for an association between ObA and RSE (BF10 = 4.15), for all other 
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fatty acids and the O3I, BF10 was below 0.33 which indicates more evidence for the H0, i.e., 
no association between fatty acids and self-esteem. BFomit indices for DHA exceed the 
threshold values (> 3), which indicates that removing this from the model would improve 
the model that contains all fatty acids.  
Discussion 
Analyses showed Bayes factors that indicated extreme evidence for a weak negative 
association between ObA levels and depression score, and substantial evidence for a weak 
positive association between ObA and self-esteem score. In other words, more ObA 
measured in blood corresponded with lower depression and higher self-esteem scores. For 
DHA and O3I, our data provided evidence for absence of associations with both 
depression and self-esteem scores. For DPA and AA, there was anecdotal evidence for an 
association with depression score and evidence for absence of an association with self-
esteem score. For EPA, the evidence for the association with depression score was 
indecisive and there was evidence for no association with self-esteem score. When the 
associations of fatty acids were adjusted for each other effects, all effect-sizes for tested 
associations decreased and 95% credible intervals for regression coefficients contained a 
zero-score.  
The evidence for the relation of depression score with DHA, EPA and O3I in the 
current study was in favour of the null hypothesis (i.e., no association) and the standardized 
effect sizes were very small. Earlier studies in adolescents that used the frequentist 
hypothesis testing showed non-significant associations between fatty acids and depression 
score [41,81]. However the disadvantage of the frequentist hypothesis testing approach is 
that a non-significant result can either imply that there is evidence for the null hypothesis 
(i.e., there is no association) or the data are insensitive in distinguishing the theory from the 
null hypothesis (i.e., nothing follows from the data) [82]. Bayesian analyses provide either 
evidence for the null hypothesis, evidence for the alternative hypothesis or indicate that 
evidence is insensitive. With the Bayesian analyses, we showed that there is evidence for an 
absent association of depression with respectively DHA, EPA, and O3I (i.e., H0 is more 
likely than H1).  
Our findings are in contrast to an earlier studies in adolescents from the general 
population in which an negative association between depression measured with the Beck 
Depression Inventory (BDI) and EPA in adipose tissue of adolescents was found (i.e., 
more EPA, lower depression score; analyse was controlled for other fatty acids but no 
correction for multiple testing) [43]. However, some researchers have suggested that the 
CES-D, like used in our study, is better at discriminating depression at lower levels than the 
BDI and the CES-D, thus, might be a better measure of depression in the general 
population [83,84]. Furthermore, an association between adipose fatty acids and brain fatty 
acids has, to our knowledge, not been established, while the association between blood 
levels and brain levels has been established in animal studies [85]. Blood levels of fatty acids 
might, therefore, be a better measure for assessing the association between fatty acids and 
depressive feelings.  
It is remarkable that the negative associations of ObA with depression and self-esteem 
score became less convincing and the relationship between ObA and depression score 
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became weaker after correction for other fatty acids. We are not aware of earlier studies 
reporting the association between ObA and depression score, although studies looking at 
other omega-6 fatty acids mostly showed positive associations (i.e., more omega-6 fatty 
acids, higher depression scores) [86,87]. ObA can, in the case of DHA deficiency, take the 
place of DHA in the brain [88]. Possibly the replacement of DHA by ObA does not 
changes the brain functionality and therefore a negative association between ObA and 
depression score in the case of DHA deficiency can be found. This surprising negative 
association between ObA and depression score does merit more research.  
Our data provided evidence for absence of associations of depression score with DHA, 
EPA and O3I in this adolescent sample, while meta-analyses that included studies in adults 
have shown that higher fish consumption, higher LCPUFA consumption or LCPUFA 
supplementation are associated with less depressive feelings [49,89–91]. One of the 
possible explanations for an absent relationship in the current study could be that the 
design of this trial led us to preselect participants with an O3I < 5%. In other fatty acid 
studies, it has been suggested that positive associations with O3I are only visible at higher 
O3I levels (i.e., 8% and up). For example, in cardiovascular health, an O3I of > 8% is 
associated with the greatest risk reduction and the study of Markhus et al. showed a linear 
relation between O3I and depressive symptoms during pregnancy only when the O3I was 
> 5.1% [47,92]. Such O3I values seem rare in the specific population of students of LGSE 
as we only had to exclude 23 out of 286 student for having an O3I > 5%, with the highest 
O3I being around 6.09%. This means that none of the adolescents reached the target O3I 
of 8-11% [47], and only 8% had a O3I > 5%. So, such a low O3I seems to be reality in this 
specific target group. Furthermore, whenever an effect of omega-3 fatty acids in trials is 
found it is mostly a small effect, which was also true in this sample where the effect sizes 
ranged between 0.001 and 0.15. Such a small effect could easily be offset by other 
environmental factors. This might especially be the case in adolescence, a period of life 
characterised by profound changes in brain development, but also social and emotional 
behaviour [93,94]. Another important issue to consider is that most of the studies looking 
at depression that find significant associations find very small effect sizes and do not use 
Bayesian statistics. In the current study we did find some regression coefficients with 95% 
CI that did not include 0 (e.g. AA and DPA predicting depression score). ‘Frequentist’ 
regressions with SPSS software showed comparable regression coefficients that were 
significant (not shown). However, Bayesian analyses did not reveal evidence for these 
relationships. This could also be the case for other studies that found significant 
associations.  
This study showed that depressive feelings are common in adolescents of LGSE; in our 
sample 29.4% of the adolescents scored 16 or higher on the CES-D which is indicative for 
a depression. When we used a stricter cut-off point (as some suggest for adolescents) of 22 
or higher 17.1% had scores indicative of depression. Although the percentage of 
adolescents with depression in this sample seems high, it is similar to percentages found in 
earlier studies in adolescents. Munhoz et al., for example, showed that 17% of the Brazilian 
adolescents had scores indicative for major depression [95]. Grant and colleagues (2015) 
also showed numbers comparable to the current study with 22% of the boys and 34.4% of 
girls showing depressive symptoms [96], and Mamalakis et al. (2006) observed a similar 
mean CES-D score (mean of 14.9 compared to 12.2 in our sample) [43]. Furthermore, it 
has long been known that, from age 13-14 onward, there is a female preponderance of 
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depression [97]. We also showed that girls in this sample had a higher incidence of 
depression than boys. In the current study, 42.3% of the girls had an indication for 
depression while, for boys, this was 15.6%.  
There are a multitude of reasons as to why depression is so common in this sample of 
adolescents with a lower education level. Both genetic and environmental factors influence 
the susceptibility of developing depression [98]. Environmental factors which have been 
associated with depressive feelings are among others early childhood adversities (e.g., 
abuse, chaotic households, loss of a parent) and negative life events (e.g., parental divorce, 
financial problems or housing problems) which are more common in a population with a 
lower educational level [12,99–101] than in a population with a higher educational level. 
Furthermore adolescents and especially adolescents from lower education levels often have 
a less favourable lifestyle [102], a suboptimal diet, high intakes of processed foods (e.g., 
cake, cookies, crisps) and lower than recommended intake of many vitamins and minerals 
[103–105]. Childhood adversities, negative life events, unhealthy diet, and vitamin and 
mineral deficiency all have been associated with depression [99,106–110]. 
This observational study has a number of limitations. The low O3I of the participants 
and low spread in the O3I could have led to low statistical power. However, as we 
explained above, the low O3I seems to be the reality in this specific target group. Moreover 
this was a cross-sectional study and can thus not be used for proving causal relationships, 
experimental studies are needed for more insight in the effects of fatty acids in depression 
and self-esteem in this specific target group.  
One of the main strengths of the current study is the use of finger prick blood samples 
to determine the fatty acids status of the adolescents. Moreover, the population was rather 
homogenous and this study is one of the first specifically focusing on adolescents of a 
lower education level. Furthermore, we used the Bayesian approach that, in contrast to the 
frequentist approach, can be used to provide evidence for the null hypothesis and to 
compare different models without issues concerning multiple testing.  
To summarise, our data in Dutch LGSE adolescents with a low O3I in blood revealed 
high depression rates and provided extreme evidence for a weak association between ObA 
levels and depression score (more ObA, lower depression score) and substantial evidence 
for a weak association between ObA and self-esteem score (more ObA, higher self-
esteem). This surprising result calls for more research into the role of ObA in depression. 
Results of the intervention study Food2Learn should shed light on the effect of krill oil 
supplementation (high in omega-3 fatty acids) on depressive feelings in adolescents of the 
LGSE.  
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Effect of 1 year krill oil supplementation on 
cognitive achievement of Dutch adolescents: a 
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Abstract  
Background: Long-chain polyunsaturated fatty acids (LCPUFA) are important for brain 
development and function, maybe especially adolescence. Observational studies 
demonstrated an association between fish consumption (source of LCPUFA) and 
cognition in adolescents, but intervention trials are lacking.  
Objective: To investigate the effect of one year krill oil (source of LCPUFA) 
supplementation on cognitive performance of adolescents with a low Omega-3 Index 
(O3I).  
Design: Double-blind, randomized, placebo controlled krill oil supplementation trial with 
repeated measurements (baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)) 
in adolescents attending lower the second year of general secondary education (LGSE). 
Participants were randomized to 400mg eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) from krill oil per day in cohort I or placebo, and 800mg EPA + DHA per day 
in cohort II or placebo. O3I was monitored by a finger prick at all time points. At T0, T2 
and T3 participants executed a neurocognitive test battery. Covariate corrected mixed 
models were run with either condition (krill or placebo) or O3I as predictors.  
Results: Krill oil supplementation lead to a small but significant increase in mean O3I, but 
few participants increased their levels as intended. There was no significant effect of 
supplementation on any of the neurocognitive tests, nor was there a relationship between 
O3I and neurocognitive test scores.  
Conclusions: One year of krill oil supplementation led to an increase in O3I, but did not 
improve neurocognitive test scores. The increase in O3I was in most participant small, 
probably due to non-adherence. Possibly the increase in O3I was too small to demonstrate 
an effect. More research on the influence of LCPUFAs on cognition in adolescents is 
needed.  
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Introduction  
The influences of long-chain polyunsaturated fatty acids (LCPUFAs) on health and 
cognition have been studied extensively. Studies have focused on varying outcomes ranging 
from cardiovascular health, diabetes, cognitive decline and cognitive development [1–4]. 
The extensive research into LCPUFAs such as docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) is not surprising as they are involved in many processes such 
as neuronal membrane fluidity, signal transduction, blood-brain barrier integrity and 
inflammation [5,6]. The possible positive influence of LCPUFAs on brain functioning has 
led to many observational and experimental studies. However, these studies have mostly 
focused on infants, pregnant women, children and elderly, while LCPUFAs might be 
especially important in adolescents.  
Adolescence is characterized by profound brain development, with especially the 
prefrontal cortex continuing to mature into the late twenties [7,8]. In this period of brain 
development, the basis is laid for executive functions (e.g., shifting, updating and short-
term memory), among others. Optimal development of the prefrontal cortex is very 
important as the executive functions have been related to academic achievements [9]. 
Considering brain development during adolescence, it is important to take the role of 
omega-3 LCPUFA into account, especially since the omega-3 LCPUFA DHA and EPA are 
important structural components of neuronal cell membranes and influence membrane 
fluidity and signal transduction [6]. Moreover, the prefrontal cortex is very rich in DHA 
[10] and an earlier study with DHA supplementation in children aged 8-10 years showed 
higher functional activity in the prefrontal cortex [11].  
Although a positive effect of LCPUFA on adolescent brain and cognition seems likely 
based on biological mechanisms, LCPUFA supplementation studies on cognition in 
healthy adolescents are, to the best of our knowledge, lacking. There are three 
observational studies in adolescents that show an association between fish consumption 
(important source of LCPUFA) and cognition and/or school performance [12–14]. 
All in all, observational studies and biological mechanisms point to a possible positive 
relationship between LCPUFAs and cognitive performance in adolescents. We aimed to 
investigate the causal relationship between LCPUFA supplementation from krill oil and 
cognitive performance in adolescents in their second year of lower general secondary 
education (LGSE) who have a low Omega-3 Index (O3I). 
Methods and participants  
Food2Learn was approved by the Medical Ethical Committee of Atrium-Orbis-Zuyd 
Hospital Heerlen, the Netherlands (NL45803.096.13) and is registered at both the 
Netherlands Trial Register (NTR4082) and at Clinicaltrials.gov (NCT02240264). Below is a 
brief description of the procedure, design and methods, more details have been reported 
previously [15].  
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Study design  
Food2Learn is a double-blind, randomized, placebo controlled intervention trial with 
repeated measurements (baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)) 
to study the effect of krill oil supplementation on among others cognitive performance of 
second year high school students in the Netherlands. The goal was to increase the Omega-
3 Index (O3I) of participants in the active treatment group to 8-11%. This target O3I was 
an estimate based on the O3I associated with the lowest mortality risk in coronary heart 
disease [16]. 
Recruitment procedure  
Seventeen schools in the south of the Netherlands participated in the study. For the 
current study, all second year students of the LGSE theoretical learning pathway (TLP) at 
the participating schools were approached in a classroom setting to participate. A research 
assistant explained the study and handed out an information letter and informed consent 
forms. The students were asked to discuss the information with their parent(s) and/or 
guardian(s). When they wanted to participate, the informed consent form had to be signed 
by the adolescent as well as by both parent(s) and/or guardian(s). When the informed 
consent form was received, a finger prick was executed to determine the O3I in blood. As 
it was expected that any effect of krill oil supplementation would be more likely in 
participants with a low O3I, only those students with an O3I < 5% were eligible to 
participate in the study. Together with the informed consent, parents and students filled 
out a short questionnaire with personal contact information, weight, height and level of 
parental education. 
Participants  
All students attending LGSE TLP level at the participating school with an O3I < 5 % were 
eligible to participate. Exclusion criteria were an O3I > 5%, an allergy to fish or shell fish, 
or hemophilia. A total of 286 participants gave informed consent of whom 267 were 
randomized. Participants were recruited in two cohorts, cohort I from November 2013 to 
February 2014 and cohort II from November 2014 to February 2015. Data were collected 
from February 2014 to April 2015 and from February 2015 to April 2016, respectively.  
Randomization and blinding  
All participants received a participant number upon entering the study and were allocated 
to a condition by an independent researcher. Participants were stratified by sex and an 
equal number of participants were allocated to krill and placebo condition; group allocation 
sequence was computer generated. Both researchers at the site and participants and parents 
were blind to treatment condition. The packing of the boxes and placebo and krill oil 
capsules were visually exactly the same. Furthermore, capsules were coloured black and a 
vanilla odour was added to ensure blinding.  
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Intervention 
The intervention started after baseline neuropsychological testing. In cohort I, participants 
were instructed to take four capsules (krill or placebo) daily with their dinner, the fattest 
meal of the day [17]. Four krill oil capsules contained 260mg EPA and 140mg DHA which 
was nearly the recommended amount of 450mg DHA + EPA per day as suggested by the 
Dutch Health Council [18]. After three months of supplementation a personalized dose 
adjustment was planned to account for interpersonal difference in metabolism. However, 
at the three month point, no participant achieved the target O3I of 8-11%. Therefore, all 
participants were instructed to increase the daily dosage to eight capsules per day (both krill 
and placebo). Furthermore, it was decided that Cohort II would immediately start with 
eight capsules. Eight capsules of krill oil contained 520mg EPA and 280mg DHA per day.  
Data collection 
Blood analyses 
Whole blood was obtained from a finger prick at T0, T1, T2 and T3 with an automated 
one-time use lancet and directly transferred to a filter paper (Whatman 903, General 
Electric, Frankfurt, Germany) pre-treated with a stabilizer. Filter papers were shipped 
immediately to Omegametrix, Martinsried, Germany for analysis. Whole blood fatty acid 
compositions were analysed according to the HS-Omega-3 Index methodology as 
described previously [15,16,19].  
Cognitive measurements  
As the neuropsychological tests have been described in more detail in [15], a brief 
description follows. Five neuropsychological tests were administered at T0, T2 and T3. 
Three were administered in a small group setting (maximum 10 students), namely: The 
Letter digit substitution task (LDST), the D2 test of attention (D2), and the Digit Span 
backward and forward (DSB and DSF). After these group tests were administered the 
Stroop Interference test and the Concept Shifting Task (CST) were administered 
individually. The LDST is a measure for speed of information processing [20,21], D2 is 
used to measure selective attention [22], DSB is a measure for working memory, DSF is a 
measure for short term memory, the Stroop Interference Test is a measure for cognitive 
inhibition, and lastly CST is a measure for cognitive shifting [23].  
Other measurements 
After the neurocognitive tests, participants filled out a number of questionnaires. Among 
others pubertal phase was assessed with the Pubertal Development Scale [24]. Students also 
filled out if they smoked cigarettes and how many, and if they drank alcohol and if so how 
often and how much. They also indicated whether they had a diagnosis which could 
influence learning (i.e., autism, dyslexia, or ADHD). At T2 and T3 questions were asked 
about adherence (how often did you forget the capsules?) and whether they experienced 
any side effects (open ended question). Lastly, at T3 students were asked to guess in which 
group they were allocated and to indicate how certain they were about their guess.  
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Statistical analyses  
Sample size calculation was executed in R Mass. To investigate the effect of the 
intervention on cognitive scores mixed model analyses were executed in R statistical 
environment (R studio version 3.2), and all other analyses were executed with SPSS 
statistics version 24 (IBM).  
Sample size  
Sample size calculation was executed in R Mass software. Based on an effect size of d=0.25 
at 6 months and an effect size equal or 10% larger at 12 months, a drop-out rate of 25% 
per measurement moment (thus 43% in total), an error variation between 0.4 and 0.5, and 
an intercept variation of 0.3 to 0.5 with fixed effects it was concluded that a sample of 183-
285 participants would be sufficient to achieve a power of 0.8.  
Group comparisons, treatment guess and adherence  
Baseline comparisons on fatty acid concentrations, neurocognitive test scores and 
participant characteristics (i.e., age, BMI, alcohol, sex, smoking, level of parental education, 
pubertal status, school, and cohort) were done with ANOVA analyses for the continuous 
variables and Chi square tests for the categorical variables. Participants in the krill oil group 
were compared with participants in the placebo group, those who completed the study with 
those who dropped-out, and those who actively finished the study (i.e., taking placebo or 
krill oil) with those who quit taking the capsules (both those that still participated in 
neuropsychological testing and those that quit completely). Moreover, fatty acid 
concentrations measured in blood at all time points in participants in the krill oil group 
were compared with fatty acid concentrations measured in blood in participants in the 
placebo group with an ANOVA. 
Treatment guess was compared for those in the krill oil group with the treatment guess 
in those in the placebo group with a Chi Square test. Students were asked to return 
capsules which they did not take as a measure of adherence. As an additional measure of 
adherence, the average increase in O3I between T0 and T2 and between T0 and T3 were 
studied. Moreover, the number of participants who had a decrease in O3I, had an increase 
up to 2.5%, and had an increase of more than 2.5% were noted 
Imputing and recoding covariates 
Data on drinking (units per week) and smoking (yes/no) were collected at T0 and at T3 
and imputed for T2, an average score between 0 and 12 months was used for drinking, and 
a cut-off score of 0.5 cigarette a week was used to code yes/no for smoking (> 0.5 as yes). 
Level of parental education was coded as low (vocational education and training and 
below) and high (university of applied sciences and higher).  
Cognitive measurements  
Intention-to-treat analyses were conducted using linear mixed models that accounted for 
repeated measurements in subjects. Models allowed a comparison between groups 
(intervention versus control condition) and within groups (baseline data compared to 
intervention at other time points). Besides time trends (baseline as a reference) and 
treatment X time interactions, all estimates were adjusted for drinking behavior, smoking 
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behavior, level of parental education, age at baseline, pubertal status at baseline, sex, body 
mass index, diagnosis related to learning, and cohort number.  
Furthermore, moderation analyses for sex and, if relevant, sub group analyses for males 
and females were executed. Secondary analyses were executed with: (1) O3I as exploratory 
analyses and (2) only participants who completed the full study (i.e., had measurements on 
and T0, and T2, and T3).  
For D2 Total, D2 Correct, LDST, Shifting and Interference the R package nlme with 
standard settings was used [25]. D2 F1 (errors of omission on D2) and D2 F2 (errors of 
commission) had skewed distributions and, therefore, the generalized linear mixed-effects 
(Poisson) model option and the bootstrapping method were used to determine the 95% 
confidence interval in the package lme4 [26]. Lastly, digit span data were analyzed with the 
package ordinal with the function for cumulative link mixed models [27]. In these ordinal 
analyses one quadrature point and flexible thresholds were used. In all cases a p <. 05 was 
considered to be statistically significant.  
Results  
A total of 286 students provided informed consent, 17 did not meet inclusion criteria, 1 
declined participation and 2 were not included due to other reasons yielding 267 
respondents who were randomized into the study. Due to logistic reasons 9 participants 
with a baseline O3I > 5% were not excluded before the start of the trial. These participants 
were excluded from data analyses. One participant quit during baseline testing and was 
excluded from analyses. Thus data were available for 257 participants for at least one time 
point. During the study 82 students (31.9%) withdrew completely from the study and 53 
(20.6%) stopped active participation (i.e., they were tested, but did not take capsules, see 
Figure 7.1). Baseline characteristics for the placebo and the krill oil group can be found in 
Table 7.1, Table 7.2, and Table 7.3. There were slightly more girls in the krill oil group than 
boys compared to the placebo group (54 girls in krill oil group 79 girls in placebo group; 
χ2 (1) = 8.56; p = .004). Furthermore, those randomized into the krill oil group had a 
slightly lower DHA concentration at baseline compared to those in the placebo group 
(F (1,255) = 3.977; p = .047). There were no other differences between the placebo and 
krill oil group in participant characteristics (all p > .175) or baseline cognitive test scores (all 
p > .126).  
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Figure 7.1: Flow chart 
Flow chart adapted from Consort Guidelines [45] 
1 Participants whom quite taking capsules and quite participation in testing. 2 Participants whom quite taking 
capsules but did participate in testing. 3 Three participants with an O3I > 5% were included in the placebo group 
of these one was lost to follow up (reason forgetting), one discontinued the intervention (reason dose adjustment) 
and one finished the intervention, they were all excluded from the analyses. 4 Six participants with an O3I > 5% 
were included in the intervention group of these one was lost to follow up (reason motivation), two discontinued 
the intervention (reason motivation/ personal)and three finished the intervention, they were all excluded from the 
analyses. 
Assessed for eligibility (n=286)
Excluded (n=19)
● Not meeting inclusion criteria (n=17)
● Declined to participate (n=1)
● Other reasons (n=1)
Allocation
Allocated to intervention (n=134)
● Received allocated intervention (n=133)
● Did not receive allocated intervention (n=1)
◦ Withdrew consent (n=1)
Allocated to placebo (n=133)
● Received allocated intervention (n=133)
● Did not receive allocated intervention (n=0)
Follow-Up
Lost to follow-up1 (n=25)
Forgetting (n=8)
Difficulty swallowing (n=6)
Motivation (n=4)
Reason not given (n=4)
Dose adjustment (n=3)
Discontinued intervention2 (n=36)
Forgetting (n=7)
Difficulty swallowing (n=9)
Motivation (n=11)
Reason not given (n=2)
Dose adjustment (n=4)
Personal (n=1)
Other (n=2) 
Lost to follow-up1 (n=31)
Forgetting  (n=2)
Difficulty swallowing (n=8)
Motivation (n=15)
Reason not given (n=3)
Dose adjustment (n=1)
Personal (n=1) 
Other (n=1)
Discontinued intervention2 (n=49)
Forgetting (n=13)
Difficulty swallowing (n=5)
Motivation (n=15)
Reason not given (n=3) 
Dose adjustment (n=3)
Personal (n=3)
Other (n=7) 
Analysis
Analysed intention to treat  (n=97)
Excluded from analysis (n=7)
◦ Included in RCT but Omega-3 Index >5% (n =6)4 
◦ Quit during test moment 1 (n =1)
Analysed intention to treat (n=106)
Excluded from analysis (n=3)
◦ Included in RCT but Omega-3 Index >5% (n =3)3
Randomized (n=267)
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Table 7.1: Participant characteristics at baseline  
 Placebo N Krill N P3 
Age (years) 14.07 ± 0.48  130 14.15 ± 0.51 127 0.175 
Male/female 
N (%) 
51/79 
(39/61) 
130 73/54 
(57/43) 
127 0.003 
Smoking1 (no/yes) 117/12 
(91/9) 
129 114/12 
(90/10) 
126 0.952 
BMI  20.13 ± 3.05 123 19.81 ± 2.96 117 0.414 
Alcohol units per week2 0.34 ± 1.16 129 0.60 ± 2.28 127 0.240 
Level of parental 
education 
5.02 ± 1.58 124 5.09 ± 1.43 116 0.686 
1 Smoking was defined as anybody who indicated to smoke more than 0 cigarettes per week; 2 Alcohol units per 
week was operationalized as number of days per week that alcohol is consumed times units per consumption 
moment; 3ANOVA was used for age, BMI, LPE and alcohol units per week, Chi Square for smoking, and sex. 
Significant differences (p < .05) are noted in bold. 
Fatty acids concentrations 
Concentrations of fatty acids in blood can be found in Table 7.2. The intervention group 
had a significant higher EPA, DPA, DHA concentrations, a significantly higher O3I (all 
p <. 001), and significant lower concentrations of AA and ObA (all p < .038) compared to 
the placebo group at T1, T2 and T3. In the supplementary Table S7.1 fatty acid 
concentrations on T1 separate for cohort 1 and cohort 2 can be found. 
Treatment guess  
After the one year supplementation period 63 participants (65.6%) in the placebo group 
and 45 participants (50.6%) in the krill oil group correctly guessed their original treatment 
allocation. The percentage that correctly guessed treatment allocation did differ 
significantly with more participants in the placebo group correctly guessing their group 
allocation (χ2 = 4.313; p = .038).  
Drop-out and adherence 
There was a baseline difference between those who finished the study completely with 
supplementation and those who quit taking capsules for school and cohort. In some 
schools more children quit supplementation than in other schools (χ2 = 11.329, p = .001). 
Moreover, there was a difference in drop-out between cohorts, more students stopped 
taking capsules in cohort II (χ2 (1) = 10.875, p = .001) compared to cohort I. All other 
participant characteristics, fatty acids and neurocognitive test scores were not significantly 
different between the groups (all p > .066) 
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Furthermore, when we compared activate participants (those who took capsules) with 
participants who only took part in neuropsychological testing (without taking capsules), and 
those participants that quit completely were compared the same patterns were seen. There 
was a difference between cohort (χ2 = 13.139, p = .001) and between pubertal status at 
baseline with those participating without taking capsules having a slightly lower pubertal 
status (M = 3.27 versus M = 3.52 for active participants and M = 3.65 for those who 
dropped-out completely; F (2,235) = 4.890; p = .023). All other participant characteristics, 
fatty acids and neurocognitive test scores were not significantly different between the 
groups (all p > .059).  
Students that were taking krill oil at T2 had an average increase, compared to T0, in the 
O3I of 2.02% (SD 1.58). At T2 compared to T0, 5 (6.8%) of the active participants in the 
krill group had a decrease in their O3I, 44 (60.3%) had an increase between 0 and 2.5% and 
24 (32.9%) had an increase of > 2.5%. At T3 compared to T2 there was an average 
decrease in the O3I of 0.70% in active krill oil participants. When looking at the O3I at T3 
compared to T2 35 (70%) of active participants in the krill oil group had a decrease in their 
O3I and were thus most likely non-adherent to the protocol, 15 (30%) had an increase 
between 0.14% and 1.96%.   
Participants were asked to return capsules at the last test moment. Of the active 
participants (i.e., those taking capsules) at T3, 56 handed in capsules and 37 counted the 
left-over number of capsules at home. On average participants handed in or counted at 
628.82 ± 395.23 left-over capsules. So on average participants did not take the capsules 
78.6 days of the approximately 180 days between T2 and T3.  
Neuropsychological tests  
The random intercept models with time moment (T0, and T2, and T3), condition (krill oil 
or placebo), the interaction term (time moment X condition) and covariates showed that 
group allocation (krill or placebo) did not predict the score on any of the neurocognitive 
tests (see Table 7.4). There was however a clear time effect (i.e., students improved over 
time) on all neurocognitive tests with exception of the digit span forward and backward. 
Moreover, there was an interaction effect for condition X time moment T3 for the number 
of target stimuli processed on the D2 (D2 correct). This indicates that the increase in 
number of correctly processed stimuli between T2 and T3 was slightly higher in the 
placebo group compared to the krill oil group, namely 4.67 stimuli more.  
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Table 7.4: Multilevel analyses of cognitive test scores predicted by condition (intention to treat) and according to 
Omega-3 Index  
   Estimate (SE) 95%CI  Estimate (SE) 95%CI 
D2- Total Test moment T2 48.05 (3.60) [41.06; 55.03] T2 47.92 (3.01) [42.08; 53.75] 
T3 88.39 (3.80) [81.02; 95.76] T3 84.90 (3.07) [78.95; 90.85] 
Condition Krill -9.67 (7.93) [-25.09; 5.74] O3I -0.20 (1.63) [-3.36; 2.96] 
Interaction T2 × krill -0.33 (5.25) [-10.51; 9.84]    
T3 × krill -8.04 (5.44) [-18.59; 2.51]    
D2- Correct Test moment T2 23.05 (1.55) [20.04; 26.06] T2 23.02 (1.30) [20.51; 25.53] 
T3 43.50 (1.64) [40.32; 46.68] T3 41.64 (1.32) [39.08; 44.20] 
Condition Krill -1.54 (3.69) [-8.71; 5.62] O3I -0.48 (0.70) [-1.85; 0.88] 
Interaction T2 × krill -0.67 (2.26) [-5.06; 3.71]    
T3 × krill -4.67 (2.35) [-9.23; -0.13]    
D2- F1 Test moment T2 -0.13 (0.04) [-0.21; -0.04] T2 -0.14 (0.04) [-0.22; -0.07] 
T3 -0.24 (0.05) [-0.32; -0.14] T3 -0.27 (0.04) [-0.34; -0.20] 
Condition Krill -0.09 (0.10) [-0.30; 0.13] O3I 0.01 (0.02) [-0.03; 0.05] 
Interaction T2 × krill -0.002 (0.06) [-0.15; 0.12]    
 T3 × krill -0.05 (0.07) [-0.18; 0.09]    
D2-F2 Test moment T2 -0.24 (0.13) [-0.48; 0.01] T2 -0.13 (0.10) [-0.33; 0.05] 
 T3 -0.53 (0.14) [-0.80; -0.27] T3 -0.56 (0.12) [-0.76; -0.34] 
 Condition Krill -0.21 (0.16) [-0.51; 0.07] O3I -0.04 (0.05) [-0.14; 0.05] 
 Interaction T2 × krill 0.16 (0.19) [-0.21; 0.53]    
 T3 × krill -0.05(0.22) [-0.50; 0.36]    
 Test moment T2 2.49 (0.48) [1.57; 3.42] T2 2.42 (0.39) [1.66; 3.18] 
LDST T3 4.74 (0.50) [3.76; 5.72] T3 4.56 (0.40) [3.78; 5.33] 
 Condition Krill -0.19 (0.81) [-1.75; 1.38] O3I -0.07 (0.74) [-0.46; 0.32] 
 Interaction T2 × krill -0.24 (0.70) [-1.59; 1.11]    
 T3 × krill -0.31 (0.72) [-1.71; 1.08]    
Shifting Test moment T2 -1.60 (0.81) [-3.17; -0.02] T2 -1.80 (0.64) [-3.03; -0.55] 
 T3 -1.23 (0.85) [-2.87; 0.41] T3 -1.87 (0.66) [-3.14; -0.59] 
 Condition Krill -0.09 (0.90) [-1.83; 1.66] O3I 0.07 (0.27) [-0.46; 0.60] 
 Interaction T2 × krill -0.24 (1.18) [-2.53; 2.06]    
 T3 × krill -1.42 (1.22) [-3.78;0.95]    
Interference Test moment T2 -4.04 (0.72) [-5.43; -2.65] T2 -3.47 (0.58) [-4.60; -2.35] 
 T3 -5.42 (0.75) [-6.87; -3.96] T3 -5.41 (0.59) [-6.55; -4.26] 
 Condition Krill -0.97 (0.97) [-2.84;0.91] O3I -0.02 (0.28) [-0.56; 0.52] 
 Interaction T2 × krill 1.10 (1.05) [-0.93;3.12]    
 T3 × krill -0.19 (1.08) [-2.28;1.90]    
D2 = D2 test of attention, D2 correct = number of target stimuli processed, D2F1 = errors of omission on D2, 
D2F2 = errors of commission on D2, LDST = letter digit substitution task, O3I = Omega-3 Index, T2 = test 
moment 6 months, T3 = test moment 12 months  
All models included test moment, condition (krill/placebo) plus covariates (alcohol consumption, smoking 
behavior, age at baseline, puberty status at baseline, BMI, highest level of parental education, sex, cohort number 
and diagnosis). Significant 95 % CI are printed in bold. The model with condition also includes the time moment 
X condition interaction factor. Note that a lower score on D2F1, D2F2, Shifting and Interference is a better 
performance. 
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Table 7.5: Multilevel analyses of digit span forward and digit span backward, predicted by either condition 
(intention to treat) or Omega-3 Index 
  Odds ratio 
(SE) 
95%CI  Odds ratio 
(SE) 
95%CI 
DSF       
Test moment T2 0.46 (1.32) [0.26;0.77] T2 0.54 (1.25) [0.35; 0.84] 
T3 1.15 (1.33) [0.66;2.02] T3 1.16 (1.25) [0.75; 1.78] 
Condition Krill 0.86 (1.41) [0.44;1.69] O3I 1.08 (1.11) [0.88; 1.32] 
Interaction T2 × krill 1.84 (1.50) [0.83;4.06]    
T3 × krill 1.21 (1.51) [0.54;2.71]    
DSB       
Test moment T2 1.38 (1.30) [0.83;2.30] T2 1.49 (1.23) [0.99; 2.22] 
T3 1.61 (1.32) [0.93;2.77] T3 1.61 (1.24) [1.05; 2.45] 
Condition Krill 0.87 (1.37) [0.47;1.61] O3I 1.00 (1.10) [0.83; 1.21] 
Interaction T2 × krill 1.14 (1.46) [0.55;2.39]    
T3 × krill 0.97 (1.49) [0.44;2.12]    
DSF = digit span forward, DSB = digit span backward, O3I = Omega-3 Index, T2 = test moment 6 months, 
T3 = test moment 12 months. 
All models included test moment, condition (krill/placebo) or Omgea-3 Index plus covariates (alcohol 
consumption, smoking behavior, age at baseline, puberty status at baseline, BMI, highest level of parental 
education, sex, cohort number and diagnosis). The model with condition also includes the time moment X 
condition interaction factor. Please note that for odds ratios significance is indicated by a 95% CI which does not 
contain 1. 
 
The random intercept with time moment (T0, and T2, and T3), O3I and covariates did not 
show an effect of O3I on neurocognitive test scores either. There was however a clear time 
effect (i.e., students improved over time) on all neurocognitive tests with exception of the 
digit span forward and backward.  
All above analyses were run with all participants, whether they had data available for 
one, two or three time points. To ensure the accuracy of the data a secondary exploratory 
analysis was executed with only those participants that had data available at all three test 
moments. The results of these analyses were similar to the results of the intention to treat 
analyses (see Supplementary Table S7.2 and S7.3).  
Side effects  
At the end of T2 and T3 we asked whether the participant had experienced any side effects. 
The question was open ended. At T2 27 participants indicated to have a side effect. 
Fourteen of these ‘side effects’ were positive; that is they mentioned to have better focus or 
better grades at school. The negative side effects which were reported were minor (3x 
stomach ache, 2x nauseous, 2x tired, 1x more hay fever, throwing up, hunger swings, more 
nervous, mood swings, dizziness, gaining weight, ‘a weird feeling in my stomach’ and throat 
ache). One participant learned during the trial that (s)he was allergic to fish. At T3, there 
were 29 participants with side effects, of whom 14 were positive. The negative side effects 
were again minor (4x head ache, 3x nauseous, 2x throat ache, 2x stomach ache, 2x less 
hunger, 1x each for tired, drier skin, sleeplessness, less focus, gaining weight, bad breath, 
belches, skin rash and ‘getting ill from it’) 
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Discussion 
This study did not show an effect of one year of krill oil supplementation on a number of 
cognitive tests in typically developing adolescents of the lower general secondary education 
level in the Netherlands with a low baseline O3I. Moreover, sensitivity analyses did not 
show the association of higher O31 and neurocognitive test score. Note that our analyses 
of both depression and self-esteem questionnaire data showed similarly no effect of 
supplementation. However, the goal of the study was that participants in the krill oil group 
would achieve a predetermined O3I of 8-11% and that two distinct groups with regard to 
O3I would be achieved (thus no or minimal overlap in O3I between krill and placebo 
group). Unfortunately, neither goal was achieved. At 6 months follow-up the average O3I 
in the krill oil group was 5.29%, at 12 months 4.80. This was an average increase of 1.58% 
and 1.14%, respectively, compared to baseline. Moreover between 6 months and 12 months 
there was actually in average decrease in O3I in participant in the krill oil group who said to 
take the capsules. Moreover, only 3, 10, and 2 participants achieved the target O3I of > 8% 
at T1, T2, and T3, respectively. Thus, the average O3I of participants in the krill oil group 
was at all time points below the intended range of 8-11% and it seems likely that 
participants were non-adherent to the protocol. The O3I was also low if compared to, for 
example, unselected adult individuals from the German and European population, who 
have an average O3I of 7.15% and 6.96% respectively [28].  
Mixed model analyses did not show an effect of krill oil supplementation on cognitive 
test scores (all p > .161), or a relationship between O3I and cognitive measures in the 
whole sample. It did show an interaction effect between condition and time moment T3 
for the number of correctly processed stimuli on the D2 indicating that the increase in the 
correctly processed stimuli between T2 and T3 was slightly higher in the placebo group 
compared to the krill oil group. However, this effect was rather small (4.67), the placebo 
group scored higher on the D2 correct at every time point (albeit not significant) and no 
relationship in the O3I analyses were found, it is therefore not considered to be notable 
finding.  
The findings that one year of krill oil supplementation did not improve cognitive test 
scores or a relationship between O3I and cognitive measures are in contrast with many 
supplementation studies in children [29–33], although not all studies in children show 
effects on cognition [34–40]. McNamara and colleagues did find increased functional 
activation of the dorsolateral prefrontal cortex after 8 weeks of DHA supplementation of 
boys 8-10 years, but this did not translate into a difference in performance task [11]. Bauer 
et al. found similar results in adults, with participants in the DHA supplementation group 
showing an increase in the functional activity in the right precentral gyrus, but no effect on 
cognitive measures [41]. Thus the fact that in this study no effect of krill oil 
supplementation on scores of cognitive tests could be shown does not preclude that there 
was increased activity in a some brain regions. It however remains to be seen what the real 
life avail would be of an increased brain activation when this does not lead to improved 
performance on the relatively short-term (up to 1 year). In a previous paper we reported on 
the baseline data of the current study and showed a positive association between higher 
O3I and better performance on the LDST in the whole sample and less D2 errors of 
omission [42]. It is unclear as to why that relationship could not be replicated in the current 
sample.  
Effect of 1 year krill oil supplementation on cognition 
127 
The small increase in the O3I is likely caused by the high number of students that quit 
taking capsules and the high non-adherence in active participants. It was tried to increase 
adherence to the protocol by sending participants a daily text message and having 
motivational talks. However, the study might just have been too long in duration (main 
reason for drop-out was loss of motivation) and the number of capsules the students had 
to take was too high (another important reason for drop-out was inability to take capsules). 
Both long study duration and high number of capsules have been suggested to influence 
adherence and drop-out [43]. This reasoning is also supported by the low drop-out and 
high adherence rates in the study of Tamman and colleagues. They studied a similar 
population but the study only lasted 16 weeks and students only had to take two capsule a 
day. They reported an adherence of 88% and a drop-out of 4.5% [44]. It is however 
important to note that if LCPUFA supplementation is found to be beneficial, long-term 
daily high dose intake of capsules might be needed to achieve and sustain effects, which 
seems to be extra problematic in adolescents.  
The strength of the current study is that the O3I was measured in blood. So a reliable 
measure for adherence was available and analyses could be executed based on blood levels. 
Moreover, participants were preselected based on a low O3I as it can be expected that any 
effects of supplementation would be more pronounced in those with a low baseline O3I.  
The main limitation of the current study is the fact that there was a relative high drop-
out rate and adherence difficulties. However, the blood values and cognitive test scores for 
the majority of those that quit taking capsules were available. Moreover, participants that 
quit taking capsules did not differ significantly from those that continued the study actively 
on any of the relevant baseline measurements and thus selection bias seems unlikely 
To summarize, the current study did not show an effect of one year of krill oil 
supplementation on cognitive measure of adolescents attending LGSE with a low baseline 
O3I. However, due to adherence problems and drop-out , it cannot be concluded that a 
relationship between krill oil supplementation and cognition does not exist. More studies 
on the influence of krill oil supplementation on cognition in adolescents are needed, 
moreover these studies should focus on achieving a set target O3I in the active group.  
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Supplemental Table S7.1: Fatty acid concentrations at T1 separated for cohort 1 and cohort 2  
 Cohort 1  Cohort 2  
Fatty acid  
(%wt/wt of total FA) 
Placebo Krill Placebo Krill 
AA 20:4n-6 11.02 ± 1.16  10.16 ± 0.95 10.92 ± 1.21 10.61 ± 1.26 
EPA 20:5n-3 0.45 ± 0.15 0.86 ± 0.35 0.40 ± 0.14 0.99 ± 0.71 
ObA 22:5n-6 0.37 ± 0.09 0.27 ± 0.06 0.46 ± 0.21 0.36 ± 0.14 
DPA 22:5n-3  1.30 ± 0.19 1.54 ± 0.23 1.29 ± 0.26 1.61 ± 0.41 
DHA 22:6n-3 2.72 ± 0.49 3.34 ± 0.64 2.49 ± 0.52 3.18 ± 0.78 
O3I 4.02 ± 0.62 5.12 ± 0.97 3.74 ± 0.65 5.09 ± 1.49 
O3I =Omgea-3 index  
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Supplemental Table S7.2: Multilevel analyses of cognitive test scores predicted by condition and Omega-3 
Index, participant whom participated in all test moments  
   Estimate (SE) 95%CI  Estimate (SE) 95%CI 
D2- Total Test 
moment 
T2 45.22 (3.73) [38.01; 52.43] T2 47.13 (3.10) [41.12; 53.14] 
T3 87.59 (3.81) [80.22; 94.96] T3 84.45 (3.07) [78.51; 90.39] 
Condition Krill -4.67 (8.85) [-21.85; 12.50] O3I -0.12 (1.63) [-3.28; 3.03] 
Interaction T2 × krill 4.08 (5.43) [-6.41; 14.58]    
T3 × krill -7.15 (5.45) [-17.69; 3.40]    
D2- Correct Test 
moment 
T2 21.72 (1.61) [18.60; 24.84] T2 22.74 (1.35) [20.13;22.74] 
T3 42.94 (1.65) [39.75; 46.13] T3 41.47 (1.33) [38.89;44.05] 
Condition Krill 0.38 (4.11) [-7.60; 8.35] O3I -0.52 (0.71) [-1.90;0.86] 
Interaction T2 × krill 1.24 (2.35) [-3.29; 5.78]    
T3 × krill -3.99 (2.36) [-8.55; 0.56]    
D2- F1 Test 
moment 
T2 -0.16 (0.04) [-0.24; -0.07] T2 -0.16 (0.04) [-0.23; -0.08] 
T3 -0.25 (0.05) [-0.34; -0.16] T3 -0.27 (0.04) [-0.35; -0.20] 
Condition Krill -0.15 (0.11) [-0.36; 0.09] O3I 0.02 (0.02) [-0.02; 0.06] 
Interaction T2 × krill 0.04 (0.07) [-0.09; 0.17]    
 T3 × krill -0.03 (0.07) [-0.17; 0.11]    
D2-F2 Test 
moment 
T2 -0.14 (0.13) [-0.40; 0.11] T2 -0.03 (0.11) [-0.23; 0.19] 
 T3 -0.46 (0.15) [-0.76; -0.19] T3 -0.48 (0.13) [-0.70; -0.26] 
 Condition Krill -0.24 (0.18) [-0.56; 0.07] O3I -0.04 (0.05) [-0.15; 0.07] 
 Interaction T2 × krill 0.19 (0.21) [-0.19; 0.55]    
 T3 × krill -0.03 (0.23) [-0.44; 0.40]    
 Test 
moment 
T2 2.29 (0.50) [1.32; 3.26] T2 2.43 (0.41) [1.64; 3.22] 
LDST T3 4.64 (0.51) [3.65; 5.63] T3 4.58 (0.40) [3.80; 5.36] 
 Condition Krill -0.62 (0.87) [-2.30; 1.07] O3I -0.07 (0.20) [-0.47; 0.33] 
 Interaction T2 × krill 0.19 (0.73) [-1.23; 1.60]    
 T3 × krill -0.06 (0.73) [-1.48; 1.36]    
Shifting Test 
moment 
T2 -1.73 (0.86) [-3.40; -0.07] T2 -1.92 (0.68) [-3.23; -0.60] 
 T3 - 1.30 (0.87) [-2.98; 0.39] T3 -1.96 (0.68) [-3.27; -0.66] 
 Condition Krill -0.06 (0.97) [-1.96; 1.83] O3I 0.15 (0.28) [-0.38; 0.69] 
 Interaction T2 × krill -0.11(1.26) [-2.54; 2.33]    
 T3 × krill -1.41 (1.26) [-3.85; 1.04]    
Interference Test 
moment 
T2 -3.85 (0.76) [-5.32; -2.39] T2 -3.39 (0.61) [-4.58; -2.21] 
 T3 -5.26 (0.77) [-6.75; -3.77] T3 -5.38 (0.61) [-6.55; -4.20] 
 Condition Krill -0.38 (1.05) [-2.42; 1.66] O3I -0.01 (0.29) [-0.57; 0.54] 
 Interaction T2 × krill 0.90 (1.11) [-1.24; 3.05]    
 T3 × krill -0.45 (1.11) [-2.59; 1.70]    
 
D2 = D2 test of attention, D2 correct = number of target stimuli processed, D2F1 = errors of omission on D2, 
D2F2 = errors of commission on D2, LDST = letter digit substitution task, O3I = Omega-3 Index, T2 = test 
moment 6 months, T3 = test moment 12 months  
All models included test moment, condition (krill/placebo) plus covariates (alcohol consumption, smoking 
behaviour, age at baseline, puberty status at baseline, BMI, highest level of parental education, sex, cohort number 
and diagnosis). Significant 95 % CI are printed in bold. The model with condition also includes the time moment 
X condition interaction factor. Note that a lower score on D2F1, D2F2, Shifting and Interference is a better 
performance.  
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Supplemental Table S7.3: Multilevel analyses of DSF and DSB predicted by condition and Omega-3 Index, 
participant whom participated in all test moments  
 Adjusted model  Adjusted model 
  Odds ratio (SE) 95%CI  Odds ratio (SE) 95%CI 
DSF       
Test moment T2 0.52 (1.34) [0.29; 0.91] T2 0.58 (1.26) [0.37; 0.92] 
T3 1.28 (1.34) [0.72; 2.28] T3 1.26 (1.26) [0.80; 1.96] 
Condition Krill 1.03 (1.46) [0.49; 2.17] O3I 1.03 (1.36) [0.84; 1.27] 
Interaction T2 × krill 1.44 (1.53) [0.30; 3.32]    
T3 × krill 1.06 (1.53) [0.46; 2.44]    
DSB       
Test moment T2 1.31 (1.32) [0.76; 2.24] T2 1.55 (1.24) [0.94; 2.21] 
T3 1.53 (1.33) [0.87; 2.68] T3 1.58 (1.25) [1.02; 2.43] 
Condition Krill 0.82 (1.41) [0.42; 1.60] O3I 0.99 (1.10) [0.82; 1.20] 
Interaction T2 × krill 1.15 (1.49) [0.52; 2.51]    
T3 × krill 1.03 (1.51) [0.46; 2.30]    
DSF = digit span forward, DSB = digit span backward, O3I = Omega-3 Index, T2 = test moment 6 months, 
T3 = test moment 12 months. 
All models included test moment, condition (krill/placebo) or Omgea-3 Index plus covariates (alcohol 
consumption, smoking behaviour, age at baseline, puberty status at baseline, BMI, highest level of parental 
education, sex, cohort number and diagnosis). The model with condition also includes the time moment X 
condition interaction factor. Please note that for odds ratios significance is indicated by a 95% CI which does not 
contain 1. 
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Abstract 
Background: Depression is common in adolescents and long-chain polyunsaturated fatty 
acids (LCPUFA) are suggested to be associated with depression. However, experimental 
research in adolescents is limited. Furthermore, self-esteem has never been studied in 
relation to LCPUFA.  
Methods: A one-year double-blind, randomized, placebo controlled krill oil 
supplementation trial with repeated measurements at baseline (T0), 3 months (T1), 6 
months (T2), and 12 months (T3) in adolescents. Students from cohort I started with 
400mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) or placebo, at T1 this 
was increased to 800mg EPA + DHA per day (or placebo). Cohort II started with this 
higher dose (or placebo). Omega-3 Index (O3I) was monitored via a finger prick during the 
study. At T0, T2 and T3 participants filled out the Centre for Epidemiologic Studies 
Depression Scale (CES-D) and the Rosenberg Self Esteem questionnaire (RSE). Mixed 
models adjusted for covariates were run for both intention-to-treat analyses and O3I as 
predictor of CES-D and RSE scores. 
Results: Krill oil supplementation led to a small but significant increase in the O3I, 
however the O3I remained relatively low probably due to non-adherence. Both intention-
to-treat and O3I analyses did not show effects on CES-D and on RSE. 
Limitations: Depressive feelings were assessed with a questionnaire. Drop-out and non-
adherence were high.  
Conclusion: The trial did not reveal evidence for an improvement of depressive feelings, 
and self-esteem after one year of krill oil supplementation. The lack of evidence might be 
explained by the very low increase in the O3I in the krill oil group as a result of drop-outs 
and non-adherence. The study thus does not preclude that an effect of krill oil 
supplementation on depressive feelings in adolescent is possible. More research with higher 
LCPUA doses and strategies to increase adherence in adolescents is needed.  
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Introduction 
According to the World Health Organisation approximately 322 million people (4.4 % of the 
world population) are affected by depression [1]. Relatively uncommon in childhood 
(prevalence in last 6-12 months of 0.4-2.5%) [2], depression prevalence increases sharply during 
adolescence [3]. About 14-25% of adolescents experience at least one episode of depression 
before age 18 [4]. Adolescent depression has serious social, mental and physical consequences, 
for example increased risk of reoccurrence of depression, increased risk of anxiety, and risk of 
suicide [5]. But it has also been associated with lower educational attainment, lower wages, 
poorer social relationships, and poorer self-rated health [6,7]. Moreover, sub-threshold 
depression (i.e., depressive symptoms present, but not enough to reach a diagnosis of major 
depression) has also been associated with negative outcomes, such as the development of major 
depression and reduced quality of life [8,9]. Sub-threshold depression is common in adolescence 
with point prevalence between 0.24 and 14%, and life-time prevalence (i.e., life-time being up to 
age of measurement during adolescences) between 1 and 22.9% [8,9]. Numbers vary in different 
populations (ages, gender, country), but also due to the manner in which depression is assessed 
and according to criteria for (subthreshold) depression used.  
Depression is a complex and incompletely understood multi-factorial disorder, and 
probably has a heterogeneous aetiology [10]. Depression has been characterized by 
biological changes such as increased levels of pro-inflammatory cytokines [11,12], 
alterations in immune function [13], elevation of plasma homocysteine levels [14], changes 
in brain structure [15,16], blood flow abnormalities [17], and decreased glucose metabolism 
[18], and a low Omega-3 Index (O3I) [19,20].  
Long chain polyunsaturated fatty acids (LCPUFA) have long attracted attention for their 
possible positive effect on depression. LCPUFA have many important functions in the body 
which are biological plausible ways in which LCPUFA intake could prevent or cure depression. 
For example LCPUFA can modulate neuroendocrine factors, have anti-inflammatory 
properties, play a role in neurogenesis and in neuroplasticity [21,22], all factors which could 
reduce or counteract biological changes associated with depression. Observational studies, 
mostly show that blood and brain concentrations of docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) are lower in people with depression compared to people without 
depression [20,23,24]. LCPUFA supplementation intervention trials in adult depressed 
participants mostly show positive results (for meta-analyse see among others [25–27]).  
Depression mostly has its onset during adolescence and adolescents’ depression can have 
profound long lasting effects [5], it is therefore an important group to study with regard to 
depression. There are a number of observational studies investigating the relationship between 
LCPUFA and depression in adolescents [20,28–31]. Most, but not all, of these observational 
studies show a relationship between LCPUFA and depression (i.e., higher intake or higher 
concentrations in blood, less depression [20,28–30]). However, LCPUFA supplementation 
studies investigating depression in adolescents from the general population are not available yet.  
The main aim of this study was to assess the influence of one year of krill oil 
supplementation, a source of the LCPUFA DHA and EPA, on depressive feelings in 
adolescents of lower general secondary education. We hypothesised that one year krill oil 
supplementation would lead to lower depressive feelings.  
Furthermore we explored the influence of the krill oil supplementation on self-esteem. 
Self-esteem is a core construct in mental health and refers to the subjective evaluation of 
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ones worth as a person [32]. Low self-esteem has been suggested to be a risk factor for the 
development of many mental illnesses including depression [32]. However to our 
knowledge, studies exploring the effect of LCPUFA supplementation (here krill oil 
supplementation) are missing.  
Methods  
This study was approved by the Medical Ethical Committee of Atrium-Orbis-Zuyd 
Hospital Heerlen, the Netherlands (NL45803.096.13). Food2Learn is registered at the 
Netherlands Trial Register (NTR4082) and at Clinicaltrials.gov (NCT02240264). Full details 
about the designs and methods of the study have been reported previously [33]. Below a 
shortened version follows. Note that in the current manuscript only the data with regard to 
mental well-being are presented. 
Design 
Food2Learn was a double-blind, randomized, placebo controlled intervention trial with 
repeated measurements (baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3)) 
to study the effect of one year of krill oil supplementation on cognitive performance, 
academic achievement and mental well-being of second year high school students attending 
lower general secondary education (LGSE) in the Netherlands. After informed consent was 
received, a finger prick was executed to determine the Omega-3 Index (O3I). Only students 
with an O3I < 5% were included in the study. Goal of the study was to increase the Omega-
3Index (O3I) of participants in the krill oil group to 8-11%. This target O3I was based on 
the O3I associated with the lowest mortality risk in coronary heart disease [34].  
Intervention 
The intervention started after baseline testing. In Cohort I participants were asked to take 
four placebo or krill oil capsules, containing 260mg EPA and 140mg DHA with their 
dinner, as this is the fattest meal of the day and this helps with absorption. After three 
months of supplementation a personalized dose adjustment was planned to account for 
interpersonal difference in metabolism. However, at T1 only 3 participants achieved the 
target O3I of 8-11%, therefore all participants (both krill and placebo) were asked to 
increase the daily dosage to eight capsules per day, containing 520mg EPA and 280mg 
DHA per day. Furthermore, it was decided that Cohort II would start with eight capsules.  
Blood analyses 
Whole blood was obtained from a finger prick at T0, T1, T2, and T3. Whole blood fatty 
acid compositions were analysed according to the HS-Omega-3 Index methodology 
[34,35]. Results are given as EPA plus DHA expressed as a percentage of total identified 
fatty acids after response factor correction. Since the O3I is defined as EPA + DHA in 
erythrocytes, it was calculated using a sliding correction factor.  
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Questionnaires  
Centre for Epidemiologic Studies Depression Scale  
Depressive feelings were assessed with the Dutch version of the Centre for Epidemiologic 
Studies Depression Scale (CES-D) [36]. Although developed for adults, the CES-D has 
been shown to have a high reliability in both clinical and non-clinical samples of children 
and adolescents (α = 0.88) and also reasonable sensitivity (α = 0.76) [37]. The questionnaire 
consists of 20 questions which assess six symptom areas of depression. The score on the 
questionnaire can vary between 0 and 60, with higher scores indicating more depressive 
feelings. Originally a cut-off score of ≥16 was suggested as indication for depression, 
although some have suggested a higher cut-off score of ≥22 for adolescents [38]. 
Moreover, it has also been suggested that the CES-D score should be considered as a 
continuum of increasing severity [8]. For the current study we used both the standard cut-
off score of ≥16 and the adolescents’ cut-off score of ≥22 for descriptive purposes, while 
for the main analyses we used CES-D score as a continuous score.  
Rosenberg Self-Esteem Questionnaire  
Self-esteem was assessed with the Dutch version of the Rosenberg Self-Esteem Questionnaire 
(RSE) [39]. The reliability of the RSE has been shown to be high (α = 0.72-0.88) [40]. The RSE 
consists of 10 questions about the evaluation of themselves. The total score of the RSE can 
range from 0 to 30 with higher scores indicating higher self-esteem. For the current study the 
RSE score was used as a continuous score.  
Additional measures 
At T0, T2, and T3 a number of variables were measured as they are known to be associated 
with depression: BMI (weight/length2 , self-reported at baseline) [41,42], sex [43,44], age in 
years [45], alcohol consumption (number of days that alcohol was consumed times number 
of standardized units of alcohol that were consumed per moment) [46], and number of 
cigarettes smoked per week (if student indicates to smoke more than 1 cigarette per week 
this was coded a smoking yes, otherwise smoking no) [47]. Moreover parental level of 
education (subdivided in 8 levels ranging from primary school to university level) as a proxy 
for socioeconomic status [48], pubertal status as assessed by the Pubertal Development Scale 
(subdivided in 5 levels from prepubertal to postpubertal) [49], and diagnosis which might 
influence learning (yes/no, e.g., autism or ADHD) [50] were assessed .  
Statistical analyses  
Sample size calculation 
Sample size calculation for multilevel analyses were executed in RMass, and showed that a 
sample of 183-285 participants would be sufficient [51]. This sample size is based on an 
effect size of 0.25 at 6 months and an effect size equal or 10% larger at 12 months, a drop-
out rate of 25% per measurement moment (thus 43% in total), an error variation between 
0.4 and 0.5 and an intercept variation of 0.3 to 0.5 with fixed effects.  
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Imputing and recoding covariates 
Data on drinking and smoking were only collected at T0 and T3, and the average score 
between 0 and 12 months was imputed for drinking at T2. A cut-off score of 0.5 cigarette 
per week was used to code yes/no for smoking at T2 (i.e., more than 0.5 cigarette per week 
was coded as yes). Level of parental education was recoded to low (vocational education 
and training and below) and high (university of applied sciences and higher).  
Some participants had a maximum of two missing items on the CES-D (11, 15, and 7 
participants at T0, T2, and T3 respectively) or the RSE (12, 6, and 6 participants at T0, T2, 
and T3 respectively). The missing items were imputed by the person average score on the 
other items as suggested by Bono et al. [52].  
Group comparison, treatment guess and adherence 
Group comparisons and treatment guess analyses were executed in SPSS statistics version 
24 (IBM). 
The following baseline comparisons were executed: krill oil group versus the placebo 
group, participants who completed the study versus participants who dropped-out, 
participants who completed the study actively (i.e., taking capsules) versus those who quit 
taking capsules (both those who dropped out completely and those who still participated in 
testing). Baseline comparisons were executed with ANOVA for continuous variables and 
Chi square test for categorical variables. We compared groups on fatty acid concentrations, 
CES-D score, RSE, score and participants’ characteristics (BMI, age, sex, alcohol 
consumption, smoking, level of parental education, pubertal status, school and cohort). We 
also compared the fatty acid concentrations measured in blood on all time points in 
participants in the krill oil group and the placebo group.  
Treatment guess was compared between participants in the krill oil group and 
participants in placebo group with a Chi Square test.  
We asked participants to hand in left-over capsules and intended to use this as an 
adherence measure. As an additional measure for adherence we noted the average increase 
in O3I between T0 and T2, and between T0 and T3. Lastly, we documented how many 
participants had a decrease in their O3I, had an increase up to 2.5%, and had an increase of 
more than 2.5%.  
Effect on depressive feelings and self-esteem  
Intention-to-treat analyses were conducted using linear mixed models that accounted for 
repeated measurements in subjects. These analyses were executed in R statistical 
environment (R studio version 3.3.2) with the package nlme (version 3.1-131) using the 
standard settings [53].  
Models allowed a comparison between groups (krill oil versus placebo condition) and 
within groups (T0 data compared to intervention at T2 and T3). Besides time trends 
(baseline as a reference) and treatment X time interactions, all estimates were adjusted for 
drinking behaviour, smoking behaviour, level of parental education, age at baseline, 
pubertal status at baseline, sex, BMI at baseline, diagnosis related to learning, and cohort 
number. Furthermore, moderation analyses for sex was executed and if necessary a sub 
group analyses (boys and girls separate) were executed. Secondary analyses were executed 
with O3I instead of group allocation. A p < .05 was considered to be statistically 
significant.  
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Results  
A total of 286 students provided informed consent, of which 267 were randomized into 
the study. 17 participants did not meet inclusion criteria, one retracted consent, one had 
other reasons. After randomization, one participant withdrew consent before starting 
supplementation and one participant quit during the first test moment; both were excluded 
from the analyses. Additionally, due to logistic issues, 9 participants with an O3I > 5% 
were not excluded before the start of the study, they were excluded from the analyses. So, 
for 256 participants data were available for at least one time moment.  
During the study 53 (20.6%) students withdrew completely from the study and 82 
(32%) stopped active participation (i.e., they were tested, but did not take capsules). Main 
reported reasons for discontinuing the study were lack of motivation, difficulty swallowing 
capsules, and difficulties remembering to take capsules (see Figure 8.1).  
Baseline characteristics for the placebo and the krill oil group can be found in Table 8.1, 
Table 8.2 and Table 8.3. There were somewhat more girls in the krill oil group than boys 
(54 girls, 72 boys) compared to the placebo group (79 girls, 51 boys; χ2 = 8.224, p = .004). 
There were no other differences between the placebo and krill oil group in participant’s 
characteristics (all p > .175), blood values (all p > .055) or baseline depressive feelings or 
self-esteem scores (p = .259 and p = .237, respectively)  
At baseline 74 students (29.5%) had a score ≥16 on the CES-D (i.e., indicative for 
depression), at T2 48 (21.3%), and at T3 54 (26.5%). Using a stricter cut-of criterion of ≥ 22, 
18.3%, 12.4% and 18.6% reached the cut off point for depression at T0, T2, and T3, 
respectively.  
Table 8.1: Participants’ characteristics at baseline  
 Placebo N Krill N P3 
Age (years) 14.07 ± 0.48  130 14.15 ± 0.51 126 0.185 
Male/female N (%) 51/79 (39/61) 130 72/54 (57/43) 126 0.004 
Smoking1 (no/yes) 117/12 (91/9) 129 113/12 (90/10) 126 0.935 
BMI  20.13 ± 3.05 123 19.84 ± 2.96 116 0.455 
Alcohol units per week2 0.34 ± 1.16 129 0.61 ± 2.29 126 0.234 
Level of parental education 5.02 ± 1.58 124 5.10 ± 1.43 115 0.652 
1 Smoking was defined as anybody who indicated to smoke more than 0 cigarettes per week 2 Alcohol units per 
week was operationalized as number of days per week that alcohol is consumed times units per consumption 
moment 3ANOVA was used for age, BMI, LPE and alcohol units per week, Chi Square for smoking, and sex. 
Significant differences (p < .05) are noted in bold. 
Blood fatty acids 
Concentrations of blood fatty acids at T0, T1, T2, and T3, can be found in Table 8.2. 
Compared to the placebo group, the krill oil group had significant higher EPA, DPA, 
DHA concentrations, a higher O3I (all p < .001), and a significant lower concentration of 
AA and ObA (all p < 0.38) at T1, T2, and T3. Note that participants in cohort 1 started 
with a different supplementation dosage than cohort 2. In the supplementary Table S8.1 
fatty acid concentrations on T1 separate for cohort 1 and cohort 2 can be found.  
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Figure 8.1: Flow charts  
Flow chart adapted from Consort Guidelines [54] 
1 Participants who quit taking capsules and quite participation in testing.2 Participants who quit taking capsules but 
did participate in testing. 3 Three participants with an O3I > 5% were included in the placebo group of these one 
was lost to follow up (reason forgetting), one discontinued the intervention (reason dose adjustment), and one 
finished the intervention, they were all excluded from the analyses. 4 Six participants with an O3I > 5% were 
included in the intervention group of these one was lost to follow up (reason motivation), two discontinued the 
intervention (reason motivation/ personal), and three finished the intervention, they were all excluded from the 
analyses 
Assessed for eligibility (n=286)
Excluded (n=19)
● Not meeting inclusion criteria (n=17)
● Declined to participate (n=1)
● Other reasons (n=1)
Allocation
Allocated to intervention (n=134)
● Received allocated intervention (n=133)
● Did not receive allocated intervention (n=1)
◦ Withdrew consent (n=1)
Allocated to placebo (n=133)
● Received allocated intervention (n=133)
● Did not receive allocated intervention (n=0)
Follow-Up
Lost to follow-up1 (n=25)
Forgetting (n=8)
Difficulty swallowing (n=6)
Motivation (n=4)
Reason not given (n=4)
Dose adjustment (n=3)
Discontinued intervention2 (n=36)
Forgetting (n=7)
Difficulty swallowing (n=9)
Motivation (n=11)
Reason not given (n=2)
Dose adjustment (n=4)
Personal (n=1)
Other (n=2) 
Lost to follow-up1 (n=31)
Forgetting  (n=2)
Difficulty swallowing (n=8)
Motivation (n=15)
Reason not given (n=3)
Dose adjustment (n=1)
Personal (n=1) 
Other (n=1)
Discontinued intervention2 (n=49)
Forgetting (n=13)
Difficulty swallowing (n=5)
Motivation (n=15)
Reason not given (n=3) 
Dose adjustment (n=3)
Personal (n=3)
Other (n=7) 
Analysis
Analysed intention to treat  (n=97)
Excluded from analysis (n=7)
◦ Included in RCT but Omega-3 Index >5% (n =6)4 
◦ Quit during test moment 1 (n =1)
Analysed intention to treat (n=106)
Excluded from analysis (n=3)
◦ Included in RCT but Omega-3 Index >5% (n =3)3
Randomized (n=267)
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Depressive feelings  
The random intercept model with time point (T0 as reference), condition (krill or placebo), 
the interaction term (time moment x condition) and covariates showed that group 
allocation did not predict score on the CES-D (see Table 8.4). Interaction analysis for sex 
and condition did not shown an interaction effect (p = .161). 
The random intercept model with time point (T0 as reference), O3I, and covariates 
showed that O3I did not predict depression score. Interaction analysis for sex and O3I did 
show an interaction effect (p = .03). Subgroup analyses showed that for girls there was a 
possible significant relationship between higher O3I and higher depression score (b = 1.08, 
SE= 0.56, p = .053, 95% CI [0.01; 2.15]), indicating that girls with a higher O3I might have 
more depressive feelings. For boys no relationship between O3I and depression score was 
shown (b = -0.37, SE= 0.36, p = .311, 95% CI [-1.06; 0.33]). Closer inspection of the data 
showed that there were 5 participants whom had a Z-score on the CES-D of > 3.29, which 
is considered to be an extreme outliers and not a reliable value [55]. These 5 participants 
were all girls, when these girls were excluded from the analyses, the interaction term 
became non-significant (p = .168).  
Self-esteem 
The random intercept model with time point (T0 as reference), condition (krill or placebo), 
the interaction term (time moment x condition) and covariates showed that group 
allocation did not predict score on the RSE. The interaction analysis for sex X condition 
did not show an interaction effect (p = .671) 
The random intercept model with time point (T0 as reference), O3I, and covariate 
showed that O3I did not predict self-esteem score. The interaction analysis for sex X O3I 
did not show an interaction effect either (p = .661) 
Treatment guess  
After the one year supplementation period 63 participants (65.6%) in the placebo group 
and 45 participants (50.6%) in the krill oil group correctly guessed their original treatment 
allocation. The percentage that correctly guessed treatment allocation did differ 
significantly with more participants in the placebo group correctly guessing their group 
allocation (χ2 = 4.313; p = .038).  
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Table 8.4: Multilevel analyses of score on the Centre for Epidemiologic Studies Depression Scale by condition 
(intention to treat) and according to Omega-3 Index.  
Condition   Omega-3 Index   
 b (SE) 95%CI  b (SE) 95%CI 
T2 -1.50 (0.82) [-3.09; 0.08] T2 -1.64 (0.66) [-2.93; -0.36] 
T3 0.95 (0.86) [-0.71; 2.61] T3 0.18 (0.67) [-1.12; 1.49] 
Krill -0.65 (1.32) [-3.20; 1.91] Omega-3 Index 0.38 (0.34) [-0.28; 1.03] 
T2 x krill 0.37 (1.18) [-1.92; 2.66]    
T3 x krill  -1.04 (1.22) [-3.41; 1.32]    
Alcohol -0.07 (0.19) [-0.44; 0.30] Alcohol -0.06 (0.19) [-0.44; 0.31] 
Smoking1  2.66 (1.22) [0.29; 5.03] Smoking1  2.72 (1.24) [0.31; 5.13] 
Age 0.47 (1.28) [-2.02; 2.96] Age 0.31 (1.28) [-2.18; 2.80] 
Pubertal status2   Pubertal status2   
Beginning -5.42 (4.46) [-14.07; 3.23] Beginning -6.04 (4.44) [-14.67; 2.60] 
Mid -1.78 (4.32) [-10.17; 6.61] Mid -2.26 (4.31) [-10.63; 6.12] 
Advanced -0.82 (4.43) [-9.41; 7.78] Advanced -1.34 (4.42) [-9.93; 7.26] 
Post 8.83 (6.23) [-3.25; 20.92] Post 8.03 (6.21) [-4.04; 20.10] 
BMI 0.49 (0.20) [0.11; 0.87] BMI 0.50 (0.20) [0.12; 0.89] 
LPE 3  0.46 (1.17) [-1.81; 2.73] LPE 3 0.39 (1.17) [-1.88; 2.67] 
Sex 4 4.83 (1.60) [1.72; 7.94] Sex 4 4.97 (1.60) [1.86; 8.07] 
Cohort 5 1.47 (1.17) [-0.80; 3.75] Cohort 5 1.45 (1.16) [-0.80; 3.70] 
Diagnosis 6 2.43 (1.17) [0.16; 4.69] Diagnosis 6 2.63 (1.16) [0.37; 4.89] 
LPE = level of parental education, T2 = test moment 6 months, T3 = test moment 12 months.  
1 No smoking as reference, 2 Pre-pubertal as reference, 3 Low level of parental education as reference,  
4 Boy as reference, 5 Cohort 1 as reference, 6 No diagnosis as reference.  
Drop-out and adherence  
There we no baseline differences between those who finished the study completely with 
supplementation and those who quit taking capsules for age, BMI, drinking behaviour, sex, 
smoking behaviour, level of parental education, or pubertal status (all p > .460), any of the 
fatty acids (all p > .066), depression score (p = .861) or self-esteem score (p = .987). There 
was a difference in drop-out between cohorts, more students stopped taking capsules in 
cohort 2 (χ2 = 11.329, p = .001). Moreover, in some schools more students dropped out 
than in other schools (χ2 = 28.299, p = .029). 
When we compared those that actively participated (with taking capsules), with those 
who only participated in neuropsychological testing (without taking capsules), and those 
that quit completely, we saw the same patterns. No difference for age, BMI, drinking 
behaviour, sex, smoking behaviour, school or, level of parental education, pubertal status 
(all p > 0.059), any of the fatty acids (all p > .102), or score on the CES-D, or RSE 
(p = .165 and p = .297). A difference between cohorts (χ2 = 13.139, p = .001) did again 
exist. 
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Table 8.5: Multilevel analyses of score on the Rosenberg's Self-Esteem Scale by condition (intention to treat) and 
according to Omega-3 Index.  
Condition  Omega-3 Index 
 b (SE) 95%CI  b (SE) 95%CI 
T2 0.64 (0.42) [-0.19; 1.46] T2 0.55 (0.35) [-0.12; 1.22] 
T3 0.47 (0.45) [-0.40; 1.34] T3 0.62 (0.35) [-0.06; 1.30] 
Krill 0.25 (0.77) [-1.25; 1.75] Omega-3 Index -0.03 (0.18) [-0.38; 0.32] 
T2 x krill -0.18 (0.62) [-1.38; 1.01]    
T3 x krill  0.23 (0.64) [-1.00; 1.47]    
Alcohol 0.11 (0.10) [-0.09; 0.31] Alcohol 0.12 (0.10) [-0.08; 0.32] 
Smoking1 -1.58 (0.67) [-2.87; -0.29] Smoking1 -1.75 (0.67) [-3.05; -0.45] 
Age -0.91 (0.78) [-2.42; 0.61] Age -0.90 (0.78) [-2.41; 0.62] 
Pubertal status2   Pubertal status2   
Beginning 4.71 (2.71) [-0.54; 9.97] Beginning 4.89 (2.70) [-0.35; 10.14] 
Mid 3.34 (2.63) [-1.76; 8.44] Mid 3.42 (2.62) [-1.67; 8.51] 
Advanced 3.13 (2.69) [-2.09; 8.34] Advanced 3.25 (2.68) [-1.97; 8.47] 
Post 2.13 (3.79) [-5.23; 9.49] Post 2.38 (3.78) [-4.98; 9.74] 
BMI -0.23 (0.12) [-0.46; 0.005] BMI -0.24 (0.12) [-0.47; -0.005] 
LPE 3  0.17 (0.71) [-1.21; 1.54] LPE 3  0.13 (0.71) [-1.25; 1.51] 
Sex 4 -3.33 (0.97) [-5.22; -1.44] Sex 4 -3.41 (0.97) [-5.30; -1.52] 
Cohort 5 0.31 (0.71) [-1.07; 1.69] Cohort 5 0.33 (0.70) [-1.04; 1.70] 
Diagnosis 6 -0.88 (0.68) [-2.20; 0.44] Diagnosis 6 -0.91 (0.68) [-2.22; 0.40] 
1 No smoking as reference, 2 Pre-pubertal as reference, 3 Low level of parental education as reference,  
4 Boy as reference, 5 Cohort 1 as reference, 6 No diagnosis as reference.  
T2 = test moment 6 months, T3 = test moment 12 months. 
 
Looking at those students that were active participants at T2, there was an average increase, 
compared to T0, in the O3I of 2.02% (SD 1.58%). Compared to T0 5 (6.8%) of the active 
participants had an decrease in their O3I, 44 (60.3%) had an increase between 0 and 2.5% 
and 24 (32.9%) had an increase of >2.5%. At T3, compared to T2, there was an average 
decrease in the O3I of 0.70% in active krill oil participants. When comparing T3 to T2, 35 
(70%) of active participants in the krill oil group had a decrease in their O3I and were thus 
most likely not compliant with the protocol, the other 15 (30%) had an increase varying 
from 0.14 to 1.96%.   
Participants were asked to return capsules at the last test moment. Of the active 
participants (i.e., those taking capsules) at test moment 12 months, 56 handed in capsules 
and 37 counted the left-over number of capsules at home. On average participants had 
628.82 ± 395.23 capsules left over. This corresponds to 78.6 days with not taking capsules 
in the approximately 180 days between T2 and T3.  
Discussion 
The current trial in adolescents attending LGSE who had a low baseline O3I did not show 
improvements of depressive feelings and self-esteem in the krill oil supplementation 
condition compared to placebo, nor did it lead to a higher self-esteem score. Sensitivity 
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analyses did not show the association of higher O3I with less depression score or better 
self-esteem score. Note that our analyses of neurocognitive test scores showed similarly no 
effect of supplementation. However, the goal of the study was that participants in the krill 
oil group would achieve a predetermined O3I of 8-11% and that two distinct groups with 
regard to O3I would be achieved (thus no or minimal overlap in O3I between krill and 
placebo group). Unfortunately, neither goal was achieved. The average O3I in the krill oil 
group was 5.29% at T2 and 4.80% at T3, which indicates an average increase in O3I of 
1.58% and 1.14% compared to T0, respectively. However, between T2 and T3 there was 
actually in average decrease in O3I in participant in the krill oil group who said to take the 
capsules. Moreover, only 3, 10, and 2 participants achieved the target O3I of >8% at T1, 
T2, and T3, respectively. Thus, the average O3I in the krill oil group was at all time-points 
well below the intended range of 8-11% and the participants were uncompliant with the 
protocol. Even if we compare the average O3I of our sample to unselected adult 
individuals from the European and German population, whom have an average O3I of 
6.96% and 7.15% respectively, the O3I in our sample after supplementation is still very 
low. It has been argued that positive effects of O3I only exist at higher levels of O3I. For 
example, in the study of Markhus and colleagues, there was only a linear relation between 
O3I and pregnancy depressive feelings when the O3I was above 5.1% [56]. Moreover, in 
cardiovascular health an O3I > 8% has been associated with the greatest risk reduction 
[57].  
Depressive feelings were very common in this sample of adolescents attending LGSE. 
When using cut-off score of ≥16 on the CES-D, 29.5%, 21.3% and 26.5% had scores 
indicative of depression at T0, T2, and T3 respectively. When using the higher cut-off 
score of ≥22, still 18.3%, 12.4% and 18.6% of participants had a score indicative of 
depression at T0, T2, and T3 respectively. Surprisingly, there were only 6 students who 
indicated to have a diagnosed depression. These numbers of students with a possible 
depression might seem high, but other studies in adolescents have shown similar rates. For 
example, Oddy et al. showed using the Beck Depression Inventory for Youth, that 21.2% 
of the sample had mild to severe depressive symptoms [31]. In the study of Grant and 
colleagues 21.7% of boys and 34.4% of girls had scores indicative of mild to extremely 
severe depression [58]. Lastly, Mamalakis et al. showed in their sample an average CES-D 
score of 14.9 [30], which is very comparable to the average scores in the current study.  
To our knowledge there are no earlier LCPUFA supplementation studies in which the 
effect on depressive feelings in adolescents is studied. LCPUFA supplementation studies in 
adults mostly show positive effects of supplementation (for meta-analyses see among 
others [25,27,59]. It is moreover uncertain if and how the results from the studies on 
depression in adults can be compared to studies in adolescents. For example it has been 
suggested that juvenile-onset and adult-onset depression are distinct with different causes 
and different outcomes [60,61]. Moreover, in adolescence the brain is still in development 
and this is accompanied by profound physical, social, emotional and cognitive development 
[62]. All these factors could influence depression, but depression in itself also disrupts these 
developmental processes which can have severe long term negative effects, which possibly 
are more profound than the long-term effects of depression in adulthood. Lastly, the use of 
the LCPUFA in the body might also be different in adolescents compared to adults. For 
example, up to 18 years old the amount of DHA in the brain rises and then it plateaus until 
the age of 88 year [63].  
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As mentioned previously the increase in O3I in the krill oil group was smaller than 
anticipated and smaller than aimed for. We aimed for an O3I of between 8-11%, but 
unfortunately only 3,10 and 2 participants achieved that at T1, T2, and T3, respectively. 
This low number of participants whom achieved the target range had to do with the large 
number of participants that quit supplementation and the non-adherence of the active 
participants. We did utilize a multitude of techniques to improve adherence: we sent 
participants a daily text message reminder, had motivational telephone talks, and handed 
out a tip sheet with tips on how to remember to take the capsules (i.e., example of tips 
were: put the capsules on the kitchen table, put a reminder alarm in your phone, or but a 
sticky note with a reminder somewhere). The study did last for 1 year, which might simple 
be too long, this is echoed in the fact that most participants quit because of lack of 
motivation/ inability to remember to take the capsules. Moreover, the students had to take 
8 capsules per day, which many students indicated to be too much and was another reason 
why many students dropped-out (inability to take capsules). Long study duration and high 
number of capsules have been suggested to influence drop-out and adherence [64]. It is 
however important to realize that if LCPUFA supplementation is found to be beneficial for 
depressive feelings, a high dose of capsules might need to be taken for a prolonged period 
of time. Adherence with medication, and thus most likely supplements as well, has already 
been found to be problematic in those with depression [65], but might even be more 
challenging in adolescents.  
The limitation of the current study is the fact self-rated questionnaires to assess 
depression were used instead of clinician interviews. Self-rated questionnaires to assess 
depression could lead to false positive, or false negatives. However, the CES- D has been 
validated and in the main analyses we did not use cut-off scores but used the continuous 
score on the CES-D. Another limitation of the current study is the fact, as discussed, that 
there was a rather high dropout rate and there were difficulties with achieving adherence to 
the protocol. However, blood samples and test scores were available of the majority of 
participants that quit taking capsules, so they could be included in sensitivity analyses. 
Moreover, participants that dropped-out did not differ significantly from those that 
continued the study actively on relevant baseline characteristics.  
To summarize the current study did not reveal an effect of one year of krill oil 
supplementation on depression score and on self-esteem score in adolescents attending 
LGSE with a low baseline O3I. However, due to the lack of adherence and high drop-out 
rate, we feel we cannot preclude that a relationship between krill oil supplementation and 
depression score or self-esteem score in adolescents does not exists. More studies in this 
specific age group with high rates of depressive symptoms are needed. Moreover specific 
attention should be payed to achieve adherence, decrease drop-out and achieve a set target 
O3I.  
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Supplemental Table S8.1: Fatty acid concentrations at T1 separated for cohort 1 and 2  
 Cohort 1  Cohort 2  
Fatty acid  
(%wt/wt of total FA) 
Placebo Krill Placebo Krill 
AA 20:4n-6 11.02 ± 1.16  10.16 ± 0.95 10.92 ± 1.21 10.61 ± 1.26 
EPA 20:5n-3 0.45 ± 0.15 0.86 ± 0.35 0.40 ± 0.14 0.99 ± 0.71 
ObA 22:5n-6 0.37 ± 0.09 0.27 ± 0.06 0.46 ± 0.21 0.36 ± 0.14 
DPA 22:5n-3  1.30 ± 0.19 1.54 ± 0.23 1.29 ± 0.26 1.61 ± 0.41 
DHA 22:6n-3 2.72 ± 0.49 3.34 ± 0.64 2.49 ± 0.52 3.18 ± 0.78 
O3I 4.02 ± 0.62 5.12 ± 0.97 3.74 ± 0.65 5.09 ± 1.49 
O3I =Omega-3 Index  
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Abstract  
Introduction: The influence of n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) 
supplementation on health outcomes has been studied extensively with randomized 
controlled trials (RCT). In many research fields, difficulties with recruitment, adherence 
and high drop-out rates have been reported. However, what is unknown is how common 
these problems are in n-3 LCPUFA supplementation studies in children and adolescents. 
Therefore, this paper will review n-3 LCPUFA supplementation studies in children and 
adolescents with regard to recruitment, adherence and drop-out rates.  
Methods: The Web of Science, PubMed and Ovid databases were searched for papers 
reporting on RCT supplementing children and adolescents (2–18 years) with a form of n-3 
LCPUFA (or placebo) for at least four weeks. As a proxy for abiding to CONSORT 
guidelines, we noted whether manuscripts provided a flow-chart and provided dates 
defining the period of recruitment and follow-up.  
Results: Ninety manuscripts (reporting on 75 studies) met the inclusion criteria. The 
majority of the studies did not abide by the CONSORT guidelines: 55% did not provide a 
flow-chart, while 70% did not provide dates. The majority of studies provided minimal 
details about the recruitment process. Only 25 of the 75 studies reported an adherence rate 
which was on average 85%. Sixty-five of the 75 studies included drop-out rates which were 
on average 17%.  
Conclusion: Less than half of the included studies abided by the CONSORT guidelines 
(45% included a flow chart, while 30% reported dates). Problems with recruitment and 
drop-out seem to be common in n-3 LCPUFA supplementation trials in children and 
adolescents. However, reporting about recruitment, adherence and dropout rates was very 
heterogeneous and minimal in the included studies. Some techniques to improve 
recruitment, adherence and dropout rates were identified from the literature, however these 
techniques may need to be tailored to n-3 LCPUFA supplementation studies in children 
and adolescents.  
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Introduction 
Fatty acids, and especially the omega-3 long-chain polyunsaturated fatty acids (n-3 
LCPUFA), are being researched extensively for a wide array of health outcomes varying 
from, but not exclusive to, cardiovascular diseases, depression and cognition [1–3]. As in 
every health related field, randomized controlled supplementation trials are the gold 
standard to demonstrate efficacy of n-3 LCPUFA [4]. For these trials, voluntary 
participants are needed, however recruitment of participants can be challenging, especially 
when it involves research in children and adolescents (< 18 years)[5]. It has been reported 
that less than 31% of British studies funded by two funding bodies between 1994 and 2002 
achieved their original recruitment target number [6]. Similarly, others have reported that 
up to 60% of the randomized controlled trials (RCT) fail to meet their participant target or 
need an extension [7] and this percentage might be even higher in paediatric and adolescent 
studies [8,9]. However, even after the recruitment phase, difficulties with conducting 
research do not end, because drop-out and non-adherence are also common. Drop-out in 
RCT is normal and attrition rates can vary enormously from 0 up to 65% [10–12]. 
Compliance and adherence are often used interchangeably, but are not the exactly same. 
Compliance is the extent to which the behaviour of a person coincides with the advice 
given by a doctor or researcher. The term compliance has received criticism because of its 
paternalistic connotation [13] and because it implies patient passivity [14]. As a more 
neutral term, adherence has been suggested, which presumes that the person agrees with 
the advice given by a doctor or researcher [14]. We choose to use the term adherence in the 
current manuscript. Adherence issues, are common, with non-adherence ranging anywhere 
from 3.5 to 80% [15,16]. One must also be aware that there is no one single definition of 
adherence. This means that somebody who is considered non-adherent in one study, might 
be considered adherent in another (e.g., one study defined a participant as non-adherent 
when the participant took less than 75% of the prescribed medicine or supplements, while 
another used a cut-off level of < 80%). As low recruitment rates, high drop-out and high 
non-adherence are common and have serious consequences [6,17,18], it is important to 
study factors which possibly affect recruitment, drop-out, and adherence rates. In 2013, we 
started a one-year long double blind randomized n-3 LCPUFA supplementation trial in 
healthy Dutch adolescents called Food2Learn [19]. We experienced difficulties in the 
recruitment, drop-out and adherence of the study participants. Furthermore, many other 
n3- LCPUFA supplementation studies have had the same difficulties (personal 
communication). However, a review of recruitment, adherence and drop-out rates in 
nutrition interventions and in specific n-3 LCPUFA supplementation studies in children 
and adolescents does not, to our knowledge, exist. Therefore, the aim is to execute a 
thorough review to summarize n-3 LCPUFA supplementation studies in children (2–12 
years) and adolescents (12–18 years) with regard to recruitment effort, drop-out and 
adherence rates.  
Materials and methods 
The Web of Science, PubMed and Ovid databases were searched up to 2 March 2017. We 
searched for human clinical trials including children aged between 2 and 18 years. We used 
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the search terms: “Omega-3”, “DHA”, “EPA”, “LCPUFA” and “PUFA” in combination 
with “RCT”, “randomized controlled trial”, “supplementation”, “trial” or “fish oil” and 
“child*)“, “adolescent”, “school”, “preschool” or “toddler”. Furthermore, a myriad of 
reviews were checked for additional studies [20–40] and reference lists of all articles were 
hand checked for additional references. Moreover, a search of the Cochrane library was 
also conducted to identify reviews regarding n-3 LCPUFA supplementation. The studies 
included in the Cochrane reviews were checked for inclusion in the current study [41–56]. 
Lastly, for all included articles, the “cited by” option of Web of Science was checked (this 
option gives all articles that cite that specific article).  
Studies were eligible for inclusion if they met the following criteria: (1) participants were 
aged between 2 and 18 years; (2) the study was a randomized placebo controlled n-3 
LCPUFA supplementation trial; (3) the trial had at least 10 participants per treatment arm; 
(4) supplementation duration was at least 4 weeks; and (5) studies were published in 
English.  
All papers were scanned by the first author, and the following information was 
extracted and entered in a database: 
 
Participants’ characteristics: Age range of participants, percentage of girls, healthy 
participants or those with a diagnosed disease, and country in which the study was 
executed; 
 
Study characteristics: Number of participants, number of measurement moments (i.e., 
how often did participants have to come to the research facility/how often did they have to 
fill out questionnaires), number of measurements, treatment condition, placebo condition, 
form of supplementation, if capsules were used then how many, if supplementation was 
taken under supervision, if supplement was taken in multiple dosages or once a day, 
whether an incentive was provided, duration of the study, manner in which adherence was 
assessed, adherence rate, whether fatty acids were determined in blood, and percentage of 
people who quit the treatment (hereafter called drop-out); and  
 
Recruitment characteristics: Invited/responded or screened, started, finished as well as 
method of recruitment, recruitment setting, and study period.  
 
 The recruitment characteristics were defined as follows:  
Invited: The total number of potential participants invited to participate;  
Responded: The total number of potential participants who responded to the invitation 
or the number of participants that were screened for participation in the study; and  
Started: The number of participants who were assessed as eligible and began 
supplementation.  
 
Furthermore, efficiency percentages were calculated, namely: started/invited (dividing 
the number of people who started by the number of people who were invited times 100), 
started/ responded (dividing the number of people who started by the number of people 
who responded times 100) and started/finished (dividing the number of people who 
finished by the number of people who started times 100). 
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As a proxy for adherence to the CONSORT guidelines, we noted whether the article 
included a flow-chart and whether the article provided the dates defining the period of 
recruitment and follow-up.  
Statistics  
All extracted data were entered in SPSS (IBM SPPS statistics for Windows, version 24, 
Armonk, NY, USA). SPSS was used to calculate averages and SDs for the participant’ 
characteristics, study characteristics and recruitment characteristics. For comparison 
reasons outpatient clinics and hospitals were combined into one setting, which was named 
“hospital setting”. Countries were furthermore grouped in regions for comparisons 
(Europe, USA/Canada, Asia, Middle East, Australia, Africa and South America). When a 
study mentioned multiple adherence rates, these were combined into one adherence rate 
for the whole study.  
Results 
Study characteristics  
The original search led to 2163 hits. Upon first screening, 1656 articles were excluded, 
additional screening of the whole articles led to a further exclusion of 173 articles. 
Additional checking of the reference lists of reviews, included articles and forward 
checking led to 15 more studies being included (see Figure 9.1, adapted from [57]). Thus, in 
total, 90 papers, describing 75 studies, were included in this review. The characteristics of 
these studies can be found in Table 9.1. Fifteen studies focussed on healthy children. The 
other 60 studies focused on children with a disorder or disease, with attention deficit 
hyperactivity disorder (ADHD) being the most studied disorder (n = 21) (see Table 9.1). 
The majority of studies focussed on children (defined as aged between 2 and 12 years, 
n = 38) or both children and adolescents (n = 31). A minority of studies focussed only on 
adolescents (n = 6) (see Table 9.1). Duration of study varied from 4 to 52 weeks, with the 
majority of studies lasting 26 weeks or less (n = 59, 79%, see Table 9.2. Number of 
measurement moments (i.e., how often did participants have to come to the research 
facility/how often did they have to fill out questionnaires) varied from 2 to 16 with a mean 
of 3.7 (SD 2.7), the number of different measurements per moment varied from 1 to 19 
with a mean of 4.9 (SD 3.7). 
Recruitment  
Most of the studies included in this review did not report the number of children or 
adolescents that were invited to participate in the study, as only 11 out of 75 studies 
mentioned the number of participants that were invited. The total number of people 
invited to participate varied from 46 to 3562 (Mean (M) = 804.5, SD = 1083.28). The 
percentage of invited participants that eventually started the study ranged from 2.4% to 
87% (see Table 9.3).  
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Forty out of 75 studies mentioned the number of participants that responded to the 
invitation or were screened for the study and this varied from 30 to 1556, with 12% to 
100% of these people actually starting the study.  
 
 
Figure 9.1. Flow diagram of study selection: 90 manuscripts were found reporting on 75 studies.  
 
Most studies did not specify the exact method(s) of recruitment, mostly just mentioning the 
recruitment setting. Most studies recruited their participants from a hospital or outpatient 
clinic setting (n = 33). Other settings from which participants were recruited were schools 
(n = 23) and the community (n = 15). Nine studies reported multiple settings for 
recruitment; one study recruited participants from a summer camp for children with 
ADHD and other disorders; one study recruited from an online registry; one study 
recruited participants from those who participated in earlier studies; and eight studies did 
not mention the recruitment setting.  
Looking at the efficiency percentages for started/invited, started/responded or 
started/finished for studies including those with an illness (averages 43.5%, 63.5%, and 
83.1%, respectively) and those without (averages 36.2%, 53.1%, and 84.2%, respectively), 
there was a clear difference for started/invited and started/responded but not for 
started/finished. A comparison for average rates between studies including only children 
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(38.8%, 62.2%, and 85.4%, respectively), only adolescents (15.5%, 56.4%, and 87.8%, 
respectively) or both (53.4%, 52.7%, and 79.6%, respectively) showed notable differences. 
For different recruitment settings, there were mainly clear differences for started/invited. 
However, for all rates, the school setting had the highest average rate: hospital (17.7%, 
56.8%, and 82.9%, respectively), community (29.9%, 57.1%, and 81.7%, respectively), and 
school (46.0%, 64.6%, and 86.8%, respectively). Lastly, when looking at these average 
efficiency percentages for the different continents, we also saw clear differences: Europe 
(35.3%, 64.3%, and 87.8%, respectively), North America (6.6%, 48%, and 77.7%, 
respectively), Asia (49.5%, 48.7%, and 92.6%, respectively), Africa (NA, 28%, and 91.1%, 
respectively), Middle East (33.2%, 64.6%, and 79%, respectively), Australia (72.9%, 69.5%, 
and 70.7%, respectively), and South America (54%, 93.2%, and 90.9%, respectively).  
Supplementation 
Most studies used capsules as the form of supplementation (n = 57), however there were 
also some other approaches (see Table 9.2). The number of capsules that participants were 
instructed to take also varied widely from 1 to 12 capsules a day, with some studies basing 
the dose per body weight of the participant (see Table 9.2). Moreover, a huge range of 
different placebos was used (see Table 9.2).  
Adherence 
The included studies mentioned a wide variety of methods to measure adherence: capsule 
count (or product weighting) (n = 30), diaries or tick-off forms (n = 13), interviews face to 
face/via phone/via e-mail (n = 11), taking the capsules under supervision (n = 8), and 
blood values (n = 5) (see Table 9.4). Thirteen studies used more than one method to assess 
adherence. Furthermore, 23 studies did not specify how or whether they assessed 
adherence. The way in which adherence was reported in the studies also varied greatly. 
Some studies mentioned percentages of capsules taken, the average number of capsules 
taken per day, blood values, or just mentioned that adherence was good or mentioned how 
many students were excluded due to non- adherence.  
Twenty-five studies mentioned a specific percentage of adherence, which varied from 
60% to 97%, mean 85% (SD 10.1). In addition, the levels of capsules that needed to be 
taken to be considered as being adherent differed per study, varying from 65% to 90%. 
Other studies defined adherence as the number of days of not taking capsules. 
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Table 9.1: Characteristics of studies 
Reference  Age range or  
mean (SD) 
Gender (%female) Population: healthy,  
disorder or disease  
Country 
[58] 3–15 44 Acute lymphoblastic leukaemia Egypt  
[59] 6–12 25 ADHD Iran 
[60] 7–15 NR ADHD Iran 
[61] 11–12 31 ADHD Canada 
[62] 8–14 0 ADHD  Netherlands 
[63] 6–16 41 (after intervention)  ADHD Israel 
[64] 7–12 20 ADHD Sweden 
[65] 6–12 38 ADHD Iran 
[66] 6–12 NR ADHD Japan 
[67,68] 8–18 15 ADHD Sweden 
[69] 12–16 0 ADHD UK 
[70,71] 6–13 23 ADHD Australia 
[72] 6–12 27 ADHD Sri Lanka 
[73] 7–13 41 ADHD Israel  
[74,75] 7–12 23 ADHD Australia 
[76] 6–13 13 ADHD USA 
[77] 8–13 25 ADHD Israel 
[78] 6–12 22 ADHD USA 
[79] 6–12 22 ADHD Germany 
[80,81] 6–13 34 ADHD Israel 
[82] 7–12 43 (after intervention) ADHD or lower IQ China 
[83] 6–14 15 ADHD Australia 
[84] 6.9–11.9 NR ADHD Canada 
[85] 8–16 48 Aggressive behaviour Mauritius 
[86] 6–14 42 Asthma  USA 
[87] 8–12 56 Asthma  Australia 
[88] 10–12 31 Asthma  Taiwan 
[89] 10.2 (2.5) fish oil, 
11.9 (3.1) control 
48 Bronchial asthma Japan 
[90] 3–8 11 Autism  USA 
[91] 5–8 NR Autism  USA 
[92] 2–5 26 Autism  Canada  
[93] 3–10 17 Autism USA 
[94] 6–17 48% placebo,  
46% flax oil 
Bipolar disorder  USA 
[95] 7.3–9.5 54 CF Italy 
[96] 5–16 47 Crohn’s disease Italy 
[97] 5–12 33 DCD UK 
[98] 10.6 43 Dyslexia  Finland 
[99] 15–18 100 Dysmenorrhea USA 
[100] 4–12 NR Epilepsy Egypt 
[101] 7–9 53 Healthy  South-Africa 
[102] 8–14 50 Healthy Indonesia 
[103] 9–12 51 Healthy Japan 
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Reference  Age range or  
mean (SD) 
Gender (%female) Population: healthy,  
disorder or disease  
Country 
[104] 9–10 50 Healthy Sweden 
[105] 10–12 49 Healthy UK 
[106] 8–10 52 Healthy UK 
[107] 5–7 NR Healthy Canada 
[108] 8–10 0 Healthy USA 
[109] 6–10 46 Healthy Australia/ 
Indonesia 
[110] 3–13 46 Healthy Australia 
[111] 8–14 51 Healthy Spain 
[112] 4 47 Healthy USA 
[113] 10–12  100 Healthy Turkey 
[114] 13–16 50 Healthy UK 
[115] 9–12 47 Healthy Thailand 
[116] 8–13 47 Hyperlipidaemia Italy 
[117] 14 (2)  31 Hypertriglyceridemia and low LDL USA 
[118–121] 6–11 49 Iron deficiency South-Africa 
[122] 8–12 15 Literacy problems UK 
[123]  8–12 58 Malnourished Mexico 
[124] 5–14 56 Migraine Iran 
[125] 7–14 NR MDD USA 
[126] 6–12 NR MDD Israel 
[127] 10–18 59 (after intervention) Metabolic syndrome  Iran  
[128] 9–17 47 NAFL and obesity Turkey 
[129,130] 11–15 14 NAFL and overweight Poland 
[131–133] 6–16 58 NAFL Italy 
[134] 10.8 (2.8) 48 NAFL and overweight  Italy 
[135] 8–18 0 NAFL Canada 
[136,137] 14–17 56 Obesity  Sweden 
[138,139] 13–15 0 Overweight Denmark 
[140] 9–18 NR Overweight + insulin resistance Mexico 
[141] 5–10 NR PKU Italy 
[142] 6–18 18 Tourette’s Disorder USA 
[143–145] 10 (7) 45 Type-1 hyperphenylalaninemia, HPA Italy  
[146,147] 6–10 47 Underperforming UK 
ADHD = attention deficit hyperactivity disorder; NAFL = non-alcoholic fatty liver; MDD = major depressive 
disorder; DCD = Developmental Co-ordination Disorder; CF = cystic fibrosis, NR = not reported. 
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Table 9.2: Treatment characteristics per study 
Reference  Treatment per day unless  
otherwise stated 
Placebo  Form of 
supplementation 
Number 
of capsules 
Duration b 
(weeks) 
[108] DHASCO a: 400 or 1200 mg 
DHA 
Corn oil  Capsules 6 8 
[106] 800 mg FO: 400 mg DHA, 56 mg 
EPA 
Olive oil Chewable 
capsules  
2 16 
[113] 670 mg FO  Olive oil Capsules 2 16 
[110] 2400 mg FO and 600 mg evening 
primrose oil: 174 mg DHA, 558 
mg EPA, 60 mg GLA.  
Palm oil Capsules 6 28.6 
[104] 174 mg DHA,558 mg EPA, 60 
mg GLA 
Palm oil Capsules 6 12 + 12 
(open) 
[102] 1260 mg DHA rich oil: 652 mg 
DHA, 101 mg EPA 
Placebo oil (656 mg 
LA, 87 mg ALA) 
Capsules 6 12 
[101] Fish flour: 892 mg of DHA per 
week 
Placebo spread 
contained bread 
flour 
Margarine  NA 14.9 
[107] 14–21 mg DHA, 20–30 mg AA Placebo supplement Sachets to mix 
into foods  
2–3 
sachets 
30 
[103] FO: 3600 mg DHA, 840 mg EPA 
per week 
50% soybean oil, 50% 
rapeseed oil (4200 mg 
LA per week) 
Bread and 
sausages 
NA 12 
[114] 541 mg FO: 116 mg DHA, 165 
mg EPA  
Sunflower oil Capsules 2 12 
[112] DHASCO-S a: 400 mg DHA High oleic sunflower 
oil 
Capsules 2 16 
[115] FO: 1 g DHA, 200 mg EPA Soybean oil  Chocolate milk NA  15.6 
[109] 88 mg DHA, 22 mg EPA Unclear  Drink NA 52 
[105] 500 mg DHASCO-S a: 200 mg 
DHA, 4 mg EPA 
Vegetable oil (15 mg 
ALA, 250 mg LA)  
Capsules 5 8 
[111] FO in dairy drink 120 mg DHA, 
60 mg EPA  
Whole milk Milk drink NA 20 
[117] 4 g FO: 1.5 g DHA, 1.86 g EPA Corn oil Unclear Unclear 8 + 8 with 4 
w wash-out 
in between 
[100] 3 mL dose of 1200 mg FO: 240 
mg DHA, 36o mg EPA.  
Corn oil Liquid oil NA 12 
[88] FO: 125 mg DHA, 230 mg EPA Corn oil Capsules Dependent 
on bw  
16 
[96] 3 g O3FA Olive oil Capsules Dependent 
on bw 
52 
[92] 1.875 mL FO: 0.75g of DHA + 
EPA. If well tolerated dose ×2 
after 2 wks. 
Olive oil and 
medium chain 
triglycerides. 
Liquid oil NA 24 
[65] 165 mg DHA, 635 mg EPA, 100 
mg other O3FA 
Olive oil Capsules NS 8 
[67,68] 174 mg DHA, 558 mg EPA, 60 
mg GLA 
Olive oil Capsules 6 12 + 12 
(open) 
[97] FO and EPO: 174 mg DHA, 558 
mg EPA, 60 mg GLA 
Olive oil Capsules 6 26 
[79] 120 mg DHA, 600 mg EPA  Olive oil Capsules 2 16 
[66] DHA-rich fish oil: 3600 mg DHA 
700 mg EPA per week. 
Olive oil Milk and bread NA 12 
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Reference  Treatment per day unless  
otherwise stated 
Placebo  Form of 
supplementation 
Number 
of capsules 
Duration b 
(weeks) 
[122] 480 mg DHA, 186 mg EPA, 96 
mg GLA, 864 mg LA, 42 mg AA, 
8 mg thyme oil  
Olive oil Capsules NR 12 
[76] 480 mg DHA, 80 mg EPA, 40 mg 
AA, 96 mg GLA 
Olive oil Capsules 8 16 
[143–145] LCPUFA supplementation: 
varying dosage  
Olive oil Capsules 1 per 4 kg 
of bw 
52 
[94] Flax seed oil: 0.55 to 6.6 g ALA Olive oil Capsules Varying up 
to 12 
16 
[89] FO: DHA 7.3 ± 11.5 mg/kg of 
bw, EPA 17.0 ± 26.8 mg/kg of 
bw 
Olive oil Capsules Dependent 
on bw: 6–
12 
43.6 
[83] PCSO-524 c: 16.5–22 mg DHA, 
21.9–29.2 mg EPA 
Olive oil, lecithin 
and coconut oil 
Capsules Dependent 
on bw: 3–4 
14 
[86] Drink containing FO (1.6 g DHA, 
3 g EPA) and borage oil (3.0 g 
GLA) 
Control drink with 
high oleic safflower 
oil 
Drink  NA 12 
[70] EPA-rich FO: 108 mg DHA, 
1,109 mg EPA or DHA-rich FO: 
1,032 mg DHA, 264 mg EPA  
Safflower oil Capsules 4 16 + 16 + 16  
[90] FO: 1.1 g DHA + EPA Safflower oil Pudding packet 2 pudding 
packs 
12 
[123]  FO: 180 mg DHA, 270 mg EPA Soybean oil Capsules 3 12 
[135] 2 g FO: 1200 mg DHA + EPA Sunflower oil Capsules 4 24 
[87] FO: 1.2 g O3FA Sunflower oil Capsules, salad 
dressing and 
margarine 
4 24 
[72] FO and EPO oil: 592.74 mg 
O3FA  
Sunflower oil Capsules 2 26 
[58] 1 g FO:120 mg DHA, 180 mg 
EPA 
Sunflower oil Capsules Unclear 24 
[61] 100–400 mg DHA, 500–100 mg 
EPA  
Sunflower oil Capsules  Dependent 
on bw: 2–4 
16 
[129,130] AO: 450–1300 mg O3FA 
(DHA: EPA in 3:2 proportion) 
Sunflower oil Capsules Dependent 
on bw  
24 
[116] AO: 500 mg DHA or  
FO:500 mg DHA + EPA  
Wheat germ oil Capsules 1 16 
[131–133] AO: 250 or 500 mg DHA  Germ oil Capsules 1 26.1 
[134] AO: 250 mg DHA Germ oil Capsules NR 26 
[95] Algae triacylglycerol 100 mg 
DHA/kg/day 1st month then 1 g 
DHA/day 
Germ oil Capsules 4 52 
[93] AO: 200 mg DHA Corn oil + soy bean 
oil  
Capsules 1 26 
[146,147] AO: 600 mg DHA Corn oil + soy oil Capsules 3 16 
[138,139] 4.9 g FO: 892 mg DHA, 191 mg 
EPA  
6:1:1 mix of palm 
shortening, soy oil, 
and rapeseed oil 
Bread NA 16 
[141] 2.5–4 g FO (12% DHA, 18% 
EPA) 
Blackcurrant seed oil 
(45.7% LA, 18% 
GLA, 14% ALA)  
Capsules Dependent 
on bw: 5-8 
26 
[62] 650 mg DHA, 650 mg EPA Normal margarine  
(1 g LA) 
Margarine  NA 16 
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Reference  Treatment per day unless  
otherwise stated 
Placebo  Form of 
supplementation 
Number 
of capsules 
Duration b 
(weeks) 
[99]] FO: 720 mg DHA, 1080 mg EPA 1800mg lactose Capsules 2 8+8 
[125] 200 mg DHA, 1400 mg EPA, 400 
mg other O3FA 
Placebo capsule Capsules 2 12 
[136,137] FO and EPO: 290 mg DHA, 930 
mg EPA, 100 mg GLA  
Placebo Capsules 10 12 + 12 with 
6w wash-out 
in between  
[91] FO: 1.1 g DHA + EPA Identical placebo Pudding packet 2 pudding 
packs 
6 
[128] 1000 mg PUFA Placebo Capsule 1 52 
[63] 2 g sage oil: 1 g ALA Lactose placebo Capsules 2 8 
[60] 240 mg DHA, 360 mg EPA Placebo Capsules 2 8 
[64] FO: 2.7 mg DHA, 500 mg EPA  Placebo Capsules 1 15 
[127] 2.4 g omega-3 Vitamin E or 
placebo 
Tablets NR 8 
[84] 100 mg DHA, 250 mg EPA, 25 
mg phospholipids 
Sunflower oil Capsules According 
to bw: 1–2  
16 
[124] 1 g FO: 120 mg DHA, 180 mg 
EPA 
Placebo capsule Capsules 1 At least 8wks  
[78] Algae oil: 345 mg DHA Placebo capsule Capsules 1  16 
[59] 241 mg DHA, 33 mg EPA, and 
180 mg omega-6 
Identical placebo Capsules  1 10 
[118–121] FO: 155 mg DHA, 29 mg EPA Placebo Capsules  2 15 
[142] Varying 500–6000 mg O3FA Placebo Capsules Varying up 
to 12 
20 
[140] Salmon oil: 360 mg DHA, 540 mg 
EPA 
Placebo (corn starch, 
lactose, magnesium 
stearate and 
polyvinyl 
pyrrolidone)  
Capsules NR 4  
[85] 300 mg DHA, 200 mg EPA, 400 
mg ALA, 100 mg of DPA 
Drink without 
omega-3 
Drink NA 24 
[77] FO: 96 mg DHA, 153 mg EPA or 
n-3 LC-PUFA containing PLs: 95 
mg DHA, 156 mg EPA 
Rapeseed oil  Chocolate 
flavoured spread 
NA 13.1  
[73] 240 mg LA, 60 mg ALA, 95 mg 
mineral oil 
Vitamin C capsules Capsules 1 7 
[69] FO and EPO: 174 mg DHA, 558 
mg EPA, 60 mg LA. 
Medium chain 
triglycerides 
Capsules 6 12 
[126] 200 mg DHA 400 mg EPA, or 
180 mg DHA, 380 mg EPA 
Olive oil or 
safflower oil  
Capsules 1–2 16 
[74,75] FO and EPO: 174 mg DHA, 558 
mg EPA, 60 mg GLA 
Palm oil  Capsules 6 30 
[98] 500 mg ethyl-EPA Triglycerides and 
cellulose 
Capsules NR 12.9 
[80,81] 1–15 wk: 120 mg EPA + DHA 
16–30 wk: 60 mg EPA + DHA 
Cellulose Capsules 4 15 + 15 
[82] 321 mg DHA, 42.2 g EPA per 
100 g egg 
Ordinary egg Egg 1 13.1 
bw: body weight, FO: fish oil, NA: not appropriate, NR: not reported 
a DHASCO is an algal triglyceride DHA; b Some studies gave duration in months or number of days 
supplementation was received, we recalculated the duration to weeks; c PCSO-524 is an lipid extract of the New 
Zealand green-lipped mussel;  
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Looking at the adherence percentage between studies in healthy and diseased children, 
there seemed to be a slightly lower average adherence in diseased children (M = 83.7%, 
SD = 11.9), compared to healthy children (M = 87.6%, SD = 7.1). When we looked at the 
different age groups recruited, there seemed to be a lower average adherence in the child 
only group (M = 82.5%, SD = 9.5), compared to adolescents (M = 89.2%, SD = 1.1) or 
the combined group (M = 88.5%, SD = 11.2). The difference in average adherence in 
different recruitment settings was less clear; hospital (M = 86%, SD = 10.6), community 
(M = 89.5%, SD = 7.8), and school (M = 83.9%, SD = 11.6). The average adherence rate 
also differed between continents with a lower average rate in Australia and USA/Canada: 
Europe (M = 87.5%, SD = 9.3), USA/Canada (M = 78.7%, SD = 6.5), Asia (M = 92%, 
SD = 1.4), Africa (M = 95%, SD = 0.5), Australia (M = 79.7%, SD = 13.5), and South 
America (M = 94.5%, just one study). There seemed to be a tendency for higher average 
adherence when capsules were used (M = 88.2%, SD = 8.0) instead of food (M = 74.8%, 
SD = 14.3) or drinks (M = 81.5%, SD = 9.2), or other forms of supplementation 
(M = 80.3%, SD = 18.0). Some studies mentioned that participants took capsules under 
supervision, but they did not show a higher mean adherence (M = 82.8%, SD = 15.2) than 
those that did not have supervision of capsule intake (M = 86.2%, SD = 8.3). Seven 
studies, that reported adherence, reported that participants consumed capsules more than 
once a day while 12 studies, that reported adherence, mentioned that the capsules were 
only taken once a day. There was no difference in average adherence between those two 
methods of supplementation (M= 87.3%, SD = 9.4 vs. M = 87.6%, SD = 7.8). Fifteen 
studies, reporting adherence, mentioned talking to parents or participants either via 
telephone or face to face (or via e-mail) during the study about the supplementation to 
increase adherence [61,67,69,70,72,90,91,107,111,113,131,134–136,143]. The studies that 
included a phone call did not have a higher average adherence rate (M = 81.5%, SD =9.5) 
than those that did not include a phone call (M = 86.2%, SD = 10.3). There were three 
studies that provided some form of incentive [98,107,146], however only one of these 
studies reported an adherence percentage. Forty-six studies mentioned that they took either 
blood or cheek samples, but only five studies mentioned that they used blood as an 
adherence measure [61,85,86,117,134] 
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Drop-out 
Sixty-five of the 75 included studies mentioned a drop-out rate or included numbers which 
made it possible to calculate the drop-out rate. The average drop-out was 17% (SD 13%), 
but it varied between 0% and 58% (see Table 9.4). There was no clear difference in average 
drop-out rate between studies in healthy (mean = 16.5%, SD = 11.5) and diseased 
populations (M = 17.9%, SD = 13.7). There was a difference in average drop-out with 
regard to the recruited age group: children M = 15%, SD = 11.1), adolescents (M = 12.3%, 
SD = 7.3) or both (M = 21.5%, SD = 14.9); with a higher average drop-out rate in the 
combined age group. 
There was also no clear difference in mean drop-out between recruitment setting: 
hospital (M = 15%, SD = 11.1), community (M = 18.2%, SD = 8.6) or school 
(M = 15.3%, SD = 13). Differences could be seen in the average drop-out according to the 
continent on which the study was executed: Europe (M = 13.3%, SD = 9.8), USA/Canada 
(M = 23.1%, SD = 11.6), Asia (M = 6.8%, SD = 7.4), Africa (M = 11.6%, SD = 3.9), 
Middle East (M = 20.1%, SD = 16.7), Australia (M = 34.9%, SD = 7.8), and South-
America (M = 9.1%, just one study). When looking at different forms of supplementation, 
no clear differences in average drop-out rate could be seen: capsules (M = 17.5%, 
SD = 12.9), food (M= 14.1%, SD = 14.9), drinks (M = 19%, SD = 13.7), and others 
(M = 17.9%, SD = 8.4). Eight studies who reported drop-out rate mentioned that capsules 
were taken under supervision, this seemed to lead to somewhat lower average drop-out rate 
(M = 13%, SD = 15.6), compared to the 57 studies in which participants did not take the 
capsules under supervision (M = 17.9%, SD = 15.6). Sixteen studies that reported drop-out 
rate divided the capsules over multiple intake moments (M = 17.2%, SD = 9.3). This did 
not seem to increase or decrease the average drop-out rate if compared to those studies 
that specified one intake moment (M = 17.1%, SD = 13.6). Fourteen studies that noted 
drop-out rate reported that they contacted the participants during the study. Studies that 
did so seemed to have a slightly higher average drop-out rate (M = 20.4%, SD = 11.4) than 
studies that did not contact participants during the study (M = 16.5%, SD = 14.4). Of the 
studies that reported giving participants an incentive, two mentioned a drop-out rate, this 
was on average 15.3% (SD 20.4). Studies that did not state an incentive had an average 
drop-out rate of 17.4% (SD 12.7). Of the 65 studies that mentioned a drop-out rate, 50 
specified a reason for drop-out (six did not have drop-out, and nine did not specify the 
drop-out). Fifty-two different reasons for drop-out were mentioned, with the most 
common reasons mentioned being lost to follow-up, poor or no adherence or inability to 
take supplement.  
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Table 9.4:. Adherence and drop out characteristics per study. 
Reference Adherence assessment Adherence (mean or nr.  
of part. non-adherent 
Blood FA 
determined? 
Drop-out rate (%) 
Treatment           Placebo 
Healthy      
[114] Supervision and tick-off 
form 
Active: 88.4%, Placebo: 88.5% Y 3.1 6.1 
[115] Supervision NR Y 0 0 
[108] NR NR Y Low DHA: 20; 
High DHA: 7.1 
17 
[112] Capsule count Nearly 100% Y 7.1 5.6 
[101] Supervision Active: 94.8%, Placebo: 94.5% Y 11 9.8 
[106] Pill diary by teacher or 
parent 
Active: 68.4%, Placebo: 66.7% Y 24 21 
[102] NR NR Y NR NR 
[103] NR > 90%. Y 6.7 7.8 
[109] Sachet count and diary 
(Australia)/Supervision 
(Indonesia) 
Australia: 73-84% 
Indonesia: 85-87% 
Y 
 
27 
3.6 
34 
5.3 
[111] Interview small increase in DHA in 
supplemented group 
Y NR NR 
[107] Diary n = 6 Y NR NR 
[105] Parental signing of diary 
card 
> 80%. N NR NR 
[113] NR NR N 5.9 19 
[110] Supervision Phase 1: 59%, Phase 2: 61% N 47 42 
With disorder or illness     
[141] NR NR Y 0 0 
[140] Pill count Active: 93%, Placebo: 96% Y NR NR 
[82] Supervision count of consumed eggs 
showed good compliance and 
% of adherence to treatment 
was 100% 
Y 5.6 3.2 
[127] Pill count pill count revealed no essential 
irregularities 
Y 13.3 Vit. E: 0, 
Placebo: 10 
[84] NR NR NR NR NR 
[80,81] Pill count n = 14 N 20 18 
[83] Pill count, compliance 
diary and telephone call 
96.7% N 23 23 
[95] NR n = 2 DHA supplementation 
induced a median plasma DHA 
enrichment of 5% suggesting 
adherence 
Y 14 5 
[138,139] Interview 90% Y NR NR 
[79] Capsule count n = 1 Y 13 11 
[86] Diary and blood values 80–85% Y 21.1 11.1 
[77] Phone calls and product 
weighting 
n = 6 Y Phospholipids: 
38, Fish oil: 25 
24 
[118–121] Supervision 95.4% Y 6.9 9.9 
[61] Blood NR Y CO CO 
[94] Capsule count and diary  75% Y 42 64 
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Reference Adherence assessment Adherence (mean or nr.  
of part. non-adherent 
Blood FA 
determined? 
Drop-out rate (%) 
Treatment           Placebo 
[70] Capsule count EPA: 83%, DHA: 86% , LA: 
85% 
Y CO CO 
[87] Capsule count 75% Y NR NR 
[76] Diary 88% Y 28 40 
[143–145] NR NR Y 17 17 
[131–133] Capsule count and 
interview 
excellent in all groups Y NR NR 
[62] Product weighting n = 1 Y 0 5.1 
[135] Capsule count and 
interview 
NR Y 0 25 
[78] Capsule count Active: 96.7%, Placebo: 100% Y 15 13 
[93] Capsule count excellent Y 21 38 
[136,137] Capsule count n = 1 Y CO CO 
[90] Parent interview Active: 69% , Placebo: 75% Y 36 23 
[69] Capsule count FA changed in the expected 
direction. 
Y 24 30 
[89] NR NR Y 27 14 
[64] Capsule count NR Y 30 19 
[116] Capsule count DHA: 96.5%, DHA + EPA: 
96.9%, Placebo: 96.7% 
Y DHA: 0, DHA + 
EPA: 0 
0 
[117] Blood value NR Y CO CO 
[129,130] Capsule count 95.5% Y 21 11 
[128] Capsule count NR Y NR NR 
[134] Blood values n = 5 Y 14 10 
[98] NR According to parents children 
took the capsules carefully 
Y NR NR 
[88] Supervision and capsule 
count 
Pill count: 91% Y 0 0 
[92] NR there was no overlap between 
the distributions of plasma 
levels between groups at week 
24 
Y 21 11 
[65] Capsule count n = 5 N NR NR 
[97] Capsule count and diary Period 1: 88.7%, Period 2: 
85.5% 
N 17 12 
[91] Parents e-mail Active: 69%, Placebo: 83% N 28 14 
[85] Parent interview and 
blood values 
Average number of drink per 
week 6.5. 
N 10 22 
[73] Capsule count Active 7.88 capsules left; 
Placebo: 14 capsules left 
N 18 21 
[125] NR 89–97% N 10 23 
[142] NR NR N 18 31 
[67,68] Parent interview Period 1: 93.4%, Period 2: 
93.3% 
N CO CO 
[126] NR n = 5 N NR NR 
[122] Capsule count Active: 90.4%, placebo 86.6% N 23 21 
[74,75] Capsule count and diary n = 2 N CO CO 
[63] Capsule count NR N 60 55 
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Reference Adherence assessment Adherence (mean or nr.  
of part. non-adherent 
Blood FA 
determined? 
Drop-out rate (%) 
Treatment           Placebo 
[59] NR NR N NR NR 
[124] NR NR N NR NR 
[100] NR NR N NR NR 
[96] NR Compliance was optimal N NR NR 
[66] NR NR N 0 0 
[146,147] Diary At school: 75% N 0.6 1.1 
[72] NR NR N 2 6.1 
[58] NR n = 5 N 8.6 5.7 
[60] NR NR N NR NR 
[123] Diary and capsule count NR N 0 20 
[104] Interview Active: 94%, Placebo: 92%, 
Period 2: 91% 
N CO CO 
[99] NR n = 1 N CO CO 
CO: cross-over study, NR: not reported. 
Discussion 
We conducted a thorough review to examine recruitment, adherence and drop-out rates in 
n-3 LCPUFA supplementation studies in children and adolescents, in order to identify 
strategies which can be implemented to improve those rates. Even though the CONSORT 
guidelines clearly state what data need to be included in the report of a RCT, the majority 
of the included studies did not provide a flow-chart (55% did not) or the dates defining the 
period of recruitment and follow-up (70% did not).  
Recruitment 
The majority of studies provided minimal details about the recruitment process. The low 
number of studies that reported the number of participants that they invited and screened 
is, however, not uncommon in research studies as similar numbers were reported by 
Toerien et al. who studied 129 studies in six major journals [148]. The literature does give 
some suggestions for methods that could increase recruitment; for example, telephone calls 
to those who do not reply, an opt-out system (participants contact the researchers if they 
do not want to participate, please do note that this is not legal in all countries), including 
incentives, making trials open, and in person recruitment [149]. The use of clinical referral 
is also suggested to be related to higher recruitment rates, as most patients will have a 
trusting relationship with their doctor [150]. When we looked at the research setting 
(hospital, community, school), though, the mean started/invited rate and mean 
started/responded rate seemed to be slightly higher in the school setting. However, in the 
studies that looked at diseased populations, the average percentage efficiency of 
started/invited and started/responded was higher than studies looking at healthy 
populations (M = 43.5% vs. M= 36.2% and M = 63.5 vs. M = 53.1%, respectively). It has 
been shown that in adolescents, giving monetary incentives does improve response rates 
and has a positive effect on their willingness to participate in studies [151]. However, the 
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provision of monetary incentives might be considered unethical in children/adolescents 
[152,153]. One might thus consider a form on non-monetary incentive, for example in 
Food2Learn participants received a cinema voucher [19]. In the current review, there were 
only three studies that provided an incentive and these studies did not have remarkably 
higher recruitment rates. Hence, more studies that do provide incentives are needed to 
elucidate whether or not incentives improve recruitment. Moreover, there are myriad 
reasons as to why somebody would or would not participate in a study. There are 
participant characteristics which in adults have been associated with a higher chance of 
non-participation such as younger age, being male, lower social economic status, and lower 
education level [154,155]. However, in the limited number of studies on recruitment in 
children, no association between age or sex has been seen, although the education level of 
parents was associated with higher enrolment rates [5]. 
Beliefs about the effectiveness of the treatment may also play a role. Examples of 
reasons as to why adolescents did not participate informally given in Food2learn included: 
(1) the belief that n-3 LCPUFA are not effective in improving health; (2) the belief that 
they already consume sufficient amount of n-3 LCPUFA/already eat healthy; (3) the belief 
that participation will take too much time/effort; and (4) lack of interest in research in 
general. These factors should be taken into account during the research process and it 
seems wise to include explanations that most people do not get enough n-3 LCPUFA in 
their diet as well as elaborating on the possible health benefits of n-3 LCPUFA specific to 
the age group being assessed. 
Adherence  
Just 25 studies mentioned a specific adherence percentage, which varied between 60% and 
97% with a mean of 85%. Moreover, most studies included in the current review used 
indirect adherence assessment methods (i.e., diaries, interviews, and capsules counts) which 
are all subject to problems with reporting bias and errors or intentional manipulation [156]. 
More direct methods such as the determination of fatty acid levels in the blood seems to be 
the most reliable method to assess adherence, which was done in only five studies. 
However, it should be noted that taking blood samples in younger children might not be 
acceptable for all parents or ethical committees and could therefore lead to lower 
recruitment numbers.  
In the current review, there was no difference in mean adherence in those studies 
where participants received a telephone call to try and increase adherence compared to 
those in which participants received no telephone call (M = 81.5% vs. M = 87.7%). There 
were only three studies that provided an incentive and only one of these studies provided 
an adherence percentage, which was 75%. There seemed to be a higher average adherence 
of capsules (M = 88.2%) compared to other forms of supplementation (M = 74.8%, 
M = 81.5%, M = 80.3%, for food, drink and other forms, respectively). Lastly, there was 
no difference in the mean adherence between those who took capsules multiple times a day 
compared to those who took capsules only once a day (M = 87.3% vs. M = 87.6%). It is 
however important to remember that all these findings are based on only 25 studies that 
mentioned an adherence rate.  
Other studies suggest factors that are associated with higher adherence in children and 
adolescents, these include: sociodemographic factors (i.e., older children and older 
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adolescents are less likely to be adherent, and boys are less likely to be adherent), disease 
associated factors (i.e., if the disease also has positive symptoms the person is less likely to 
be adherent), the belief and attitude that a person has towards the treatment (i.e., those that 
belief that the treatment will be effective are more likely to be adherent), their mood 
(i.e., those with depression are less likely to be adherent) and the social context (i.e., those 
who are supported by family and friends are more likely to be adherent)[157,158]. Methods 
to increase adherence rates have also been suggested. Methods that have been employed to 
increase adherence include: educating participants about adherence, making medicine (or 
supplementation) more palatable, providing incentives/tokens, and involving parents or 
schools [159,160]. However, one must take into consideration that the vast majority of 
studies looking at which methods can help increase adherence have been executed in a 
medical setting with patients requiring medications and these results do not by definition 
translate to nutritional interventions in healthy participants or those with diagnosed 
disorders such as ADHD. 
Some suggestions for improving adherence for n-3 LCPUFA supplementation studies 
may include: providing sufficient information about the importance of adherence (i.e., 
explaining the importance of adherence to get valid results), getting parents involved, and 
providing appropriate incentives [159,160].  
Drop-out 
In the current review, the average drop-out was 17% (range 0–58%). Three studies 
mentioned some form of incentive [98,107,146] and they reported a slightly lower average 
drop-out than those that did not use (or did not report) an incentive (M = 15.3% vs. 
M = 17.4%). There were differences in average drop-out rates between continents, with 
drop-out rates being higher in Australia (M = 34.9%), USA/Canada (M = 23.1%), and the 
Middle East (M = 20.1%) compared to Europe (M= 13.3%), Africa (M = 11.6%) and Asia 
(M = 6.8%). We can only speculate about explanations for this difference (e.g., individualistic 
vs. collective societies) and do point out that these differences have to be interpreted with 
caution as the number of studies per continent did differ greatly. A number of methods to 
decrease drop-out in studies involving adults has been suggested. They include emphasizing 
the benefit of participation, flexible scheduling of appointments, regular positive 
communication from the research team to the participants (e.g., birthday and Christmas 
cards, newsletters, etc.), a consistent research staff so participants can build a bond with the 
researchers, and appropriate incentives [150,161–163]. Other strategies that have been 
suggested include decreasing the complexity of the treatment and limiting the number of 
follow-up visits to the bare minimum [164]. Furthermore, a combination of multiple 
strategies is suggested to be most effective in increasing retention [161,164]. All these 
methods to decrease drop-out have been studied in adults; more research on methods to 
decrease drop-out in children and adolescents in RCT is warranted. 
Suggestions for decreasing drop-out in n-3 LCPUFA supplementation trial include: 
keeping in regular contact with the participants, providing flexible appointment 
possibilities, providing incentives for participants and providing reminders. With regard to 
the supplement, one should keep the regime as simple as possible e.g., one (concentrated) 
capsule per day [150,161–164]. 
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Strengths and limitations  
Limitations of the current review include the fact that many of the included studies did not 
report all data on recruitment, dropout and (assessment of) adherence. Due to the 
incomplete reporting of data, results should be viewed with caution. The main advantage of 
the current review is the fact that we included all studies investigating n-3 LCPUFA 
supplementation in children/adolescents regardless of whether they were healthy 
children/adolescents or children/adolescents with a disease or disorder.  
Conclusions 
The conclusions drawn are based on minimal reporting from the included studies in this 
review. Less than half of the included studies abided by the CONSORT guidelines. 
Problems with recruitment and drop-out seem to be common in n-3 LCPUFA 
supplementation trials in children and adolescents. However, since the reporting about 
recruitment, adherence and dropout rates was very heterogeneous and minimal in the 
included studies, we cannot provide specific suggestions to improve LCPUFA 
supplementation studies in children and adolescents.  
Recommendations 
It is important for future studies to report on recruitment effort and rate, adherence 
(including the method of assessing adherence) and drop-out rates according to the 
CONSORT Guidelines. 
Suggestions from other scientific areas to increase recruitment, adherence and minimize 
drop-out include: the provision of sufficient information about the importance of 
adherence (i.e., explaining the importance of adherence to get valid results), getting parents 
involved, provision of appropriate incentives, emphasizing the benefit of participation, 
being flexible with the scheduling of appointments, the research team engaging in regular 
positive communication with the participants, having a consistent research staff member so 
participants can build a bond with the researchers and to keep the supplementation regime 
as simple as possible. 
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This thesis investigated the influence of long-chain polyunsaturated fatty acids (LCPUFA) 
on brain functioning in children and adolescents. To do so three aspects related to brain 
functioning were studied: school performance, cognition, and mental well-being.  
To study the association between LCPUFA, measured during pregnancy, at birth, and 
at age 7, and school performance in children at age 7, data from the Maastricht Essential 
Fatty Acid Birth (MEFAB) cohort were used. The data used from the MEFAB cohort were 
the maternal plasma fatty acid concentrations during pregnancy (i.e., at study entry (before 
16 weeks of pregnancy), at 22, and 32 weeks of pregnancy), maternal plasma fatty acid 
status at birth, cord fatty acid concentration, child plasma fatty acid concentration at age 7, 
and scores on standardized school tests (spelling, reading, arithmetic).  
To investigate the influence of n-3 LCPUFA supplementation on cognition, 
Food2Learn was designed. Food2Learn was a double-blind randomized, placebo controlled 
repeated measures intervention trial in adolescents attending lower general secondary 
education. Participants received either krill oil (source of n-3 LCPUFA) or a placebo for 
one year. During that year blood samples (via a finger prick) were taken at baseline, 3, 6, 
and 12 months. At baseline, 6, and 12 months participants executed a number of 
neurocognitive tests, and filled out a number of mental well-being questionnaires. To study 
the influence of n-3 LCPUFA on mental well-being, defined as depression and self-esteem, 
data from the mental well-being questionnaires from Food2Learn were used. Below the 
results of both studies will be discussed in a general perspective. This discussion starts with 
an overview of the dissertation and the main findings. 
Dissertation overview and main findings  
Chapter 1 provides a general and theoretical introduction to this dissertation. Chapter 2 
provides an overview of the MEFAB cohort, why it was designed, which data were collected 
and when, moreover the main findings of MEFAB are reported. In Chapter 3, data from the 
MEFAB cohort was used to assess the association between LCPUFA concentrations during 
pregnancy, at birth, birth, and age 7, and school performance at age 7. A clear negative 
association between maternal docosahexaenoic acid (DHA) concentration during pregnancy, 
at birth, and child arithmetic score at age 7 was shown. Moreover, child DHA concentration 
at age 7 was positively associated with reading and spelling at age 7. In Chapter 4, the design 
of Food2learn and the rationale behind the research design are presented. In Chapters 5 and 
6, baseline results of Food2Learn are presented. In Chapter 5 it is reported that a higher 
baseline Omega-3 Index (O3I) was associated with higher information processing speed, 
and less inattention/impulsivity. In Chapter 6 it was shown with Bayesian analysis that there 
was highly significant negative association between Osbond acid (C22:5n-6, ObA) levels and 
depression score (i.e., higher ObA, less depression). Moreover, a highly significant positive 
association between ObA and self-esteem (i.e., more ObA, higher self-esteem) is shown. In 
Chapter 7 and 8 the effects of one year of krill oil supplementation on cognitive measures 
and mental well-being measures, respectively are reported. There was no significant effect of 
supplementation on either the cognitive measures or mental well-being measures. The most 
likely explanation was the non-adherence of participants with the protocol. While executing 
Food2Learn, there were difficulties with recruiting participants, but also with drop-out and 
adherence. Other researchers have experienced similar problems (personal communication). 
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Given that a review about recruitment, adherence and drop-out in n-3 LCPUFA 
supplementation studies in children and adolescents had not been reported, such a review 
was thus conducted. Results of this review are reported in Chapter 9. In each respective 
chapter, the studies and their results are discussed extensively. In the discussion below, the 
results are put into a broader and more general perspective.  
Discussion of this dissertation  
The following discussion focusses on the three main outcome measurements discussed in 
this dissertation: school performance, cognition, and mental well-being. The discussions for 
each of these outcome measures are presented below and includes the findings from the 
studies included in this thesis, but also compares the studies to earlier similar studies 
identified via a scoping review and puts the results in a broader perspective. Note that for 
cognition separate discussions for observational studies and intervention studies are 
included. Thereafter, the strength and the limitations of both MEFAB and Food2Learn are 
discussed. Then recommendations for future research are suggested and implications for 
the general public are discussed. Lastly, the conclusions of this dissertation are presented.  
LCPUFA and school performance  
School performance is the most important outcome measure of education and has been 
associated with long term educational attainment, health outcomes, socio economic status 
and mental well-being [1]. There is a large number of factors which can influence school 
performance such as personal characteristics, cognitive abilities, family characteristics, and 
school environment [1]. However, lifestyle factors including nutrition might also influence 
school performance. It has, for example, been suggested that providing adequate 
docosahexaenoic acid (C22:6n-3, DHA) may lead to small improvements in multiple 
cognitive functions, which combined could influence school performances such as reading 
and spelling [2].  
To investigate the association between LCPUFA concentrations and school 
performance, the data collected in the MEFAB cohort were used. First, the association 
between fatty acid levels measured in maternal blood at study entry (before 16 weeks of 
pregnancy), at 22 and 32 weeks of pregnancy, and at delivery, and school performance 
scores for arithmetic, reading, and spelling at age 7 were investigated. Second, the 
association between LCPUFA concentrations determined in umbilical cord plasma and 
blood plasma at age 7, and school performance at age 7 was investigated. Results of these 
analyses showed, in contrast to the hypotheses, a clear negative association between 
maternal DHA levels throughout pregnancy and at birth, and arithmetic scores at age 7. 
This association was supported by the fact that ObA, a functional deficiency marker of 
DHA, showed a positive association with arithmetic score. In contrast, DHA concentration 
at age 7 was positively associated with reading and spelling scores at age 7.  
As noted in the discussion in Chapter 3, there are to our knowledge no other studies 
investigating the association between prenatal LCPUFA exposure and school performance 
in later life. While the main focus of this study was on the potential prenatal programming 
effect of the LCPUFA, also associations between LCPUFA concentration at age 7 and 
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school performance at age 7 were investigated. The mixed associations which were shown in 
MEFAB (i.e., negative association between prenatal DHA and arithmetic, positive 
association between DHA at age 7 and reading/ spelling), made us curious as to what is 
known about the relationship between LCPUFA and school performance in 
children/adolescents. Therefore, a scoping review was executed. Web of Science was 
searched with the following search terms: ‘LCPUFA’, ‘EPA’, ‘DHA’, ‘Omega-3’, ‘school 
performance’, ‘academic achievement’, or ‘grade’. Moreover, a number of reviews was 
checked for additional references [2–6]. Studies were included if (1) participants were 
between 4 and 18 years old; (2) an objective measurement of LCPUFA in the body (e.g., 
blood, cheek cells, adipose tissue) was included, or the study was a LCPUFA 
supplementation study; (3) a measure of school performance such as grades, or spelling, 
reading or math ability was included. Spelling, reading and math scores were only acceptable 
if they were assessed with a standardized test. Finally, the study had to be published in 
English to be included in the review. Information on study population, test used to assess 
school performance, the LCPUFA measurement method and outcomes were extracted.  
In the scoping review five studies in which the relationship between LCPUFA and 
school performance was investigated were found (see Table 10.1). One was an 
observational study [7], the other four concerned LCPUFA intervention studies [8–11]. 
Looking at the school performance measure assessed in the studies: five investigated 
reading [7,9–12] three spelling [9,10,12], two math [7,12], and only one actual school grades 
[8] (see Table 10.1). Note that these numbers include our own study [12]. 
Of the five studies that looked at reading, four showed positive associations between n-3 
LCPUFA concentration and reading, or an effect of n-3 LCUPFA supplementation on 
reading performance, albeit in a subgroup or a borderline effect [7,9,11,12] One study 
investigating the effect of n-3 LCPUFA supplementation on reading did not show a 
significant effect [10]. It is however important to note that the study that did not show a 
significant effect was executed in a very wide age range and included children of <6 years 
which are most probably not able to read yet. Summarizing, preliminary conclusions point to 
a positive effect of, or association with n-3 LCPUFA and reading performance in children. 
Three studies included in the review assessed spelling [9,10,12]. One showed no effect of 
n-3 LCPUFA supplementation on spelling [10], one showed a positive effect of n-3 
LCPUFA supplementation on spelling [9], and one showed a positive association between 
DHA and spelling [12]. It is, however, important to note that the study of Perletta et al. that 
did not show a significant effect [10] was executed in a very wide age range and included 
children of <6 years which are most probably unable to execute a spelling test. Moreover, 
do note that the study of Parletta et al. was executed in an Aboriginal population. Aboriginals 
do not communicate through written text, but through storytelling and pictures. The 
children do not practice spelling and reading (i.e., communication through written text) at 
home, this could influence results. The study did show a positive association on the picture 
based Draw-A-Person test (see LCPUFA and cognition – supplementation studies section). 
The study that did show an effect of n-3 LCPUFA supplementation on spelling noted that 
the result was caused by a decline in spelling ability in the placebo group. In sum, this 
suggests that the evidence for an effect of n-3 LCPUFA, or an association with n-3 
LCPUFA and spelling are rather limited and that clear conclusions about the effectiveness 
of n-3 LCPUFA supplementation on spelling cannot be drawn. 
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The two studies that reported on math performance showed contradicting results 
[7,12]. Sorensen et al. showed a positive correlation between DHA and eicosapentaenoic 
acid (C20:5n-3, EPA) and math performance[7], while in MEFAB no significant 
association between either DHA or EPA at age 7 and math performance was shown [12]. 
However, the children in the Sorensen et al. study were older, and possibly in another brain 
development stage in which the brain regions responsible for math performance (i.e., 
prefrontal cortex) might be sensitive to LCPUFAs, while this was not the case in MEFAB. 
Earlier research suggests that brain development might be characterized by specific 
‘sensitive periods’ [13,14]. The scientific proof for n-3 LCPUFA effects on math 
performance is thus still very limited and more research is needed. 
Table 10.1: Observational studies and RCT investigating the relationship between LCPUFA and school 
performance in children.  
Author, kind of 
study, n 
(reference) 
Age 
population
 Academic test Outcome 
Sorensen 
Observational1 
n 747  
[7]  
8-11 Danish standard test for reading 
and math 
Positive correlation between DHA + EPA and 
math performance, and the percentage of 
sentences that were correct out of the total 
number of sentences read. For girls DHA + EPA 
positively correlated with reading speed and 
number correct on sentence reading test.  
MEFAB2 
Observational  
n 170  
[12] 
7-8 Standard Dutch Cito tests for 
spelling, reading and arithmetic 
Plasma DHA level at age 7 was positively 
associated with reading and spelling. Maternal 
plasma DHA levels during pregnancy were 
negatively associated with child arithmetic scores 
at age 7 
Portillo-Reyes 
RCT  
n 55  
[8] 
8-12 Average score on the subjects 
Spanish, Mathematics, History 
and Geography, Science, and Civic 
Education 
No difference between LCPUFA 
supplementation group and placebo group. 
Dalton  
RCT 
n 183 
[9] 
7-9 Reading and Spelling test There was a significant intervention effect for 
spelling, due to a significant decline in the scores 
in the placebo group. For reading a borderline 
significant (0.065) effect was seen.  
Richardson 
RCT 
n 362 
[11] 
7-9 Word reading achievement sub-
test of the British Ability Scale 
Preplanned subgroup analyses showed that for 
children with baseline reading < 20th percentile 
improvement was greater in active treatment, for 
those in < 10th percentile the treatment effect was 
slightly greater. 
Parletta 
RCT 
n 408 
[10] 
3-133 Wide range achievement test – 
subtest word reading and spelling 
No treatment by group interaction for reading 
and spelling. 
1 The study of Sorensen was an intervention assessing the effect of a Nordic Diet school lunch on among other 
cognition. Here only the baseline results were used. 2 Chapter three of the current thesis. 3 Only two out of 408 
participants were three years old, it was therefore decided to include this study despite inclusion criteria. 
 
Portillo-Reyes et al. was the only study investigating the effect on school grades [8], albeit 
the average over school five subject. They did not show an effect of n-3 LCPUFA 
supplementation on average score. However, taking the average of multiple subjects can 
lead to the averaging out of the negative association in one school subject by the positive 
association in another subject. Therefore this finding has to be interpreted with caution.  
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All in all, there is some evidence that n-3 LCPUFA might influence school performance 
in children, specifically for reading, and possibly for spelling. Furthermore, research on 
math performance and actual school grades is very limited; these areas need more research. 
Lastly, MEFAB seems to be the only study in which the relationship between prenatal 
LCPUFA exposure and later school performance has been assessed. Especially considering 
the consistent negative associations between DHA during pregnancy, and at birth and 
arithmetic scores at age 7 found in MEFAB, more research is needed.  
LCPUFA and cognition – observational studies  
Cognitive abilities are very important for school performance. LCPUFA have many 
functions in the body and can influence brain function in a multitude of manners (see 
chapter 1). It, therefore, should not come as a surprise that a multitude of observational 
studies have investigated the relationship between LCPUFA and cognition. There are, 
however, to our knowledge, no studies investigating the association between LCPUFA and 
cognition in adolescents. Therefore, Food2Learn was designed and conducted.  
The baseline results of Food2Learn reported in Chapter 5 showed that a higher O3I 
was associated with better performance on the letter digit substitution task (LDST). This 
indicates that a higher baseline O3I in the adolescents participating in Food2Learns was 
associated with better information processing speed. Moreover, a higher O3I was also 
associated with fewer errors of omission on the D2 test of attention, which is a measure of 
inattention/impulsivity.  
Food2Learn was, to our knowledge, the first study in which the association between 
fatty acid concentrations measured in blood and cognitive measures in adolescents was 
assessed. There are, however, studies available in children, investigating the link between 
O3I and cognition. It was therefore decided to compare the findings of Food2learn to 
those of earlier observational studies investigating the relationship between LCPUFA and 
cognition in children. To do so a second scoping review was executed.  
Web of Science was searched with the following search terms: ‘LCPUFA’, ‘EPA’, 
‘DHA’, ‘Omega-3’, ‘cogniti*, ‘child*’, or ‘adolescen*’. Moreover, a number of reviews was 
checked for additional references [2–6]. Studies were eligible for inclusion if (1) participants 
were between 4 and 18 years old; (2) the study included an objective measurement of 
LCPUFA in the body (e.g., blood, cheek cells, adipose tissue); (3) the study included a 
measure of cognition; (4) the study was of observational nature; (5) the study was published 
in English. Information on study population, test used to assess cognition, the LCPUFA 
measurement method and outcomes was extracted. Our goal was to see whether higher 
O3I was associated with positive outcomes, i.e., whether there is some sort of cut-off point 
above which a positive association between O3I and cognitive measures is apparent. 
Therefore, the measured DHA and eicosapentaenoic acid (EPA) concentrations reported 
in the studies were recalculated to the O3I. The O3I is defined as the sum of DHA + EPA 
in erythrocytes, expressed as a percent of total erythrocyte fatty acids, but there are non-
validated conversion formulae available for measurements from other blood fractions (i.e., 
determined in whole blood or plasma) [15].  
The review led to eight studies which met inclusion criteria (see Table 10.2) [7,16–23]. 
Unfortunately, the studies were very heterogeneous in study population (i.e., age and 
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nutritional status) and cognitive test used (i.e., specific tests or test battery such as 
Kaufman). This heterogeneity makes comparison of the studies rather difficult.  
Of the eight studies included in the review, six studies included data that made it possible 
to calculate an O3I [7,16–21](see Table 10.2). The calculated O3I in those six studies varied 
between 3.37% [17] and 4.57% [7], which is rather similar to the baseline O3I measured in 
Food2Learn (i.e., 3.89% including all participants, also participants with O3I > 5%). The O3I 
in all studies were thus rather low and well below the recommended 8-11% for cardiovascular 
health and the target level we originally aimed for to reach with our supplement. As the O3I 
were so low and so similar, it was not possible to determine whether a O3I cut-off point, 
above which a positive association with cognition is apparent, exists.  
Table 10.2: Observational studies in children investigating the association between measured LCPUFA 
concentrations and cognition.  
Author 
(reference) 
Age 
population 
Blood 
fraction 
Calculated 
O3I 
Outcome 
Jumbe [16] 
n 130 
4-6 WB 4.36 In an adjusted model DHA was positively associated with score 
on Dimensional Change Card Sorting task (measures executive 
functioning).  
Eilander [17] 
n 541 
6-10 E 3.37 No association between either DHA or EPA and any of the 
cognitive measures (fluid reasoning, short term memory, retrieval 
ability and cognitive speediness).  
Bakker [18] 
n 306 
7 PP 3.63 No significant association between DHA at age 7 and score on 
Kaufman Assessment Battery for Children score (measures 
intelligence and achievement).  
Montgomery 
[19] 
n 493 
7-9 WB 3.63 Significant positive association between DHA + EPA and score 
for recall of digits forward (working memory), no significant 
associations for digit recall backward.  
Sorensen [7] 
n 747 
8-11 WB 4.57 Positive correlation between EPA + DHA and processing speed 
and concentration performance measured on D2 test. For boys, a 
higher DHA + EPA was associated with lower D2 error% and 
impulsivity error%. For girls, a higher DHA + EPA was 
associated with higher inattention errors. 
Food2Learn 
[20]1 
n 267 
14-16 WB 3.83 Positive association between O3I and score on the LDST 
(information processing), negative association with number of 
errors of omission on D2 (inattention/impulsivity). 
Boucher [21] 
n 151 
10-13 PP 3.43 No association was shown between current DHA levels and 
score on the digit span forward (immediate memory), and the 
California Verbal Learning Task (short and long-term memory)  
Kirby [23] 
n 411 
8-10 CC2 NA A positive correlation between DHA and non-verbal IQ on the 
Kaufman brief intelligence test was shown. Moreover, a positive 
correlation between DHA/EPA ratio and working memory. No 
significant association between either DHA or EPA, and 
working memory, Wechsler individual achievement test, test of 
everyday attention, or matching familiar figures tasks.  
Haapala [22] 
n 444 
6-8 PP3  
TG 
CE 
NA Higher EPA and DHA measured in plasma TG was associated 
with higher score on Raven’s coloured progressive matrices 
(non-verbal reasoning), but only in overweight children.  
ALA = alfa linolenic acid, CC = cheek cell, CE = cholesteryl esters, DHA = docosahexaenoic acid, E = 
erythrocytes EPA = eicosapentaenoic acid, NA = not appropriate, PP = plasma phospholipids, WB = whole 
blood  
1 Chapter 4 of this thesis 2 For cheek cells no conversation factor is available. 3 Fatty acids concentrations were 
reported as mol% 
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When looking at the cognitive tests used in the studies included in the review, studies could 
be divided in those using tests of general ability (i.e., the Kaufman, and the Raven) and 
those using tests assessing individual cognitive domains (i.e., attention or memory) . Of the 
studies included in the review, three studies assessed a general ability [17,18,22], five studies 
assessed one or more specific cognitive domain(s) [7,16,19–21], and one assessed both [23]. 
Interestingly, four out of five studies assessing a specific cognitive domain showed a 
positive association between LCPUFA concentration and the cognitive measure 
[7,16,19,20]. Moreover, the only study in which no significant association was shown, 
borderline significant associations between plasma DHA level and score on the digit span 
forward were apparent [21]. Furthermore, a borderline significant association between 
plasma DHA level and recognition on the California verbal learning task was also found.  
In contrast, of the three studies [17,18,22] assessing a general ability only one showed a 
positive association, namely Haapala et al. [22]. In the study of Haapala and colleagues an 
association between DHA and EPA measured in plasma triacylglycerols and score on 
Raven’s coloured progressive matrices was shown [22]. However, this association was only 
apparent in a relative small subgroup of 58 children with overweight/obesity, no 
association was shown for the 386 healthy children. Moreover, the association was only 
apparent for plasma triacylglycerols, which reflects the fatty acid intake of the last few 
hours, and not for cholesteryl esters and phospholipids, which reflect fatty acid intakes 
over the last days [24]. All in all, it seems very unlikely that such a short term fatty acid 
intake would relate to such a broad general ability.  
Kirby and colleagues included both a general test (Kaufmann) and cognitive domain 
specific tests [23]. They showed a significant correlation between DHA and score on the 
Kaufmann non-verbal subscale. Moreover, they showed a correlation between DHA/EPA 
ratio and score on the digit recall, a measure of working memory. However, the 
correlations were weak r < 0.15 and they executed a large number of statistical test (> 300 
statistical tests) without correction of the p-value for multiple testing. These results need to 
be interpreted with caution given the potential for false positive results.  
As noted above there are no observational studies investigating the association between 
LCPUFA measured in blood and cognitive performance in adolescents. There are however 
two studies that investigated the association between fish consumption, which is the most 
important source of LCPUFA, and cognition, or score on a vocabulary test. Åberg and 
colleagues reported an association between high fish consumption at age 15 and better 
cognitive performance at age 18 [25]. De Groot et al. showed an inverted u-shape 
association between fish consumption and score on a vocabulary test (i.e., higher fish 
consumption was associated with higher vocabulary score up to 1-2 times fish per week) 
[26]. These observational studies assessing fish consumption do point to a possible positive 
association between LCPUFA and cognition in adolescents.  
All in all, observational studies, including the baseline result of Food2Learn, do point to 
a positive relationship between LCPUFA concentration in blood and performance on 
individual cognitive domains. Although, the O3I in the studies included was very low (all 
< 5%), very cautiously there is an indication that a higher O3I is related to better cognitive 
performance. However, observational studies cannot provide evidence for causality, 
therefore placebo controlled randomized controlled trials (RCT) are needed.  
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LCPUFA and cognition – supplementation studies  
The observational studies discussed above point to a possible positive relationship between 
LCPUFA and cognition in children. Moreover, the baseline results of Food2Learn and 
observational studies investigating the association between fish consumption and cognition 
do point to a similar positive association in adolescents. However, to prove causality, 
placebo controlled RCTs are needed. Therefore, Food2Learn was designed to elucidate the 
effect of LCPUFA supplementation on, among others, cognitive performance in typically 
developing adolescents. One year of krill oil supplementation in Food2Learn did not lead 
to higher scores on any of the cognitive measures (reported in Chapter 7). However, due to 
issues with drop-out and non-adherence in Food2Learn, it cannot be precluded that a 
relationship between krill oil supplementation and cognition in adolescents does not exist.  
To compare our findings to those of earlier studies, investigating the effect of LCPUFA 
supplementation on cognition in children/adolescents, a third scoping review was 
executed. Web of Science was searched with the following search terms: ‘LCPUFA’, ‘EPA’, 
‘DHA’, ‘Omega-3’, ‘cogniti*, ‘child*’ or ‘adolescen*’. Reviews on this topic were also 
checked for additional studies to include [2-6]. Studies were eligible for inclusion if (1) 
participants were between 4 and 18 years old; (2) participants received supplementation 
with DHA and/or EPA; (3) the study included a measure of cognition; (4) the study was a 
randomized placebo controlled trial; (5) the study was published in English. Information 
on study population, supplementation, test used to assess cognition, LCPUFA 
measurement method if included and outcomes were extracted. To compare the results of 
studies included in the review to the results of Food2Learn, the measured fatty 
concentrations, if reported, were converted to the O3I with the formulae as suggested by 
Stark and colleagues [15].  
After reviewing the literature, 11 placebo controlled RCTs investigating the influence of 
LCPUFA supplementation on cognition could be included [6,8–11,27–32] (see Table 10.2 
and Table 10.3). Unfortunately, no studies in adolescents were located. The age of 
participants included in the studies varied from 3 to 13 years. Studies were very 
heterogeneous (i.e., they differed on population, duration, form of supplementation etc.) 
which makes comparison very difficult. 
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 Firstly, studies were compared on the increase of O3I. Of the 11 studies included in 
this review, seven reported that fatty acid concentrations were measured [6,9,27,28,30–32]. 
Unfortunately, the recalculation to the O3I was not possible for four [9,30–32] of the seven 
studies reporting the fatty acid values. One study only reported the log transformed EPA 
concentration [9], one did not report EPA concentration at all [31], one determined fatty 
acid concentration in cheek cells (no recalculation factor is available) [23], and one reported 
the fatty acid concentrations as micrograms per millilitre [32]. When looking at the three 
studies that allowed for recalculation to the O3I, they showed an increase in the O3I of 
3.11, 2.75, and 2.19%, after 15, 16, and 52 weeks of supplementation, respectively (see 
Table 10.2).  
The average increase in O3I was higher in all three studies than the average increase in 
O3I of 1.14% after 12 months in the krill oil group in the intention to treat analysis of 
Food2Learn. It is noteworthy that all three studies had a shorter duration and a lower 
supplementation dosage of DHA + EPA compared to Food2Learn and they still had a 
higher increase in O3I. This does point to an adherence problem in Food2Learn (for more 
on this see the strength and limitation section). However, similar to our results none of the 
three studies showed an effect of the supplementation on any cognitive measures in the 
main analyses in the overall sample. This would suggest that n-3 LCPUFA supplementation 
is not effective in increasing cognitive performance in children.  
Although the increase of O3I was higher in the three studies compared to Food2Learn, 
the O3I was still relatively low after supplementation (6.3%, 4.83%, and 5.57%) for all 
three studies, at least well below the recommended target range of 8-11%, where we 
originally aimed for in our Food2Learn study (see chapter 4). Moreover, similar to 
Food2Learn, in the three studies there also seemed to be an overlap in the O3I between 
the placebo and the LCPUFA supplemented group. Such an overlap in O3I between 
placebo and treatment group could have caused the non-significant treatment effects [33], 
as analyses were not executed according to O3I, but according to group allocation. It is 
interesting to note that Ryan et al. did execute secondary preplanned analyses according to 
blood values and did show an association between higher DHA concentration and higher 
score on the Peabody Picture Vocabulary scale [34]. Additionally, Muthayya and 
Baumgartner [27,28] made use of general ability tests (i.e., subtests of Kaufman, Wechslers 
Intelligence Scale and Rey auditory Verbal scale), while it has been suggested that domain 
specific tests are more suitable to pick up the subtle effects of nutrition interventions [35]. 
Also note that many of the participants included in the studies of Muthayya and 
Baumgartner did have nutrient deficiencies and some were undernourished in general. Both 
nutrient deficiencies and undernourishment can influence cognitive performance negatively 
[36,37] and possible counteract any positive effects of n-3 LCPUFA supplementation.  
The second aspect which could be considered in relation to the effectiveness of 
LCPUFA supplementation on cognition is daily supplementation dosage. The 
supplementation dosage of DHA + EPA varied immensely in the 12 included studies, 
varying from 86 to 100mg DHA per day, and from 0 to 558mg EPA per day. From Figure 
10.1 it can be deduced that a supplementation dosage of > 400 mg DHA + EPA per day 
does seem to lead to positive effects on cognition. While studies with a lower 
supplementation dosage, with the exception of Dalton et al.[9], did not find a significant 
cognitive health benefit.  
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Figure 10.1: LCPUFA supplementation studies that studied cognition in children. Line indicates dosages of above 
400mg DHA + EPA per day. Studies indicated with a * are those studies in which positive effects of 
supplementation are reported, studies with ● are those with significant positive effects in secondary analyses.  
 
Of the non-significant studies with dosages above 400mg, two did show significant 
effects/associations in secondary analyses. Kirby and colleagues did show significant 
effects of supplementation on visual attention and impulsivity in those that were compliant 
with the protocol [30]. Furthermore, Ryan et al. did show an association between DHA 
measured in blood and score on the Peabody Picture Vocabulary Test in a preplanned 
secondary analysis [6]. The one study that did show significant effects with a dose below 
400mg/day was the study of Dalton et al. in which fish flour was used as supplementation 
source [10]. Fish flour also includes other nutrients (e.g., protein) which could, especially 
for the undernourished children included in the study of Dalton et al., provide additional 
cognitive benefits.  
The study of Kennedy et al. was the only study with a dosage above 400mg DHA + 
EPA per day which did not show significant effects on cognition [29]. This study did have 
a relatively short supplementation duration of 8 weeks. The study did not include blood 
values. It is thus unsure whether the supplementation was successful and whether there 
was no overlap in fatty acid status between the three groups (i.e., placebo, 400mg DHA, 
1000mg DHA per day) Moreover the study did only include 88 participants and was, 
according to the authors themselves, underpowered.  
All in all, there seems to be some evidence that a dosage above 400mg DHA + EPA 
per day does lead to improved cognition in children. In contrast, in the studies that 
included data which made it possible to calculate the O3I [27,28,34], higher O3I in the 
supplemented group did not lead to better cognitive performance. However, due to the 
limited number of studies for which determination of the O3I was possible, the overlap 
between the placebo and intervention group, and the relative low O3I even after 
supplementation makes it difficult to draw conclusions. Moreover, possibly there is a cut-
off point above which a positive effect could be seen, similar to the fact that O3I > 8% has 
been associated with the lowest mortality risk in coronary heart disease [38]. None of the 
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studies which included data, which made it possible to calculate the O3I, achieved such a 
high O3I.  
It is important to note that the included studies are very heterogeneous and thus 
difficult to compare. The studies differed on among others: the study population (i.e., age, 
nutritional status), composition of supplementation (i.e., EPA/DHA ratio, but also 
inclusion of other fatty acids or nutrients), and duration of supplementation. For the 
assessment of cognition, a wide variety of cognitive tests were used, often with multiple 
subtests, assessing all different aspects of cognition. Additionally, the number of (sub)tests 
used varied from one to 21. In the studies with multiple tests, chance findings might be a 
problem.  
It is also unsure whether and how the results in children translate to adolescents. In 
Food2Learn, which was plagued by drop-out and non-adherence, it was not possible to 
show an effect of one year of krill oil supplementation on cognition in adolescents. Taking 
into account that Food2Learn was the first LCPUFA supplementation study in adolescents 
assessing cognition, and the limitations of Food2Learn, more studies in adolescents should 
be executed. These studies should include blood values, supplement with > 400mg DHA + 
EPA per day and try to achieve higher O3I at the end of treatment (also see suggestion for 
future research).  
LCPUFA and mental well-being  
Fish consumption and LCPUFA consumption have long received attention for their 
possible influence on mental well-being, specifically depression. However, the focus has 
mostly been on adults. This is unfortunate, as depression is very common in adolescence. 
Furthermore, adolescent depression has been associated with important long term negative 
consequences, such as reoccurrence of depression, increased risk of anxiety, risk of suicide, 
poorer social relationships, poorer self-rated health, lower grades, and lower educational 
attainment [39–43]. Adolescent depression is, thus, very important to investigate both from 
an individual adolescent’s perspective, but also from a public health perspective. Therefore, 
Food2Learn, the first n-3 LCPUFA supplementation intervention trial in typically 
developing adolescents from the general population was designed and conducted.  
Baseline results of Food2Learn (reported in Chapter 6) indicated that there was 
extreme evidence (i.e., Bayesian analysis indicates how strong the evidence is for the 
alternative hypothesis) for a weak negative association between ObA levels and depression 
score as assessed with Bayesian analysis, i.e., higher ObA levels less depression. Note that 
Bayesian analysis gives an indication of how strong the evidence is for the alternative 
hypothesis e.g., extreme evidence or substantial evidence. Moreover, there was substantial 
evidence for a weak positive association between ObA levels and self-esteem, i.e., higher 
ObA better self-esteem. Thus, higher ObA measured in blood was associated with lower 
depression and higher self-esteem. At baseline, there was evidence for the null hypothesis 
(i.e., no association) when analysing the relationship between depression and DHA, EPA, 
and O3I.  
There are a few observational studies investigating the association between LCPUFAs 
and depressive symptoms in adolescents [44–47]. There is, however, only one study in 
which similarly to our study the association between LCPUFA status and depressive 
symptoms and adolescents in the general population was investigated. Mamalakis and 
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colleagues measured fatty acid concentrations in adipose tissue and measured depression 
score with both the Center for Epidemiologic Studies Depression Scale (CES-D) and the 
Becks Depression Inventory (BDI)[48,49]. They showed a negative association between 
EPA status and score on the CES-D (i.e., more EPA, less depression), but only after 
correction for covariates. Moreover, they also showed a positive association between 
dihomo-gamma linolenic acid (C20:3n-6, DGLA) and score on the BDI (i.e., less DGLA, 
less depression), again only after correction. However, these associations just reached 
significance (p=.04 and p=.05), among a total of twenty analyses, one can therefore not 
exclude that these are chance finding. This is also supported the associations that were 
found with one of the depression questionnaires and not the other, while both are 
validated in adolescents [50]. Moreover, EPA and DHA are only present in very small 
amounts in adipose tissue [51] and an association between adipose fatty acids and brain 
fatty acids has, to our knowledge not been established, while the association between blood 
and brain fatty acids levels has been established in animal studies [52] .  
One year of krill oil supplementation in Food2Learn did not lead to lower depression 
scores, or higher self-esteem score (reported in Chapter 8). Moreover, a higher O3I was 
not related with score on either depression or self-esteem questionnaire. It is however 
important to note that due to non-adherence and drop-out the increase in O3I was limited.  
As noted, there are, to our knowledge, no earlier studies in which the influence of 
LCPUFA supplementation on depressive feelings in adolescents has been studied. There 
are a large number of LCPUFA supplementation in adults, with some showing a positive 
effect of LCPUFA supplementation, but most certainly not all studies (for meta-analyses 
see[53–57]. It is, however, uncertain if and to what extend results from studies in 
depression in adults can be translated to depressive feelings in adolescents. Adolescence is 
very different from adulthood as it is characterized by profound brain, physical, social, 
emotional and cognitive development [58]. Furthermore, there is also discussion about 
possible differences in causes and outcomes of juvenile-onset and adult-onset depression 
[59,60]. Thus, if supplementation of LCPUFA is an effective treatment for depression in 
adults, this does not automatically mean LCPUFA are effective for treatment of depression 
in adolescents.  
To summarize, Food2Learn is the first LCPUFA supplementation study investigating 
mental well-being (depression and self-esteem) in adolescents. Baseline results showed an 
association between ObA and both depression and self-esteem. The intervention, although 
having major limitations, did not show an effect of one year of krill oil supplementation 
and an increase in O3I on either depression or self-esteem. All in all, more research 
investigating the effect of both n-3 and n-6 LCPUFA in adolescent depression is needed, as 
this is an age group with a high prevalence of depression and in which depression has 
serious negative long-term consequence both on a personal and a public health level.  
Strengths and limitations of MEFAB and Food2Learn  
In this section, the strengths and limitations of MEFAB and Food2Learn are elaborated 
upon. The names of the studies are printed in bold in this section so it is easier to recognize 
to which study the strength or limitation is related.  
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The main strengths of the studies in the current thesis are that for both MEFAB and 
Food2Learn blood values were available. Many of the studies investigating the effect of 
LCPUFA supplementation on cognition or school performance included in the reviews in 
this discussion did not include measurements of LCPUFA levels in the body (i.e., blood, 
cheek cells, adipose tissue). When there is no biological measure of LCPUFA, it is 
impossible to know whether the supplementation was actually successful. One cannot be 
sure that participants were actually compliant with the protocol. Moreover, there are large 
interpersonal differences in metabolism which can influence tissue EPA and DHA levels. 
For example, in one study participants received 0.5g DHA + EPA per day for 8 weeks [61]. 
After 8 weeks, there was an average increase of 2.43%, but the ‘increase’ ranged from -
0.03% to +7.16%. In other words, there was 13-fold difference in response to the 
supplementation. This difference could have been caused by, among others, differences in 
metabolism, adherence, or other personal factors. But whatever the cause, it leads to 
different O3I while the LCPUFA dose is the same. These differences could influence 
results and it is thus important to measure O3I. When no blood levels are taken, one is also 
not aware of the baseline DHA/EPA levels, while it can be expected that any effect of 
DHA/EPA supplementation is more pronounced in participants with low baseline levels. 
In addition, a wide range of starting O3I can lead to similar end O3I in both placebo and 
treatment group and thus similar outcomes. These issues were tackled in Food2Learn by 
measuring blood levels at the start and three time points during the year of 
supplementation and by including only participants with an O3I below 5%. Furthermore, it 
was planned to execute a personalized supplementation dosage adjustment after three 
months of supplementation to deal with interpersonal metabolism. Unfortunately, none of 
the participants had achieved the set target O3I of 8 to 11%. Therefore, all participants 
received an increase in dosage. However, it is very likely that participants in Food2Learn 
were non-compliant. It is therefore still recommended to measure blood levels in these 
kinds of nutritional trials and to do dosage adjustments during a study to control for 
individual differences in response to supplementation. 
Most earlier studies asked participants to take capsules at breakfast time or did not 
specify the time at which capsules needed to be taken. The absorption of EPA and DHA is 
dependent on the food matrix with which it is taken. It has been reported that LCPUFA 
absorption is three times higher when LCPUFA capsules are taken with a high fat meal 
compared with a low fat meal [62]. Food2Learn participants were therefore specifically 
asked to consume the krill oil capsules with dinner, the fattiest meal of the day [63].  
It has been suggested that the neurocognitive tests used should be selected based on 
the most plausible cognitive outcome and/or brain regions to be influenced by the nutrient 
to be tested [35,64]. For Food2Learn tests that tap into the three core executive functions 
(i.e., shifting, updating of working memory, inhibition) were selected. The executive 
functions were chosen as they are mainly located within the (pre)frontal cortex, the brain 
region which is still in development during adolescence [65] and has been shown to have 
increased activity after DHA supplementation [31]. The selected tests are thus the tests 
which are most likely sensitive to LCPUFA supplementation in adolescents.  
MEFAB is one of a few birth cohorts with measurements during pregnancy and a very 
long follow-up (up to age 23). The longitudinal nature is the only way to relate the early life 
exposure to later life outcomes, as was done in Chapter 3 by relating LCPUFA status 
during pregnancy to school performance at age 7. Moreover, birth cohorts are the only way 
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to assess the possibility of early life programming; that is, whether exposure early in life can 
be related to health and disease in later life [66].  
The main limitation of Food2Learn is that it had rather high drop-out rates and 
difficulties with achieving adherence. Approximately 20% of the students withdrew 
completely from the study and 32% stopped active participation (i.e., they stopped taking 
supplements, but continued testing). The main reasons for stopping supplementation were 
lack of motivation, difficulties swallowing capsules, and difficulties remembering to take 
capsules. The drop-out seems high, but Food2Learn is not the only LCPUFA study with 
such high drop-out, as reported in Chapter 9. Therefore, during the study a number of 
techniques were used to try to increase adherence. A daily text message reminder was sent 
out, and motivational telephone talks were held. Moreover, a tip sheet was handed out at 
the start of the study with tips on how to remember to take capsules and how to make 
swallowing capsules easier (i.e., examples are: put the capsules at a clearly visible place, take 
the capsules with a tablespoon of custard, yoghurt or apple sauce, and put an alarm in your 
phone). The methods which were utilized to increase adherence, and decrease drop-out are 
also in line with the suggestions from the literature, as summarized in Chapter 9. Despite 
these efforts, adherence was not increased. Between test moments two and three there was 
actually a decrease in the average O3I of participants in the krill oil group that did not 
indicate to us to have stopped taking capsules. Moreover, only 3, 10, and 2 participants 
achieved the set target O3I range of 8-11% after 3, 6, and 12 months of supplementation, 
respectively. Fortunately, the blood values of 199 participants were available, which did 
make it possible to do the analyses according to blood O3I status.  
One of the limitations of MEFAB is the fact that such a longitudinal study of prenatal 
exposure, does not take into account what the children themselves consume during their 
life. This intake during life could possibly bias results.  
Lastly, only 21% of the original MEFAB participants had school performance scores 
available. These missing data could have influenced results, especially since the number of 
children with lower scores was limited. However, when those with school performance 
scores available and those without were compared, no differences on covariates were 
shown, indicating that the participants with school performance data available was a 
representative sample of the overall cohort.  
In summary, a great effort was made to reduce these limitations. Unfortunately, these 
limitations seem to be inherent to this type of research. It is however important to report 
these studies to the scientific community and inform them about the limitations, so future 
studies can try to tackle these limitations. 
Suggestions for future research  
Based on the findings from the studies reported in this thesis and other studies there were 
reviewed, a number of suggestions for future research are described below.  
Objectively measured LCPUFA concentration  
As described in the strengths and limitations section, there are large interpersonal differences 
in the metabolism of LCPUFA and the uptake of LCPUFA. However, there are many 
studies that do not include objectively measured LCPUFA concentrations albeit in a blood 
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fraction, cheek cells or adipose tissue. For example, when looking LCPUFA 
supplementation studies in children with a focus on cognition reported in Table 10.2 and 
10.3 only 4 out of 12 studies did not include any measure of LCPUFA concentration in the 
body. When the LCPUFA concentrations are not measured, one is not aware whether 
participants actually need additional LCPUFA (i.e., if a participant has an O3I of 8.4% at 
baseline, additional EPA/DHA is probably not necessary). Additionally, one is also not 
aware whether supplementation was effective and/or whether participants were compliant. 
Lastly, one does not know whether there was actually a difference in LCPUFA 
concentrations between the placebo and treatment group after the supplementation period. 
It is suggested that future research always includes an objective measure of LCPUFA 
concentrations at least at baseline and at the end of the intervention. Moreover, future 
studies should always report the value of all measured fatty acids in % weight of total fatty 
acids in their manuscript (and absolute concentrations were possible), to make comparisons 
between studies possible.  
High dose supplementation  
The recommended amount of DHA + EPA/day varies widely across countries and 
organizations (summarized in [67]), with recommendations for healthy adults varying from 
90mg/day suggested by the US National Academy of Sciences to 1g per day suggested by 
the European Society of Cardiology. The recommendation of the Dutch Health Council of 
450mg per day falls somewhere in the middle of these reported recommendations. Note 
that these recommended amounts are in general based either on the prevention of 
deficiency or the prevention of cardiovascular diseases [67]. Moreover, in the Netherlands 
no specific recommendations for children are available. It has been suggested that the brain 
can incorporate about 4mg DHA per day [68]. However only 0.5% of circulating DHA is 
delivered to the central nervous system [68]. It thus seems that to achieve such level of 
incorporation a relative high intake of DHA is needed. When looking at the studies 
investigating the influence of LCPUFA supplementation in children, the majority of studies 
that supplemented > 400mg DHA + EPA/day had significant effects. It is thus suggested 
that in future studies in children and adolescents, supplementation is at least 400mg DHA 
+ EPA/day.  
Long term supplementation 
It has been suggested that red blood cells achieve a new steady state after about 4-6 months 
of DHA supplementation [51]. The amount of DHA produced de novo in the brain is 
negligible, thus brain DHA levels are maintained via the blood supply. The incorporation 
of DHA into the brain is rather slow at a rate of about 4mg/day, while the total brain 
contains about 5g of DHA [68]. So any full effect of brain enrichment with DHA, would 
only be expected after an extended period of supplementation (i.e., at least 4-6 months of 
supplementation [69]). The majority LCPUFA supplementation studies in children with a 
focus on cognition reported in Table 10.2 and 10.3 had a duration of 16 weeks (i.e., 4 
months) or less. Only 4 of the 12 studies had a duration of more than four months. Of 
these four studies, only one showed positive effects. However two of the studies used a 
very low dosage of < 110 mg DHA + EPA per day [28,32], and as noted effects are not 
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expected at such low dosages. The third study with no effect was Food2Learn and as noted 
before this study had high drop-out and low adherence. All in all, it is suggested that future 
studies use supplementation durations of at least four months, but preferably longer.  
Personalized dose adjustment  
As noted above there are large interpersonal differences in the metabolism of LCPUFA. It 
thus seems odd to give all participants in one trial the same dosage, as not everybody needs 
the same dosage to achieve a certain target concentration in the body. Moreover, all 
participants have a different baseline status, thus again to achieve a target concentration 
everybody needs a different dosage. It thus seems wise to make use of personalized 
supplementation dose. As a person’s LCPUFA metabolism is not known, one can use 
personalized dose adjustments. For example, start all participants on the same dosage, but 
monitor the blood fatty acid concentrations and adjust the dosage based on blood 
concentrations after 3-4 months of supplementation and repeat if necessary.  
Adolescents  
Food2Learn was the first LCPUFA supplementation study investigating cognition and 
mental well-being in adolescents from the general population. Adolescence is an extremely 
important period of life to investigate the influence of LCPUFA on both cognition and 
depressive feelings. It is a period of life characterized by profound brain development, as 
well as emotional, social, and physical development. For a child/adolescent to achieve 
her/his optimal (intellectual) potential there needs to be an optimal environment, which 
includes optimal nutrition [35]. LCPUFA intake could be an especially important aspect of 
nutrition as they can both structurally influence the brain, but can also affect the levels and 
activity of neurotransmitters. Moreover, LCPUFA have also been related to depressive 
feelings, which in turn can influence cognitive performance. All in all, biological 
mechanisms point to an important role of LCPUFA in adolescence for both cognition and 
depressive feelings. As Food2Learn was the first study in adolescents, and taking the 
limitations of Food2Learn into account, more omega-3 supplementation studies in 
adolescents should take place. 
Recruitment, adherence and drop-out  
In executing Food2Learn, problems with recruiting sufficient participants were 
experienced, but also in achieving adherence and retention into the study. This led us to 
review how other LCPUFA supplementation studies in children and adolescents dealt with 
recruitment, but also to what extent they experienced adherence and drop-out (reported in 
Chapter 9). It was difficult to draw conclusions from the review, because of the minimal 
reporting on recruitment, adherence and drop-out in the included studies. However, 
additional literature research did lead to a number of suggestions to improve recruitment, 
adherence, and drop-out (see Chapter 9). It is suggested that future studies take 
recruitment, adherence, and retention into account when designing them. For example, 
there is evidence that simple supplementation regimes lead to less drop-out. Thus, one 
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could provide one concentrated capsule per day, or provide capsules during lunchtime at 
school under supervision of a responsible teacher.  
Analyses: intention to treat, per protocol, and according to blood  
Intention to treat analysis (ITT) is the analysis in which all participants are included in the 
group to which they were originally randomized. Regardless of whether the participant 
actually took the treatment, deviated from the protocol, or dropped out for the analysis 
they are included in the original group they were randomized to. Or as others have put it: 
“once randomized, always analysed” [70,71]. The main advantage of ITT is that it preserves 
sample size and thus statistical power and it is the ‘gold standard’ of analysing RCTs. It is 
also more ecological valid, in that it takes into account that there will always be people who 
do not adhere to the protocol and drop-out [70]. However, there are also many arguments 
to prefer per protocol (PP) analysis. PP analysis is a comparison of treatment groups that 
only include participants that actually completed the treatment that they were originally 
assigned to. The estimated effect of treatment assessed with ITT is conservative, as this 
also includes those that were not compliant and dropped out. PP gives a true estimate of 
the efficacy of the treatment. However, PP analysis does not necessarily depict the real-life 
situation (i.e., people will be non-adherent and quit treatment). As there are both 
advantages and disadvantages to both ITT and PP analyses and the results of both analyses 
depict a different perspective (i.e., ecological valid effect, and true effect), it is 
recommended to do both analyses. Moreover, if reliable blood values are available, analyses 
according to blood values should always be included, because of the interpersonal 
difference in baseline fatty acid concentrations and difference in metabolism.  
Publishing non-significant and negative results  
In MEFAB negative associations were shown, and in Food2Learn non-significant results 
were shown. It has long been known that there is a publication bias, in that studies with 
positive significant results are published faster and more often [72]. However it has been 
suggested that negative / non-significant results actually offer more information gain, in 
that they can counteract possibly false beliefs about a previously thought positive 
intervention [73]. Moreover, for Food2Learn there were many difficulties and limitations, 
but if these results are published, others can learn from the difficulties and limitations and 
design new trials which possibly counteract these. All in all, trials with both negative and 
neutral results can contribute uniquely to the field and should therefore be published.  
Implications for the general public  
One might wonder: how do the results of this thesis translate to ‘the real world’? What 
would recommendations be for an individual or a parent? It seems important to convey 
that nutrition, and in the light of this thesis specifically LCPUFA consumption, possibly 
influence cognition and school performance. Moreover, individuals and parents need to be 
aware, that the LCPUFA have to be consumed via the diet and that most people consume 
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far too little DHA and EPA. It is thus advised that individuals eat two portions of fatty fish 
a week to get sufficient amounts of DHA and EPA in their diet, as suggested for 
cardiovascular health benefits. If fatty fish consumption is not possible (i.e., due to dislike 
or unavailability), long-term, probably lifelong, n-3 LCPUFA supplementation of at least 
400mg EPA + DHA per day is advised. The effect of n-3 LCPUFA supplementation on 
cognition might remain equivocal, the positive effect for cardiovascular health is rather 
robust and no serious adverse effects of fish consumption or n-3 LCPUFA 
supplementation are known. Therefore, we belief that two servings of fatty fish per week 
or 400mg EPA + DHA per day in the form of supplements is a sensible advice.  
Furthermore, taking the results of MEFAB into account, a programming effect of 
LCPUFA seems plausible. It is thus important that pregnant women, and those planning to 
become pregnant know that the nutrition a child receives before birth (i.e., the food the 
mother eats) can impact the development of that child in later life.  
Concluding remarks  
In the present thesis, the relationship between LCPUFA and cognition, school 
performance and mental well-being in children and adolescents was investigated. A 
negative association between prenatal exposure to DHA and arithmetic scores at age 7 was 
shown. Moreover, a positive association between DHA concentrations at age 7 and spelling 
and reading scores at age 7 was reported. An association between baseline O3I and some 
cognitive measures in adolescents was found. However, one year supplementation with krill 
oil in our study did not influence any of the cognitive measures. Additionally, an 
association between baseline ObA concentration and lower depression and higher self-
esteem in the same adolescents was shown. Again, one year supplementation with krill did 
not influence either depressive feelings or self-esteem in our study. Unfortunately, the 
majority of adolescents did not adhere to the study protocol and did not achieve the set 
target O3I of 8-11%.  
To conclude, our findings do not provide conclusive results on the relationship 
between LCPUFA and school performance, cognition and mental well-being in children 
and adolescents. The findings showed negative associations, non-significant associations 
and effects and positive associations. More omega-3 supplementation studies in adolescents 
are needed and the studies should pay specific attention to achieve adherence, decrease 
drop-out and achieve a sufficient high O3I.  
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A number of studies show that essential fatty acids and their longer chain derivatives (long-
chain polyunsaturated fatty acids, LCPUFA), play a significant role in brain functioning, 
because they are important constituents of the cell membrane. A sufficient LCPUFA status 
has been related to better cognitive functioning of both children and adults, as well as less 
cognitive decline in elderly. The relationship between LCPUFA and school performance 
has been studied to a lesser extent. In adults, a beneficial LCPUFA status has been related 
to less depression.  
Because the brain of children and adolescents is still profoundly developing, it can be 
presumed that LCPUFA might be especially important, as building blocks, in these periods 
of development. The goal of this dissertation was to study the relationship between 
LCPUFA and school performance in children, and to study the influence of LCPUFA 
supplementation on cognition and mental well-being in adolescents.  
In Chapter 1 a general and theoretical introduction to this dissertation is provided, 
information on the following topics is given: fatty acid metabolism, importance of intake of 
LCPUFA, in what foods LCPUFA are present, and the advantages of krill oil 
supplementation (the form of supplementation used in the studies in this dissertation) over 
fish oil supplementation. Next, six possible mechanisms in which LCPUFA can possibly 
influence brain functioning are elaborated upon. Then the brain development from birth 
throughout childhood and adolescence is explained. To finish, theoretical background 
information on the outcome variables investigated in this dissertation (i.e., school 
performance, cognition, and mental well-being) is provided.  
In this dissertation data, collected in two studies, were used to answer the goals 
described above. In Chapter 2 an overview of one of these studies, the Maastricht 
Essential Fatty Acids Birth Cohort (MEFAB cohort) is given. The MEFAB cohort was set 
up in 1989 to study the change in fatty acid concentrations during pregnancy and how this 
relates to the fatty acid concentrations of the neonate. Moreover, the association between 
the fatty acid concentrations and a number of birth outcomes (e.g., weight, length and head 
circumference) was assessed. The MEFAB cohort has three follow-up studies at age 4, 7 
and 12 of the child. Data on cognitive development, asthma/atopy, growth, and 
cardiovascular disease risk factors among others, were collected. Besides the description of 
the design, the main earlier findings of the MEFAB cohort are discussed.  
In Chapter 3 data from the MEFAB cohort is used to assess the associations between 
maternal LCPUFA concentrations during pregnancy, at birth, and child’s LCPUFA 
concentration at age 7, and school performance at age 7. Analyses with correction for 
covariates showed a negative association between maternal DHA concentration during 
pregnancy, maternal and child’s DHA concentration at birth, and child’s arithmetic score at 
age 7. Moreover, maternal Osbond acid (ObA) levels at 22 and 32 weeks of pregnancy, and 
ObA level in umbilical cord blood plasma were positively associated with arithmetic score 
at age 7. This last finding confirms the negative relationship between DHA status and 
arithmetic scores, as ObA is a deficiency marker of DHA (i.e., higher ObA levels reflect 
lower DHA levels). In contrast, child’s DHA concentration at age 7 was positively 
associated with both the reading and spelling score at age 7. 
Chapter 4 concerns the design of the second study, Food2Learn. In Chapter 4 the 
unique characteristics and the rationale behind the research design are presented. 
Food2Learn was a double-blind, randomised, placebo controlled intervention trial in 
adolescents (age 13–15 years) attending lower general secondary education. The goal of 
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Food2Learn was to determine the influence of increasing Omega-3 Index (O3I) on 
cognitive functioning, academic achievement and mental well-being of typically developing 
adolescents. Unique characteristics of Food2Learn are among others the fact that: 
participants were recruited based on a low O3I at baseline, students were asked to take krill 
oil capsules at dinner time to increase LCPUFA absorption, a personalized krill oil dose 
adjustment was planned, and the study focused on students of a lower educational level. 
In Chapters 5 and 6, baseline results of Food2Learn are presented. In Chapter 5 the 
associations between baseline O3I of the participants of Food2Learn and scores on the 
cognitive measures are reported. Analyses revealed a significant positive association 
between the O3I and score on the Letter Digit Substitution Task (i.e., measure for 
information processing speed). Moreover, a significant negative association between the 
O3I and errors of omission on the D2 (i.e., measure for inattention/impulsivity) was 
shown. Thus, participants with a higher O3I had a higher information processing speed, 
and less inattention/impulsivity  
In Chapter 6 the associations between baseline O3I and other fatty acids (DHA, 
eicosapentaenoic acid (EPA), arachidonic acid (AA), docosapentaenoic acid (DPA), and 
ObA) and both depressive feelings and self-esteem are reported. Bayesian analyses showed 
a weak negative association between ObA and depression score, and a weak positive 
association between ObA and self-esteem score. In other words, more ObA measured in 
blood corresponded with less depression and more self-esteem. There was no evidence for 
an association between DHA, EPA, and O3I, and depression and/or self-esteem. 
In Chapter 7 and 8 the effects of one year of krill oil supplementation on respectively 
cognitive measures (chapter 7) and mental well-being measures (chapter 8) are reported. 
There was no significant effect of krill oil supplementation on either the cognitive measures 
or mental well-being measures. The most likely explanation for these non-significant 
effects, is the high amount of drop-out and non-adherence with the protocol. Due to these 
problems, it cannot be concluded that a relationship between krill oil supplementation and 
cognition, and mental well-being does not exist. 
While executing Food2Learn, there were difficulties with recruiting participants, drop-
out, and adherence. It was however unknown how common those problems are in 
LCPUFA supplementation studies in children and adolescents. Therefore, a systematic 
review focussing on recruitment, adherence, and drop-out rates in LCPUFA 
supplementation studies in children and adolescents was executed in Chapter 9. Problems 
with recruitment and drop-out were common in LCPUFA supplementation trials in 
children and adolescents. Techniques to improve recruitment, adherence and dropout rates 
were identified in the literature and are reported in Chapter 9 as well.  
In Chapter 10, the main results of the studies in this dissertation are discussed, and 
using an additional literature review, evaluated and put into a broader perspective.  
To conclude, MEFAB and Food2Learn do not provide conclusive evidence for a 
relationship between LCPUFA and school performance, cognition and mental well-being 
in children and adolescents. However, associations between LCPUFA concentrations and 
both school performance, and cognition were found. Future studies should pay attention 
to, among other things, objectively measuring LCPUFA concentrations, long-term high 
dose LCPUFA supplementation, personalised dose adjustment, and focus on adolescence, 
as this is a period of profound brain development. The relevance for society of both 
MEFAB and Food2Learn can be translated into the advice to consume either two servings 
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of fatty fish per week or, based on the literature review in chapter 10, take a supplement 
with at least 400mg DHA + EPA per day, as this amount has by all means a positive effect 
on general health, and possibly a positive effect on brain functioning as well.  
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Verschillende studies laten zien dat essentiële vetzuren en hun langere-keten derivaten 
(meervoudig onverzadigde vetzuren, long-chain polyunsaturated fatty acids [LCPUFA]) een 
grote rol spelen in het breinfunctioneren, omdat zij een belangrijke bouwsteen van het 
celmembraan zijn. Een gunstige LCPUFA status wordt in verband gebracht met beter 
cognitief functioneren van kinderen en volwassenen, alsmede minder cognitieve 
achteruitgang bij ouderen. De relatie tussen LCPUFA en schoolprestatie is in mindere mate 
onderzocht. Verder is er bij volwassenen een duidelijk verband tussen een gunstige 
LCPUFA status en minder depressie gevonden.  
Omdat met name het brein van kinderen en adolescenten nog volop in ontwikkeling is, 
wordt verondersteld dat LCPUFA mogelijk extra belangrijk zijn, als bouwsteen, in deze 
periode van groei. Het doel van dit proefschrift was de relatie tussen LCPUFA en 
schoolprestaties onder kinderen, en de invloed van LCPUFA-suppletie op cognitie en mentaal 
welbevinden bij adolescenten te onderzoeken.  
Hoofstuk 1 geeft een algemene en theoretische introductie op dit proefschrift, waarbij 
de volgende onderwerpen aan bod komen: het vetzuurmetabolisme, het belang van 
LCPUFA-inname, in welke voedingsmiddelen de LCPUFA voorkomen en de voordelen van 
krilloliesuppletie (de suppletievorm die in de studies in dit proefschrift wordt gebruikt) ten 
opzichte van visoliesuppletie. Daarna zijn zes mogelijke werkingsmechanismen genoemd via 
welke de LCPUFA het breinfunctioneren zouden kunnen beïnvloeden. Vervolgens is de 
hersenontwikkeling gedurende de kindertijd en de adolescentie beschreven.  
Hoofdstuk 1 eindigt met de theoretische achtergrond van de uitkomstvariabelen die in 
dit proefschrift onderzocht werden; schoolprestaties, cognitie en mentaal welbevinden.  
Voor dit proefschrift werden in twee separate wetenschappelijke studies gegevens 
verzameld die gebruikt zijn voor beantwoording van bovenstaande doelstellingen. In 
hoofdstuk 2 is het onderzoeksdesign van één van deze studies beschreven; het Maastricht 
Essential Fatty Acids Birth (MEFAB) cohort. Het MEFAB-cohort is opgericht in 1989 om 
de veranderingen in vetzuurconcentraties tijdens de zwangerschap te bestuderen en hoe 
deze verband houden met de vetzuurconcentraties van de foetus. Ook is de associatie 
tussen de vetzuurconcentratie en een aantal geboorte-uitkomsten (bv. gewicht, lengte en 
hoofdomtrek) onderzocht. Het MEFAB-cohort heeft drie follow-up momenten, op 4-, 7- 
en 12-jarige leeftijd van het kind. Gegevens over onder andere cognitieve ontwikkeling, 
astma / atopie, groei, en risicofactoren voor hart- en vaatziekten zijn op die momenten 
verzameld. Naast de beschrijving van het design komen in hoofdstuk 2 tevens de reeds 
gedane bevindingen van het MEFAB-cohort aan de orde. 
In hoofdstuk 3 is, op basis van gegevens uit het MEFAB-cohort, de LCPUFA-
concentraties van de moeder gemeten tijdens de zwangerschap en bij de geboorte van het 
kind, en de LCPUFA-concentraties van het 7-jarige kind, gerelateerd aan de schoolprestaties 
van het kind op 7-jarige leeftijd. Na correctie voor covariaten, werden er negatieve 
associaties aangetoond tussen enerzijds DHA-concentraties bij de moeder tijdens de 
zwangerschap en bij zowel moeder als kind bij de geboorte, en anderzijds de rekenscore van 
het kind op 7-jarige leeftijd. Bovendien waren de concentraties Osbondzuur (ObA) van de 
moeder bij 22 en 32 weken zwangerschap en het niveau in navelstrengbloedplasma positief 
geassocieerd met rekenscores op 7-jarige leeftijd. Deze laatste bevinding bevestigt de 
negatieve relatie tussen DHA-status en rekenscores, gezien een hogere ObA-concentratie 
een lagere DHA-concentratie weerspiegelt. De DHA-concentratie gemeten op 7-jarige 
leeftijd was daarentegen positief geassocieerd met lezen en spellen op 7-jarige leeftijd.  
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Hoofdstuk 4 betreft het design van de tweede studie, Food2Learn. Bovendien zijn in 
hoofdstuk 4 de unieke kenmerken en de redenering achter het onderzoeksdesign 
gepresenteerd. Food2Learn was een dubbelblind, gerandomiseerde, placebogecontroleerde 
interventie onder adolescenten (13-15 jaar) die op VMBO-TL zaten. Het doel van 
Food2Learn was de invloed van het verhogen van de Omega-3 Index (O3I) op cognitie, 
schoolprestaties en mentaal welbevinden van adolescenten te bepalen. Enkele unieke 
kenmerken van Food2Learn zijn: het feit dat deelnemers werden geworven op basis van 
een lage O3I, deelnemers gevraagd werden de krilloliecapsules bij de avondmaaltijd in te 
nemen om de LCPUFA-absorptie te verhogen, een gepersonaliseerde aanpassing van de 
krilloliedosis gepland was, en dat de studie gericht was op leerlingen van een laag 
onderwijsniveau. 
In hoofdstukken 5 en 6 zijn de baseline-resultaten van Food2Learn gepresenteerd. In 
hoofdstuk 5 zijn de associaties tussen baseline O3I van de deelnemers in Food2Learn en 
scores op de cognitieve maten onderzocht. Analyses lieten een significante associatie zien 
tussen de O3I en score op de Letter Digit Substitution Task (maat voor informatie-
verwerkingssnelheid). Bovendien was er een significante associatie tussen de O3I en een 
D2-uitkomstmaat voor onoplettendheid / impulsiviteit. Deelnemers met een hogere O3I 
hadden dus een hogere informatieverwerkingssnelheid en waren oplettender.  
In hoofdstuk 6 zijn de associaties tussen enerzijds baseline O3I en andere vetzuren 
(DHA, EPA, arachidonzuur (AA), docosapentaeenzuur (DPA) en ObA), en anderzijds 
depressieve gevoelens en zelfvertrouwen gerapporteerd. Bayesiaanse analyses toonden een 
zwakke negatieve associatie tussen ObA en depressie, en een zwakke positieve associatie 
tussen ObA en zelfvertrouwen. Oftewel, een hogere ObA-concentratie in het bloed was 
gerelateerd aan minder depressieve gevoelens en een beter zelfvertrouwen. Er was echter 
geen bewijs voor een associatie tussen enerzijds DHA, EPA en O3I en anderzijds depressie 
en/of zelfvertrouwen.  
In hoofdstuk 7 en 8 zijn de effecten van één jaar krilloliesuppletie op respectievelijk 
uitkomstmaten ten aanzien van cognitie (hoofdstuk 7) en mentaal welbevinden (hoofdstuk 
8) gerapporteerd. Er was geen significant effect van krilloliesuppletie op uitkomstmaten ten 
aanzien van cognitie en mentaal welbevinden. De meest waarschijnlijke verklaring voor 
deze niet-significante effecten is de grote hoeveelheid deelnemers die tussentijds hun 
studiedeelname beëindigden, of het protocol niet nakwamen (d.w.z. de capsules niet 
slikten). Vanwege deze moeilijkheden kan echter ook niet worden geconcludeerd dat er 
geen relatie bestaat tussen enerzijds krilloliesuppletie en anderzijds cognitie en mentaal 
welbevinden.  
Tijdens het uitvoeren van Food2Learn werden moeilijkheden ondervonden met het 
werven van deelnemers, deelnemers die studiedeelname beëindigden (drop-out genoemd) en 
deelnemers die zich niet aan het protocol hielden (adherence genoemd). Het was echter 
onbekend hoe vaak zulke problemen zich voordoen bij andere LCPUFA-suppletiestudies 
onder kinderen en adolescenten. Daarom werd in hoofdstuk 9 een systematische review 
uitgevoerd naar wervings-, adherence- en drop-out-percentages in LCPUFA-suppletiestudies 
bij kinderen en adolescenten. Problemen met werving en drop-out kwamen ook veel voor in 
andere LCPUFA-suppletiestudies onder kinderen en adolescenten. Technieken om de 
wervings-, adherence- en drop-outpercentages te verbeteren werden in de literatuur 
geïdentificeerd en zijn eveneens gerapporteerd in hoofdstuk 9.  
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Tenslotte zijn in hoofdstuk 10 de belangrijkste bevindingen van de bovenstaande 
studies bediscussieerd en met behulp van additioneel literatuuronderzoek geëvalueerd en in 
een breder perspectief geplaatst. 
Concluderend, MEFAB en Food2Learn leveren geen onomstotelijk bewijs voor een 
relatie tussen enerzijds LCPUFA, en anderzijds schoolprestaties, cognitie en mentaal 
welbevinden bij kinderen en adolescenten. Wel zijn er associaties gevonden tussen 
LCPUFA concentraties en zowel schoolprestaties als cognitie. Vervolgonderzoek zou zich 
daarom onder andere moeten richten op het objectief meten van LCPUFA concentraties in 
bloed, langdurige suppletie met een hoge dosis LCPUFA, gepersonaliseerde dosis-
aanpassing, en als doelgroep specifiek de adolescentenpopulatie. De maatschappelijk 
relevantie van zowel MEFAB als Food2Learn kan vertaald worden in het advies om twee 
keer per week vette vis te consumeren dan wel, gebaseerd op de resultaten van de 
literatuurreview in hoofdstuk 10, minimaal 400mg DHA + EPA in de vorm van een 
supplement te nemen. Deze hoeveelheid heeft in ieder geval een positief effect op de 
algehele gezondheid en mogelijkerwijs een positief effect op breinfunctioneren.  
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Pap en mam, dat was een verrassing toen jullie dochter opeens weer in Maastricht 
kwam wonen voor haar werk. Dat hadden jullie vast niet verwacht. Ik weet dat het niet 
altijd gemakkelijk is geweest, maar dank jullie wel voor alle hulp (schilderen, verhuizen, 
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mijn leven. Nogmaals, bedankt!  
 
Inge van der Wurff 
6 december 2017. 
  
 227 
Curriculum vitae 
 
 
 
 
Inge van der Wurff was born on the 18th of April 1989 in Maastricht, the Netherlands. In 
2007, after receiving her gymnasium diploma from the Porta Mosana College in Maastricht, 
she started the study Nutrition and Health at Wageningen University. In 2010 Inge finished 
the bachelor Nutrition and Health and in 2013 the Master Nutrition and Health. During 
her master study she visited Karolinska University, Stockholm, Sweden for three months to 
study the influence of food particle size on the cumulative intake curve and eating 
behavior. After completing her master degree, Inge worked as an education assistant at 
Wageningen University, where she, among others, developed an e-module on good sensory 
practice and simple sensory tests. In 2013, she started as a PhD student at the Open 
University under supervision of Prof. Dr. Renate de Groot (Open University of the 
Netherlands), Prof. Dr. Paul Kirschner (Open University of the Netherlands) and Prof. Dr. 
Maurice Zeegers (Maastricht University). In her research she explored the relationship 
between long-chain polyunsaturated fatty acids, cognition, school performance and mental 
well-being in children and adolescents. During her PhD, Inge visited the University of 
Wollongong, Australia for three months to conduct additional research under supervision 
of Prof. Dr. Barbara Meyer. The results of her research have already been published in five 
scientific publications, three additional ones are currently under revision. Inge presented 
her work at four international conferences. To visit these conferences she received three 
travel grants, namely for the International Society for Nutritional Psychiatry Research 
conference, the International Society for the Study of Fatty Acids and Lipids conference, 
and the Mind-Body Interface International Symposium. Above, Inge won a new 
investigators award from the International Society for the Study of Fatty Acids and Lipids. 
Inge will continue her work as an assistant professor at the Open University of the 
Netherlands. 
  
   
 229 
 
 
 
ICO dissertation series  
 
In the ICO Dissertation Series dissertations are published of graduate students from 
faculties and institutes on educational research within the ICO Partner Universities: 
Eindhoven University of Technology, Leiden University, Maastricht University, Open 
University of the Netherlands, University of Amsterdam, University of Twente, Utrecht 
University, VU University Amsterdam, and Wageningen University, and formerly 
University of Groningen (until 2006), Radboud University Nijmegen (until 2004), and 
Tilburg University (until 2002). The University of Groningen, University of Antwerp, 
University of Ghent, and the Erasmus University Rotterdam have been ‘ICO ‘Network 
partner’ in 2010 and 2011. From 2012 onwards, these ICO Network partners are full ICO 
partners, and from that period their dissertations will be added to this dissertation series. 
 
331. De Beer, H.T. (11-05-2016). 
Exploring Instantaneous Speed in Grade 
Five: A Design Research. Eindhoven: 
Eindhoven University of Technology. 
332. Ebbeler, J. (12-05-2016). 
Implementing data use in schools: 
effects on the professional development 
of educators and the role of school 
leaders in data teams. Enschede: 
University of Twente. 
333. Draaijer, S. (10-06-2016). 
Supporting Teachers in Higher 
Education in Designing Test 
Items.Amsterdam: Vrije Universiteit 
Amsterdam. 
334. Bos, L.T. (15-06-2016). Moving 
Beyond Words. Supporting Text 
Processing Using a Situation Model 
approach. Amsterdam: Vrije Universiteit 
Amsterdam. 
335. Vrugte, J. ter (16-06-2016). Serious 
support for serious gaming. Enschede: 
University of Twente. 
336. Kock, Z.D.Q.P. (23-06-2016). 
Toward physics education in agreement 
with the nature of science: Grade 9 
electricity as a case. Eindhoven: 
Eindhoven University of Technology. 
337. Trinh Ba, T. (28-6-2016) 
Development of a course on integrating 
ICT into inquiry-based science 
education. Amsterdam: Vrije Universiteit 
Amsterdam. 
338. Gerken, M. (29-06-2016). How do 
employees learn at work? Understanding 
informal learning from others in 
different workplaces. Maastricht: 
Maastricht University. 
339. Louws, M.L. (06-07-2016) 
Professional learning: what teachers 
want to learn. Leiden: Leiden University. 
 230 
340. Geel, M.J.M. van, & Keuning T. 
(08-07-2016). Implementation and 
Effects of a Schoolwide Data Based 
Decision Making Intervention: a Large-
Scale Study. Enschede: University of 
Twente. 
341. Bouwer, I.R., & Koster, M.P. (02-
09-2016) Bringing writing research into 
the classroom: The effectiveness of 
Tekster, a newly developed writing 
program for elementary students. 
Utrecht: Utrecht University. 
342. Reijners, P.B.G. (02-09-2016.) 
Retrieval as a Cognitive and 
Metacognitive Study Technique to Learn 
from Expository Text. Heerlen: Open 
University of the Netherlands. 
343. Hubers, M.D. (08-09-2016). 
Capacity building by data team members 
to sustain schools’ data use. Enschede: 
University of Twente. 
344. Hsiao, Y.P. (23-09-2016). Peer 
Support to Facilitate Knowledge Sharing 
on Complex Tasks. Heerlen: Open 
University of the Netherlands. 
345. Scheer, E.A. (23-09-2016). Data-
based decision making put to the test. 
Enschede: University of Twente. 
346. Bohle Carbonell, K. (28-9-2016). 
May I ask you….? The influence of 
Individual, Dyadic, and Network Factors 
on the Emergence of Information in 
Exchange Teams. Maastricht: Maastricht 
University. 
347. Claessens, L.C.A. (30-09-2016). Be 
on my side, I’ll be on your side: 
Teachers’ perceptions of teacher– 
student relationships. Utrecht: Utrecht 
University. 
348. Jansen in de Wal, J. (18-11-2016). 
Secondary school teachers' motivation 
for professional learning. Heerlen: Open 
University of the Netherlands. 
349. Kock, W.D. de. (24-11-2016). The 
effectiveness of hints during computer 
supported word problem solving. 
Groningen: University of Groningen. 
350. Oonk, C. (07-12-2016). Learning 
and Teaching in the Regional Learning 
Environment: Enabling Students and 
Teachers to Cross Boundaries in Multi-
Stakeholder Practices’. Wageningen: 
Wageningen University. 
351. Beckers, J. (09-12-2016). With a 
little help from my e-portfolio; 
supporting students’ self directed 
learning in senior vocational education. 
Maastricht: Maastricht University. 
352. Osagie, E.R. (14-12-2016) Learning 
and Corporate Social Responsibility. A 
study on the role of the learning 
organization, individual competencies, 
goal orientation and the learning climate 
in the CSR adaptation process. 
Wageningen: Wageningen University. 
 
 
Open Universiteit
www.ou.nl
Open Universiteit
w .ou.nl
